Patient_ID	Cohort	Age	Sex	AML_type	ELN_2017_Risk	ELN_2022_Risk	Time_to_OS_years	OS_status	WBC	Hemoglobin	Platelet	BM_blasts	PB_blasts	Karyotype	source_file
TCGA-AB-2802-03	TCGA	50	Male	De novo	Favorable	Favorable	1	1			231	52		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2803-03	TCGA	61	Female	De novo	Intermediate	Intermediate	2.17	1			90	0		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2804-03	TCGA	30	Male	De novo	Intermediate	Intermediate	7	0			114	6		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2805-03	TCGA	77	Male	De novo	Adverse	Adverse	1.58	1			105	56		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2806-03	TCGA	46	Male	De novo	Favorable	Favorable	2.59	1			90	81		Other/Unknown	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2807-03	TCGA	68	Female	De novo	Adverse	Adverse	0.5	1			63	55		Other/Unknown	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2808-03	TCGA	23	Male	De novo	Intermediate	Favorable	7.83	0			38	0		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2809-03	TCGA	64	Female	De novo	Favorable	Favorable	0.17	1			100	0		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2810-03	TCGA	76	Female	De novo	Favorable	Favorable	0.09	1			32	88		Other/Unknown	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2811-03	TCGA	81	Male	De novo	Favorable	Favorable	0.66	1			32	37		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2812-03	TCGA	25	Female	De novo	Intermediate	Intermediate	1	1			23	87		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2813-03	TCGA	78	Male	De novo	Adverse	Adverse	0.09	1			98	6		Complex	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2814-03	TCGA	39	Female	De novo	Adverse	Adverse	2.17	1			215	4		Other/Unknown	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2815-03	TCGA	49	Male	De novo	Favorable	Favorable	2.25	1			14	48		Other/Unknown	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2816-03	TCGA	57	Female	De novo	Favorable	Favorable	0.67	1			56	84		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2817-03	TCGA	64	Male	De novo	Adverse	Adverse	0.75	1			19	70		Other/Unknown	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2818-03	TCGA	62	Female	De novo	Favorable	Favorable	0.83	1			110	53		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2819-03	TCGA	52	Female	De novo	Favorable	Favorable	6.83	0			22	18		Other/Unknown	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2820-03	TCGA	76	Male	De novo	Adverse	Adverse	0	1			85	82		Complex	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2821-03	TCGA	64	Male	De novo	Adverse	Adverse	2.25	1			42	5		Other/Unknown	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2822-03	TCGA	65	Male	De novo	Intermediate	Intermediate	2.66	1			16	34		Other/Unknown	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2823-03	TCGA	61	Female	De novo	Favorable	Favorable	0	1			22	68		Other/Unknown	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2824-03	TCGA	45	Male	De novo	Favorable	Favorable	0.08	1			50	5		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2825-03	TCGA	31	Female	De novo	Favorable	Favorable	0.58	1			42	6		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2826-03	TCGA	64	Female	De novo	Favorable	Favorable	2	1			15	90		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2827-03	TCGA	33	Male	De novo	Intermediate	Intermediate	0.75	1			61	0		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2828-03	TCGA	55	Male	De novo	Intermediate	Intermediate	6.25	0			65	67		Other/Unknown	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2829-03	TCGA	50	Male	De novo	Adverse	Adverse	0.75	1			50	0		Other/Unknown	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2830-03	TCGA	64	Female	De novo	Adverse	Intermediate	0.75	1			134	22		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2831-03	TCGA	59	Male	De novo	Intermediate	Intermediate	1.75	1			102	12		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2832-03	TCGA	60	Female	De novo	Intermediate	Intermediate	1	1			57	0		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2833-03	TCGA	77	Male	De novo	Intermediate	Intermediate	1.25	1			29	2		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2834-03	TCGA	33	Male	De novo	Intermediate	Intermediate	0.67	1			111	14		Other/Unknown	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2835-03	TCGA	48	Male	De novo	Favorable	Favorable	4.58	0			50	3		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2836-03	TCGA	35	Male	De novo	Intermediate	Intermediate	1.42	1			44	18		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2837-03	TCGA	66	Female	De novo	Favorable	Favorable	0	1			34	7		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2838-03	TCGA	67	Male	De novo	Adverse	Adverse	1	1			28	17		Complex	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2839-03	TCGA	51	Female	De novo	Favorable	Favorable	1.33	1			232	79		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2840-03	TCGA	74	Male	De novo	Adverse	Favorable	0.08	1			42	0		Other/Unknown	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2841-03	TCGA	51	Female	De novo	Favorable	Favorable	3.84	1			58	40		Other/Unknown	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2842-03	TCGA	65	Male	De novo	Intermediate	Intermediate	0	1			27	0		Other/Unknown	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2843-03	TCGA	77	Male	De novo	Intermediate	Adverse	0.59	1			86	8		Other/Unknown	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2844-03	TCGA	63	Male	De novo	Intermediate	Intermediate	0.33	1			23	71		Other/Unknown	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2845-03	TCGA	37	Female	De novo	Favorable	Favorable	0.83	1			38	33		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2846-03	TCGA	57	Female	De novo	Favorable	Favorable	3.84	1			76	17		Other/Unknown	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2847-03	TCGA	53	Male	De novo	Adverse	Adverse	1.66	1			108	41		Other/Unknown	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2848-03	TCGA	62	Male	De novo	Favorable	Favorable	1.25	1			52	65		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2849-03	TCGA	39	Male	De novo	Intermediate	Intermediate	6.08	0			175	53		Other/Unknown	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2850-03	TCGA	72	Female	De novo	Adverse	Adverse	0.17	1			52	0		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2851-03	TCGA	66	Female	De novo	Intermediate	Intermediate	0.66	1			132	11		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2853-03	TCGA	51	Male	De novo	Intermediate	Intermediate	0.24	1			23	85		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2854-03	TCGA	51	Female	De novo	Intermediate	Intermediate	1	1			143	2		Other/Unknown	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2855-03	TCGA	18	Male	De novo	Adverse	Adverse	0.58	1			30	90		Complex	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2856-03	TCGA	63	Male	De novo	Intermediate	Intermediate	0.41	1			41	39		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2857-03	TCGA	54	Male	De novo	Adverse	Adverse	0.84	1			9	0		Complex	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2858-03	TCGA	75	Female	De novo	Favorable	Favorable	1.58	1			21	54		Other/Unknown	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2859-03	TCGA	40	Male	De novo	Favorable	Favorable	0.83	1			95	23		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2860-03	TCGA	60	Female	De novo	Adverse	Adverse	1.17	1			59	0		Complex	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2861-03	TCGA	76	Male	De novo	Favorable	Adverse	0	1			79	0		Other/Unknown	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2862-03	TCGA	33	Female	De novo	Intermediate	Intermediate	3.91	0			38	0		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2863-03	TCGA	63	Male	De novo	Intermediate	Favorable	0.09	1			11	97		Other/Unknown	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2864-03	TCGA	54	Female	De novo	Adverse	Adverse	1.58	1			68	42		Other/Unknown	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2865-03	TCGA	75	Male	De novo	Adverse	Adverse	0.17	1			22	48		Other/Unknown	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2866-03	TCGA	67	Male	De novo	Intermediate	Intermediate	0.42	1			141	61		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2867-03	TCGA	66	Female	De novo	Intermediate	Intermediate	0.5	1			168	6		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2868-03	TCGA	77	Male	De novo	Adverse	Adverse	0.41	1			70	0		Complex	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2869-03	TCGA	64	Female	De novo	Favorable	Favorable	0.66	0			41	46		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2870-03	TCGA	76	Male	De novo	Favorable	Favorable	0.42	1			21	55		Other/Unknown	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2871-03	TCGA	51	Male	De novo	Intermediate	Adverse	0.42	0			25	10		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2872-03	TCGA	42	Male	De novo	Adverse	Adverse	1.75	0			35	2		Complex	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2873-03	TCGA	51	Female	De novo	Intermediate	Intermediate	0.75	0			14	0		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2874-03	TCGA	59	Male	De novo	Adverse	Adverse	1.08	0			20	48		Other/Unknown	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2875-03	TCGA	43	Male	De novo	Adverse	Favorable	0.58	0			67	39		Other/Unknown	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2876-03	TCGA	45	Female	De novo	Intermediate	Intermediate	3.34	0			116	37		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2877-03	TCGA	60	Female	De novo	Intermediate	Intermediate	1.75	0			45	43		Other/Unknown	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2878-03	TCGA	47	Female	De novo	Adverse	Adverse	1	1			57	0		Complex	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2879-03	TCGA	68	Female	De novo	Intermediate	Intermediate	0.67	0			8	91		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2880-03	TCGA	24	Male	De novo	Adverse	Favorable	1.16	1			34	76		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2881-03	TCGA	48	Female	De novo	Favorable	Favorable	1.08	0			32	41		Other/Unknown	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2882-03	TCGA	73	Female	De novo	Adverse	Adverse	1	1			60	16		Other/Unknown	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2883-03	TCGA	60	Male	De novo	Adverse	Adverse	2	0			93	30		Complex	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2884-03	TCGA	44	Female	De novo	Favorable	Favorable	2	1			145	17		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2885-03	TCGA	71	Male	De novo	Adverse	Adverse	0.59	1			48	54		Complex	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2886-03	TCGA	26	Male	De novo	Favorable	Favorable	0.5	0			33	50		Other/Unknown	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2887-03	TCGA	60	Female	De novo	Adverse	Adverse		1			50	65		Other/Unknown	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2888-03	TCGA	57	Male	De novo	Intermediate	Intermediate	0.91	0			129	0		Other/Unknown	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2889-03	TCGA	55	Male	De novo	Favorable	Favorable	0.83	0			9	59		Other/Unknown	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2890-03	TCGA	69	Male	De novo	Adverse	Adverse	0	1			61	22		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2891-03	TCGA	42	Male	De novo	Adverse	Adverse		1			176	51		Complex	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2892-03	TCGA	42	Female	De novo	Favorable	Favorable	2.58	0			12	16		Other/Unknown	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2893-03	TCGA	45	Male	De novo	Intermediate	Intermediate	0.58	1			53	6		Other/Unknown	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2894-03	TCGA	50	Female	De novo	Adverse	Adverse	0.5	1			136	10		Other/Unknown	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2895-03	TCGA	41	Female	De novo	Intermediate	Intermediate	0.42	1			40	90		Other/Unknown	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2896-03	TCGA	21	Female	De novo	Favorable	Favorable	0.59	1			73	72		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2897-03	TCGA	50	Female	De novo	Favorable	Favorable	0.66	0			27	0		Other/Unknown	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2898-03	TCGA	69	Female	De novo	Intermediate	Intermediate	1.08	0			12	32		Other/Unknown	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2899-03	TCGA	76	Female	De novo	Adverse	Adverse	1.84	1			166	0		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2900-03	TCGA	70	Male	De novo	Favorable	Favorable	0.5	1			30	49		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2901-03	TCGA	27	Male	De novo	Adverse	Adverse	0.16	0			87	88		Complex	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2903-03	TCGA	76	Female	De novo	Favorable	Favorable	0	1			40	98		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2904-03	TCGA	65	Male	De novo	Adverse	Adverse	1.42	1			94	0		Complex	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2905-03	TCGA	48	Male	De novo	Favorable	Favorable	4.41	0			52	0		Other/Unknown	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2906-03	TCGA	59	Male	De novo	Adverse	Favorable	1.58	0			23	15		Other/Unknown	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2907-03	TCGA	69	Male	De novo	Adverse	Adverse		1			127	0		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2908-03	TCGA	81	Male	De novo	Adverse	Adverse	0.09	1			39	0		Complex	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2909-03	TCGA	22	Male	De novo	Adverse	Intermediate	0.08	0			57	94		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2910-03	TCGA	61	Female	De novo	Intermediate	Intermediate	0	1			35	55		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2911-03	TCGA	51	Female	De novo	Adverse	Adverse	3.25	0			21	39		Complex	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2912-03	TCGA	63	Male	De novo	Adverse	Adverse	0.75	1			148	9		Other/Unknown	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2913-03	TCGA	61	Male	De novo	Intermediate	Adverse	3.33	0			25	86		Other/Unknown	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2914-03	TCGA	22	Female	De novo	Favorable	Favorable	2.17	0			149	70		Other/Unknown	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2915-03	TCGA	73	Female	De novo	Adverse	Adverse	0	1			64	11		Complex	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2916-03	TCGA	48	Female	De novo	Intermediate	Intermediate	2.42	0			351	5		Other/Unknown	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2917-03	TCGA	41	Female	De novo	Adverse	Adverse	3.33	0			71	74		Complex	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2918-03	TCGA	47	Female	De novo	Intermediate	Intermediate		1			53	79		Other/Unknown	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2919-03	TCGA	54	Female	De novo	Favorable	Favorable	0.17	0			22	90		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2920-03	TCGA	44	Male	De novo	Adverse	Adverse	1	1			35	83		Complex	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2921-03	TCGA	56	Female	De novo	Intermediate	Intermediate		1			31	57		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2922-03	TCGA	83	Male	De novo	Adverse	Intermediate	0	1			46	74		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2923-03	TCGA	78	Male	De novo	Intermediate	Intermediate	0.09	1			85	28		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2924-03	TCGA	59	Male	De novo	Favorable	Favorable	0.25	0			18	17		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2925-03	TCGA	57	Male	De novo	Intermediate	Intermediate	0.66	1			80	4		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2926-03	TCGA	57	Female	De novo	Intermediate	Intermediate	1.25	1			62	91		Other/Unknown	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2927-03	TCGA	88	Female	De novo	Adverse	Adverse	0.25	1			156	0		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2928-03	TCGA	43	Female	De novo	Adverse	Adverse	0.14	1			32	91		Other/Unknown	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2929-03	TCGA	71	Female	De novo	Adverse	Adverse	0.34	1			50	50		Complex	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2930-03	TCGA	63	Female	De novo	Adverse	Intermediate		1			69	49		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2931-03	TCGA	75	Male	De novo	Intermediate	Intermediate	0	1			31	80		Other/Unknown	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2932-03	TCGA	62	Male	De novo	Favorable	Favorable	0	0			20	22		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2933-03	TCGA	58	Male	De novo	Adverse	Adverse	0.33	1			57	64		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2934-03	TCGA	65	Male	De novo	Intermediate	Intermediate	0.08	0			142	84		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2935-03	TCGA	66	Male	De novo	Adverse	Adverse	0.17	1			37	12		Other/Unknown	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2936-03	TCGA	61	Female	De novo	Adverse	Adverse	0.16	0			79	14		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2937-03	TCGA	36	Female	De novo	Favorable	Favorable	0.59	1			66	86		Other/Unknown	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2938-03	TCGA	76	Male	De novo	Adverse	Adverse	0.83	1			21	6		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2939-03	TCGA	72	Male	De novo	Adverse	Adverse	1.25	0			31	18		Complex	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2940-03	TCGA	35	Male	De novo	Favorable	Favorable		1			88	40		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2941-03	TCGA	73	Male	De novo	Adverse	Adverse	0	1			11	0		Other/Unknown	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2942-03	TCGA	67	Female	De novo	Favorable	Favorable	1.75	0			15	61		Other/Unknown	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2943-03	TCGA	70	Female	De novo	Adverse	Adverse		1			82	6		Complex	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2944-03	TCGA	48	Male	De novo	Intermediate	Intermediate		1			53	87		Other/Unknown	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2945-03	TCGA	65	Female	De novo	Adverse	Adverse	0.66	1			76	0		Complex	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2946-03	TCGA	41	Male	De novo	Intermediate	Intermediate		0			51	62		Other/Unknown	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2947-03	TCGA	52	Male	De novo	Favorable	Favorable	0.09	0			68	51		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2948-03	TCGA	67	Male	De novo	Intermediate	Intermediate	1.59	1			64	6		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2949-03	TCGA	58	Male	De novo	Adverse	Adverse	1.91	0			55	72		Complex	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2950-03	TCGA	34	Female	De novo	Favorable	Favorable	0.84	0			40	59		Other/Unknown	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2952-03	TCGA	60	Female	De novo	Adverse	Adverse	0.09	1			90	29		Complex	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2954-03	TCGA	55	Female	De novo	Intermediate	Intermediate	4.08	0			37	24		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2955-03	TCGA	56	Female	De novo	Favorable	Favorable	1.34	1			45	96		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2956-03	TCGA	61	Male	De novo	Intermediate	Intermediate	0.5	1			36	0		Other/Unknown	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2957-03	TCGA	31	Male	De novo	Favorable	Favorable	1.67	0			52	53		Other/Unknown	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2959-03	TCGA	71	Male	De novo	Adverse	Adverse	1.34	1			86	13		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2963-03	TCGA	56	Male	De novo	Favorable	Favorable	4.5	1			88	45		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2964-03	TCGA	58	Female	De novo	Intermediate	Adverse	3.5	0			35	61		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2965-03	TCGA	60	Male	De novo	Favorable	Favorable	0.92	1			174	56		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2966-03	TCGA	57	Female	De novo	Intermediate	Intermediate	2.34	1			28	35		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2967-03	TCGA	58	Male	De novo	Favorable	Favorable	2.83	0			121	10		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2968-03	TCGA	79	Male	De novo	Intermediate	Adverse	1.25	1			131	0		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2969-03	TCGA	55	Male	De novo	Favorable	Favorable	3.09	0			17	8		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2970-03	TCGA	34	Female	De novo	Adverse	Adverse	0.84	1			152	58		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2971-03	TCGA	76	Female	De novo	Intermediate	Intermediate	2.17	1			52	16		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2972-03	TCGA	82	Female	De novo	Favorable	Adverse	0.08	1			30	25		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2973-03	TCGA	68	Female	De novo	Favorable	Favorable	1.67	1			79	10		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2974-03	TCGA	67	Female	De novo	Favorable	Favorable	0.25	1			79	3		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2975-03	TCGA	54	Male	De novo	Intermediate	Intermediate		1			87	71		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2976-03	TCGA	53	Male	De novo	Intermediate	Intermediate	2.5	1			30	52		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2977-03	TCGA	71	Female	De novo	Intermediate	Intermediate	0.09	1			44	67		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2978-03	TCGA	61	Female	De novo	Adverse	Adverse	1.91	0			140	32		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2979-03	TCGA	30	Female	De novo	Favorable	Favorable	1.84	0			59	88		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2980-03	TCGA	50	Male	De novo	Adverse	Favorable	1.91	0			58	10		Other/Unknown	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2981-03	TCGA	35	Female	De novo	Intermediate	Intermediate	1.33	0			19	8		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2982-03	TCGA	29	Female	De novo	Favorable	Favorable	0.41	0			29	0		Other/Unknown	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2983-03	TCGA	45	Male	De novo	Adverse	Adverse	0.92	1			156	0		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2984-03	TCGA	38	Male	De novo	Favorable	Favorable	3.17	0			19	97		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2985-03	TCGA	81	Female	De novo	Intermediate	Intermediate	0.75	1			61	7		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2986-03	TCGA	31	Female	De novo	Intermediate	Intermediate	0.58	1			36	45		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2987-03	TCGA	75	Female	De novo	Adverse	Adverse	0.5	1			11	0		Other/Unknown	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2988-03	TCGA	67	Female	De novo	Favorable	Favorable	0.08	1			71	49		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2989-03	TCGA	29	Male	De novo	Favorable	Favorable	1	1			13	9		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2990-03	TCGA	51	Male	De novo	Favorable	Favorable	1.25	0			45	85		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2991-03	TCGA	40	Female	De novo	Favorable	Favorable	5	0			34	0		Other/Unknown	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2992-03	TCGA	32	Female	De novo	Favorable	Favorable	4.67	1			39	70		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2993-03	TCGA	57	Female	De novo	Intermediate	Intermediate	2.08	1			82	91		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2994-03	TCGA	25	Male	De novo	Adverse	Favorable	4.92	0			18	7		Other/Unknown	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2995-03	TCGA	63	Male	De novo	Intermediate	Intermediate	4.25	0			43	0		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2996-03	TCGA	74	Male	De novo	Intermediate	Adverse	4.33	0			118	2		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2997-03	TCGA	25	Female	De novo	Favorable	Favorable		1			32	0		Other/Unknown	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2998-03	TCGA	68	Female	De novo	Adverse	Favorable	0.09	1			73	32		Other/Unknown	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-2999-03	TCGA	62	Male	De novo	Favorable	Favorable	4.75	0			15	11		Other/Unknown	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-3000-03	TCGA	25	Male	De novo	Favorable	Favorable	3.42	0			60	71		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-3001-03	TCGA	31	Female	De novo	Favorable	Favorable	4.33	0			208	0		Other/Unknown	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-3002-03	TCGA	68	Male	De novo	Intermediate	Intermediate	3.92	1			96	48		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-3005-03	TCGA	45	Male	De novo	Intermediate	Intermediate	5.75	0			257	0		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-3006-03	TCGA	61	Male	De novo	Adverse	Intermediate	1.33	1			61	14		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-3007-03	TCGA	35	Male	De novo	Adverse	Adverse	4.33	0			12	7		Other/Unknown	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-3008-03	TCGA	22	Male	De novo	Intermediate	Favorable	2.25	1			32	90		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-3009-03	TCGA	23	Male	De novo	Adverse	Adverse	1.58	1			23	63		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-3011-03	TCGA	21	Female	De novo	Favorable	Favorable	5.16	0			52	83		Normal	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
TCGA-AB-3012-03	TCGA	53	Male	De novo	Favorable	Favorable	5.17	0			46	29		Other/Unknown	laml_tcga/data_clinical_patient.txt + data_clinical_sample.txt
2476	Beat AML	27	Female	Other	Intermediate		4.01	1	58.8	6.3	13	85	90	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2157	Beat AML	34	Male	Other	NonInitial		1.63	1	0.6	9.1	14	90	30	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2053	Beat AML	70	Female	De novo	FavorableOrIntermediate		1.4	1	112.3	10.9	8	97	90	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2269	Beat AML	11	Male	Other	NonInitial		4.53	1	2.2	14.3	50	80		Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2295	Beat AML	74	Male	Other	NonInitial		3.46	1	16.1	10.7	69	85	77	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2030	Beat AML	73	Male	De novo	FavorableOrIntermediate		1.16	1	94	6.8	89	94		Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2551	Beat AML	69	Male	De novo	Adverse		1.15	1	282.1	7.7	66	80	19	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2401	Beat AML	59	Female	De novo	IntermediateOrAdverse		1.48	1	29.7	7.9	48	91		Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2302	Beat AML	66	Male	Secondary	NonInitial		1	1	11.9	12	74	75	63	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2479	Beat AML	60	Female	Other	NonInitial		1.08	1	48.2	10.4	57	83	41	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2451	Beat AML	60	Male	De novo	Intermediate		0.33	1	65.2	10.6	136	40	51	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2313	Beat AML	68	Male	Other	NonInitial		3.39	1	47.2	7.6	32			Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2380	Beat AML	70	Male	Other	NonInitial		1.1	1	2.5	9.1	43	75	30	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2164	Beat AML	65	Female	Secondary	Intermediate		1.06	1	51.8	9.1	123	70	75	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2207	Beat AML	31	Female	Other	NonInitial		2.29	1	0.9	11.3	13	83		Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2751	Beat AML	38	Female	Other	NonInitial		3.11	1	46	11.1	6			Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2418	Beat AML	71	Female	De novo	Intermediate		1.09	1	14.9	7.6	125	68		Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2374	Beat AML	56	Male	Other	NonInitial		4.75	1	7.9	9.3	9	77.5	75	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2099	Beat AML	70	Male	Secondary	MissingMutations		0.85	1	21	9.7	47	36	9	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2503	Beat AML	60	Male	Other	NonInitial		3.5	1	2.22	11.2	83	20		Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2391	Beat AML	55	Female	Other	FavorableOrIntermediate		1.94	1	17.9	9.6	19	88		Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2059	Beat AML	71	Male	De novo	Adverse		0.85	1	179.1	8.7	83	81	60	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2446	Beat AML	54	Male	Other	NonInitial		3.77	1	33.8	11.7	119	71	83	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2799	Beat AML	68	Male	Secondary	NonInitial		1.61	1	17.3	11.5	63			Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2007	Beat AML	53	Male	De novo	Favorable		2.03	1	64.3	8.2	62	93	99	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2398	Beat AML		Male	Other	NonInitial		0	0						Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2580	Beat AML	32	Female	Other	NonInitial		6.88	1	2	10.2	17	90	30	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2271	Beat AML	50	Female	De novo	Favorable		8.57	0	84.1	9.1	8	90	82	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2545	Beat AML	81	Female	Secondary	NonInitial		0.4	1	37.1	8.8	46			Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2491	Beat AML	57	Female	Other	NonInitial		0.7	1						Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2518	Beat AML	72	Male	De novo	Adverse		0.01	1	97	5.6	51	95	82.5	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2193	Beat AML	65	Male	De novo	Favorable		3.52	1	20.7	8.8	14		15	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2771	Beat AML	68	Male	Other	NonInitial		0.94	1	1.2	9.5	72	20	occasional	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2340	Beat AML	61	Male	De novo	Intermediate		0.09	0	16.5	8.8	72	46		Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2384	Beat AML	72	Male	Other	NonInitial		1.7	1	0.98	7.4	68	45		Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2489	Beat AML	83	Female	Secondary	Favorable		7.68	0	6	8.1		75	70	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2606	Beat AML	34	Male	De novo	Intermediate		8.27	0	31.9			88		Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2038	Beat AML	24	Male	De novo	Intermediate		6.93	1	21.7	10.9	89	88		Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2034	Beat AML	61	Female	Other	Adverse		0.04	1	53	8.4	24	50	89	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2087	Beat AML	70	Male	Secondary	NonInitial		3.19	1						Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2787	Beat AML	83	Male	Secondary	Adverse		0.28	1	25	11.6	242	43	51	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2762	Beat AML	64	Female	Other	NonInitial		0.73	1						Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2642	Beat AML	74	Male	Secondary	NonInitial		0.38	1	13.7	9.4	16	64	90	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2710	Beat AML	70	Male	Secondary	Adverse		0.32	1	72	9.8	50	80		Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2635	Beat AML	41	Male	De novo	Favorable		8	0	12.8	8.8	42	N/A	74	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2821	Beat AML	31	Female	De novo	Favorable		4.57	0	123			51.7	86	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2469	Beat AML	64	Female	De novo	Favorable		3.04	0	1.5	10.9	32	76	0	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2378	Beat AML	83	Male	Other	Favorable		0.02	1	82	6.2	14		90	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2832	Beat AML	62	Female	De novo	Intermediate		4.03	1	2.9	10.4	19	26		Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2828	Beat AML		Male	Other	NonInitial		0	0						Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2745	Beat AML	65	Male	Secondary	Adverse		0.79	1	7.2	9.5	20	45	45	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2466	Beat AML	70	Male	Other	NonInitial		0.53	1	24.4	8.2	18		78	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2081	Beat AML	7	Female	De novo	Favorable		0.43	1	4.8	9.4	71	85	30	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2298	Beat AML	78	Male	Other	NonInitial		0.73	1	8.5	10.6	15	87	72	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2005	Beat AML	52	Male	Other	NonInitial		1.11	1	14	11.1	152	50		Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2407	Beat AML	60	Female	De novo	Favorable		7.67	0	53.9	13.4	228	80		Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2278	Beat AML	24	Male	De novo	Favorable		8.33	0	13.8	9.2	53	50		Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2239	Beat AML	33	Female	De novo	Intermediate		1.2	1				70.8		Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2173	Beat AML	65	Male	Other	NonInitial		2.79	1	19.5	9.3	22		77	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2286	Beat AML	74	Male	Secondary	Adverse		0.34	1	11.8	7.1	107	60		Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2326	Beat AML	66	Male	De novo	Favorable		7.55	0	28	7.9	122	90		Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2501	Beat AML	56	Male	Other	FavorableOrIntermediate		0.68	1	61.2	10.7	38	90	64	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2235	Beat AML	53	Male	De novo	Favorable		2.06	1	22.79			73	32	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2097	Beat AML	65	Female	De novo	Favorable		0.02	1	9.8	6.8	10	72	57	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2125	Beat AML	62	Male	Other	NonInitial		0.7	1	0.6	9	22	0.5	0	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2249	Beat AML	41	Female	De novo	Favorable		4.1	1	5.8	8.2	9	80	55	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2070	Beat AML	31	Female	Secondary	NonInitial		7.29	1	1.3	10.2	91	18	0	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2015	Beat AML	22	Female	De novo	Intermediate		7.47	0	29.4	8	34	56	55	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2091	Beat AML	2	Female	Other	NonInitial		10.58	0	1.5	9.4	106			Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2417	Beat AML	72	Male	Secondary	Adverse		0.48	1	22.8	8.7	23	35	5	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2312	Beat AML	53	Female	Other	Favorable		7.68	0	5.1			69		Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2509	Beat AML	8	Male	De novo	Favorable		7.29	0	19.5	10.3	109	30		Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2473	Beat AML	78	Male	Secondary	NonInitial		0.97	1						Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2191	Beat AML	42	Female	De novo	Adverse		0.75	1	7.9	12	13	70		Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2506	Beat AML	14	Male	De novo	Favorable		6.81	0	13.3	6.3	63	62	64	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2022	Beat AML	64	Female	Other	NonInitial		1.25	1	26	9.7	11	81	94	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2220	Beat AML	77	Male	De novo	Adverse		0.35	1	25.3				47	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2142	Beat AML	56	Male	Secondary	NonInitial		0.31	1	40.8	9.1	136			Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2339	Beat AML	18	Female	De novo	Favorable		1.48	0	8.8	7.4	23	50	22	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2578	Beat AML	51	Female	De novo	FavorableOrIntermediate		0.61	1	21.7	8.2	99	50		Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2290	Beat AML	79	Female	Secondary	Adverse		0.52	1	8.7			73	56	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2396	Beat AML	53	Male	De novo	FavorableOrIntermediate		3.43	0				96		Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2682	Beat AML	78	Male	Secondary	MissingKaryo		0.58	1	91.25	6.7	22		75.2	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2683	Beat AML	51	Male	De novo	Favorable		2.88	0	2.8	8.3	23	47	48	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2055	Beat AML	35	Female	Other	NonInitial		2.08	1	140			92	97	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2559	Beat AML	53	Female	Other	NonInitial		6.9	0	4.3			82	25	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2274	Beat AML	31	Male	Other	NonInitial		3.77	0	4			28	23	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2429	Beat AML	30	Female	Other	Intermediate		0.74	1	29.25	7.5	29	64	65	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2579	Beat AML	46	Female	Other	NonInitial		1.31	1	0.8	7.9	11	41	42	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2230	Beat AML	73	Male	Other	NonInitial		0.9	1	16.2			84	71	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2543	Beat AML	72	Female	De novo	Adverse		1.15	1						Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2198	Beat AML	71	Female	De novo	Intermediate		1.97	1	4.2			34	8	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2245	Beat AML	52	Male	De novo	Adverse		3.39	1	3.42	8.5	22	21	5	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2259	Beat AML	63	Male	De novo	Adverse		0.62	1	5.23	11	24	51		Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2403	Beat AML	62	Male	De novo	Adverse		0.01	1	250.23	8.5	92	95	95	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2071	Beat AML	71	Male	De novo	FavorableOrIntermediate		0.35	1	2			84	44	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2195	Beat AML	75	Male	Other	NonInitial		1.05	1						Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2188	Beat AML	77	Male	De novo	Adverse		0.06	1				32		Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2221	Beat AML	40	Female	De novo	Intermediate		3.93	0	9.1	12	34	84	29	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2261	Beat AML	79	Female	Other	NonInitial		0.34	1						Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2128	Beat AML	31	Female	De novo	Favorable		0.39	0	13.63	7.4	30	57	45	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2186	Beat AML	61	Male	Other	NonInitial		1.01	1	5.5	8.5	40	19	10	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2789	Beat AML	71	Male	De novo	Intermediate		0.49	1	93.46			84.2	93	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2826	Beat AML	73	Male	De novo	Adverse		6.78	0	2.07	11.1	70	57	1	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2256	Beat AML	57	Male	Other	NonInitial		7.4	0	4	9.5	152	<1		Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2115	Beat AML	35	Female	De novo	Favorable		5.06	0	49.4	4.8	36	70	27	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2079	Beat AML	62	Male	Other	NonInitial		1.56	1	1.8	10.7	17	81	59	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2408	Beat AML	33	Female	De novo	Favorable		2.52	0	26.3	9	18	72	18	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2281	Beat AML	71	Male	Other	Adverse		0.43	1	7.5	8.5	93	76	58	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2179	Beat AML	55	Male	De novo	Intermediate		0.67	1	10.21	12.2	32	75	23	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2485	Beat AML	73	Male	Secondary	NonInitial		1.8	1	24.2	11	90	32	67	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2288	Beat AML	68	Female	Secondary	Adverse		0.93	1	11.36			29	40	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2105	Beat AML	21	Male	Other	NonInitial		1.51	1	3.2	9.1		88	92	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2504	Beat AML	55	Male	De novo	Favorable		2.31	0	1.04			N/A	54	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2108	Beat AML	68	Male	Secondary	Adverse		0.08	1	9.5				41	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2248	Beat AML	71	Male	Other	NonInitial		1.52	1				82		Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2419	Beat AML	51	Male	Other	NonInitial		4.07	0	3.2	8.7	16	82	1	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2047	Beat AML	74	Male	Other	NonInitial		1.14	1				60.1		Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2272	Beat AML	64	Male	De novo	Adverse		1.6	1	1.3	9.1	47	30		Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2212	Beat AML	61	Male	Secondary	NonInitial		0.58	1	96.64	9.8	243	25	20	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2254	Beat AML	64	Female	De novo	Adverse		2.8	0				79		Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2365	Beat AML	39	Male	Other	NonInitial		0.46	1	1.7			59.3	28	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2260	Beat AML	85	Male	Other	NonInitial		0.91	1	13.22	8.2	18			Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2270	Beat AML	30	Female	Other	NonInitial		1.56	1	20.2		10	65	47	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2109	Beat AML	51	Female	De novo	Favorable		0.71	1	4.06	8.7	108	50	24	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2777	Beat AML	71	Female	De novo	Adverse		0.9	1	68.85	6.8	9	25	40	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2229	Beat AML	53	Male	Secondary	Adverse		0.67	0	3.28	8.6	24	65	35	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2159	Beat AML		Male	Other	NonAML		0.32	1				3		Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2036	Beat AML	63	Male	De novo	Adverse		3.69	0	33			86	85	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2405	Beat AML	47	Female	Other	NonInitial		2.56	1	1.2	5.3	10	84	72	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2359	Beat AML	67	Male	De novo	Intermediate		2.06	1				20		Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2499	Beat AML	62	Female	De novo	Favorable		0.65	0	12.9			52	57	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2012	Beat AML	48	Female	Other	NonInitial		0.34	1	0.3			36	0	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2016	Beat AML	21	Male	De novo	Adverse		1.66	0	2.1			66	1	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2539	Beat AML	62	Male	Other	Intermediate		2.68	1	14.66			93	58	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2369	Beat AML	60	Male	De novo	Favorable		7.58	0	11.93	10.6	141	30	55	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2075	Beat AML	55	Male	De novo	Adverse		1.06	1	16.66	6.6	47	54	40	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2330	Beat AML	72	Male	Secondary	Adverse		0.29	1	12.44	7.2	42		41	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2540	Beat AML	56	Male	De novo	FavorableOrIntermediate		3.8	0	13.26	3.7	20	95		Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2373	Beat AML	72	Male	De novo	Favorable		0.09	1	24.2			94	71	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2576	Beat AML	74	Male	Secondary	Adverse		0.98	1						Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2492	Beat AML	74	Female	De novo	Favorable		0.08	0	35.91	9.4	71	60	9	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2399	Beat AML	38	Male	Secondary	NonInitial		1.14	0	4.01	10.6	215	N/A	16	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2017	Beat AML	55	Male	Other	Favorable		7.48	0	3.85	10.1	15	50	25	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2567	Beat AML	71	Female	De novo	Adverse		2.76	0	2.6			22	8	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2297	Beat AML	47	Female	Other	NonInitial		1.59	1	58.5	12.1	29	62	66	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2023	Beat AML	71	Male	De novo	Adverse		0.72	1						Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2413	Beat AML	68	Male	Other	NonAML		0.82	1	2.42	7	26	N/A	15	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2273	Beat AML	80	Female	De novo	Adverse		0.03	1				84		Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2458	Beat AML	58	Male	Other	NonInitial		0.98	1	1.6	9.4	75	10	6	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2045	Beat AML	51	Male	Other	NonAML		7.55	0	2.31	11	99	10		Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2006	Beat AML	62	Female	Other	NonAML		1.89	1	5.9	8.3	91	12	1	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2345	Beat AML	17	Male	De novo	Intermediate		1.95	1	4.34	9.1	25	90		Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2563	Beat AML	46	Male	De novo	MissingKaryo		0	0						Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2562	Beat AML	71	Female	Other	Adverse		0.81	1	12.87	6.4	11	46	49.1	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2314	Beat AML	63	Female	De novo	Favorable		6.67	0	63.75	7.3	57	29	14	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2300	Beat AML	56	Male	De novo	Adverse		0.54	1	12.9			72	88	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2574	Beat AML	41	Male	Other	NonInitial		6.43	0				1.2		Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2067	Beat AML	10	Female	De novo	Favorable		6.72	0	55.35	8.3	31	50		Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2227	Beat AML	37	Male	Other	NonInitial		0.57	1	38.47	7.9	20		95	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2581	Beat AML	63	Female	Secondary	NonInitial		0.46	1	6.23	11.3	299	30	14	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2554	Beat AML	72	Male	Other	Adverse		0.69	1	20.82	6.6	33	55	46	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2205	Beat AML	85	Male	De novo	Intermediate		0.98	1						Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2325	Beat AML	77	Male	Secondary	Intermediate		0.19	1	1.6			67	67	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2231	Beat AML	75	Male	De novo	Intermediate		0.92	1	4.67			64	7	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2331	Beat AML	62	Male	Secondary	Adverse		7.52	0	2.51	10.6	131	39	5	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2162	Beat AML	46	Male	De novo	MissingKaryo		2.75	1	3.6			25.9	0.5	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2561	Beat AML	5	Male	Other	Adverse		6.14	1	95.2	5.7	34		80	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2123	Beat AML	56	Male	De novo	Favorable		1.15	1	8.2			N/A	54	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2204	Beat AML	47	Female	Other	NonAML		10.68	0	31.85			10	17	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2569	Beat AML	62	Male	Other	NonInitial		7.09	0	0.49	10.7	31	20		Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2029	Beat AML	46	Female	De novo	Favorable		3.76	1	57.23	8.4	107	80		Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2241	Beat AML	57	Female	Other	Adverse		0.38	1	19.5	9.6	64	76	79	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2512	Beat AML	63	Male	Other	NonAML		5.75	1	1.9	11.7	115	22	1	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2020	Beat AML	78	Female	De novo	Adverse		0.1	1	51.64	8.3	50		1	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2027	Beat AML	72	Male	De novo	Adverse		0.77	1	1.2			78	15	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2305	Beat AML	65	Female	De novo	FavorableOrIntermediate		1.2	1	58.86	9.6	112	70		Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2560	Beat AML	74	Male	Other	Adverse		2.18	1	1.5	8.3	68	45	25	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2459	Beat AML	40	Female	Other	NonAML		1.07	0	3.42	7.7	13	8	2	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2317	Beat AML	34	Female	De novo	Favorable		2.45	0	99.3			87	87	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2348	Beat AML	52	Female	De novo	Favorable		0.1	0	28.1			91	79	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2394	Beat AML	23	Male	Other	Adverse		0.87	1	40.76	5.7	24	3	30	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2165	Beat AML	71	Male	De novo	MissingKaryo		2.66	1	2	11.2	89	N/A	0	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2243	Beat AML	73	Female	Other	Adverse		0.05	1	0.92			54.8	25	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2474	Beat AML	72	Female	De novo	Adverse		0.88	1	44.76			59.3	40	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2397	Beat AML	61	Male	De novo	Favorable		0.19	0	152.75	10.1	20	81	68	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2252	Beat AML	79	Female	Secondary	Adverse		0.72	1						Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2130	Beat AML	78	Male	De novo	Adverse		1.93	1						Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2447	Beat AML	58	Male	De novo	Favorable		3.42	0				50.8		Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2042	Beat AML	72	Male	Secondary	NonInitial		0.11	1	2.2			78	1	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2008	Beat AML	48	Male	Other	NonAML		5.79	0	0.94	10.2	105	17	5.3	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2279	Beat AML	67	Male	Secondary	Adverse		0.08	1				33		Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2102	Beat AML	78	Female	Secondary	NonInitial		2.66	1	2.7	8.9	221	10	0	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2082	Beat AML	54	Male	Other	Adverse		0.87	1	2.12	8.3	30	29	0	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2684	Beat AML	18	Male	Other	Intermediate		0.92	1	13.67	15.5	291	0.5	0	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2134	Beat AML	51	Female	De novo	Favorable		2.3	0	34.4			74	61	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2448	Beat AML	47	Female	De novo	Favorable		6.02	0	25.11	6.5	9	85	75	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2176	Beat AML	69	Female	De novo	Intermediate		0	0	137.6			94	83	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2423	Beat AML	75	Female	De novo	Adverse		0.22	1	2.37	10.5	38	70	17	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2490	Beat AML	48	Female	De novo	Intermediate		4.67	1	49.29	9.7	87			Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2336	Beat AML	78	Female	Other	Intermediate		0.44	1	5.6			78	77	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2388	Beat AML	69	Male	Secondary	NonInitial		0.5	1	1.2	9.1	3	55		Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2166	Beat AML	51	Male	Other	NonAML		0.78	1	2.23	7.5	20	4	6	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2160	Beat AML	22	Female	De novo	Intermediate		2.26	0	40.2			65	90	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2148	Beat AML	65	Male	Other	NonInitial		1.08	1	0.1			96	85	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2184	Beat AML	62	Female	De novo	Adverse		0.46	1	10.75	9.5	34	22	17.399999999999999	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2457	Beat AML	47	Male	De novo	Adverse		0.62	1	261.2			70	79	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2416	Beat AML	62	Male	Other	NonInitial		0.42	1	2.78	8.5	46	25		Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2354	Beat AML	44	Female	De novo	IntermediateOrAdverse		0.94	1	11.38			86.1	65	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2376	Beat AML	55	Male	De novo	Favorable		2.8	0	16.11		283	37	20	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2352	Beat AML	62	Female	Secondary	Adverse		0.22	1	0.81	7.4	6	50	50	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2233	Beat AML	68	Male	Other	Adverse		1.05	1	2.22	11.2	57	42	43.8	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2406	Beat AML	60	Female	Other	NonInitial		7.01	0	1.8	11.7	15	6		Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2113	Beat AML		Male	De novo	Adverse		0	0						Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2385	Beat AML	35	Male	De novo	Intermediate		3.16	0				86		Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2003	Beat AML	71	Male	Secondary	Adverse		0.15	1	45.6	7.7	11	N/A	50	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2118	Beat AML	60	Female	De novo	Intermediate		0.1	0	1			56	1	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2167	Beat AML	62	Male	Other	NonInitial		1.49	1	11.7	12.1	127	82	47	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2089	Beat AML	69	Female	Other	NonInitial		0.94	1	1.75	8.5	26	78	15	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2112	Beat AML	17	Male	De novo	Intermediate		0.2	0						Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2149	Beat AML	27	Female	De novo	Favorable		2.17	0	5.1			69	68	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2054	Beat AML	69	Female	De novo	Favorable		0.09	0	16.03	8.1	33	83	77	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2452	Beat AML	53	Female	Other	NonInitial		1.07	1		9.7	10	68	54	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2199	Beat AML	57	Male	Other	Adverse		0.1	1	5.92	9.1	77	45		Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2529	Beat AML	68	Male	Other	Favorable		3.29	0	41.4	6.8	61	79	54	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2454	Beat AML	71	Female	Other	Intermediate		1.26	1	78.71	7	19	95	88	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2104	Beat AML	45	Male	Secondary	Adverse		0.71	1	22.95	8.3	59	20	30	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2558	Beat AML	75	Male	De novo	IntermediateOrAdverse		0.9	1	98.9	9.1	45	90		Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2013	Beat AML	68	Female	Secondary	Adverse		0.19	1	29.1			33	37	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2289	Beat AML	53	Female	De novo	Intermediate		0.38	1	2.1	7.4	38	9	4	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2106	Beat AML	69	Male	De novo	Adverse		1.29	1	2.05	7.5	47	80		Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2510	Beat AML	36	Female	Other	NonInitial		1.46	1	7.08	10.3	38			Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2169	Beat AML	69	Male	Other	NonInitial		0.83	1						Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2026	Beat AML	75	Female	Other	NonInitial		3.1	1						Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2370	Beat AML	31	Male	De novo	Favorable		1.63	0	41.35	10.2	34	80	56	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2135	Beat AML	77	Male	Other	NonInitial		0.94	0	13.8			73	84	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2200	Beat AML	48	Male	Other	NonInitial		1.21	1				1.6		Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2358	Beat AML	64	Female	De novo	Adverse		6.8	0	6.44	7.7	56	90	30	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2050	Beat AML	37	Male	De novo	Favorable		3.69	0	8.15	5.5	42			Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2729	Beat AML		Male	De novo	Intermediate		1.53	0				96		Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2455	Beat AML	59	Female	De novo	Intermediate		0.7	1	89.17			51.5	72	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2389	Beat AML	75	Male	De novo	Adverse		0.08	1	1.31	9.3	31	23		Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2267	Beat AML	57	Male	De novo	Adverse		0.67	1	3.53	10.1	91	50		Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2335	Beat AML	64	Male	Other	NonAML		14.78	0				15		Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2480	Beat AML	63	Male	Secondary	Adverse		3.16	0	1.8	8.3	72	20	0	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2516	Beat AML	65	Male	De novo	Intermediate		1.82	0	5.39	7.4	17	90	60	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2058	Beat AML	49	Female	De novo	Favorable		3.2	0				54	3	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2415	Beat AML	65	Male	Other	Adverse		0.43	1	161.89	6.7	40	18	12	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2308	Beat AML	50	Female	Other	NonInitial		5.31	1	3.8			72	81	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2523	Beat AML	74	Male	Other	Adverse		2.75	1	2	8.8	60	17	0	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2121	Beat AML	32	Female	De novo	Intermediate		3.01	0	1.4	9	67	24	2	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2575	Beat AML	40	Female	De novo	Favorable		6.86	0	1.9	7.1	53	90	20	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2144	Beat AML	83	Male	Secondary	Intermediate		0.13	1				78		Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2124	Beat AML	65	Male	Secondary	Adverse		0.18	1	19.99	6.2	9	30	7	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2484	Beat AML	39	Male	De novo	Adverse		0.59	1	21.12	10.7	31	>90		Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2127	Beat AML	51	Female	Other	NonAML		1.39	0		9.1	74	9	11	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2051	Beat AML	40	Female	Other	NonInitial		6.86	0	1.09	9.4	58	3		Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2813	Beat AML	59	Male	Secondary	NonInitial		0.68	1				10		Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2482	Beat AML	72	Female	Secondary	NonInitial		1.14	0						Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2178	Beat AML	84	Male	De novo	Adverse		0.18	1	30			85	88	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2435	Beat AML	69	Male	De novo	Favorable		0.57	0	7.62	9.9	118	60	51	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2517	Beat AML	71	Male	De novo	Adverse		0.44	1	71.19	10	59	80	80	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2119	Beat AML	61	Male	De novo	Favorable		6.63	0	427.46	5.2	34	90	90.5	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2043	Beat AML	36	Female	De novo	Favorable		0.04	1	117.53	7.1	12	74	82	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2404	Beat AML	68	Male	Secondary	NonInitial		0.31	1	53.76	7.2	17			Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2582	Beat AML	61	Male	Secondary	NonInitial		4.22	1	5.16	14	188	3	0	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2477	Beat AML		Male	Other	Adverse		0	0						Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2461	Beat AML	53	Male	De novo	Adverse		0.06	0	180		123	66	56	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2573	Beat AML	26	Male	De novo	Favorable		0.58	0	4.95	6.3	105	81	37	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2150	Beat AML	65	Female	De novo	Adverse		6.64	0	31.66	7.4	60		30	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2486	Beat AML	61	Male	De novo	Adverse		0.28	1	13.68	6.9	57	80		Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2180	Beat AML	71	Male	De novo	Intermediate		2.98	0	0.9		31	40	rare	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2364	Beat AML	77	Female	Secondary	Favorable		0.04	1	3.65	8.6	8	95	9	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2151	Beat AML	57	Male	Other	NonInitial		0.3	1	7.1			70	8	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2103	Beat AML	75	Female	De novo	Intermediate		0.88	1				90		Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2294	Beat AML	80	Male	De novo	Intermediate		1	1	64.6	11.1	110	21	47	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2032	Beat AML	43	Female	Other	NonInitial		3.03	0						Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2346	Beat AML	30	Female	De novo	Favorable		2.8	0	55	11	33	36	22	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2141	Beat AML	66	Female	Other	Favorable		4.7	1	66.67	6.1	10	95	90.2	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2552	Beat AML	76	Male	Secondary	NonInitial		1.86	1	4.5		46	70	55	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2244	Beat AML	82	Female	Secondary	NonInitial		0.1	1	17.63	11	21			Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2583	Beat AML	53	Male	Other	NonInitial		2.51	1	7.5	10.2	365	1	0	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2283	Beat AML	81	Male	Other	Adverse		0.2	1	33.1	10.5	117		12	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2175	Beat AML	80	Male	Secondary	Adverse		0.09	1	6.6		65	90	48	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2056	Beat AML	69	Male	Secondary	NonInitial		1.24	0						Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2285	Beat AML	42	Male	De novo	Adverse		2.78	0	48.03	9.5	39	81	85	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2293	Beat AML	68	Male	Other	NonInitial		0.22	0	2.9		51	15	rare	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2301	Beat AML	70	Male	Other	NonInitial		3.8	1	4.85	8.1	23	90	91	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2262	Beat AML	28	Female	Other	NonInitial		2.31	1	20.18	9.2	8			Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2258	Beat AML	61	Male	De novo	Favorable		4.88	1	3.28	6.7	21	25	39	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2225	Beat AML	46	Male	Other	NonInitial		2.39	0				90		Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2324	Beat AML	53	Female	Other	NonInitial		0.2	1						Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2214	Beat AML	75	Male	Other	Adverse		0.01	0	12.8	12.1	36	58	31	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2189	Beat AML	42	Male	De novo	Favorable		0.1	1	93.94	7.3	176	50	55	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2250	Beat AML	50	Male	Secondary	Adverse		0.27	1	50.74	6.3	14	76	93	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2409	Beat AML	67	Female	Other	Adverse		1.23	1	3.3	9.9	288	24	6	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2400	Beat AML	80	Male	Other	Adverse		0.85	1			4	80	86	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2237	Beat AML	73	Male	Secondary	Adverse		1.21	1	46.8		25	55	39	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2001	Beat AML	68	Male	Secondary	NonInitial		0.92	1				60		Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2174	Beat AML	83	Female	De novo	Adverse		0.07	1	20.1		77	85	92	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2362	Beat AML	71	Female	De novo	Favorable		2.86	0	1.6		96	65		Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2217	Beat AML	65	Female	Other	NonInitial		0.65	1	4.7		51	35	44	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2303	Beat AML	25	Male	De novo	Favorable		0.1	0	18.25	7.7	16	90		Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2069	Beat AML	29	Female	De novo	IntermediateOrAdverse		6.52	0	68.79	7.9	12	95	78	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2000	Beat AML	65	Male	De novo	Favorable		0.74	1	1.6	7.2	23	10	1	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2275	Beat AML	61	Male	De novo	Intermediate		0.53	0	20.8	10.3	20	64	47.4	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2170	Beat AML	43	Female	De novo	Adverse		0.67	1	22.95	7.5	59			Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2242	Beat AML	59	Male	De novo	Favorable		1.18	1	3.6	7.6	35	35	27.4	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2366	Beat AML	60	Male	De novo	Favorable		2.38	1	70.84	4.6	80	90	61	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2024	Beat AML	60	Male	Secondary	Adverse		0.17	1	0.94	7.1	417	15		Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2263	Beat AML	76	Male	De novo	Adverse		0.08	0	5.6		91	20		Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2445	Beat AML	65	Female	De novo	Favorable		0.06	1						Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2306	Beat AML	64	Male	Other	Favorable		5.95	0	8.69	7.7	53			Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2334	Beat AML	85	Male	Other	NonInitial		0.46	1	25.63	10.7	8			Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2584	Beat AML	63	Female	Other	NonInitial		1.08	1	25.7					Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2114	Beat AML	16	Female	De novo	Intermediate		6.22	0	24.72	6.1	39	93		Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2495	Beat AML	57	Female	De novo	Favorable		0.22	1	26.5			55	47	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2342	Beat AML	48	Female	De novo	Intermediate		2.57	0	81			86	77	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2464	Beat AML	60	Male	De novo	Favorable		1.59	1	29		42	33	23	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2323	Beat AML	42	Female	Other	Favorable		2.61	0		7.6	35	92	83	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2110	Beat AML	48	Female	Other	NonInitial		8.4	1	1.46	8.3	53	62	5	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2246	Beat AML	60	Male	Secondary	Adverse		0.56	1	3.1		136	13	rare	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2585	Beat AML	50	Male	Other	NonInitial		3.21	0	0.7			30	0	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2502	Beat AML	77	Female	De novo	Adverse		0.08	1	2.1	6.1	5	86	12.9	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2533	Beat AML	74	Male	Other	NonInitial		0.89	1	2.3	11.1	178	32	5	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2566	Beat AML	10	Female	De novo	Favorable		5.87	0	39.69	9.1	74	80	75	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2453	Beat AML	76	Male	Other	Adverse		1.42	1	4.48	7.6	104	50	5	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2098	Beat AML	1	Female	Other	NonInitial		2.14	1	3.87	9.3	247	35	7	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2327	Beat AML	63	Male	Secondary	Adverse		0.02	1	73.4	7	126	9	15.4	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2586	Beat AML	56	Male	Other	NonInitial		3.72	1	1.6			10	9.5	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2587	Beat AML	59	Female	Other	NonAML		0.08	0	2.8			2		Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2470	Beat AML	33	Female	Other	NonInitial		0.19	0	0.1		21	80		Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2107	Beat AML	44	Male	Secondary	Adverse		0.02	1	8	7.2	18	62	19	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2048	Beat AML	29	Male	De novo	Adverse		3	1	1.23	7.6	193		27.8	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2442	Beat AML	69	Male	De novo	Favorable		0.68	1	33			60		Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2236	Beat AML	32	Male	De novo	Favorable		5.76	0	7.19	6.3	49	80		Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2412	Beat AML	71	Male	De novo	Intermediate		0.79	1		9.8	73	34		Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2073	Beat AML	65	Male	De novo	Adverse		0.57	1	19.8		33	95	62	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2521	Beat AML	83	Male	Other	MissingKaryo		0.14	1						Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2571	Beat AML	81	Female	Other	Adverse		2.27	0	1		104	50	11	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2487	Beat AML	36	Female	De novo	Favorable		5.97	0	103.66	8.2	25	90	90	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2101	Beat AML	87	Male	Secondary	Intermediate		0.68	1	139.9		43	60	39	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2456	Beat AML	72	Female	Secondary	NonInitial		1.27	1	58.2	8.8			25	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2133	Beat AML	10	Male	De novo	IntermediateOrAdverse		5.74	0	133.63	6.9	42	75	86	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2387	Beat AML	2	Female	De novo	Adverse		5.3	0	57.08	6.9	40	80	70	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2064	Beat AML	42	Female	Other	NonInitial		1.23	1	10.7		256	50	51	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2338	Beat AML	61	Male	De novo	Adverse		0.11	1	25			84	78	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2066	Beat AML	62	Female	De novo	Adverse		0.87	1	87.72	9.1	26	95	70	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2449	Beat AML	74	Female	Other	NonAML		0.51	1	2.5	7.4	18	4	2	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2077	Beat AML	71	Female	Other	Intermediate		0.77	1	133.7			82	66	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2350	Beat AML	55	Male	De novo	Intermediate		0.12	0	9.4	7.1	34	91	61	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2240	Beat AML	61	Female	Secondary	Adverse		2.42	0	4.8		26	40	28	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2329	Beat AML	42	Female	De novo	Adverse		2.4	0	49.7		35	35	2	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2343	Beat AML	51	Male	De novo	Adverse		1.72	1	0.5	8.2	77	90		Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2304	Beat AML	24	Female	De novo	Adverse		1.73	1				85		Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2532	Beat AML	68	Female	De novo	Adverse		0.86	1	11.01	7.5	8		49	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2019	Beat AML	77	Male	Secondary	Intermediate		0.1	1	33.1		174	70	72	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2010	Beat AML	52	Female	Other	Intermediate		2.2	0				51		Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2494	Beat AML	85	Male	Secondary	Intermediate		0.22	1	40.53	9.6	46	36		Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2292	Beat AML	52	Female	De novo	Favorable		1.73	1	22.1	8.3	48	83	48.6	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2147	Beat AML	70	Female	De novo	Adverse		2.18	0				70.599999999999994		Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2424	Beat AML	61	Male	De novo	Adverse		5.97	0	84.96	6.8	49	92	98	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2524	Beat AML	54	Female	De novo	Adverse		0.1	1	37.2		9	75		Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2291	Beat AML	68	Male	De novo	FavorableOrIntermediate		2.36	1	134.36	10.8	83	86		Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2072	Beat AML	83	Female	Other	Adverse		0.31	0	2.2		133	45		Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2088	Beat AML	63	Female	De novo	Adverse		0.07	1	1.61	9.4	6	41		Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2402	Beat AML	72	Female	Other	NonInitial		1.55	1	35	9.6	10	81	94	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2039	Beat AML	66	Female	De novo	Adverse		5.95	0	14.94	7.7	92	60	52	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2328	Beat AML	50	Female	Other	NonInitial		0.83	1	206.64	6.4	31			Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2060	Beat AML	35	Female	De novo	Favorable		5.3	0	12.78	6.8	63	42		Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2588	Beat AML	40	Female	Other	NonInitial		8.87	1	2.56	11.7	125	0		Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2065	Beat AML	51	Male	De novo	FavorableOrIntermediate		2.09	0	12			78.5	71	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2357	Beat AML	70	Female	De novo	Favorable		2	0				25	0	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2076	Beat AML	66	Female	Other	Intermediate		4.07	0	4.33	7.7	226	13		Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2014	Beat AML	53	Female	De novo	Favorable		5.02	0	42.34	8.8	36	93	80	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2513	Beat AML	61	Male	De novo	Favorable		5.18	0	16.84	8.9	74	68		Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2360	Beat AML	34	Female	Other	Favorable		5.15	0	0.5	10.7	32	96		Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2371	Beat AML	59	Male	Other	NonInitial		0.7	1	42.91			93.2	47.5	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2356	Beat AML	36	Male	De novo	Favorable		1.51	0	24.98	7.5	29	25	38	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2577	Beat AML	23	Male	De novo	Favorable		2.05	0				88		Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2589	Beat AML	38	Male	Other	NonInitial		1.96	1	34			71	46	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2432	Beat AML	71	Male	Secondary	Adverse		0.03	1	21.6		17	60	14	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2116	Beat AML	78	Male	Secondary	Adverse		0.95	1	5.79	15.3	15	25	4	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2080	Beat AML	68	Male	Secondary	Adverse		0.33	1	140.18	11.4	104		83	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2202	Beat AML	62	Male	Secondary	Adverse		1.16	1	3.74	6.8	174	21	2.5	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2265	Beat AML	61	Male	De novo	Adverse		1.36	0	1.39	7.6	27	45	48	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2111	Beat AML	40	Male	De novo	Favorable		5.92	0	2.68	13.2	66	80	27.8	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2411	Beat AML	14	Female	De novo	Favorable		5.7	0				18		Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2238	Beat AML	53	Male	Other	NonInitial		0.46	1	16.65	9.1	170	9		Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2437	Beat AML	53	Female	De novo	Intermediate		0.35	1	137.54	9.6	33	45	50	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2215	Beat AML	64	Male	Other	Favorable		1.72	1	24.64	7.7	10	90	60	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2025	Beat AML	66	Male	Other	NonInitial		0.63	1	8.94	10.2	345	0	0	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2122	Beat AML	48	Male	De novo	FavorableOrIntermediate		0.09	1	6.3	14	330	13		Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2049	Beat AML	72	Male	Secondary	NonInitial		0.51	1	8.21				58	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2511	Beat AML	62	Male	Other	Favorable		0.07	0	52.8		32	50	20	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2386	Beat AML	8	Male	De novo	Favorable		5.36	0	67.53	9.3	40	70		Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2420	Beat AML	76	Female	De novo	Favorable		0.07	1	27.17	10.3	29	95	54	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2478	Beat AML	71	Male	Secondary	Adverse		0.14	1	44.8	8.1	13	20	10	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2393	Beat AML	65	Female	De novo	FavorableOrIntermediate		5.37	0	84.69	7.2	150	74	60	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2044	Beat AML	72	Female	Other	NonInitial		0.32	1	24.01	9.9	211	90	78	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2137	Beat AML	54	Male	De novo	Favorable		1.24	1	8.43	13.2	358	4		Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2218	Beat AML	24	Male	De novo	Intermediate		5.84	0	21.84	11.3	102			Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2257	Beat AML	72	Female	De novo	Favorable		0.49	1				41		Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2375	Beat AML	44	Female	De novo	Favorable		1.98	0	3.63	10.6	36	18	2	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2381	Beat AML	73	Male	Other	NonInitial		0.1	1	19.64				79	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2018	Beat AML	44	Female	Other	NonInitial		3.37	0	6.5	9.6	5	90	45	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2156	Beat AML	76	Female	Other	NonInitial		0.41	1	14.3	7.8	27	86	50	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2226	Beat AML	74	Female	Other	NonInitial		6.42	0	4.26	13	206			Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2351	Beat AML	50	Female	Other	NonInitial		1.16	1	10.08			0.5		Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2177	Beat AML	30	Female	Other	NonInitial		1.33	0	5.3	8.5	5	27	43	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2425	Beat AML	66	Male	Secondary	Adverse		0.83	1	4.42	8.4	21		23	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2074	Beat AML	25	Female	Other	NonInitial		0.89	1	67.7	8.9	81	98	95	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2172	Beat AML	63	Female	Other	NonInitial		0.95	1	19.76	7.1	18	85	38.5	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2251	Beat AML	52	Female	De novo	MissingKaryo		1.6	1	65.58	6.5	21			Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2507	Beat AML	61	Female	De novo	Favorable		5.55	0	67.36	6.5	32	>95		Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2140	Beat AML	70	Female	De novo	Adverse		0.1	0	7.7	8.2	35	90	17	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2498	Beat AML	83	Male	Secondary	NonInitial		1.19	1	3.72	6.8	213	12	3	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2004	Beat AML	75	Male	Other	Favorable		0.05	1	62.87	8.5	28	90	90	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2433	Beat AML	44	Female	De novo	Intermediate		0.87	1	69.84	7.4	42	75	80	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2139	Beat AML	81	Female	Other	Favorable		0.04	1	97.26	7.3	29	90	70	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2368	Beat AML	36	Female	De novo	Favorable		5.68	0	20.44	7.6	24	40	60	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2138	Beat AML	26	Male	De novo	Favorable		1.77	0				35		Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2410	Beat AML	82	Female	Other	Intermediate		0.73	1	1.36	9.2	44	50		Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2201	Beat AML	77	Male	Secondary	IntermediateOrAdverse		0.79	0	2.2			41	18	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2590	Beat AML	69	Male	Other	NonInitial		8.43	0	7.92	9.6	103	95	50	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2421	Beat AML	68	Female	Other	NonAML		5.37	0	3.38	7.5	20	1		Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2287	Beat AML	56	Male	Other	Favorable		1.74	0	31.02		54	89.6	51	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2196	Beat AML	55	Male	De novo	Adverse		1.83	0	181.08	6.2	28	91	99.2	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2068	Beat AML	58	Female	Secondary	Favorable		5.59	0	2.35	11.9	119	23	3	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2514	Beat AML	54	Female	De novo	Favorable		1.84	0	175.91	6.6	28	92	97	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2210	Beat AML	50	Male	Other	NonInitial		1.58	0	17.1	8	26	75	73	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2319	Beat AML	70	Male	Other	Intermediate		0.01	1	96			65		Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2009	Beat AML	62	Male	De novo	Adverse		1.59	1	1.04	8.2	35	40	8	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2341	Beat AML	46	Female	Other	Adverse		1.74	1	42.57	9.5	92	25	16	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2136	Beat AML	77	Female	Other	NonInitial		0.93	1	8.29	7.9	16			Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2344	Beat AML	51	Female	De novo	Favorable		5.23	0	25.02	6.6	57	95	95	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2565	Beat AML	63	Female	Other	NonAML		0.12	0	2.68	8.8	31	6		Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2090	Beat AML	24	Female	Other	Favorable		2.36	1	181.66	6.2	15	N/A	97	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2222	Beat AML	53	Female	De novo	Intermediate		1.79	0	6.63	6.2	38	20	8	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2155	Beat AML	24	Male	De novo	Favorable		1.06	0	42.35	8.3	55	86	73	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2183	Beat AML	69	Male	De novo	Adverse		0.65	1	1.6			39	11	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2041	Beat AML	67	Female	De novo	Favorable		0.09	0	56.03	9.5	42	85	7.7	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2322	Beat AML	78	Male	Other	NonInitial		1.66	1	240.43	8.1	23		70	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2145	Beat AML	37	Female	De novo	Intermediate		1.48	1	26.57	9.2	49	95	74	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2337	Beat AML	79	Male	Secondary	NonInitial		0.42	1	116.52	7.8	438		35	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2316	Beat AML	72	Male	De novo	Favorable		0.26	0	125.9			97	96	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2232	Beat AML	76	Male	Secondary	Favorable		0.02	1	230.05	10.4	17		96	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2031	Beat AML	36	Male	De novo	Favorable		1.65	0	55.42			91.8	95	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2197	Beat AML	42	Female	De novo	Favorable		1.84	0	18.3	7.3	71	90		Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2568	Beat AML	85	Male	Other	Intermediate		0.09	0	11.4	16.1	141	2		Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2347	Beat AML	74	Male	De novo	Adverse		0.04	1	47.5	7.8	35	19	7	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2436	Beat AML	74	Male	Secondary	NonInitial		1.48	0	2.1	12.7	43	6		Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2383	Beat AML	73	Female	Secondary	NonInitial		1.53	1	3.8	10.9	6			Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2465	Beat AML	58	Male	De novo	Adverse		0.53	0	100.2			57	24	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2035	Beat AML	75	Male	Secondary	Adverse		0.44	1	3.09	9.3	121	27	2	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2219	Beat AML	67	Male	De novo	Favorable		2.37	1	125.16	10.1	30	93	94	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2526	Beat AML	65	Male	Other	Intermediate		0.52	1	3.49	10.2	41	28	3	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2266	Beat AML	67	Male	Secondary	Adverse		0.63	1				60		Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2544	Beat AML	67	Male	Secondary	Adverse		0.45	1	0.9	7.2	84	80	10	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2057	Beat AML	86	Male	Other	NonInitial		1.63	1	10	9	299	23		Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2310	Beat AML	67	Male	Other	Favorable		1.59	0	16.24			71.5	56	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2276	Beat AML	75	Male	Secondary	NonInitial		0.83	0	25			60	50	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2534	Beat AML	58	Male	De novo	Adverse		0.74	1	2.64			78.3	37	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2426	Beat AML	44	Female	De novo	Favorable		5.08	0	2.41	7.8	222	65	11.2	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2061	Beat AML	22	Female	De novo	Intermediate		1.65	0	22.01	6	176	63	42	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2537	Beat AML	62	Female	De novo	Intermediate		0.46	1				20.399999999999999		Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2206	Beat AML	64	Male	Other	Favorable		1.74	0	53.3	8.7	39	83	74	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2471	Beat AML	65	Female	De novo	Intermediate		0.39	1	166.91	12.4	42	95	92.9	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2321	Beat AML	73	Female	De novo	Favorable		0.01	1	122.89	8.2	19	90	98.4	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2522	Beat AML	56	Female	De novo	Favorable		0.88	1	58.7	9.5	28	1.5	2	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2395	Beat AML	71	Male	Secondary	Adverse		1.5	1	5	7.7	24	75	26	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2515	Beat AML	72	Male	Other	NonInitial		0	0				20		Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2146	Beat AML	72	Male	Other	NonAML		0.8	1	66.7	8.2	32		4	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2691	Beat AML	29	Female	Other	NonInitial		0.67	1				1		Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2046	Beat AML	70	Female	Other	NonAML		0.09	1	109.77	8.9	208	13	6.8	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2441	Beat AML	59	Male	De novo	Favorable		1.63	1	4.4	8.9	101	30	10.5	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2497	Beat AML	46	Female	De novo	Favorable		5.34	0				40		Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2037	Beat AML	79	Male	De novo	Adverse		0	1	70.01		27	86	87	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2161	Beat AML	59	Male	Secondary	NonInitial		0.57	1	9.1	7.3	22		1	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2430	Beat AML	50	Female	De novo	Intermediate		5.29	0	1.13	9.8	94	63		Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2488	Beat AML	37	Male	Other	Intermediate		5.19	0	5.35	14.4	162	1		Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2311	Beat AML	64	Female	Other	NonInitial		1.23	0	4.2		100	1		Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2468	Beat AML	78	Female	Secondary	Adverse		0.07	1	6.28	8.2	17	60		Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2171	Beat AML	65	Male	De novo	Adverse		0.81	1	3.49	10.3	29	50	50	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2531	Beat AML	75	Male	De novo	Intermediate		5.3	0	1	9.1	28	23	rare	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2535	Beat AML	62	Male	De novo	Favorable		4.71	0	9.87	7	38	90		Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2591	Beat AML	59	Male	Secondary	Adverse		0.21	1	4.54	8.6	11	30	25	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2181	Beat AML	61	Female	Other	NonInitial		0.72	1	73.28	8.2	49			Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2185	Beat AML	58	Male	De novo	Intermediate		0.76	1	4.17			44.6		Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2052	Beat AML	12	Male	De novo	Adverse		5.22	0	214.49	4.6	49	70	85	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2085	Beat AML	50	Male	De novo	Favorable		1.16	0	71.1	8.7	28	70	91	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2592	Beat AML	49	Male	Other	NonInitial		2.66	1	4.53	10.3	193			Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2550	Beat AML	39	Female	Secondary	NonInitial		0.64	1						Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2450	Beat AML	60	Female	Other	NonInitial		0.92	1						Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2527	Beat AML		Female	Other	NonAML		0	0				15		Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2309	Beat AML	29	Female	Other	Adverse		0.35	1	2.42	9.4	18	98		Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2247	Beat AML	72	Female	Other	Adverse		0.41	1	104.44	11.9	33	90	90	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2318	Beat AML	33	Female	De novo	Favorable		1.53	0	12.75		26			Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2572	Beat AML	60	Female	Other	NonInitial		0.71	1	5.54	11.4	219	2	0	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2182	Beat AML	34	Male	De novo	Adverse		0.8	1	6.13	11.7	916	60	40	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2320	Beat AML	47	Male	De novo	Favorable		1.59	1	8.98	15	34	75		Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2040	Beat AML	34	Female	De novo	Favorable		5.23	0	3.21	10.6	148		21	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2213	Beat AML	26	Female	De novo	Adverse		4.41	0	9.27	7.4	154	75		Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2355	Beat AML	63	Female	Other	NonAML		1	1	7.14	7	69			Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2549	Beat AML	66	Female	De novo	Intermediate		0.04	1	129.5				16	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2463	Beat AML	29	Male	Other	Intermediate		0.18	1	3.88	9.1	52	82	20	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2553	Beat AML		Male	Other	NonInitial		0	0						Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2078	Beat AML	66	Male	Other	NonAML		0.52	0	239		37	5	5	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2277	Beat AML	81	Female	Other	NonAML		0	0	35.1		30	5	0	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2100	Beat AML	39	Male	Other	NonInitial		0.22	0	3.6	10.2	24	41	14	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2440	Beat AML	62	Male	Secondary	Intermediate		0.77	0	16.4	12.4	237		1	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2462	Beat AML	58	Male	Secondary	Adverse		0.17	1	6.69		75	60	25	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2208	Beat AML	68	Male	Other	NonInitial		0.82	0	3.5		66	70		Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2062	Beat AML	64	Female	Other	NonInitial		1.05	1	42.9	6.6	35	35	40	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2519	Beat AML	67	Male	Other	NonAML		0.83	0				17	7	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2264	Beat AML	59	Male	De novo	MissingKaryo		0	0						Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2367	Beat AML	46	Male	De novo	Intermediate		0.02	1	151.6	6.2	31	92	75	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2209	Beat AML	77	Male	Other	NonInitial		1.37	0						Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2363	Beat AML	59	Male	Other	NonInitial		4.99	1		8.3	46	59.5	12	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2332	Beat AML	70	Male	Other	NonInitial		0.84	0	5.05	7.1	35	44	31	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2296	Beat AML	71	Female	Other	Favorable		0	0						Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2528	Beat AML	62	Female	Secondary	NonInitial		0.54	1	8.35	10.7	36	34	3.3	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2556	Beat AML	69	Female	Other	Adverse		1.55	1	61.22	7.1	12		40	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2094	Beat AML	58	Female	Secondary	Adverse		5.23	0	13.83	11	360	21	0	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2192	Beat AML	81	Male	Secondary	NonInitial		0.27	1	2.2	9.5	28	33	8	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2530	Beat AML	50	Female	Other	NonInitial		1.96	0	1.5		16	12		Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2033	Beat AML	34	Female	Other	NonInitial		0.43	1	26.4		426	15		Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2414	Beat AML	61	Female	De novo	Favorable		5.01	0	44.83	11.6	146	83		Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2228	Beat AML	65	Female	Secondary	Adverse		0.07	0				59.4		Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2083	Beat AML	60	Female	De novo	Favorable		4.93	0	34.6	8.8	175	75	44	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2129	Beat AML	67	Male	Secondary	NonInitial		1.24	1	1.27	7.9	22	42.5	54	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2664	Beat AML	49	Male	De novo	Intermediate		1.25	0	7.9	12.2	210	15	50	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2557	Beat AML	73	Male	Other	NonInitial		4.08	1	3	9.4	23	95	48	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2542	Beat AML	73	Male	Secondary	Intermediate		0.08	1	58.97	11.2	55	88	38	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2255	Beat AML	61	Female	De novo	Intermediate		0.02	1	30.54	7.1	43	93	85	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2390	Beat AML	25	Male	Other	NonInitial		1.27	1	1.6	6.5	33		14	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2153	Beat AML	45	Female	Secondary	NonInitial		1.27	0	1.3		69	3		Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2095	Beat AML	55	Female	Other	Favorable		1.05	0	16.43		75	40	57	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2618	Beat AML	30	Male	Secondary	NonInitial		1.3	1	19.23	8	36	87		Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2536	Beat AML	83	Female	Other	NonInitial		1.65	1	19.67	9.2	46			Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2422	Beat AML	42	Male	De novo	Adverse		1.17	0				80		Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2599	Beat AML	72	Male	Other	NonInitial		0.02	0	32.2		19	92		Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2187	Beat AML	50	Female	Other	NonInitial		5.57	0	2.49	9.8	143	1		Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2158	Beat AML	52	Female	De novo	Adverse		0.03	1	1.04	6.7	44	26	9.5	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2830	Beat AML	68	Male	De novo	Adverse		0.06	0				67		Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2439	Beat AML	69	Female	De novo	MissingKaryo		0.7	0						Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2333	Beat AML	70	Male	Other	NonInitial		1.33	0	25.85	7	103	85	77.8	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2444	Beat AML	55	Female	De novo	Adverse		1.17	0	10.6	9.9	83	30	0	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2284	Beat AML	46	Female	Other	NonInitial		0.74	1	6.18	8.1	14			Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2224	Beat AML	52	Female	De novo	Favorable		1.53	1	116.57	10.2	45	51.5	72	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2379	Beat AML	62	Female	De novo	MissingKaryo		0.41	1	2.18	7.2	32	18	7	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2203	Beat AML	67	Female	Other	NonInitial		2.58	1	108.9	8.6	28		94	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2546	Beat AML	78	Male	De novo	Adverse		1.02	1	4.9	8.5	30	20	3.8	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2028	Beat AML	56	Female	Secondary	Adverse		4.74	0	40.02	5.9	53	80	68	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2816	Beat AML	75	Male	Other	NonAML		1.61	1	2.3	7.7	49	1		Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2467	Beat AML	69	Female	De novo	Favorable		4.22	0	34.36	8.6	39	90		Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2483	Beat AML	68	Male	De novo	Favorable		0.1	0	2.16	11.9	106	24	10	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2126	Beat AML	61	Male	De novo	Intermediate		0	0	2.43	12.6	175	48	6	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2555	Beat AML	44	Female	De novo	Intermediate		1.01	0	99.87		90	64	74	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2481	Beat AML	65	Male	Other	Favorable		0.01	1						Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2382	Beat AML	72	Female	De novo	Adverse		1.02	0	44.63		16	30	5	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2377	Beat AML	33	Male	De novo	Favorable		1.1	0	93.2	6.5	31	72	95	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2493	Beat AML	61	Male	De novo	Favorable		1.09	0	115.15		57	86	89	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2194	Beat AML	46	Female	Other	NonInitial		0.99	1	8.16	13.2	145	37		Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2803	Beat AML	66	Male	De novo	Favorable		1.1	0				60.5	55	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2190	Beat AML	77	Female	Other	NonInitial		2.55	1						Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2434	Beat AML	28	Female	Other	NonInitial		4.54	0	1.65	9	42	31		Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2520	Beat AML	81	Male	De novo	Favorable		1.59	1	33.81	8.8	16	80	80	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2307	Beat AML	50	Male	Other	Adverse		0.55	1	119.6	6.5	12	75	82	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2168	Beat AML	65	Female	Secondary	Adverse		0.93	0				20.6		Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2117	Beat AML	53	Male	Other	NonInitial		1.49	1	118	8.1	25	75	90	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2280	Beat AML	63	Male	De novo	Intermediate		0.84	0	9.28		69	26.3	12	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2538	Beat AML	47	Male	De novo	Favorable		0.59	0	18.71	10.2	24	83	82	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2234	Beat AML	73	Male	De novo	Adverse		0.08	1	24.23		22	83	59	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2431	Beat AML	61	Female	Secondary	Intermediate		0.87	1						Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2282	Beat AML	39	Female	Other	NonInitial		1.19	1	73	9.9	66		91	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2547	Beat AML	73	Female	De novo	Adverse		0.33	0	63.4	7.8	95	71	3	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2756	Beat AML	64	Male	Other	Intermediate		4.73	0	1.93	9.3	81	37		Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2508	Beat AML	38	Female	De novo	Favorable		4.34	0	46.27			47		Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2670	Beat AML	51	Female	Other	NonInitial		6	0	2.52	9.2	50	11	0	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2120	Beat AML	59	Female	De novo	Favorable		0.08	0	47.35	6.7	30	90	90	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2315	Beat AML	61	Female	Other	NonInitial		0.99	0						Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2143	Beat AML	64	Male	Other	NonInitial		0.22	1	2.2		43	17		Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2268	Beat AML	72	Female	Other	NonInitial		2.21	0						Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2673	Beat AML	72	Female	De novo	Adverse		4.49	0	1.62	9.4	57	47	0	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2475	Beat AML	66	Male	Other	NonInitial		0.82	0	9	12.5	165		8	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2570	Beat AML	39	Female	Other	Intermediate		0.81	0	190			70	80	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2163	Beat AML	44	Female	Other	NonInitial		2.1	1	85.5	9.9	63	83	80	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2216	Beat AML	74	Male	Other	Favorable		0.16	1						Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2131	Beat AML	55	Male	De novo	Intermediate		0.77	1	24.9	10.9	54	88.5	64	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2827	Beat AML	77	Male	Secondary	Adverse		0.88	0	224.2	7.4	72	90	92	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2500	Beat AML	70	Male	Secondary	NonInitial		0.99	1	92.55	9.8	14		15	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2372	Beat AML	43	Female	Secondary	Intermediate		0.1	0	41.91		27		48	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2086	Beat AML	57	Male	Secondary	Adverse		0.84	0	19.3		49	20		Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2695	Beat AML	63	Male	De novo	Adverse		0.68	1	1.9		79		5	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2709	Beat AML	45	Female	De novo	Favorable		0.76	0						Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2668	Beat AML	35	Female	De novo	Favorable		3.34	1	4.73	7.8	34	60	10	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2735	Beat AML	70	Female	Other	NonInitial		0.41	0				15		Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2624	Beat AML	60	Male	De novo	Adverse		0.8	0	25.5	9.9	48	95	70	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2701	Beat AML	67	Male	De novo	Adverse		0.48	0	35.04			35		Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2811	Beat AML	26	Female	De novo	Intermediate		0.79	0	138.2	7.6	19	89.5	88	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2809	Beat AML	21	Female	Other	NonInitial		1.86	1				13		Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2761	Beat AML	72	Female	Secondary	Intermediate		0.24	1	1.48	8.7	15	22	0	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2666	Beat AML	31	Female	De novo	Adverse		0.42	0	11.23		18	80	69	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2615	Beat AML	48	Female	Secondary	Adverse		0.96	0	4.8	6.7	21	25	7	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2747	Beat AML	61	Male	Secondary	Adverse		0.14	1	19.22	7	166	25	26	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2780	Beat AML	47	Female	De novo	Favorable		3.23	0	58.66	6.5	48	85	70	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2645	Beat AML	45	Female	De novo	Intermediate		0.28	0	185.9	7.4	59	85	70	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2727	Beat AML	0	Female	De novo	Adverse		2.34	1	133.39	5.6	28		82	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2790	Beat AML	49	Female	De novo	Favorable		0.62	0	57.75		32	58	44	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2792	Beat AML	62	Female	De novo	Intermediate		0.06	1	28.53	8.6	73	81	43	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2758	Beat AML	74	Male	De novo	Adverse		0.01	1	29.15	7.7	93	42	4	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2626	Beat AML	27	Female	De novo	Adverse		4.14	0	24.3	7.1	53	61	82	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2661	Beat AML	63	Female	De novo	Adverse		1.31	1	1.71	7.5	26	88	57	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2815	Beat AML	75	Female	De novo	Adverse		0.04	1	142.8	11.1	35	80.5	60	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2801	Beat AML	68	Male	Other	NonAML		3.57	1				9	1	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2655	Beat AML	72	Female	De novo	Adverse		0.07	1	95.49	7.7	144	85	75	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2733	Beat AML	63	Male	De novo	Favorable		0.13	0						Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2689	Beat AML	64	Female	Secondary	Adverse		0.74	1	1.8	6.9	71	30		Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2819	Beat AML	60	Male	De novo	Adverse		2.74	1	0.75	8.7	147	44		Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2823	Beat AML	76	Male	Other	NonInitial		2.47	0	13.3	14.6	47	10		Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2630	Beat AML	44	Male	De novo	Favorable		0.33	0	102.09		23	74.8	83	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2613	Beat AML	79	Male	De novo	Adverse		0.37	1	20.17	9	97	85	49	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2633	Beat AML	61	Male	De novo	Favorable		0.79	1	4.17	8.1	35	40	25	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2767	Beat AML	62	Male	De novo	Adverse		0.85	1	44.8	7	50	35	39	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2822	Beat AML	58	Female	Other	NonInitial		3.06	1	0.84	10.2	202	30	0	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2652	Beat AML	61	Male	Secondary	NonInitial		0.77	1	6.5	9.2	34	14		Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2608	Beat AML	47	Female	De novo	Favorable		0.72	0	66.7	9.5	237	70		Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2708	Beat AML	68	Female	De novo	Favorable		0.64	0	22	10.3	131	85	30	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2686	Beat AML	66	Male	De novo	Adverse		4.33	0	67.35	7.8	14	61		Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2598	Beat AML	75	Male	Other	NonInitial		1.03	1	5.29	12.2	343	1	0	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2678	Beat AML	69	Male	Secondary	NonInitial		1.04	0				3		Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2766	Beat AML	21	Male	Other	NonInitial		1.42	0	55				96	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2631	Beat AML	75	Female	Secondary	NonInitial		0.25	1						Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2835	Beat AML	56	Female	Other	NonInitial		8.02	0						Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2824	Beat AML	72	Male	Secondary	Adverse		0.07	1	2.2	10.3	40	50		Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2829	Beat AML	62	Female	Secondary	Adverse		0.15	0	18	8	30	50.5	53	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2785	Beat AML	14	Female	De novo	Favorable		4.17	0	13.58	6.4	80		60	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2596	Beat AML	33	Male	Other	NonInitial		0.7	0	5.8	8.4	59		18	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2605	Beat AML	49	Female	Other	NonInitial		0.94	0	19	8.7	78	90	96	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2784	Beat AML	45	Female	Other	NonInitial		1.25	1	9.3	7.7	23		97	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2719	Beat AML	55	Male	De novo	Adverse		1.1	1	17.99	9.6	21	60		Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2818	Beat AML	65	Male	De novo	Favorable		0.58	0	8.6	8.1	101	66.5	37	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2644	Beat AML	74	Female	Secondary	NonInitial		0.84	0				65	30	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2614	Beat AML	60	Male	Other	Favorable		3.9	0	23.32	9.2	146	87	83	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2681	Beat AML	63	Male	De novo	Favorable		0.59	0	52.1	8.5	51	92	96	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2617	Beat AML	21	Male	De novo	Adverse		0.87	1	55.69	6.8	54	91	90	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2627	Beat AML	68	Female	Other	Adverse		0.06	1				74		Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2704	Beat AML	38	Male	De novo	Intermediate		0.44	0	25.29			94	55	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2622	Beat AML	66	Female	De novo	Favorable		0.17	1	70.1	7.7	66	75	86	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2732	Beat AML	56	Male	Other	NonInitial		4.29	0	1.92	6.8	94	1		Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2713	Beat AML	51	Male	Other	Intermediate		0.33	1						Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2702	Beat AML	65	Male	De novo	Adverse		0.14	1				25		Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2656	Beat AML	53	Female	Secondary	Adverse		0.42	0				42	9	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2734	Beat AML	75	Female	Other	Intermediate		0.1	1	88.2	7.5	45	73	79	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2659	Beat AML	52	Female	De novo	Intermediate		0.5	0						Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2714	Beat AML	36	Female	De novo	Favorable		1.01	1	59.05	4.6	58	30	40	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2671	Beat AML	29	Male	Other	NonInitial		1.1	0	54				91	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2677	Beat AML	61	Male	De novo	Adverse		0.48	0	111.5		179	65		Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2728	Beat AML	60	Female	Other	Intermediate		0	1	166.8			90	87	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2643	Beat AML	57	Male	Other	NonAML		0.21	0						Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2794	Beat AML	62	Male	De novo	Adverse		0.33	1				50		Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2698	Beat AML	64	Female	De novo	Favorable		2.47	1	4	11.9	130	45	32	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2690	Beat AML	87	Male	De novo	Adverse		0.11	1	1.4			90	70	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2736	Beat AML	39	Female	De novo	Adverse		4.14	0	173.2	6.7	12	>90	90	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2807	Beat AML	67	Male	De novo	Adverse		0.32	1	1.88	10	18	20	7	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2609	Beat AML	55	Male	Secondary	Adverse		0	1	43.7	10.4	31	80	67	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2638	Beat AML	43	Female	Other	Intermediate		0.17	1	91.72	11.4	120	80	55	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2646	Beat AML	68	Male	Other	Favorable		0	0	27.1			90.8		Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2755	Beat AML	23	Female	De novo	Favorable		4.13	0	29.58	8.9	54	80		Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2768	Beat AML	29	Female	Other	Adverse		0.7	1				95		Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2740	Beat AML	20	Male	De novo	Favorable		0.27	0	68.59		16	50		Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2616	Beat AML	70	Female	Other	NonInitial		0.52	1	1.4	9.4	50			Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2705	Beat AML	68	Female	De novo	Adverse		0.51	1	6.7	8.5	53	20		Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2699	Beat AML	73	Male	De novo	Intermediate		0.06	1	64.4			90	94	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2694	Beat AML	22	Male	De novo	Adverse		0.9	1	82.99	9.5	95	92	91	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2597	Beat AML	63	Female	De novo	Adverse		0.07	1	9.4			85	54	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2662	Beat AML	88	Female	Other	Adverse		0.01	1	23.4			80	24	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2770	Beat AML	27	Male	De novo	Intermediate		0.32	0					60	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2725	Beat AML	55	Male	De novo	Intermediate		0.74	1	118.21	7.4	234	90	80	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2834	Beat AML	53	Male	De novo	Adverse		0.18	1	3.81	8.4	23	95		Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2775	Beat AML	59	Female	Secondary	Adverse		0.16	0	3.7	7.4	51	3		Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2647	Beat AML	45	Female	De novo	Favorable		0.19	0				69		Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2667	Beat AML	60	Female	De novo	Adverse		0.58	0				7		Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2628	Beat AML	62	Female	De novo	Intermediate		0.14	0				48	26	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2700	Beat AML	46	Male	De novo	Favorable		1.49	1	47.64	12.7	42	36	28	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2738	Beat AML	47	Female	De novo	Intermediate		0.03	1	134.63	10.3	22		95	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2675	Beat AML	69	Male	Other	Adverse		0.11	0				35	2	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2752	Beat AML	27	Female	De novo	Adverse		3.98	0	22.95	8.3	16	90	85	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2764	Beat AML	76	Female	De novo	Favorable		0.05	0	44.4			90	85	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2796	Beat AML	33	Male	De novo	Intermediate		0.08	0	4.52		70	69	28	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2772	Beat AML	78	Male	Secondary	NonInitial		0.87	1						Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2601	Beat AML	71	Male	Secondary	Adverse		1.38	1				17		Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2663	Beat AML	62	Female	De novo	Adverse		4.21	0				38	17	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2743	Beat AML	68	Male	Secondary	NonInitial		2.68	1	49.48	11.8	28	79	56	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2640	Beat AML	76	Female	De novo	Adverse		0.13	0						Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2669	Beat AML	67	Male	De novo	Intermediate		0.68	1				82		Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2810	Beat AML	65	Female	De novo	Adverse		0.23	0				40		Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2648	Beat AML	51	Male	De novo	Favorable		0.22	0				80	85	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2769	Beat AML	75	Male	De novo	Adverse		0.21	0				90		Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2660	Beat AML	23	Male	De novo	Adverse		3.79	0	98.29	8.6	56	95	85	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2593	Beat AML	83	Female	De novo	Adverse		0.04	0	14.17		78	80		Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2632	Beat AML	73	Female	De novo	Intermediate		0.04	1	123.2		44	85	79	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2748	Beat AML	26	Female	De novo	Favorable		1.97	0				41		Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2820	Beat AML		Female	Other	NonInitial		0	0						Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2802	Beat AML	58	Male	Other	Adverse		0.22	1				24		Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2831	Beat AML		Female	Other	NonInitial		0	0	21.7					Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2680	Beat AML	67	Female	Secondary	Adverse		0.13	1	44.52	9.1	85	70	88	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2707	Beat AML	22	Male	De novo	Favorable		3.86	0	99.89	8.2	50	61	12	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2741	Beat AML	63	Female	De novo	Intermediate		0.46	1	59.23	8.5	60	95	86	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2711	Beat AML	79	Female	Secondary	Adverse		0.05	1	130.45	6.2	126	90		Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2612	Beat AML	54	Male	De novo	Adverse		0.59	1	8.94	8.1	23		65	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2742	Beat AML		Female	Other	NonInitial		0	0						Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2746	Beat AML		Male	Secondary	Favorable		0.01	1				93		Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2754	Beat AML	51	Male	De novo	Adverse		1.33	1	80.58	6.3	17	14		Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2753	Beat AML	66	Male	Secondary	Adverse		0.64	1	6.21	8.3	16	17	22	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2641	Beat AML	65	Male	Other	Adverse		0.06	1	89.55	6.6	18	90	96	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2634	Beat AML	84	Male	De novo	Intermediate		1.08	1				90		Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2651	Beat AML	78	Female	Secondary	Adverse		0.22	1				35	23	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2676	Beat AML	20	Male	De novo	Adverse		3.71	0	34.16	8.3	102	80	75	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2603	Beat AML	41	Male	De novo	Favorable		3.43	0	39.57	13.5	55	72	86	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2715	Beat AML	77	Male	Secondary	Intermediate		0.31	1				22		Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2600	Beat AML		Female	Other	NonInitial		0	0						Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2730	Beat AML		Male	Other	NonInitial		0	0						Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2658	Beat AML	65	Male	De novo	Favorable		0.04	1				85		Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2798	Beat AML	64	Male	Secondary	NonInitial		0.92	1	15.38	8.2	46	51	65	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2674	Beat AML	79	Male	Other	Adverse		0.15	1	13.72	9.2	92	60	74	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2720	Beat AML	74	Male	Secondary	Intermediate		0.07	1				21	8	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2783	Beat AML	62	Male	Other	NonInitial		1.02	1	39.59	9.5	20	25		Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2636	Beat AML	72	Female	De novo	Favorable		1.43	0				97		Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2717	Beat AML	68	Female	Secondary	NonInitial		1.35	0	105.01	7.8	482			Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2817	Beat AML	50	Male	De novo	Favorable		1.47	0				73		Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2637	Beat AML	62	Female	Other	Adverse		1.48	0				62		Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2825	Beat AML	79	Female	De novo	Adverse		0.04	1	11.5	8.3	31	65	15	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2814	Beat AML	47	Female	De novo	Favorable		1.18	0	65.11	7.4	189	18	9	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2625	Beat AML	60	Male	De novo	Adverse		0.55	1	62.69	9.1	133	85	72	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2808	Beat AML	58	Male	De novo	Favorable		3.21	0	10.53	10.1	31	65	50	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2757	Beat AML		Male	Other	NonInitial		0	0	16.24					Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2602	Beat AML	56	Female	De novo	FavorableOrIntermediate		1.41	0				80		Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2724	Beat AML	69	Male	Other	Adverse		0.43	1				94		Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2797	Beat AML	63	Male	Other	Adverse		0.14	1				59		Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2657	Beat AML	46	Female	De novo	Favorable		3.17	0	61.13	9.9	220	81	84	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2650	Beat AML	70	Female	De novo	Favorable		3.25	0	159.73	5.6	45	95	96	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2653	Beat AML		Male	Other	NonInitial		0	0	12					Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2833	Beat AML	74	Female	Other	Intermediate		0.41	1	43.06	6.3	111	81	85	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2685	Beat AML	53	Female	Other	NonInitial		2.29	1	43.57	8.8	34		90	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2718	Beat AML	58	Male	De novo	Favorable		0.06	1	26.58	7.4	29	82	63	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2779	Beat AML	49	Male	De novo	Adverse		2.89	0	6.53	6.8	81	30	10	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2793	Beat AML	66	Male	De novo	Favorable		0	1	310.71	5.6	57		82	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2812	Beat AML	57	Female	De novo	Adverse		0.35	1	3.65	6.9	32	83	12	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2804	Beat AML	30	Male	De novo	Favorable		2.95	0	41.42	5.7	14	80	75	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2806	Beat AML	72	Male	Other	NonAML		0.84	1				2		Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2621	Beat AML	73	Male	Other	Favorable		0.03	1	21.23	9	96		80	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2737	Beat AML	68	Male	De novo	Intermediate		0.07	1	38.83	6.8	64	74		Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2654	Beat AML	63	Female	De novo	Intermediate		2.86	0	40.36	9.2	135			Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2786	Beat AML		Male	Other	NonInitial		0	0						Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2765	Beat AML	53	Female	De novo	Favorable		0.89	1	1.87	8.2	40	34	0	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2739	Beat AML	66	Female	De novo	Favorable		3.09	0	145.55	10.1	130	90		Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2763	Beat AML	63	Male	Other	Favorable		2.61	0	50.68	7.1	27	57	70	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2723	Beat AML		Male	Other	NonInitial		0	0						Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2744	Beat AML		Male	Other	NonInitial		0	0						Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2639	Beat AML		Male	Other	NonInitial		0	0						Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2649	Beat AML	47	Male	De novo	Adverse		1.45	0	12.35	8.2	32	95	60	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2726	Beat AML		Male	Other	NonInitial		0	0						Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2688	Beat AML	75	Male	De novo	Favorable		0.25	1	84.29	10.1	39	80		Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2693	Beat AML	31	Male	De novo	Adverse		2.94	0	17.92	8.6	196	90		Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2679	Beat AML	82	Female	De novo	Intermediate		0.04	1	87.73	9.4	71	50	50	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2805	Beat AML	65	Male	De novo	Adverse		1.48	1	32.75	8.5	29	80	80	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2629	Beat AML	35	Male	De novo	Favorable		2.91	0	4.18	7.6	18	85	53	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2692	Beat AML		Female	Other	NonInitial		0	0						Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2672	Beat AML	83	Female	De novo	Intermediate		0.08	1	44.85	6.5	273	75	52	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2773	Beat AML	73	Female	De novo	Adverse		2.81	0	11.49	8.3	48	92	90	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2619	Beat AML	56	Male	Secondary	Adverse		0.45	1	85.46	8.7	112		35	Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2696	Beat AML	71	Female	De novo	Adverse		2.66	1	4.92	9.5	100	98	44.8	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2703	Beat AML	43	Male	De novo	Favorable		1.29	1	79.15	5.5	21	70	68	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2778	Beat AML	61	Female	De novo	Favorable		2.15	0	4.68	10.8	104	90	65	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2731	Beat AML	73	Male	De novo	Favorable		0.01	1	104.23	6	35	90		Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2623	Beat AML	72	Female	De novo	Favorable		2.54	0	5.6	7.2	93	95		Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2788	Beat AML	75	Male	De novo	Intermediate		1.6	1	10.15	8.7	16	48		Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2620	Beat AML	70	Female	Secondary	Intermediate		0.23	1	27.26	9.5	57	85	78	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2716	Beat AML	82	Male	De novo	Favorable		0.05	1	44.35	7.8	23	90	70	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2665	Beat AML	76	Female	De novo	Favorable		1.16	1	97.67	7.3	10		predominant	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2782	Beat AML	56	Male	Other	NonInitial		1.56	1	26.1	6	11			Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2776	Beat AML	42	Male	De novo	Favorable		0.38	1	22.79	8	18	70		Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2697	Beat AML	69	Male	Secondary	Adverse		0.21	1	5.79	7.4	15	90	78	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2760	Beat AML		Male	Other	NonInitial		0	0						Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2610	Beat AML	61	Male	Secondary	Intermediate		0.3	1	69.09	7.6	23	20	20	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2781	Beat AML	58	Female	De novo	Intermediate		2.2	0	145	6.5	26	91		Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2721	Beat AML	76	Female	Other	NonInitial		2.48	0	3.89	10	140	15	1.5	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2706	Beat AML	59	Male	De novo	Favorable		0.08	0	263.9	6.3	83		75 (by Flow)	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2759	Beat AML	39	Male	De novo	Favorable		2.06	1	20.76	7.6	13	36	28	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2595	Beat AML	0	Male	De novo	Intermediate		0.86	1	95.48	6	90	90	92	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2749	Beat AML	63	Female	De novo	Intermediate		0.47	1	62.54	8.8	30	95	85	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2774	Beat AML		Female	Other	NonInitial		0	0						Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2594	Beat AML	50	Female	De novo	Favorable		0.72	1	31.8	6.8	29	88		Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2607	Beat AML	54	Male	De novo	Intermediate		0.07	1	4.67	7.8	8	92	85	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2604	Beat AML	31	Female	Other	NonInitial		4.78	1	2.96	8.5	28	30		Complex	beataml2_data/beataml_wv1to4_clinical.xlsx
2611	Beat AML	69	Male	Other	Adverse		1.28	1	9.32	10.9	21	60		Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2712	Beat AML	60	Male	De novo	Favorable		1.98	0	5.18	7.1	39	35	25	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2795	Beat AML			Other	NonInitial		0	0						Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2791	Beat AML		Male	Other	NonInitial		0	0	122.41					Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2800	Beat AML	56	Male	De novo	Favorable		0	0	8.39	8.1	23	68	55	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
2722	Beat AML	4	Female	De novo	MissingKaryo		0.65	1	20.03	6.3	71		80	Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2687	Beat AML	68	Female	Other	NonInitial		2.25	0	3.45	11.2	133	5		Other/Unknown	beataml2_data/beataml_wv1to4_clinical.xlsx
2750	Beat AML	57	Male	De novo	Favorable		1.63	1	16.71	9.1	142	40	29	Normal	beataml2_data/beataml_wv1to4_clinical.xlsx
PD10789a	AML-SG	43	Male	AML	Favorable		2.97	0	2.7	6.2	20	45	4	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD10790a	AML-SG	56	Female	AML	Adverse		0.76	1	59.4	7.6	76	15	16	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD10792a	AML-SG	48	Male	AML	Intermediate		1.83	1	1.5	16	99	32	0	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD10793a	AML-SG	54	Male	AML	Adverse		4.71	0	9.8	6.8	60	30	0	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD10794a	AML-SG	46	Female	AML	Favorable		5.67	0	8.2	7.6	74	52	4	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD10795a	AML-SG	49	Female	AML	Favorable		4.51	0	1.6	8	58	50	3	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD10796a	AML-SG	53	Male	AML	Favorable		2.85	0	56.3	7.4	50	88		Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD10798a	AML-SG	58	Male	AML	Favorable		4.49	1	0.8	6.4	25	62	3	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD10800a	AML-SG	18	Male	AML	Adverse		1.2	0	41.4	9.1	43	77	66	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD10801a	AML-SG	49	Female	AML	Adverse		1.48	1	9.9	11.9	42	80	2	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD10802a	AML-SG	50	Female	AML	Adverse		4.1	0	57.3	8.9	130	80	9	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD10803a	AML-SG	44	Female	AML	Favorable		5.13	0	50	8	80		90	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD10804a	AML-SG	57	Male	AML	Adverse		1.92	1	124.6	7.7	157	60	85	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD10805a	AML-SG	48	Female	AML	Adverse		1.26	1	108	7.7	119	90	91	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD10806a	AML-SG	58	Male	oAML	Adverse		0.57	1	2.6	11.2	449	58	13	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD10807a	AML-SG	46	Female	AML	Intermediate		0.67	1	20.1	7.7	55	60	14	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD10808a	AML-SG	54	Female	tAML	Adverse		1.08	1	5	5.4	16	25	1	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD10809a	AML-SG	44	Female	AML	Favorable		5.27	0	91.1	10.4	64	80	92	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD10810a	AML-SG	41	Male	AML	Intermediate		5.91	0	20.2	8	17	90	96	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD10811a	AML-SG	51	Female	AML	Favorable		5.47	0	34	12.8	46	75	89	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD10812a	AML-SG	38	Female	AML	Adverse		5.74	0	143.1	9.7	47		74	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD10813a	AML-SG	49	Male	AML	Favorable		2.89	0	9.3	9.4	33	75	34	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD10814a	AML-SG	49	Male	AML	Intermediate		4.88	0	14.9	9.8	50	86	12	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD10815a	AML-SG	50	Male	AML	Favorable		4.59	0	52.7	9.8	36	85	92	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD10816a	AML-SG	53	Male	AML	Intermediate		0.13	1	13.6	8.6	33	81	45	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD10817a	AML-SG	51	Male	AML	Adverse		0.79	1	0.9	13.6	178	90	37	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD10818a	AML-SG	34	Male	AML	Favorable		5.01	0	56.2	5	40	96	79	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD10819a	AML-SG	55	Male	AML	Adverse		0.99	1	71.6	8.7	40	90	75	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD10820a	AML-SG	39	Male	AML	Adverse		0.66	1	8.5	7.3	81	75		Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD10821a	AML-SG	38	Male	AML	Adverse		1.12	1	1.5	8.8	21	63	5	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD10822a	AML-SG	57	Female	AML	Adverse		1.91	1	3.9	7.5	55	80	23	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD10823a	AML-SG	21	Male	sAML	Adverse		0.39	1	22.4	5.7	12	30	40	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD10824a	AML-SG	52	Male	AML	Favorable		5.55	0	42.8	10	146	40	5	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD10825a	AML-SG	44	Female	AML	Adverse		4.9	0	1.7	10.3	125	60	0	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD10826a	AML-SG	27	Female	AML	Adverse		0.66	1	12.7	9.7	299	71	76	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD10827a	AML-SG	38	Female	AML	Adverse		1.49	1	34	10.7	39	99	80	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD10828a	AML-SG	46	Male	AML	Favorable		4.35	0	1.5	9.8	16	90	0	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD10829a	AML-SG	39	Male	AML	Intermediate		0.62	1	60.2	13.3	105	88	49	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD10830a	AML-SG	51	Female	AML	Favorable		2.69	1	13	8.5	15	80	63	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD10831a	AML-SG	28	Female	AML	Adverse		0.61	1	172	9	26	95	80	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD10832a	AML-SG	46	Male	AML	Favorable		5.59	0	12.4	6.5	31	68		Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD10833a	AML-SG	51	Female	AML	Intermediate		2.8	0	2	11.9	95		33	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD10834a	AML-SG	43	Female	tAML	Intermediate		0.43	1	0.8	9.5	20	80		Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD10835a	AML-SG	46	Male	AML	Adverse		4.58	0	1.7	8	44	50	7	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD10836a	AML-SG	55	Female	AML	Adverse		1	1	65.8	11.8	85		65	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD10837a	AML-SG	22	Male	AML	Favorable		5.75	0	7.2	14.5	319	4	0	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD10838a	AML-SG	58	Male	AML	Adverse		0.7	1	1.7	12.3	49	54	0	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD10839a	AML-SG	61	Female	AML	Adverse		5.29	0	2.8	10.4	266		27	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD10840a	AML-SG	56	Male	AML	Adverse		0.57	1	3.5	6.6	43	25	12	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD10841a	AML-SG	38	Female	AML	Intermediate		1.25	1	54.8	11.5	80	90	94	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD10842a	AML-SG	49	Male	sAML	Adverse		4.53	0	2.4	9	63	80	66	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD10843a	AML-SG	39	Female	AML	Favorable		5.37	0	3.6	9	79	30	4	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD10844a	AML-SG	43	Female	AML	Favorable		5.2	0	25.5	7	139	60	10	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD10845a	AML-SG	43	Male	AML	Intermediate		1.13	1	38.9	10.3	17	90	7	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD10846a	AML-SG	41	Male	AML	Intermediate		1.45	1	3.1	9.1	119	85	0	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD10847a	AML-SG	42	Female	AML	Favorable		1.01	1	59.3	7.6	120	70	12	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD10848a	AML-SG	54	Male	AML	Adverse		4.13	0	21.3	10.7	247	80	64	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD10849a	AML-SG	60	Male	AML	Adverse		4.33	0	2.6	5.8	31	96	90	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD10850a	AML-SG	50	Female	AML	Favorable		5.56	0	40.9	10.9	159	90	70	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD10851a	AML-SG	45	Female	AML	Intermediate		1.39	1	4.4	8.4	18	80	70	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD10852a	AML-SG	46	Female	AML	Intermediate		0.72	1	5.7	6.7	39	95	33	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD10853a	AML-SG	51	Female	tAML	Favorable		0.94	1	38.6	8.2	148	80	30	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD10855a	AML-SG	47	Male	oAML	Intermediate		0.27	1	99.6	10.8	38	95	95	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD10856a	AML-SG	51	Male	AML	Adverse		0.48	1	2.8	7.3	10	20	1	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD10857a	AML-SG	58	Male	oAML	Adverse		1.75	1	2.1	6.7	10	40	6	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD10859a	AML-SG	56	Female	oAML	Adverse		1.83	1	53.6	7.8	66	37	44	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD10860a	AML-SG	59	Female	AML	Adverse		1.59	1	1.4	9.8	15	65	11	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD10861a	AML-SG	49	Female	AML	Favorable		5.52	0	4	13	28	80	60	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD10862a	AML-SG	52	Male	AML	Favorable		3.73	1	8.7	10.4	93	70	29	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD10863a	AML-SG	29	Male	AML	Adverse		4.06	0	20.3	7.6	42	92	82	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD10864a	AML-SG	57	Male	AML	Adverse		1.33	1	13.5	9.6	316	90	58	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD10865a	AML-SG	58	Male	AML	Adverse		5.46	0	1.8	11.3	145	40	0	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD10866a	AML-SG	23	Female	AML	Favorable		5.07	0	15.2	10.9	44	85	92	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD10867a	AML-SG	34	Male	AML	Adverse		3.72	1	2	5.9	63	85	4	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD10868a	AML-SG	24	Male	AML	Adverse		5.18	0	2.9	4.8	41	95	47	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD10869a	AML-SG	58	Male	AML	Intermediate		3	1	3.6	9.1	260	90	6	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD10870a	AML-SG	34	Male	AML	Adverse		2.33	1	36.9	8.9	23	85	35	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD10871a	AML-SG	25	Female	AML	Favorable		4.31	0	14.9	6.6	35	50	59	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD10873a	AML-SG	55	Male	sAML	Intermediate		0.74	1	1.4	10.5	35	80	0	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD10874a	AML-SG	51	Female	AML	Adverse		4.94	0	2.4	9	47	90	80	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD10875a	AML-SG	58	Male	sAML	Adverse		0.58	1	66.6	9.7	32	40	42	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD10876a	AML-SG	56	Male	AML	Favorable		2.17	1	18.3	11.2	43	85		Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD10877a	AML-SG	61	Female	AML	Adverse		0.61	1	14.7	10.5	60	85	17	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD10878a	AML-SG	24	Male	AML	Intermediate		3.96	1	122	7.2	34	90	93	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD10879a	AML-SG	55	Male	AML	Intermediate		5.46	0	5	7.5	26		50	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD10880a	AML-SG	52	Female	tAML	Intermediate		1.72	1	209.1	10.8	58	93	94	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD10881a	AML-SG	53	Male	AML	Favorable		2.08	1	4.8	8	83	46	19	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD10882a	AML-SG	39	Female	AML	Intermediate		5.42	0	3.9	10.2	45	70	27	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD10883a	AML-SG	51	Female	AML	Adverse		1.1	1	87.1	6.8	18	78	78	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD10884a	AML-SG	30	Female	AML	Intermediate		5.07	0	126.8	10.9	58	95	80	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD10885a	AML-SG	62	Female	AML	Favorable		12.29	0	76.3	9.1	40	1.5		Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD10886a	AML-SG	75	Male	AML	Favorable		0.36	1	114.5	8.1	52	91	97	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD10887a	AML-SG	61	Female	AML	Adverse		1.19	1	30	7.5	330	80	61	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD10888a	AML-SG	79	Female	AML	Intermediate		2.83	1	1.13	12.2	112	23		Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD10889a	AML-SG	58	Female	AML	Adverse		0.07	1	29.7	7.7	22	30	43	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD10890a	AML-SG	44	Male	AML	Favorable		4.47	0	41.9	7.7	62	70	68	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD10891a	AML-SG	47	Male	AML	Favorable		5.24	0	144	7.7	40	100	97	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD10892a	AML-SG	53	Male	AML	Intermediate		1.24	1	1.5	11	22	50	2	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD10893a	AML-SG	56	Male	AML	Adverse		0.1	1	2.9	9.3	45	60	0	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD10894a	AML-SG	58	Male	AML	Adverse		5.46	0	46.5	11.2	122	80	1	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD10895a	AML-SG	47	Male	AML	Intermediate		0.99	1	20.8	8.1	28	90	19	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD10896a	AML-SG	54	Female	AML	Adverse		4.15	0	81.9	5.9	80	80	52	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD10897a	AML-SG	54	Female	AML	Favorable		4.14	0	8.1	10.4	114	90	19	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD10898a	AML-SG	46	Male	AML	Adverse		4.71	0	4.4	9.6	14	53	43	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD10899a	AML-SG	55	Male	AML	Favorable		4.47	0	18.9	8.3	97	55	78	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD10900a	AML-SG	40	Female	AML	Adverse		0.75	1	12.8	10.4	102	63	49	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD10902a	AML-SG	47	Male	AML	Intermediate		1.1	1	1.8	9.6	61	40	11	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD10903a	AML-SG	56	Male	tAML	Adverse		3.75	1	5.6	9.1	66	21	19	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD10904a	AML-SG	54	Male	AML	Intermediate		3.92	0	28.1	12.7	40	60	53	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD10905a	AML-SG	28	Female	AML	Favorable		4.05	0	5.1	9	80	90	52	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD10906a	AML-SG	35	Male	AML	Adverse		0.89	0	77	9.3	43	100	96	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD10907a	AML-SG	59	Female	oAML	Adverse		4.81	0	11.7	7.4	47	90		Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD10908a	AML-SG	54	Female	tAML	Adverse		0.36	1	0.7	8.5	8	90	20	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD10909a	AML-SG	51	Female	tAML	Adverse		4.83	0	2.3	8.4	35	32	16	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD10910a	AML-SG	49	Male	AML	Favorable		2.23	0	21.8	7.3	69	60	50	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD10912a	AML-SG	55	Male	AML	Adverse		1.44	1	9.1	9.9	32	20	25	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD10913a	AML-SG	25	Male	AML	Favorable		1.31	0	18	8.8	41	80	56	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD10914a	AML-SG	26	Female	AML	Favorable		5	0	89.1	4.6	26	25	92	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD10915a	AML-SG	52	Male	AML	Adverse		2.36	1	0.8	7.5	27			Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD10916a	AML-SG	44	Male	AML	Adverse		5.11	0	10.7	7.9	234	94	75	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD10917a	AML-SG	51	Female	AML	Favorable		3.2	0	10	11.5	22	73	58	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD10918a	AML-SG	55	Male	AML	Favorable		1.41	1	97.2	8.1	73	93	89	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD10919a	AML-SG	41	Male	AML	Adverse		0.53	0	93.2	7.5	25	100	96	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD10920a	AML-SG	30	Male	AML	Favorable		3.9	1	5.9	7	20	30		Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD10921a	AML-SG	51	Male	AML	Favorable		5.11	0	33.7	9.1	43	68	80	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD10923a	AML-SG	54	Male	AML	Intermediate		5.06	0	19.6	9.1	32	60	28	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD10924a	AML-SG	49	Female	AML	Favorable		4.18	0	55.5	8.9	133	80		Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD10925a	AML-SG	54	Female	AML	Favorable		4.61	0	36.2	8.2	30	90	39	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD10926a	AML-SG	38	Female	AML	Adverse		0.81	1	98.9	12.3	63	95	80	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD10927a	AML-SG	28	Female	AML	Adverse		1.69	1	145.7	8.5	518	88	84	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD10928a	AML-SG	55	Male	AML	Adverse		4.27	0	3.1	10.4	87	20	0	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD10929a	AML-SG	38	Female	AML	Adverse		4.92	0	2.4	10.5	71	34	8	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD10930a	AML-SG	60	Female	AML	Favorable		4.52	0	3.6	8	312	90		Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD10931a	AML-SG	60	Male	AML	Adverse		0.35	1	3.9	10.2	87	40	4	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD10933a	AML-SG	49	Female	AML	Adverse		3.87	0	20.3	7.9	71	94	72	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD10934a	AML-SG	43	Female	AML	Favorable		4.39	0	1.2	7.5	46	65	46	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD10935a	AML-SG	45	Female	oAML	Intermediate		0.54	1	15.6	7.8	145	85	7	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD10936a	AML-SG	20	Female	sAML	Intermediate		4.81	0	10.4	11.4	41	29	1	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD10937a	AML-SG	53	Male	AML	Adverse		4.58	0	1.4	9.4	231	97	11	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD10938a	AML-SG	24	Female	AML	Intermediate		3.75	0	24.7	8.2	29	60	51	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD10939a	AML-SG	55	Male	AML	Favorable		4.81	0	2.3	7.5	11	90	52	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD10940a	AML-SG	45	Male	AML	Favorable		2.61	1	7.6	8.7	22	90	77	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD10941a	AML-SG	44	Female	AML	Intermediate		3.94	0	1.2	8.9	119	43	0	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD10942a	AML-SG	44	Male	AML	Favorable		3.2	0	4.8	8.6	16	80	49	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD10943a	AML-SG	57	Male	AML	Favorable		0.08	1	106.8	7.5	35	80	87	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD10944a	AML-SG	53	Female	AML	Intermediate		4.5	0	3.2	8.9	137	90	5	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD10945a	AML-SG	46	Female	AML	Favorable		3.68	0	2.9	7.7	23	90	8	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD10946a	AML-SG	46	Female	AML	Adverse		4.07	0	19.5	8.7	23	42	10	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD10947a	AML-SG	47	Female	AML	Intermediate		0.97	1	39.5	10.2	53	80	29	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD10948a	AML-SG	43	Male	AML	Adverse		0.46	1	46	13.2	72	86	30	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD10949a	AML-SG	60	Male	sAML	Adverse		1.85	1	4.7	8.8	30	20	14	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD10950a	AML-SG	46	Male	AML	Favorable		0.1	0	83.9	9.1	43	85	54	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD10951a	AML-SG	26	Male	AML	Intermediate		0.06	1	109	7.7	76	89	63	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD10952a	AML-SG	59	Male	AML	Adverse		3.91	0	4.3	10.5	84	20	4	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD10953a	AML-SG	23	Female	AML	Favorable		4.71	0	1.1	7.8	43	52	20	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD10954a	AML-SG	52	Male	AML	Favorable		3.99	0	39.8	7.4	58	90	0	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD10956a	AML-SG	60	Male	AML	Adverse		0.94	0	17	6.1	5	80	74	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD10957a	AML-SG	52	Male	AML	Favorable		3.87	0	187.5	10.4	31	96	98	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD10958a	AML-SG	40	Female	AML	Adverse		4.45	0	190.1	11.1	94	80	7	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD10959a	AML-SG	29	Female	AML	Favorable		2.05	0						Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD10960a	AML-SG	54	Female	tAML	Favorable		0.19	1	13.1	10	28	80	72	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD10961a	AML-SG	43	Female	AML	Intermediate		1.64	1	18.1	7.9	57	82	86	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD10962a	AML-SG	59	Female	AML	Intermediate		3.62	0	1.8	10.6	123			Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD10963a	AML-SG	54	Female	sAML	Adverse		0.15	1	34.3	9.6	28	20	0	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD10964a	AML-SG	54	Female	AML	Favorable		0.5	1	14.2	9.8	45	95	16	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD10965a	AML-SG	33	Female	AML	Intermediate		4.64	0	21.8	7.9	87	84	24	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD10966a	AML-SG	45	Male	AML	Favorable		4.4	0	83.7	8.7	55	90	6	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD10967a	AML-SG	44	Female	AML	Favorable		3.65	0	24.9	7.3	119	90	69	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD10969a	AML-SG	46	Female	AML	Adverse		0.86	1	53.5	8.9	34	95	78	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD10970a	AML-SG	52	Male	AML	Favorable		3.7	0	43.7	8.8	69	84	80	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD10971a	AML-SG	60	Female	AML	Favorable		0.28	1	78.6	8.7	59	39	2	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD10972a	AML-SG	19	Male	AML	Intermediate		3.47	0	150.8	6.1	43	90	89	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD10973a	AML-SG	57	Female	AML	Favorable		0.94	1	122.4	9.1	103	94	36	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD10974a	AML-SG	59	Male	AML	Adverse		1.8	1	3.2	10	74	24	2	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD10975a	AML-SG	31	Female	AML	Favorable		0.74	1	54.2	10.1	60	90	58	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD10976a	AML-SG	58	Male	AML	Adverse		3.6	0	8.9	8.9	265	80	2	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD10977a	AML-SG	42	Female	AML	Favorable		3.01	1	15.7	8.8	108	75	14	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD10978a	AML-SG	44	Female	AML	Favorable		4.67	0	1.5	9.5	92	30	0	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD10979a	AML-SG	20	Male	AML	Intermediate		4.72	0	0.9	6.9	39	88	0	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD10980a	AML-SG	33	Male	AML	Favorable		3.13	0	10.1	11.6	61	90	22	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD10981a	AML-SG	55	Female	AML	Adverse		3.41	0	84.9	12.7	28	90	91	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD10982a	AML-SG	58	Female	tAML	Adverse		0.06	1	5.1	7.2	27	90	2	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD10983a	AML-SG	59	Male	AML	Intermediate		2.45	1	1.9	10.6	348	50	0	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD10984a	AML-SG	56	Female	AML	Favorable		1.81	0	58.3	9.4	35	90	12	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD10985a	AML-SG	61	Female	AML	Intermediate		0.12	1	0.9	9.9	20	25	4	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD10986a	AML-SG	62	Male	AML	Intermediate		3	1	0.4	10.3	27	100	2	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD10987a	AML-SG	70	Male	AML	Adverse		1.14	1	35.14	7.7	77	75	52	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD10988a	AML-SG	69	Male	AML	Favorable		1.42	1	5	11.5	196	95	69	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD10989a	AML-SG	48	Male	AML	Adverse		0.27	1	28.7	8.6	114	75	74	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD10990a	AML-SG	56	Male	AML	Adverse		0.66	1	2.8	9.8	132	42	30	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD10991a	AML-SG	56	Male	AML	Favorable		3.41	0	7.7	11.1	23	88	38	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD10992a	AML-SG	57	Female	AML	Intermediate		0.21	1				54		Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD10993a	AML-SG	44	Female	AML	Favorable		3.56	0	13	9.5	169	90	22	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD10994a	AML-SG	34	Female	AML	Adverse		0.71	1	107	9.5	22	80	77	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD10995a	AML-SG	43	Male	AML	Favorable		2.31	0	95.6	7.9	80	50	68	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD10996a	AML-SG	54	Male	AML	Adverse		1.04	1	51.2	6.7	49	20	1	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD10997a	AML-SG	60	Male	AML	Favorable		0.06	1	3.4	9.8	128	70	53	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD10998a	AML-SG	27	Male	AML	Favorable		4.38	0	294.9	11	380	71	84	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD10999a	AML-SG	50	Female	AML	Favorable		3.61	0	1.6	7.9	251	60	4	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11001a	AML-SG	51	Male	AML	Favorable		2.45	0	61	7.1	37	66	82	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11002a	AML-SG	40	Female	AML	Favorable		0.06	1	1.4	11.5	148	40	5	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11003a	AML-SG	39	Male	AML	Intermediate		4.15	0	16.1	9.4	37	70	56	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11004a	AML-SG	60	Male	AML	Intermediate		3.2	0	1.7	9.4	125	85	20	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11005a	AML-SG	44	Male	AML	Favorable		3.55	0	46	6.3	26	89	0	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11006a	AML-SG	22	Male	AML	Adverse		1.72	0	86.7	6.9	56	80		Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD11007a	AML-SG	60	Male	AML	Intermediate		1.06	1	2.2	7.3	78	40	8	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11008a	AML-SG	51	Female	sAML	Adverse		4.08	0	1.9	6.9	38	81	46	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11009a	AML-SG	20	Female	AML	Intermediate		4.16	0	12.5	6.5	120	60		Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11010a	AML-SG	42	Female	AML	Favorable		4.53	0	19.9	9.7	173	40	59	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11011a	AML-SG	32	Male	AML	Adverse		4.42	0	5.8	5.7	84	95	51	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11012a	AML-SG	50	Male	AML	Adverse		0.43	1	16.1	7.7	64	75	36	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD11013a	AML-SG	51	Male	AML	Adverse		0.85	1	71	7	25	82	44	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11014a	AML-SG	55	Female	AML	Intermediate		4.33	0	0.9	7.3	91	65		Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11015a	AML-SG	59	Male	AML	Adverse		1.46	1	1.9	8	31	14	27	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD11016a	AML-SG	42	Male	AML	Intermediate		3.34	0	141	10.1	17	80		Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11017a	AML-SG	43	Male	AML	Adverse		1.93	1	7.2	7.7	21	61	21	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11018a	AML-SG	30	Male	AML	Intermediate		3.66	0	88	6.9	38	66	56	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11019a	AML-SG	60	Male	AML	Intermediate		0.16	1	13	10.7	45	50	17	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11020a	AML-SG	56	Female	AML	Adverse		0.67	1	8.8	6.7	27	80	73	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD11021a	AML-SG	44	Male	AML	Favorable		4.1	0	5	7.8	71	90	23	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11022a	AML-SG	19	Female	tAML	Adverse		3.09	0	8.1	9.8	68	20	11	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11024a	AML-SG	60	Male	AML	Intermediate		4.36	0	59.8	6.1	14	98	25	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11025a	AML-SG	58	Female	AML	Adverse		3.44	0	17.5	8	117	56	89	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11026a	AML-SG	59	Male	AML	Intermediate		0.63	1	7.1	11.3	72	35	10	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11027a	AML-SG	56	Male	oAML	Adverse		0.22	1	303	10	19	50	0	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11028a	AML-SG	40	Male	AML	Intermediate		1.41	1	2.3	10.6	67	75	0	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11029a	AML-SG	37	Female	AML	Favorable		0.98	1	5.6	4.7	192	70		Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11030a	AML-SG	48	Male	AML	Adverse		0.79	1	1	7.8	20	26	0	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD11031a	AML-SG	50	Male	AML	Adverse		0.32	1	5.1	9	575	70	35	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD11032a	AML-SG	51	Female	AML	Adverse		1.72	1	2.5	9.1	53	50	31	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11033a	AML-SG	55	Female	AML	Favorable		3.98	0				36	13	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11034a	AML-SG	54	Male	AML	Adverse		2.2	1	4.8	12	138	40	0	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD11035a	AML-SG	50	Female	oAML	Adverse		4.22	0	2	8	93	54	60	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11036a	AML-SG	50	Female	AML	Favorable		3.76	0	21.9	7.9	26		11	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11037a	AML-SG	30	Male	AML	Favorable		3.78	0	2.9	9.2	211	90	0	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11038a	AML-SG	42	Female	AML	Favorable		4.22	0	13.5	9.1	26	10	8	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11039a	AML-SG	24	Male	AML	Intermediate		2	1	3.9	11.6	216	0	0	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11040a	AML-SG	55	Male	AML	Adverse		0.48	1	2.5	11.4	29	90	0	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11041a	AML-SG	45	Male	AML	Intermediate		3.75	0	17.3	5.8	43	90	39	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11042a	AML-SG	51	Male	AML	Adverse		4.37	0	0.5	11.1	49	42	24	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11043a	AML-SG	59	Male	AML	Intermediate		2.05	1	126.5	12.2	96	52	3	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11044a	AML-SG	47	Female	tAML	Adverse		0.74	1	1.5	6.8	86	50	16	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD11045a	AML-SG	47	Female	AML	Intermediate		3.12	0	28.7	10.5	70	90	53	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11046a	AML-SG	50	Female	sAML	Adverse		2.81	1	12.6	12	57	80	59	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11047a	AML-SG	44	Male	tAML	Favorable		3.93	0	0.8	11	54	89	4	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11048a	AML-SG	46	Male	AML	Favorable		0.87	0	118.4	9.4	31	87	97	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11049a	AML-SG	39	Male	AML	Intermediate		0.96	1	7.8	16	394	76	50	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11050a	AML-SG	37	Male	AML	Favorable		3.43	0	13	10	46	50	50	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11051a	AML-SG	38	Female	AML	Favorable		3.01	0	15.1	6.6	22	20	12	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11052a	AML-SG	61	Female	AML	Intermediate		3.83	0	96.6	10.1	26	95		Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11053a	AML-SG	42	Female	AML	Favorable		3.2	0	98.4	9.1	17	90	97	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11054a	AML-SG	60	Male	AML	Favorable		0.38	1	42.3	8.4	47	80	24	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11055a	AML-SG	39	Male	tAML	Favorable		4.02	0	1.2	8.5	34	44	50	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11056a	AML-SG	60	Female	AML	Adverse		0.1	1	24.8	9	30	40	17	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD11057a	AML-SG	59	Male	AML	Favorable		2.98	0	5.2	10.6	352	50	9	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11058a	AML-SG	57	Male	AML	Favorable		1.01	1	19	9.2	14	90	49	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11059a	AML-SG	21	Male	AML	Favorable		1.26	1	10.9	9.6	78	80	58	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11060a	AML-SG	51	Male	sAML	Adverse		4.11	0	2.1	12.9	5	55	0	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11061a	AML-SG	20	Female	AML	Intermediate		3.98	0	6.4	11	177	75	2	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11062a	AML-SG	27	Male	AML	Adverse		1.56	1	68.1	9.7	69	80	35	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11063a	AML-SG	37	Female	AML	Favorable		1.08	1	23	10.8	129	80	88	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11064a	AML-SG	61	Male	AML	Adverse		1.87	0	54.9	11.7	190	95	63	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11065a	AML-SG	57	Female	sAML	Adverse		0.19	1	6.2	8.3	78	40	37	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11066a	AML-SG	20	Female	AML	Adverse		1.71	1	1.7	9.5	82	50	0	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD11067a	AML-SG	34	Female	AML	Intermediate		0.53	1	49.9	8	37	90	46	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11068a	AML-SG	48	Male	AML	Adverse		0.55	1	4.5	9	56		3	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD11069a	AML-SG	31	Female	AML	Adverse		2.09	1	1.2	9.6	149	90	21	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD11070a	AML-SG	37	Female	AML	Favorable		3.02	0	32	7.7	54	75	11	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11071a	AML-SG	42	Male	AML	Favorable		3.09	0	9.4	9.3	53		16	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11072a	AML-SG	57	Female	AML	Favorable		1.24	1	55.9	7.7	77		18	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11073a	AML-SG	48	Male	AML	Favorable		2.3	1	1.4	11	30	94	87	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11074a	AML-SG	39	Female	AML	Intermediate		3.99	0	4.9	5.4	26	80	82	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11075a	AML-SG	44	Female	AML	Adverse		2.23	1	1.7	13.3	88	70		Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD11076a	AML-SG	43	Male	AML	Adverse		3.84	0	62.7	12.4	133	80	88	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11077a	AML-SG	48	Female	AML	Favorable		3.99	0	44	10.7	20			Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11078a	AML-SG	19	Male	AML	Favorable		4.04	0	10.2	6.7	10	65	50	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11079a	AML-SG	56	Female	AML	Intermediate		3.66	0	6.2	6.4	24	25		Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11080a	AML-SG	32	Female	AML	Adverse		3.56	0	1.2	8.9	46	23		Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11081a	AML-SG	41	Male	AML	Adverse		2.4	1	26.7	10.5	209	63	11	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11082a	AML-SG	31	Female	AML	Favorable		3.29	0	9.7	4.6	5	99	99	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11083a	AML-SG	51	Female	AML	Adverse		4.02	0	65.9	10.6	17	47	4	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11084a	AML-SG	57	Male	AML	Adverse		0.1	1	1.7	9.8	34	55	0	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11085a	AML-SG	66	Male	AML	Adverse		0.05	1	7.7	6.4	23	80	70	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD11086a	AML-SG	69	Female	AML	Adverse		0.08	1	3.85	9.6	25		3	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11087a	AML-SG	61	Male	AML	Intermediate		0.19	1	110	8.8	29	72	99	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11088a	AML-SG	61	Male	AML	Adverse		2.7	1	0.5	7.5	72	25	3	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11089a	AML-SG	29	Female	AML	Adverse		1.02	1	4.8	4.9	12	22	18	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11090a	AML-SG	53	Male	AML	Favorable		3.66	0	5.1	11.3	81	35	38	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11091a	AML-SG	33	Male	AML	Favorable		0.43	0	84.1	8.7	54	60	50	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11092a	AML-SG	21	Male	AML	Favorable		2.86	0	90.9	5.2	18	80	73	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11093a	AML-SG	46	Female	AML	Favorable		3.04	0	35.9	9.1	85	82	80	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11094a	AML-SG	59	Male	AML	Adverse		0.05	1	66.1	8.3	136	77	6	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11095a	AML-SG	60	Male	AML	Favorable		1.66	0	70.6	11.5	58	90	5	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11096a	AML-SG	47	Female	AML	Adverse		3.79	0	126.3	10.8	72	80	95	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11097a	AML-SG	33	Male	AML	Adverse		0.79	1	39	7.2	52	80		Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11098a	AML-SG	49	Male	AML	Intermediate		1.24	1	17.9	7.3	60	100	22	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11099a	AML-SG	52	Female	AML	Adverse		3.52	0	4.6	8.3	24	50	3	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11100a	AML-SG	54	Female	AML	Favorable		3.56	0	6.1	10	307	25	1	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11101a	AML-SG	55	Male	AML	Favorable		2.82	0	1.3	12.9	115	70	0	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11102a	AML-SG	59	Male	tAML	Adverse		0.76	1	2.5	9	36		38	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD11103a	AML-SG	61	Female	AML	Intermediate		2.62	1	14.9	12.2	29	95	52	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11104a	AML-SG	29	Female	AML	Favorable		3.63	0	13.5	8.3	28	80	76	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11105a	AML-SG	56	Male	AML	Intermediate		0.64	1	2.7	11.2	294	65	5	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11106a	AML-SG	36	Female	AML	Adverse		0.48	1	159.6	9.1	32	57	75	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11107a	AML-SG	52	Female	AML	Adverse		3.63	0	9.2	10.8	39	80	73	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11108a	AML-SG	50	Female	AML	Favorable		3.62	0	41.7	9.9	125	60	51	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11109a	AML-SG	60	Male	AML	Favorable		3.46	0	76.7	6.9	63	90	72	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11110a	AML-SG	41	Male	AML	Intermediate		0.89	1	1.4	9.4	184	98	0	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11111a	AML-SG	45	Female	AML	Intermediate		1.38	1	52.1	6.3	107	60	46	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11112a	AML-SG	46	Male	AML	Favorable		3.54	0	11.2	8.2	48	50	37	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11113a	AML-SG	60	Male	AML	Favorable		3.49	0	21.5	8.1	81	90	4	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11114a	AML-SG	39	Female	AML	Intermediate		3.6	0	3.2	9.7	187	80	13	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11115a	AML-SG	32	Male	AML	Favorable		3.78	0	59.2	3.8	28	95	30	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11116a	AML-SG	70	Male	AML	Adverse		1.32	1	3.12	7.5	39.6	25	16	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11117a	AML-SG	69	Male	AML	Favorable		3.96	1	1.23	9.6	192	90	6	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11118a	AML-SG	67	Female	AML	Intermediate		1.4	1	5.17	7.1	164	50	22	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11119a	AML-SG	63	Male	AML	Adverse		1.04	1	69	7	28	95	73	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11120a	AML-SG	73	Female	AML	Intermediate		1.09	1	30.66	7.5	67	80	33	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11122a	AML-SG	68	Male	AML	Favorable		14.37	1	17.7	7.2	47	86	69	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11123a	AML-SG	60	Male	sAML	Adverse		0.85	1	5.5	8.3	11	29	32.7	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD11124a	AML-SG	73	Male	AML	Adverse		0.96	1	17	9.5	109	75	9	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11125a	AML-SG	79	Female	AML	Favorable		0.53	1	68	10.7	98	80	86	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11127a	AML-SG	66	Male	AML	Adverse		0.08	1	33.02	8.8	123	59	21	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD11128a	AML-SG	63	Male	AML	Adverse		1.06	1	6.48	7.7	134	60	35	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11129a	AML-SG	65	Male	oAML	Adverse		0.25	1	37.5	8.1	40	95	76	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11130a	AML-SG	63	Male	AML	Intermediate		3.33	1	2.3	10.6	50	35	7	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11131a	AML-SG	69	Female	AML	Intermediate		2.02	1	1.46	11.5	165	90	21	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11132a	AML-SG	62	Female	oAML	Favorable		0.13	1	0.67	9.7	12	33		Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11133a	AML-SG	62	Female	AML	Favorable		8.89	0	7.22	7.7	32		69	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11134a	AML-SG	62	Male	AML	Adverse		0.28	1	2.06	8.7	41	40	12	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11135a	AML-SG	75	Male	AML	Adverse		1.07	1	7	8.2	12	27	22.9	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD11136a	AML-SG	61	Female	tAML	Adverse		0.99	1	26.8	8.1	84	20	23	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11137a	AML-SG	65	Male	AML	Adverse		0.13	1	9.1	5.6	135	95	76	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD11138a	AML-SG	69	Male	AML	Adverse		0.41	1	2.3	6.6	139	80	35	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11139a	AML-SG	66	Male	AML	Adverse		1.17	1	6.2	7.1	234		22	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD11140a	AML-SG	62	Male	AML	Intermediate		0.31	1	1.6	9.1	131	50	16	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11141a	AML-SG	68	Female	AML	Favorable		2.99	1	19	8.6	13	73	21	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11143a	AML-SG	78	Female	AML	Adverse		0.37	1	6.7	10.5	6	40	6	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD11144a	AML-SG	60	Female	AML	Adverse		1.5	1	1.37	9.1	17	50		Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11145a	AML-SG	64	Male	AML	Adverse		0.49	1	19.8	7.5	47	70	11	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD11146a	AML-SG	61	Male	sAML	Adverse		0.27	1	0.98	8.7	32	15		Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11147a	AML-SG	63	Male	AML	Adverse		1.34	1	112	11.8	22	90	66	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11148a	AML-SG	61	Male	AML	Favorable		0.07	1	17.4	6.6	64	80	25	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11149a	AML-SG	66	Male	AML	Intermediate		2.88	1	2.1	9.6	21	40	3	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11150a	AML-SG	73	Female	tAML	Favorable		0.23	1	81	12.4	68	80	87	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11151a	AML-SG	63	Female	AML	Adverse		0.91	1	8.1	10.7	36		31	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11152a	AML-SG	67	Male	AML	Adverse		0.8	1	3.3	6.1	16	30	10	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD11153a	AML-SG	69	Male	AML	Adverse		3.39	1	91.1	13.6	123	70		Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11154a	AML-SG	71	Female	AML	Adverse		0.31	1	12.2	10.7	89		23	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD11155a	AML-SG	72	Male	AML	Favorable		0.38	1	5.83	9.9	35	60	24	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11156a	AML-SG	63	Female	AML	Adverse		0.03	1	116	7.2	44		66	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD11158a	AML-SG	67	Male	AML	Favorable		14.2	0	0.6	9.3	18	30		Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11159a	AML-SG	61	Female	AML	Favorable		8.17	0	72.3	11	151	100	29	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11160a	AML-SG	64	Female	tAML	Adverse		0.45	1	3.65	10.8	57	32	4	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD11161a	AML-SG	73	Male	AML	Intermediate		4.49	1	1.4	9.4	30	82.5	0	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11162a	AML-SG	67	Male	AML	Favorable		0.35	1	158	7.8	133	90		Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11163a	AML-SG	61	Female	AML	Adverse		0.93	1	1.2	8.8	204	73	42	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11164a	AML-SG	67	Male	AML	Intermediate		0.26	1	56.3	6	95	85	16	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11165a	AML-SG	77	Female	AML	Favorable		1.85	1	4.7	12	130	55	41	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11166a	AML-SG	65	Female	AML	Intermediate		1.59	1	1.31	11.4	200	70		Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11167a	AML-SG	63	Female	AML	Intermediate		5.95	0	9.5	5	28		24	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11168a	AML-SG	73	Male	AML	Adverse		0.07	1	1.95	11.3	66	70		Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD11169a	AML-SG	79	Male	AML	Adverse		0.08	1	17.6	7.7	17	90	90	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11170a	AML-SG	61	Female	AML	Intermediate		2.66	1	30	10.3	86	44	42.6	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11171a	AML-SG	71	Female	AML	Intermediate		0.31	1	93.4	9.1	58	91	86	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11172a	AML-SG	65	Male	AML	Favorable		12.42	0	39.1	8.6	69	34	43	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11174a	AML-SG	73	Male	oAML	Favorable		0.19	1	158	12.4	86	97		Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11176a	AML-SG	63	Male	AML	Favorable		1.59	1	85.6	11.3	30	94.5	92	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11177a	AML-SG	71	Male	AML	Intermediate		0.06	1	1.17	9	33			Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11178a	AML-SG	74	Male	AML	Adverse		0.07	1	52.3	9.3	13	60	86	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11179a	AML-SG	73	Female	AML	Intermediate		0.07	1	1.1	11.5	82	23	23	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11181a	AML-SG	73	Male	sAML	Adverse		0.84	1	1.6	10	43	40	1	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11182a	AML-SG	75	Female	AML	Intermediate		7.66	0	0.5	8.7	74			Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11183a	AML-SG	65	Male	AML	Adverse		1.4	1	2.4	8.2	11	30	22	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11184a	AML-SG	61	Male	AML	Intermediate		0.59	1	18.3	6.9	100	92.5	19	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11185a	AML-SG	66	Male	AML	Favorable		0.84	1	19.8	9.1	35	51	69	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11186a	AML-SG	63	Female	AML	Favorable		4.86	0	2.3	11	109	66	15	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11187a	AML-SG	71	Male	AML	Favorable		0.17	1	5.7	6.9	132	35	17	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11189a	AML-SG	68	Female	AML	Intermediate		2.2	1	12.6	11.8	129	85	20	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11190a	AML-SG	65	Female	AML	Favorable		1.57	1	34.2	8.9	137		35	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11191a	AML-SG	58	Male	AML	Intermediate		4.57	1	1.4	7.1	20	80		Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11192a	AML-SG	72	Female	AML	Favorable		0.08	1	49.7	7.1	28	76	63	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11193a	AML-SG	65	Male	sAML	Intermediate		1.2	1	1.2	8.8	75		18	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11195a	AML-SG	60	Female	AML	Favorable		9.94	0	12.9	6.3	119	90	29	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11196a	AML-SG	68	Male	AML	Favorable		1.71	1	29.6	10.2	24	50	35	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11197a	AML-SG	65	Male	AML	Adverse		0.01	1	89.8	10.3	55	89	82	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11198a	AML-SG	71	Male	AML	Intermediate		0.29	1	7.4	8.6	44	90	0	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11199a	AML-SG	64	Female	AML	Adverse		4.13	1	7.1	9.4	64	90	15	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11200a	AML-SG	62	Male	AML	Adverse		0.21	1	2.34	11.3	72	28	13	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD11201a	AML-SG	72	Female	AML	Favorable		6.08	0	1.5	12.2	164	39		Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11202a	AML-SG	65	Female	tAML	Favorable		2.32	1	1.4	8.1	65	30		Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11203a	AML-SG	69	Male	AML	Intermediate		0.08	1	64.6	10.2	19	91	97	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11204a	AML-SG	63	Male	AML	Adverse		0.56	1	54	9.7	54	80	74	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11205a	AML-SG	62	Female	AML	Adverse		5.71	0	0.87	11	161	40		Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11206a	AML-SG	62	Female	AML	Favorable		7.42	0	61.68	9.6	41	80	81	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11207a	AML-SG	67	Male	sAML	Intermediate		0.08	1	1.5	9.1	42	30	6	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11208a	AML-SG	65	Male	AML	Adverse		7.26	0	31.9	9.8	32	100	78	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11209a	AML-SG	75	Male	AML	Adverse		0.94	1	73.2	11.8	120	72	9	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11210a	AML-SG	70	Female	AML	Adverse		0.89	1	34	11.6	38	80	31	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11211a	AML-SG	62	Female	sAML	Intermediate		0.9	1	16	8	114	70		Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11212a	AML-SG	70	Female	AML	Favorable		2.12	1	61.78	9.4	6	85	67	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11213a	AML-SG	63	Male	AML	Adverse		0.43	1	5	7.1	12	60	2	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD11214a	AML-SG	71	Male	AML	Favorable		1.48	1	5.4	7.2	19	85	3	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11215a	AML-SG	61	Male	AML	Adverse		0.64	1	1.2	6.7	11	60		Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD11216a	AML-SG	75	Female	tAML	Intermediate		0.31	1	7.7	10	77	50	40	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11217a	AML-SG	63	Female	AML	Favorable		0.6	1	41.5	8	75	59	54	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11218a	AML-SG	69	Female	AML	Favorable		0.22	1	157.5	8.5	37	90	96	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11219a	AML-SG	63	Female	AML	Intermediate		0.77	1	91.5	8.8	120	70	10	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11221a	AML-SG	73	Male	AML	Favorable		0.11	1	1.2	9.6	7	90	38	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11222a	AML-SG	65	Male	AML	Adverse		2.06	1	2.5	11.2	96	35		Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11223a	AML-SG	65	Male	AML	Adverse		0.1	1	1.6	10.7	257	83	2	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD11224a	AML-SG	61	Male	AML	Adverse		1.11	1	78	12	126	89	82	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11225a	AML-SG	63	Female	AML	Intermediate		10.13	0	1.8	10.3	156	80	1	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11226a	AML-SG	74	Female	oAML	Adverse		0.97	1	21.2	10.8	111	91	43	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11227a	AML-SG	72	Male	AML	Adverse		0.1	1	3.5	6.8	137	90	45	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD11228a	AML-SG	84	Female	AML	Intermediate		1.44	1	1.1	9.4	13	52	0	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11229a	AML-SG	67	Female	AML	Adverse		1.87	1	31.7	7.7	39		91	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11230a	AML-SG	78	Male	AML	Adverse		0.19	1	100.4	11.5	107	30	31	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11231a	AML-SG	73	Male	AML	Favorable		0.08	1	57.5	9	39	90	57	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11232a	AML-SG	61	Female	AML	Adverse		1.73	1	103	9.4	143		97	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11233a	AML-SG	77	Female	AML	Favorable		0.04	1	149	11	20	90	95	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11234a	AML-SG	62	Female	AML	Intermediate		0.5	1	0.7	9.9	101	80		Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11235a	AML-SG	69	Male	sAML	Intermediate		1.4	1	78	7.7	93	70	65	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11236a	AML-SG	62	Male	tAML	Intermediate		0.65	1	1.6	9.3	20	70	5	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11237a	AML-SG	68	Male	AML	Intermediate		1.44	1	1.4	14.1	100	38.5		Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11238a	AML-SG	73	Female	AML	Adverse		0.53	1	0.8	9	54	81		Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11239a	AML-SG	62	Male	AML	Intermediate		2.23	1	15.6	7.5	42	95	62	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11240a	AML-SG	69	Female	AML	Favorable		5.58	0	12.7	7.8	42	90	54	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11241a	AML-SG	72	Male	oAML	Adverse		3.47	1	1.3	6.8	111	50	8	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD11242a	AML-SG	66	Male	oAML	Adverse		2.58	1	3.3	9.6	362	75		Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11243a	AML-SG	68	Female	AML	Favorable		5.11	0	35.3	9.1	76		13	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11244a	AML-SG	69	Female	AML	Favorable		0.7	1	190.4	10.7	53	100	100	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11245a	AML-SG	80	Female	AML	Favorable		0.59	1	84.3	9.2	83	90	45	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11246a	AML-SG	73	Male	sAML	Adverse		0.15	1	24.5	9.9	28	30	64	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11247a	AML-SG	76	Male	AML	Adverse		0.09	1	2.4	13.9	166	60	20	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD11248a	AML-SG	61	Female	AML	Favorable		3.48	1	7.9	10.3	18	80	53	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11249a	AML-SG	60	Female	AML	Adverse		0.19	1	25.2	10.6	55	80	80	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11250a	AML-SG	72	Male	AML	Favorable		0.3	1	303	11.4	32	95	96	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11251a	AML-SG	65	Female	AML	Adverse		0.84	1	42.9	6.9	123	100	100	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11252a	AML-SG	67	Male	oAML	Intermediate		6.84	0	1	7.9	105		4	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11253a	AML-SG	70	Female	AML	Adverse		1.6	1	1	10.8	47	80	11	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD11254a	AML-SG	68	Female	AML	Favorable		1.43	1	52.1	9.9	115	65	79	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11255a	AML-SG	64	Male	AML	Adverse		2.35	1	5.1	8.5	75	15	0	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11256a	AML-SG	67	Female	AML	Adverse		0.34	1	10.6	9	68	90	38	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11257a	AML-SG	74	Male	AML	Adverse		0.06	1	2.1	7.9	80	55	8	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11258a	AML-SG	74	Male	AML	Intermediate		0.87	1	1.3	7.7	24			Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11259a	AML-SG	70	Male	AML	Adverse		1.06	1	5.2	7.5	16	50	10	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11260a	AML-SG	66	Female	AML	Adverse		0.19	1	11	7	28	68	17	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11261a	AML-SG	63	Male	AML	Favorable		1.33	1	224	7.6	99	80	96	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11263a	AML-SG	72	Male	AML	Intermediate		0.32	1	133	9.3	41	31	13	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11265a	AML-SG	62	Female	AML	Favorable		6.27	0	1	9.8	157		6	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11266a	AML-SG	62	Male	AML	Intermediate		1.19	1	1.6	10.3	445	50		Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11267a	AML-SG	65	Male	AML	Intermediate		1.62	1	1.5	10.7	37	30		Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11268a	AML-SG	70	Male	AML	Adverse		0.6	1	2.39	10.9	130	50	50	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11269a	AML-SG	64	Female	AML	Intermediate		1.46	1	5.4	9.4	85	59	38	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11270a	AML-SG	65	Male	sAML	Intermediate		2.4	1	0.8	10.2	32	31		Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11271a	AML-SG	65	Male	AML	Adverse		0.82	1	33.4	9.4	66	75	69	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD11272a	AML-SG	66	Female	AML	Intermediate		1.73	1	1.09	10.1	74	25		Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11273a	AML-SG	64	Female	AML	Intermediate		1.36	1	1.4	10.1	239	30	10	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11274a	AML-SG	68	Female	AML	Favorable		12.6	0	0.5	8.3	10	70		Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11275a	AML-SG	65	Female	AML	Intermediate		0.71	1	74	8.9	42	80	89	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11276a	AML-SG	65	Male	AML	Intermediate		1.58	1	3.9	10	16	60	36	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11277a	AML-SG	65	Male	AML	Adverse		1.26	1	5.9	4.7	28	29		Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD11278a	AML-SG	65	Female	AML	Adverse		2.64	1	2.1	12.8	246	70		Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11279a	AML-SG	60	Female	tAML	Intermediate		0.93	1	105.4	8.9	197	90	0	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11280a	AML-SG	72	Male	oAML	Favorable		0.09	1	61.1	9.9	217	70	80	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11281a	AML-SG	62	Female	AML	Intermediate		1.04	1	134	7.9	17	50	33	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11282a	AML-SG	66	Male	AML	Adverse		1.47	1	162	10	38	80	44	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11283a	AML-SG	63	Male	AML	Adverse		0.34	1	1.6	10	35	80	20	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11284a	AML-SG	75	Male	oAML	Intermediate		1.11	1	11.1	11.5	27	80	83	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11285a	AML-SG	68	Female	AML	Adverse		1.75	1	2.56	9.1	275	80		Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD11286a	AML-SG	71	Male	AML	Favorable		1.49	1	1.8	9.2	118		9	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11287a	AML-SG	69	Male	AML	Adverse		0.65	1	69.7	9.6	101	70	36	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD11288a	AML-SG	64	Male	AML	Adverse		0.17	1	10.7	10	220	70	66	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD7607a	AML-SG	38	Female	AML	Favorable		3.49	0	2.7	11.89999962	90	44	21	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7610a	AML-SG	47	Female	tAML	Favorable		11.81	0	58	7.099999905	11	90	6	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7611a	AML-SG	32	Male	AML	Favorable		4.55	0	77.6	11.5	61	81	74	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7612a	AML-SG	33	Female	AML	Favorable		6.87	0	10.8	7.300000191	126	40	20	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7613a	AML-SG	56	Male	AML	Intermediate		4.95	1	2.6	8.800000191	88	10	1	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7614a	AML-SG	34	Male	AML	Favorable		5.32	0	11.5	11.80000019	19	0	2	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7615a	AML-SG	19	Male	AML	Favorable		10.89	0	8.9	10.69999981	29	90	70	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7617a	AML-SG	34	Female	AML	Intermediate		11.66	0	4	7.599999905	13	96	34	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7618a	AML-SG	35	Male	AML	Favorable		4.76	0	36.1	7.199999809	48	95	86	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7619a	AML-SG	35	Male	AML	Favorable		11.34	0	69.9	11.69999981	11	91	90	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7620a	AML-SG	57	Male	AML	Adverse		0.88	1	18.7	9.300000191	80	95	77	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7621a	AML-SG	56	Male	AML	Adverse		7.25	0	2.3	7.900000095	33	40	27	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7622a	AML-SG	38	Female	AML	Favorable		7.16	0	66.5	6.5	12	96	30	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7623a	AML-SG	55	Male	AML	Favorable		4.72	0	1.1	14.10000038	220	6	0	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7624a	AML-SG	34	Female	AML	Intermediate		7.41	0	3.18	10.5	32	75	8	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7625a	AML-SG	39	Female	AML	Adverse		0.59	1	14.1	10.10000038	11	88	76	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD7626a	AML-SG	34	Male	AML	Adverse		0.64	1	177.5	11.19999981	57	80	90	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7627a	AML-SG	42	Male	AML	Favorable		7.44	0	9.09	6.5	12	44	8	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7628a	AML-SG	19	Female	AML	Favorable		12.07	0	2.3	7	28	100	15	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7630a	AML-SG	23	Female	AML	Favorable		5.47	0	1.2	10.30000019	153	80	0	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7631a	AML-SG	31	Male	AML	Favorable		11.91	0	112	8.800000191	31	95	0	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7632a	AML-SG	56	Female	tAML	Intermediate		0.26	1	10.7	8	35	81		Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7633a	AML-SG	23	Male	AML	Adverse		5.34	0	13.8	10.39999962	22	25	49	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7634a	AML-SG	40	Female	AML	Adverse		7.44	0	24.75	7.699999809	234	85	60	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7635a	AML-SG	47	Male	AML	Favorable		7.21	0	0.6	8.399999619	6	23	0	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7636a	AML-SG	34	Female	AML	Favorable		1.41	1	37.8	6.5	34	50	50	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7637a	AML-SG	23	Male	tAML	Intermediate		0.06	1	81.3	9.699999809	49	85	84	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7638a	AML-SG	49	Male	tAML	Intermediate		2.92	1	1.2	11	274	80	0	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7639a	AML-SG	24	Male	AML	Intermediate		11.34	0	4.97	4.099999905	68	90	30	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7640a	AML-SG	36	Female	AML	Favorable		7.34	0	84.9	8.399999619	25	85	16	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7641a	AML-SG	52	Female	AML	Favorable		5.97	0	0.5	9.899999619	68	90		Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7642a	AML-SG	34	Male	AML	Intermediate		2.12	1	45.5	9.300000191	127	90	87	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7643a	AML-SG	43	Female	AML	Favorable		3.53	1	21.5	6.800000191	22	80	34	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7644a	AML-SG	39	Female	AML	Favorable		10.13	0	175.1	6.300000191	26	85	38	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7645a	AML-SG	35	Female	AML	Favorable		7.61	0	77.1	11.30000019	84	80	80	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7646a	AML-SG	40	Female	AML	Adverse		0.5	1	5.1	10.39999962	92	45	3	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7647a	AML-SG	51	Female	AML	Intermediate		0.76	1	1.5	8.600000381	28		16	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7648a	AML-SG	51	Female	tAML	Intermediate		12.48	0	1.8	10.19999981	62	40	40	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7650a	AML-SG	25	Male	AML	Intermediate		0.83	1	57.5	6.300000191	33	90	44	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7651a	AML-SG	50	Male	AML	Favorable		0.14	1	3.8	6.900000095	21	50	58	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7652a	AML-SG	60	Female	AML	Adverse		0.81	1	20	12	12	50	50	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7653a	AML-SG	19	Female	AML	Favorable		10.05	0	4.7	7.800000191	27		52	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7654a	AML-SG	31	Male	AML	Favorable		7.86	0	50.8	9.609999657	27.8		29	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7655a	AML-SG	53	Male	AML	Favorable		5.97	1	105.4	11	39	90	0	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7656a	AML-SG	47	Female	AML	Adverse		0.4	1	114	12.19999981	50	90	75	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7657a	AML-SG	49	Male	AML	Favorable		7.85	0	12	8.579999924	68	40	19	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7658a	AML-SG	57	Female	sAML	Intermediate		1.71	1	2.2	7.900000095	55	90	55	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7659a	AML-SG	58	Female	AML	Intermediate		1.3	1	3.39	8.399999619	28	20	2	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7660a	AML-SG	45	Male	AML	Favorable		7.79	0	17	5.400000095	42	32	25	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7661a	AML-SG	36	Male	AML	Favorable		12.36	0	1.8	8.800000191	109	30	9	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7662a	AML-SG	54	Female	AML	Adverse		0.01	1	145.4	6.900000095	73	88	18	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7663a	AML-SG	32	Female	AML	Intermediate		4.36	1	2.6	13.10000038	40	25	1	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7664a	AML-SG	50	Male	AML	Intermediate		1.39	1	9.2	9.5	72	90	27	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7665a	AML-SG	41	Male	AML	Favorable		4.94	1	30.2	7.5	39	70	78	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7666a	AML-SG	27	Male	AML	Intermediate		0.42	1	2.23	8.149999619	119	88	27	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7667a	AML-SG	51	Female	AML	Intermediate		7.6	0	22.1	11.60000038	110	30	33	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7668a	AML-SG	30	Male	AML	Intermediate		7.44	0	2.4	7.599999905	131	56	5	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7669a	AML-SG	54	Male	AML	Intermediate		3.6	1	2.6	9.800000191	27	80	36	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7670a	AML-SG	58	Male	oAML	Favorable		12.56	0	28	7.599999905	133		75	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7671a	AML-SG	47	Female	AML	Intermediate		12.33	0	0.9	8.699999809	81	56	3	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7672a	AML-SG	43	Female	AML	Favorable		0.12	1	42.7	7.300000191	107	24	24	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7673a	AML-SG	37	Male	AML	Adverse		2.32	1	1.3	13.10000038	246	62	0	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD7674a	AML-SG	50	Male	sAML	Adverse		2.23	1	1.4	8.100000381	51	48	7	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD7675a	AML-SG	45	Female	AML	Favorable		11.72	0	2.4	7.800000191	13	80	26	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7676a	AML-SG	60	Female	AML	Adverse		0.51	1	3.2	9.5	139	90	59	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD7677a	AML-SG	58	Female	sAML	Favorable		0.54	1	12.4	8.300000191	20	50	14	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7678a	AML-SG	50	Female	AML	Intermediate		0.21	1	42.6	8.600000381	242	100	71	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7679a	AML-SG	50	Male	AML	Favorable		2.03	1	29	11	33		72	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7680a	AML-SG	38	Male	AML	Favorable		9.73	1	20.1	8.699999809	95	80	90	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7681a	AML-SG	42	Female	AML	Adverse		1.52	1	9.05	8.300000191	58	45	14	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7682a	AML-SG	59	Female	AML	Adverse		1.08	1	87.6	7.400000095	149	80	82	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7683a	AML-SG	40	Female	AML	Favorable		6.18	1	47.5	8.699999809	145	45	45	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7684a	AML-SG	49	Female	AML	Favorable		4.99	0	1	9.899999619	9	80	20	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7685a	AML-SG	47	Female	AML	Intermediate		1.27	1	13.9	7.300000191	20	66	66	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7686a	AML-SG	58	Female	AML	Adverse		11.16	1	3.87	8.800000191	18	49	16	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7687a	AML-SG	46	Male	AML	Favorable		5.65	1	9.14	7.400000095	35	50	50	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7688a	AML-SG	33	Male	AML	Favorable		11.07	0	32	7.900000095	128	91	91	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7689a	AML-SG	54	Female	AML	Intermediate		0.84	1	66.8	7.400000095	63	70	46	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7690a	AML-SG	55	Male	AML	Favorable		4.53	0	46.7	5.900000095	147	90	1	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7691a	AML-SG	42	Female	AML	Adverse		8.94	0	0.9	6.099999905	33	90	61	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7692a	AML-SG	34	Male	AML	Favorable		0.87	1	13.85	9.600000381	42	75	80	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7694a	AML-SG	38	Male	AML	Intermediate		1.92	1	30.4	10.30000019	47	30	71	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7695a	AML-SG	45	Male	AML	Adverse		9.71	1	33	11.69999981	66	91	71	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD7696a	AML-SG	57	Male	tAML	Adverse		0.07	1	2.4	4.199999809	14	45	0	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD7697a	AML-SG	48	Male	AML	Favorable		6.88	0	1.8	14	127	6	0	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7698a	AML-SG	59	Male	tAML	Adverse		1.07	1	1.9	6.699999809	42	25	16	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD7699a	AML-SG	55	Male	AML	Favorable		1.81	1	116.1	9.899999619	33	60	83	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7700a	AML-SG	28	Female	AML	Intermediate		12.66	0	1	6.300000191	51	34		Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7702a	AML-SG	28	Male	AML	Adverse		0.9	1	26.2	6.699999809	30	90	76	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7703a	AML-SG	43	Female	AML	Adverse		12.08	0	10.4	5.900000095	108	51	30	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7704a	AML-SG	35	Male	AML	Intermediate		0.84	1	1.57	11.30000019	228	72	8	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7705a	AML-SG	32	Female	AML	Favorable		0.39	1	17.4	7.5	199	80	2	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7706a	AML-SG	39	Male	AML	Intermediate		0.44	1	2.3	9.600000381	67	50	5	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7707a	AML-SG	51	Male	AML	Favorable		4.79	1	10.1	9.699999809	24	10	22	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7708a	AML-SG	59	Female	AML	Favorable		6.19	1	8.1	11.39999962	33	66	24	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7709a	AML-SG	53	Female	sAML	Favorable		0.07	1	6.9	11.39999962	43	22	20	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7710a	AML-SG	31	Female	AML	Adverse		7.9	0	30.1	9.609999657	45.9	90	80	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD7711a	AML-SG	58	Male	AML	Adverse		1.1	1	67	9	38	90	90	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7712a	AML-SG	55	Male	AML	Adverse		0.09	1	74.7	8.699999809	12	93	87	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7713a	AML-SG	38	Female	AML	Intermediate		4.72	0	3	10.39999962	30	31		Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7714a	AML-SG	56	Female	AML	Intermediate		3.44	1	1.9	9.800000191	435	30	1	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7715a	AML-SG	57	Male	AML	Adverse		1.92	1	2.4	13.39999962	45	20	0	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7716a	AML-SG	53	Female	AML	Adverse		1.11	1	19	9.899999619	6	90	27	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7717a	AML-SG	57	Male	AML	Adverse		0.3	1	1.5	9.5	53	30	3	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD7718a	AML-SG	35	Male	AML	Adverse		0.97	1	22.27	11.30000019	91	60	60	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD7720a	AML-SG	36	Female	AML	Adverse		6.62	0	1.1					Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7721a	AML-SG	31	Male	AML	Intermediate		6.85	0	7.3	10.10000038	173	65	47	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7722a	AML-SG	61	Male	sAML	Adverse		1.86	1	2.5	7.800000191	53			Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7723a	AML-SG	32	Female	AML	Favorable		6.1	0	6.7	12.39999962	26	99	26	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7724a	AML-SG	40	Female	AML	Favorable		6.55	0	17.3	11.60000038	27	50	64	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7725a	AML-SG	48	Male	AML	Favorable		6.62	0	26.6	10.39999962	61	35	39	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7726a	AML-SG	59	Male	AML	Intermediate		11.2	0	53.9	9.699999809	19	86	72	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7727a	AML-SG	27	Male	AML	Intermediate		6.58	0	3.9	6.300000191	18	20	0	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7728a	AML-SG	50	Male	AML	Favorable		1.82	1	23.9	12.10000038	44	40	90	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7730a	AML-SG	57	Male	AML	Favorable		10.46	0	6.3	10.5	98	20	19	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7731a	AML-SG	57	Female	AML	Intermediate		6.67	0	2.2	6.300000191	82	50	50	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7732a	AML-SG	42	Male	AML	Favorable		3.21	1	13.3	10.39999962	31	90	26	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7733a	AML-SG	22	Female	AML	Favorable		11.54	0	22.5	10.10000038	33	75	10	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7735a	AML-SG	59	Male	AML	Adverse		0.68	1	3.4	8.399999619	13	91	19	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD7736a	AML-SG	41	Male	AML	Favorable		1.15	1	10.8	7	6	90	78	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7737a	AML-SG	57	Male	AML	Intermediate		0.88	1	6.2	12.80000019	107	92	84	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7739a	AML-SG	57	Female	sAML	Favorable		0.2	1	2	12.30000019	169	28	8	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7740a	AML-SG	35	Male	AML	Favorable		9.98	0	13.6	6	40	0	0	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7741a	AML-SG	53	Female	AML	Adverse		1.83	1	4	10.10000038	120	90	48	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7742a	AML-SG	51	Male	AML	Favorable		0.08	1	22.1	9.699999809	30	25	10	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7743a	AML-SG	35	Male	AML	Adverse		12.17	0	2	12.10000038	126	90	4	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7744a	AML-SG	59	Female	oAML	Adverse		0.13	1	7.45	10.10000038	11	69	30	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD7745a	AML-SG	53	Female	AML	Favorable		3.79	0	16.97	8.800000191	253	65	54	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7747a	AML-SG	54	Male	AML	Favorable		9.95	0	5.18	7.099999905	26	95	38	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7748a	AML-SG	38	Male	AML	Favorable		6.46	0	66	11.80000019	86	76	93	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7749a	AML-SG	38	Female	AML	Favorable		6.35	0	60.3	10.10000038	41	80	74	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7750a	AML-SG	29	Female	AML	Favorable		0.07	1	9.5	10.19999981	10	95	85	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7751a	AML-SG	39	Male	AML	Adverse		1.17	1	20.3	7.800000191	88	88	71	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7752a	AML-SG	59	Male	AML	Adverse		0.66	1	7.7	7.400000095	16	85	50	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD7753a	AML-SG	32	Male	AML	Favorable		11.12	0	9.4	11.5	25	32	33	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7754a	AML-SG	34	Female	AML	Favorable		6.17	0	61.2	11.69999981	124		82	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7755a	AML-SG	31	Male	AML	Intermediate		0.94	1	0.7	10.89999962	130	30	6	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7756a	AML-SG	34	Male	AML	Intermediate		0.9	1	54	6.900000095	21	80	35	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7757a	AML-SG	60	Female	AML	Adverse		5.97	0	1.2	9.5	10	100	30	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7758a	AML-SG	58	Male	sAML	Intermediate		2.74	1	1.25	9.5	65	20	0	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7759a	AML-SG	47	Female	AML	Intermediate		0.74	1	91.1	7.099999905	90	95	77	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7760a	AML-SG	24	Female	AML	Intermediate		1.09	1	58.7	3.900000095	25	90	66	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7761a	AML-SG	55	Male	AML	Favorable		6.64	0	3.5	8.399999619	470	50	18	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7762a	AML-SG	34	Male	tAML	Adverse		0.73	1	5.4	11	202	90	0	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD7763a	AML-SG	54	Male	AML	Intermediate		10.77	0	0.7	9.5	109	51		Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7764a	AML-SG	49	Female	AML	Favorable		3.22	1	13	8.800000191	54	51	30	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7765a	AML-SG	59	Female	AML	Favorable		5.01	1	32	5.400000095	13	86	86	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7766a	AML-SG	37	Male	AML	Favorable		0.27	1	23.2	14.69999981	13	94	68	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7767a	AML-SG	52	Male	oAML	Adverse		0.44	1	30.7	10.10000038	327	57	31	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7768a	AML-SG	39	Male	AML	Adverse		1.03	0	67.9	7.400000095	85	95	88	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7769a	AML-SG	57	Female	sAML	Intermediate		0.08	1	3.4	8.199999809	34	87	16	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7770a	AML-SG	60	Male	oAML	Intermediate		0.94	1	189.1	11	32	50	61	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7771a	AML-SG	55	Female	sAML	Intermediate		0.85	1	13.9	6.099999905	35	47	0	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7773a	AML-SG	54	Female	AML	Intermediate		7.29	0	1.5	7.800000191	32	48		Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7774a	AML-SG	43	Male	AML	Favorable		1.29	1	26.1	7	30	6	90	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7775a	AML-SG	59	Male	AML	Adverse		0.02	1	37.7	7.300000191	39	72	72	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7776a	AML-SG	44	Male	AML	Adverse		0.77	1	34.6	10.80000019	108	95		Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7777a	AML-SG	34	Female	AML	Intermediate		8.57	0	105.2	9	252	90	66	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7778a	AML-SG	42	Female	AML	Favorable		11.9	0	13.7	11.30000019	13	80	47	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7779a	AML-SG	52	Female	AML	Adverse		2.45	1	32.1	8.800000191	184		70	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7780a	AML-SG	35	Male	AML	Favorable		6.49	0	46.8	8.100000381	27	55	55	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7781a	AML-SG	60	Female	AML	Adverse		0.32	1	9.4	8.600000381	36	66	60	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7782a	AML-SG	39	Male	AML	Intermediate		0.55	1	3.8	4.800000191	11	25	3	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7783a	AML-SG	48	Female	AML	Favorable		3.78	1	45.4	9.899999619	30	51	45	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7784a	AML-SG	41	Male	AML	Favorable		0.58	1	130.3	8.600000381	20	79		Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7785a	AML-SG	54	Male	AML	Intermediate		6.46	1	1.8	9.600000381	27		1	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7786a	AML-SG	40	Male	AML	Favorable		0	1	72	13.30000019	24	40	80	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7787a	AML-SG	58	Male	AML	Favorable		0.47	1	6.7	10.19999981	63	50	4	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7788a	AML-SG	38	Female	AML	Favorable		8.52	0	8.4	8.5	21	47	44	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7789a	AML-SG	51	Male	AML	Favorable		0.28	1	25.8	11.19999981	55	75	98	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7790a	AML-SG	45	Female	AML	Adverse		6.22	0	1.8	9.800000191	214	40	22	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7791a	AML-SG	57	Male	AML	Intermediate		0.84	1	62.9	9.399999619	104	80	0	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7792a	AML-SG	49	Male	AML	Favorable		6.73	0	2	12.5	24	90	46	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7793a	AML-SG	44	Female	AML	Intermediate		6.74	0	69.4	8.5	26	73	65	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7794a	AML-SG	48	Male	AML	Favorable		11.04	0	9.8	14.5	33	80	42	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7795a	AML-SG	57	Female	AML	Adverse		0.73	1	3	9.100000381	33	20		Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7796a	AML-SG	54	Female	AML	Favorable		0.04	1	80.7	10.60000038	251	60	3	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7797a	AML-SG	38	Female	AML	Intermediate		0.38	1	72.5	8.600000381	23	90	80	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7798a	AML-SG	52	Male	AML	Favorable		5.83	0	0.7	8.800000191	32	80	0	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7799a	AML-SG	57	Female	AML	Adverse		0.54	1	83.1	8.399999619	15	87	54	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7800a	AML-SG	49	Female	AML	Favorable		11.27	0	3.4	6.900000095	92	30	4	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7801a	AML-SG	52	Female	AML	Adverse		6.49	0	5.5	6.699999809	81	20	0	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7802a	AML-SG	50	Male	AML	Favorable		0.69	1	2.9	8.199999809	89	53	28	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7803a	AML-SG	43	Male	AML	Favorable		6.5	0	0.2	7.599999905	53	95	80	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7804a	AML-SG	56	Male	AML	Favorable		0.45	1	365	8.300000191	107	90	99	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7805a	AML-SG	34	Male	AML	Favorable		6.44	0	57.1	11.19999981	361	95	60	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7806a	AML-SG	58	Female	AML	Adverse		0.12	1	2.2	8.600000381	67	40	1	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD7807a	AML-SG	44	Male	AML	Favorable		6.44	0	43.4	12.5	82	80	11	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7808a	AML-SG	26	Female	AML	Favorable		2.48	0	1.4	10.89999962	10	40	15	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7810a	AML-SG	50	Female	AML	Favorable		6.61	0	21	8	118	38	33	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7811a	AML-SG	49	Female	tAML	Favorable		6.36	0	23.3	11.10000038	14	90	78	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7812a	AML-SG	47	Female	AML	Favorable		1.17	1	69.2	6.199999809	26	90	36	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7814a	AML-SG	55	Male	AML	Adverse		0.22	1	3	8.899999619	31	80	13	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD7815a	AML-SG	47	Male	AML	Favorable		6.31	0	4.8	10.80000019	153		87	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7816a	AML-SG	43	Male	AML	Favorable		6.29	0	3.5	11.60000038	12	75	7	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7817a	AML-SG	49	Male	AML	Intermediate		0.6	1	15.9	9.399999619	131		0	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7818a	AML-SG	46	Male	AML	Adverse		0.05	1	9.2	10.5	77	70	10	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7819a	AML-SG	52	Male	AML	Adverse		0.42	1	60.4	10.10000038	25	56	56	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7820a	AML-SG	45	Female	AML	Favorable		0.04	1	9.9	7.099999905	17	35	66	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7821a	AML-SG	33	Female	AML	Favorable		0.05	1	42.8	8.399999619	29	99	79	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7822a	AML-SG	60	Female	AML	Intermediate		0.01	1	238.2	6.800000191	22	99	99	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7823a	AML-SG	48	Male	AML	Adverse		1.74	1	39	7.900000095	488		38	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7824a	AML-SG	60	Male	sAML	Adverse		0.63	1	40	8.699999809	102	40	35	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7825a	AML-SG	37	Male	AML	Intermediate		11.87	0	0.7	14.69999981	123		0	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7827a	AML-SG	28	Female	AML	Favorable		8.44	0	68	7.800000191	27		5	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7828a	AML-SG	38	Female	AML	Favorable		2.75	1	31.5	8.800000191	243	17	4	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7829a	AML-SG	52	Male	sAML	Adverse		0.84	1	1.2	7	12	70	0	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7830a	AML-SG	34	Female	AML	Favorable		12.03	0	30.77	9.699999809	47	93	90	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7831a	AML-SG	60	Female	AML	Adverse		1.2	1	24.1	7.800000191	37	20	29	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7832a	AML-SG	52	Male	AML	Adverse		0.2	1	3.4	7.5	22	15	1	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD7833a	AML-SG	55	Male	AML	Favorable		0.98	1						Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7834a	AML-SG	45	Male	AML	Favorable		6.69	1	5.71	10.30000019	89	90	85	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7835a	AML-SG	47	Female	AML	Intermediate		0.56	1	65	10.69999981	71	84	1	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7836a	AML-SG	28	Male	AML	Adverse		1.45	1	14.2	7.900000095	178	81	83	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD7837a	AML-SG	47	Female	AML	Favorable		6.72	0	11.1	9	34		34	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7838a	AML-SG	37	Male	AML	Favorable		2.3	1	4.72	9.850000381	226			Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7839a	AML-SG	36	Female	AML	Adverse		0.28	1	2	6.5	36	80	16	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD7840a	AML-SG	37	Female	AML	Favorable		1.66	1	165.6	3	15	26	36	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7841a	AML-SG	47	Male	AML	Adverse		1.83	1	70	7.400000095	6			Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7842a	AML-SG	55	Female	AML	Favorable		6.85	0	77.7	5.900000095	25	31	81	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7843a	AML-SG	56	Female	sAML	Intermediate		2.45	1	0.7	8.199999809	99	20	6	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7844a	AML-SG	53	Female	AML	Adverse		11.66	0	2.4	8	183	25		Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7845a	AML-SG	56	Male	AML	Adverse		6.84	0	2.6	8.399999619	105	49	46	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7846a	AML-SG	37	Female	AML	Favorable		4.81	0	2.7	10.69999981	16.9	91	23	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7847a	AML-SG	20	Male	AML	Intermediate		1.22	1	18.4	8.600000381	97	90	78	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7848a	AML-SG	29	Female	AML	Favorable		6.76	0	11	7.5	57	100	44	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7849a	AML-SG	46	Male	AML	Favorable		2.15	1	33.3	3.099999905	27	30	33	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7850a	AML-SG	51	Male	AML	Intermediate		1.16	1	1.4	12.80000019	156	82	6	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7851a	AML-SG	25	Female	AML	Favorable		6.72	0	1.1	10.89999962	34	9	0	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7852a	AML-SG	58	Female	AML	Adverse		0.16	1	2.4	7.300000191	136	90		Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD7853a	AML-SG	57	Male	AML	Adverse		1.06	1	46.9	8.899999619	39	26	9	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD7854a	AML-SG	28	Male	AML	Adverse		1.13	1	235	6.300000191	32	87	86	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7855a	AML-SG	54	Female	AML	Favorable		1.19	1	133.5	11.19999981	315	99	93	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7856a	AML-SG	56	Male	AML	Favorable		4.19	1	0.5	5.5	7		4	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7857a	AML-SG	19	Male	AML	Adverse		1.52	1	49	9	35	85	80	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7858a	AML-SG	55	Male	AML	Intermediate		0.68	1	2.2	8.300000191	72	20	0	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7859a	AML-SG	36	Female	AML	Adverse		0.18	1	18.2	8.699999809	72	66	57	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7860a	AML-SG	58	Female	AML	Intermediate		1.11	1	229	9	14		90	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7861a	AML-SG	26	Female	AML	Favorable		0.08	0	73.8	6.599999905	38	85	85	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7862a	AML-SG	43	Male	sAML	Favorable		0.79	1	15.5	14.10000038	116	99		Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7863a	AML-SG	59	Male	AML	Favorable		9.59	0	0.8	7.599999905	23	13	4	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7864a	AML-SG	53	Male	AML	Adverse		5.52	0	2.9	9.300000191	56	9	64	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7865a	AML-SG	49	Female	AML	Intermediate		0.6	1	40	11.80000019	44	35	1	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7866a	AML-SG	58	Male	oAML	Adverse		7.7	0	5.9	7.900000095	58	64	1	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7867a	AML-SG	28	Male	tAML	Intermediate		10.4	0	14	9	45	62		Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7869a	AML-SG	60	Female	AML	Adverse		0.09	1	1.4	7.699999809	105	65	0	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD7870a	AML-SG	34	Male	AML	Favorable		10.32	0	2.3	14.80000019	85		40	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7871a	AML-SG	57	Male	AML	Adverse		0.83	1	55.4	7.5	87	56	76	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7872a	AML-SG	46	Male	AML	Intermediate		10.21	0	26.6	6.400000095	61	68	84	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7873a	AML-SG	56	Male	tAML	Adverse		0.44	1	3.15	9.5	378		15	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD7874a	AML-SG	40	Female	AML	Favorable		5.52	0	7.6	9.600000381	35		52	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7875a	AML-SG	53	Female	AML	Adverse		0.63	1	34.7	10	45	36	35	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7876a	AML-SG	29	Female	AML	Intermediate		1.1	1	17.5	10.60000038	211	90	39	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7877a	AML-SG	51	Male	AML	Adverse		1.95	1	8.3	8.600000381	29	90	75	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7878a	AML-SG	51	Male	AML	Intermediate		0.77	1	39.9	8.100000381	73	91	85	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7879a	AML-SG	51	Female	AML	Adverse		0.49	1	8.4	9	45	90	35	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7880a	AML-SG	41	Female	AML	Adverse		0.76	1	113.6	5.699999809	32	85	60	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7881a	AML-SG	51	Male	AML	Favorable		8.55	0	25.2	8.800000191	51	80	58	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7882a	AML-SG	56	Male	AML	Adverse		2.52	1	23.8	9.300000191	9	24	6	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7883a	AML-SG	33	Male	AML	Favorable		2.34	1	136.9	11	42	57	88	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7884a	AML-SG	20	Female	tAML	Favorable		9.9	0	5.6	10.89999962	19		14	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7885a	AML-SG	55	Male	AML	Intermediate		3.65	1	1.5	10.2	138	40	25	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7886a	AML-SG	60	Male	AML	Intermediate		2.56	0	36.93	12.39999962	263	68	68	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7887a	AML-SG	24	Female	AML	Intermediate		6.42	0	14.7	9.5	87	74	82	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7888a	AML-SG	24	Female	AML	Intermediate		0.06	1	100	4.199999809	45	94	81	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7889a	AML-SG	60	Male	AML	Intermediate		0.55	1	1.54	9.199999809	15	80	20	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7890a	AML-SG	52	Male	AML	Favorable		5.37	0	49	7	32	65	67	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7891a	AML-SG	58	Male	tAML	Adverse		4.1	0	1.2	11.69999981	113	83	15	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7892a	AML-SG	30	Male	AML	Favorable		7.33	0	200	6.699999809	56	64		Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7893a	AML-SG	52	Female	AML	Favorable		9.6	0	26.3	10.60000038	106	25	25	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7894a	AML-SG	23	Female	AML	Favorable		9.25	0	13.4	8.699999809	16	59	81	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7895a	AML-SG	54	Female	AML	Favorable		7.2	1	5.4	8	48	60	62	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7896a	AML-SG	53	Female	AML	Favorable		1.48	1	65.4	8.699999809	40	95	92	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7897a	AML-SG	47	Female	AML	Intermediate		5.17	0	48.5	10	85	21	7	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7898a	AML-SG	28	Female	AML	Favorable		3.75	1	34.9	10.19999981	16	71	32	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7899a	AML-SG	49	Male	AML	Intermediate		0.95	1	111.8	7.5	27	90	89	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7900a	AML-SG	51	Male	sAML	Adverse		1.73	1	6.74	5.900000095	2		9	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD7901a	AML-SG	54	Male	AML	Favorable		10.87	0	39	7.099999905	39	66	37	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7902a	AML-SG	35	Male	AML	Favorable		5.52	0	2.8	9.5	13	79	33	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7903a	AML-SG	21	Male	AML	Adverse		4.61	0	88.8	10.80000019	85	70	30	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7904a	AML-SG	49	Female	AML	Favorable		5.17	0	108.2	8.699999809	74	90	11	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7905a	AML-SG	55	Female	AML	Favorable		0.97	1	88.8	7.800000191	41	90	41	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7906a	AML-SG	46	Male	AML	Adverse		0.15	1	13.6	8.600000381	73	39	40	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7907a	AML-SG	57	Female	AML	Intermediate		1.63	1	0.9	8.800000191	64	60	4	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7908a	AML-SG	35	Male	AML	Adverse		1.26	1	18.04	11.60000038	40	80	76	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7909a	AML-SG	43	Male	AML	Intermediate		3.58	1	16.9	14	183	95	87	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7910a	AML-SG	35	Female	AML	Adverse		0.66	1	13.8	7.699999809	135	97	52	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7911a	AML-SG	41	Male	AML	Intermediate		2	1	61.2	10.30000019	164	96	87	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7912a	AML-SG	45	Male	AML	Favorable		8.82	0	4.8	3.200000048	23	80	44	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7913a	AML-SG	30	Male	AML	Adverse		10.37	1	11.6	9.300000191	32	80	41	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7914a	AML-SG	46	Male	AML	Favorable		10.87	0	4.4	10.5	48	35	0	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7915a	AML-SG	19	Male	AML	Favorable		5.96	0	60.45	9.399999619	74	52	87	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7916a	AML-SG	41	Male	AML	Favorable		4.96	1	116	11.80000019	48	95	96	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7917a	AML-SG	52	Male	AML	Favorable		5.32	0	4.85	10.89999962	134	39	29	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7918a	AML-SG	19	Female	AML	Favorable		6.89	0	102.7	10.30000019	32	50	38	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7919a	AML-SG	52	Female	tAML	Intermediate		0.18	1	10.2	8.199999809	76	97	64	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7920a	AML-SG	38	Male	AML	Intermediate		5.31	0	0.5	6.599999905	159	90	36	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7921a	AML-SG	54	Female	AML	Favorable		10.65	0	1.9	7.699999809	22	17	67	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7922a	AML-SG	54	Female	AML	Favorable		1.11	1	13.4	9.699999809	97	32	40	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7923a	AML-SG	37	Male	AML	Favorable		1.17	1	2.9	8.199999809	174	65	9	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7924a	AML-SG	59	Male	AML	Adverse		1.17	1	31.3	7.300000191	41		89	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD7926a	AML-SG	49	Male	AML	Intermediate		4.63	1	157.4	9.399999619	34	95	84	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7927a	AML-SG	56	Female	AML	Favorable		0.34	1	14.4	10.30000019	123	28	9	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7928a	AML-SG	47	Female	AML	Intermediate		9.16	0	24.9	8.399999619	23	90	80	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7929a	AML-SG	34	Male	AML	Adverse		3.1	1	1.1	9	191	50	79	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7930a	AML-SG	42	Female	AML	Intermediate		6.82	1	3.8	11	79	89	24	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7931a	AML-SG	50	Female	AML	Adverse		0.88	1	7.9	6.699999809	115	90	51	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD7932a	AML-SG	56	Female	AML	Favorable		3.29	0	1.62	10.60000038	39	80	33	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7933a	AML-SG	44	Female	AML	Favorable		1.99	1						Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7934a	AML-SG	44	Female	AML	Favorable		1.16	1	52.2	8.5	71		26	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7935a	AML-SG	45	Male	AML	Favorable		0.33	1	112	11.80000019	41	66	58	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7936a	AML-SG	52	Female	AML	Favorable		5.5	0	67.1	8.699999809	89	85	27	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7937a	AML-SG	56	Male	AML	Favorable		5.46	0	2.85	9	50	31	17	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7938a	AML-SG	23	Male	AML	Favorable		4.47	0	18	9.199999809	34	90	67	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7939a	AML-SG	43	Female	tAML	Intermediate		1.63	1	57.5	7.199999809	12	96	98	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7940a	AML-SG	47	Female	AML	Adverse		1.72	1	2.4	9.399999619	24			Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7941a	AML-SG	41	Female	AML	Adverse		1.2	1	13.1	9.100000381	101	40	7	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7942a	AML-SG	56	Male	AML	Adverse		1.65	1	65.9	11.5	108	85	67	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7943a	AML-SG	18	Male	AML	Intermediate		6.19	0	7.1	7.300000191	119	26	13	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7944a	AML-SG	53	Female	oAML	Intermediate		0.82	1	41.6	10.89999962	65	97	85	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7945a	AML-SG	58	Female	AML	Intermediate		0.44	1	106.9	6.099999905	29	70	50	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7946a	AML-SG	42	Female	AML	Favorable		4.4	0	32	10.10000038	203	75	52	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7947a	AML-SG	41	Male	AML	Adverse		0.77	1	157	4.5	125	62	80	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7948a	AML-SG	56	Female	AML	Intermediate		1.31	1	1.3	12.5	249	35		Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7949a	AML-SG	43	Female	tAML	Adverse		0.48	1	38.4	8.899999619	32	49	40	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD7950a	AML-SG	40	Male	AML	Intermediate		0.75	1	65.2	8.600000381	28	12	9	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7951a	AML-SG	56	Female	sAML	Adverse		0.54	1	30.4	9.5	232		71	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7952a	AML-SG	53	Male	AML	Adverse		1.36	1	118	6.400000095	326	85	75	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7953a	AML-SG	56	Male	AML	Favorable		9.43	0	1.04	12.19999981	56		10	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7954a	AML-SG	38	Male	AML	Favorable		8.95	0	70	8.9	12	57	91	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7955a	AML-SG	42	Female	AML	Favorable		2.37	1	108.8	7.1	22	95	93	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7956a	AML-SG	32	Female	AML	Favorable		2.8	1	14.99	8.899999619	300	80	79	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7957a	AML-SG	52	Female	AML	Favorable		0.03	1	8.9	8.699999809	49		83	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7958a	AML-SG	48	Male	AML	Intermediate		1.83	1	5.7	13.19999981	33	22	20	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7959a	AML-SG	21	Female	AML	Adverse		1.51	1	8	7.800000191	128	95	20	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7960a	AML-SG	59	Female	sAML	Intermediate		6.76	0	2.8	8.100000381	90	40	0	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7961a	AML-SG	42	Female	AML	Intermediate		0.46	1	34.8	10.39999962	45	88	96	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7962a	AML-SG	57	Female	AML	Favorable		0.01	1	58.7	8.5	22	98	97	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7963a	AML-SG	25	Male	AML	Intermediate		10.85	0	205	10.5	15	80	78	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7964a	AML-SG	58	Female	AML	Intermediate		0.56	1	96.1	10.60000038	78	91	79	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7965a	AML-SG	42	Male	AML	Favorable		5.83	1	3.5	10	15	91		Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7966a	AML-SG	52	Male	AML	Adverse		0.61	1	3.43	8.899999619	22		16	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD7967a	AML-SG	43	Female	AML	Favorable		8.57	0	32	9.5	70.8		13	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7968a	AML-SG	60	Male	AML	Adverse		0.13	1	96.8	13.5	116	90	43	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD7969a	AML-SG	59	Female	AML	Favorable		5.26	1	152	7.800000191	71	50	0	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7970a	AML-SG	51	Male	AML	Intermediate		5.54	0	2.4	10.60000038	155	43	4	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7971a	AML-SG	48	Male	AML	Intermediate		1.67	1	8.6	13.89999962	399	90	0	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7972a	AML-SG	47	Male	oAML	Adverse		2.34	1	6.2	8.100000381	152	70	35	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7973a	AML-SG	50	Male	AML	Favorable		10.92	0	10.9	11.5	22	70	65	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7974a	AML-SG	37	Male	AML	Favorable		9.91	0	10.9	6.300000191	25	80	47	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7976a	AML-SG	57	Female	AML	Intermediate		1.42	1	1.4	7.400000095	80	75	28	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7977a	AML-SG	57	Female	AML	Intermediate		0.74	1	13.2	11.19999981	115	41	43	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7978a	AML-SG	59	Female	AML	Favorable		8.92	0	15.1	11.69999981	10	60	60	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7979a	AML-SG	40	Female	AML	Favorable		1.96	1	102	11.69999981	40	84	81	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7980a	AML-SG	36	Male	AML	Intermediate		4.88	0						Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7981a	AML-SG	39	Female	AML	Adverse		4.5	0	4.4	8.9	21	95	61	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7982a	AML-SG	46	Male	AML	Adverse		1.36	1	18.1	6.800000191	67	30	42	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7983a	AML-SG	52	Male	AML	Adverse		0.32	1	42	6.800000191	35	79	73	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD7984a	AML-SG	47	Male	AML	Adverse		5.99	1	12.8	12.4	147	90	68	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7985a	AML-SG	29	Female	AML	Favorable		10	0	73.1	10.39999962	529	95	32	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7986a	AML-SG	49	Female	sAML	Adverse		6.41	1	4	8	89	40	1	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7987a	AML-SG	31	Female	AML	Favorable		9.43	0	22.2	8	58	90	10	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7988a	AML-SG	58	Female	AML	Adverse		0.45	0	3.1	9.6	204	68	11	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7989a	AML-SG	55	Female	AML	Adverse		0.91	1	2.9	7.300000191	22	90	28	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7990a	AML-SG	54	Male	AML	Favorable		1.23	1	3	9.300000191	98	80	60	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7991a	AML-SG	27	Female	AML	Favorable		4.17	0	86.2	11.5	146	90	16	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7992a	AML-SG	59	Female	AML	Intermediate		0.72	1	4	10.19999981	47	75	75	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7993a	AML-SG	42	Male	AML	Favorable		0.8	1	1.2	7.300000191	30	86	38	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7994a	AML-SG	48	Female	AML	Adverse		3.13	1	7.4	5.400000095	249	80	41	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7995a	AML-SG	49	Male	AML	Adverse		0.15	1	143	9.600000381	61	90	68	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7996a	AML-SG	37	Female	AML	Favorable		3.98	0	15.2	12.30000019	22	61	30	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD7997a	AML-SG	18	Male	AML	Intermediate		8.28	0	2	10.30000019	367	96	20	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD7998a	AML-SG	55	Male	AML	Adverse		0.04	1	13.1	13.9	88	46	13	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD7999a	AML-SG	41	Female	AML	Favorable		4.22	0	0.38	8.899999619	36	90		Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8000a	AML-SG	42	Female	AML	Favorable		3.65	1	13.9	9.800000191	17	80	44	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8001a	AML-SG	43	Female	AML	Intermediate		4.38	1	0.83	11.89999962	69	73	8	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8002a	AML-SG	25	Female	AML	Favorable		3.99	0	1.07	9.699999809	36	81	10	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8003a	AML-SG	41	Female	AML	Intermediate		8.87	0	55.5	9.5	122	80	33	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8004a	AML-SG	53	Female	AML	Favorable		0.07	1	72.3	6.599999905	40	90	0	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8005a	AML-SG	56	Female	AML	Favorable		8.64	0	120.6	7.099999905	247	30	10	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8006a	AML-SG	53	Male	oAML	Favorable		3.99	0	9.79	11.5	81	64	11	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8007a	AML-SG	26	Female	AML	Favorable		4.64	0	6.01	12.19999981	137	60	5	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8008a	AML-SG	53	Female	oAML	Adverse		0.26	1	8.8	10.80000019	250	38	6	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8009a	AML-SG	39	Male	AML	Intermediate		0.94	1	1.6	9.600000381	81	20	1	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8010a	AML-SG	37	Female	AML	Favorable		9.31	0	1.1	8.899999619	56	0	0	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8011a	AML-SG	48	Female	AML	Adverse		0.07	1	1.6	7.699999809	91	91		Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8012a	AML-SG	36	Male	AML	Intermediate		0.65	1	127	9.300000191	157	80	40	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8013a	AML-SG	52	Male	AML	Favorable		0.01	1	137	8.399999619	22	90	24	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8014a	AML-SG	39	Male	AML	Favorable		5.22	0	29.8	11.69999981	16	72	74	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8015a	AML-SG	34	Male	AML	Adverse		5.1	0	26.4	6.599999905	52	40	98	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8016a	AML-SG	41	Male	AML	Intermediate		0.08	1	1.05	9.800000191	72	80	1	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8017a	AML-SG	23	Male	AML	Favorable		4.03	0	7.3	9.100000381	13	70	29	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8018a	AML-SG	34	Male	AML	Favorable		6.64	0	82.1	7.5	28	75	35	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8019a	AML-SG	57	Female	AML	Adverse		9	0	32	6.5	9.2	50	13	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8020a	AML-SG	34	Female	AML	Intermediate		1	1	3.55	6.800000191	14	44	3	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8021a	AML-SG	58	Female	AML	Intermediate		0.76	1	27.9	12	24	80	70	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8022a	AML-SG	55	Female	AML	Favorable		0.04	1	59	10.19999981	73	90	67	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8023a	AML-SG	40	Female	AML	Favorable		4.15	1	38	9.699999809	47		67	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8024a	AML-SG	51	Male	AML	Favorable		2.09	0	20.2	9	20	70	1	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8025a	AML-SG	19	Female	AML	Favorable		8.05	0	6.1	6.5	48	90	13	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8026a	AML-SG	58	Male	AML	Adverse		0.19	1	2.6	9.399999619	111	37	0	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD8027a	AML-SG	50	Male	AML	Intermediate		4.11	0	16.45	8.800000191	17	90	58	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8028a	AML-SG	52	Male	AML	Favorable		8.48	0	2.1	6.099999905	17	95		Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8029a	AML-SG	53	Female	AML	Intermediate		3.33	1	156.3	9.300000191	85	95	96	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8030a	AML-SG	30	Female	AML	Favorable		0.92	0	33.01	6.900000095	48	80	26	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8031a	AML-SG	59	Female	AML	Intermediate		8.81	0	22.6	7.400000095	52	80	80	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8032a	AML-SG	56	Female	sAML	Adverse		0.11	1	32.6	10.69999981	103	21	19	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8033a	AML-SG	51	Male	AML	Favorable		6.52	1	97	7.300000191	19	80	92	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8034a	AML-SG	32	Male	AML	Adverse		1.08	1	7.8	5.099999905	20	90	50	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8035a	AML-SG	41	Male	AML	Favorable		4.27	0	2.68	12.69999981	96	20	7	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8036a	AML-SG	59	Female	AML	Favorable		1.02	1	15.3	9.199999809	48	88	90	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8037a	AML-SG	37	Female	AML	Favorable		5.15	0	32.8	9.100000381	19	80		Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8038a	AML-SG	29	Male	AML	Favorable		0.35	1	190.7	8.899999619	73	75	14	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8040a	AML-SG	48	Female	AML	Favorable		4.94	0	10	10	150	90	87	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8041a	AML-SG	61	Male	AML	Adverse		1.11	1	23.1	9.800000191	44	80	76	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD8042a	AML-SG	54	Female	AML	Favorable		2.38	1	7.3	10.69999981	16	24	52	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8043a	AML-SG	55	Male	AML	Favorable		10.18	0	3.1	9.399999619	121	70	38	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8044a	AML-SG	44	Female	AML	Favorable		2.31	1	2.5	9.399999619	124	80	1	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8045a	AML-SG	43	Male	AML	Adverse		0.03	1	372	7.900000095	32	90		Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8046a	AML-SG	46	Female	AML	Favorable		1.12	1	10.5	8.600000381	51	43	5	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8047a	AML-SG	60	Female	AML	Intermediate		0.12	1	110.5	7.300000191	4	95	95	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8048a	AML-SG	32	Female	AML	Adverse		1.32	1	64	7.5	61	70	51	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8049a	AML-SG	57	Female	AML	Intermediate		0.11	1	1.5	11	171	56		Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8050a	AML-SG	32	Female	AML	Favorable		4.4	0	25.7	11.10000038	15	80	47	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8051a	AML-SG	52	Male	AML	Intermediate		0.48	1	3.3	8.899999619	238	50	1	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8052a	AML-SG	51	Male	AML	Intermediate		1.5	1	101	7.800000191	65	30	0	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8053a	AML-SG	52	Female	AML	Favorable		9.65	0	1.1	9.899999619	274	50	0	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8054a	AML-SG	49	Male	AML	Adverse		1.41	1	2.96	10.19999981	51.2	40		Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD8055a	AML-SG	39	Male	AML	Intermediate		0.42	1	54.2	11.39999962	126	80	57	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8056a	AML-SG	55	Female	AML	Favorable		9.51	0	3	10.19999981	344	95	61	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8057a	AML-SG	54	Male	AML	Favorable		1.03	1	55.6	6.900000095	40	80	68	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8059a	AML-SG	34	Female	AML	Favorable		2.12	1	19.5	7.599999905	48	90	60	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8060a	AML-SG	59	Male	AML	Favorable		0.06	1	41.8	9.199999809	97	90	86	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8061a	AML-SG	34	Male	AML	Intermediate		1.13	1	66.1	8.699999809	188	31	96	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8062a	AML-SG	60	Male	AML	Adverse		0.02	1	1.4	11.5	32	50	10	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8063a	AML-SG	50	Male	AML	Favorable		7.43	0	10.6	9.399999619	24	20	4	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8064a	AML-SG	29	Female	AML	Intermediate		0.76	1	59.2	9.699999809	34	80	76	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8065a	AML-SG	48	Female	AML	Favorable		3.31	1	82.7	7.300000191	40	88	89	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8066a	AML-SG	61	Male	AML	Adverse		1.37	1	3.75	8	40	22	57	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD8067a	AML-SG	59	Male	sAML	Adverse		1.25	1	2.8	7.300000191	14		25	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8068a	AML-SG	60	Male	AML	Adverse		0.17	1	4.6	9	45	20		Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8069a	AML-SG	59	Female	AML	Intermediate		2.71	1	1.7	9.699999809	105	40		Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8070a	AML-SG	22	Female	AML	Intermediate		0.65	1	77.4	14	66	80	84	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8071a	AML-SG	55	Male	AML	Favorable		0.05	1	13.5	9.300000191	43	80	4	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8072a	AML-SG	47	Male	AML	Favorable		4.35	0	13.5	11.89999962	34	10	83	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8073a	AML-SG	39	Female	AML	Intermediate		1.52	1	18	10.5	56	84	10	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8074a	AML-SG	52	Female	AML	Favorable		4.19	0	11.7	9.199999809	45	91	90	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8075a	AML-SG	31	Male	AML	Favorable		8.33	0	60.8	2.5	35	70	44	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8076a	AML-SG	50	Male	AML	Favorable		7.51	0	0.83	8.100000381	56		4	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8077a	AML-SG	52	Male	AML	Adverse		0.42	1	210	7.5	14		77	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8078a	AML-SG	39	Male	AML	Adverse		0.02	1	58.6	17.60000038	29	94	87	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8079a	AML-SG	60	Female	AML	Favorable		0.57	1	2.2	8.899999619	70	51	60	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8080a	AML-SG	46	Female	AML	Adverse		9.19	0	3.2	8.100000381	50	90	80	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8081a	AML-SG	43	Female	AML	Adverse		2.15	0	2.8	7.3	116	25	0	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8082a	AML-SG	57	Female	AML	Favorable		2.18	1	32.7	10	111	23	0	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8083a	AML-SG	59	Female	oAML	Adverse		0.05	1	133.2	8.699999809	50	85	68	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8084a	AML-SG	57	Male	AML	Adverse		0.11	1	10.2	9.699999809	66	90	52	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8085a	AML-SG	56	Female	AML	Adverse		0.77	1	0.8	7.800000191	79	55	6	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8086a	AML-SG	65	Female	AML	Favorable		1.67	1	18.2	10.39999962	66	85	42	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8087a	AML-SG	46	Female	AML	Intermediate		0.22	1	29.1	8.300000191	205	59	80	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8088a	AML-SG	39	Female	AML	Intermediate		0.68	1	113.5	7.400000095	115	60	30	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8089a	AML-SG	47	Male	AML	Adverse		0.24	1	43.5	8.899999619	35	52	42	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD8090a	AML-SG	55	Female	AML	Favorable		8.92	0	4.3	11	45	50		Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8091a	AML-SG	47	Female	AML	Favorable		4.2	0	16.6	14.69999981	196	37	20	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8092a	AML-SG	39	Male	AML	Favorable		4.28	0	17.8	7.300000191	54	25	19	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8093a	AML-SG	36	Female	AML	Adverse		0.87	1	6	5.300000191	9	60	64	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8094a	AML-SG	21	Male	AML	Favorable		9.33	0	36.2	11.69999981	41	63	40	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8095a	AML-SG	52	Male	AML	Favorable		0.15	1	5.4	9	28	90	77	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8096a	AML-SG	23	Male	tAML	Adverse		1.37	1	32.4	13.69999981	221	85	0	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD8097a	AML-SG	55	Female	AML	Favorable		8.41	0	42.9	8.600000381	72	90	76	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8098a	AML-SG	56	Female	AML	Favorable		0.92	1	5.75	8.899999619	71	44	41	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8099a	AML-SG	56	Male	AML	Favorable		0.07	1	1.57	9.819999695	267	80		Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8101a	AML-SG	53	Female	AML	Favorable		1.89	1	22.7	10.89999962	12	30	54	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8102a	AML-SG	54	Male	AML	Favorable		8.15	0	3.3	6.699999809	10	80	60	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8103a	AML-SG	60	Male	AML	Adverse		0.68	1	3.2	10.39999962	173	56	10	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8104a	AML-SG	49	Female	AML	Favorable		8.43	0	2.5	11.10000038	9	89		Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8105a	AML-SG	47	Male	AML	Adverse		0.37	1	2.8	7.400000095	14	40	1	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8106a	AML-SG	48	Male	AML	Favorable		1.62	1	9.2	9.4	26	40	18	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8107a	AML-SG	55	Female	AML	Adverse		0.32	1	6.08	8.300000191	76	84	37	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8108a	AML-SG	60	Male	AML	Adverse		1.96	1	21.8	5	13	37	4	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8109a	AML-SG	59	Female	AML	Favorable		2.61	0	13.89	7.5	72	24	42	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8111a	AML-SG	51	Male	AML	Favorable		4.93	1	50	10.80000019	71	95	74	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8112a	AML-SG	55	Male	sAML	Adverse		0.82	1	13	13.60000038	37	95	67	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8113a	AML-SG	56	Female	tAML	Adverse		1.46	1	46.08	9.800000191	44	95	88	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8114a	AML-SG	48	Male	AML	Adverse		3.95	1	6.5	9.199999809	239	85	52	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8115a	AML-SG	53	Male	AML	Favorable		4.08	0	27.3	8.899999619	26	30	12	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8116a	AML-SG	43	Female	tAML	Favorable		4.91	0	73.2	8.899999619	16	83	57	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8118a	AML-SG	52	Female	AML	Adverse		0.31	1	1.1	7.900000095	78	90	12	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8119a	AML-SG	24	Female	AML	Adverse		3.14	1	5.4	10.60000038	152	90	18	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8120a	AML-SG	61	Female	AML	Intermediate		3.52	0	0.7	9.300000191	29	97	62	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8121a	AML-SG	60	Male	AML	Adverse		3.32	0	4.07	6	60	82	72	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8122a	AML-SG	48	Female	AML	Adverse		0.06	1						Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD8123a	AML-SG	43	Female	AML	Favorable		3.69	0	3.9	8.699999809	22	10	5	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8124a	AML-SG	37	Male	AML	Favorable		0.05	1	295	7.199999809	42		65	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8125a	AML-SG	29	Female	AML	Adverse		1.26	1	95.5	10.69999981	105	100	88	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8126a	AML-SG	35	Female	AML	Favorable		0.26	1	16.2	8.100000381	69	79	59	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8127a	AML-SG	38	Female	AML	Favorable		3.22	0	56.3	7.900000095	41	96	73	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8128a	AML-SG	42	Male	AML	Adverse		1.02	1	75.5	6.699999809	35	75	68	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8129a	AML-SG	55	Male	AML	Adverse		0.21	1						Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8130a	AML-SG	50	Female	AML	Favorable		0.98	1	17.1	12.89999962	49	90	50	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8132a	AML-SG	37	Female	tAML	Adverse		3.42	0	1.9	9.100000381	85	23	1	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8133a	AML-SG	56	Male	AML	Adverse		1.19	1	53.2	10.9	176	23	8	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD8134a	AML-SG	52	Female	AML	Adverse		8.19	0	7.7	8.3	86	70	10	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8136a	AML-SG	38	Male	AML	Intermediate		3.29	0	2.4	13.60000038	54	50		Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8137a	AML-SG	42	Male	AML	Favorable		1.38	0	170.24	10.30000019	27	90	90	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8138a	AML-SG	47	Female	AML	Adverse		0.22	1	3.1	7.8	17	30	0	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8139a	AML-SG	44	Male	AML	Adverse		0.13	1	532.7	7.2	42	83	89	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8140a	AML-SG	28	Male	AML	Intermediate		1.69	1						Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8141a	AML-SG	56	Male	AML	Adverse		1.11	1	14.8	8.3	448	33	69	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8142a	AML-SG	39	Male	AML	Adverse		4.25	1	2.7	9.100000381	66	85	3	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD8143a	AML-SG	44	Male	AML	Adverse		1.35	1	40.6	11.2	151	69	82	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8144a	AML-SG	48	Male	AML	Favorable		0.04	1	63.5	11.7	69	89.5	61	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8145a	AML-SG	60	Male	AML	Adverse		2.06	1	3.3	8.9	74	34	0	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD8146a	AML-SG	57	Female	AML	Adverse		0.6	1	56.3	9.9	20	88	72	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8147a	AML-SG	40	Female	AML	Adverse		8.34	0	1.6	8	54	95	44	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD8148a	AML-SG	61	Female	sAML	Favorable		0.88	1	3.2	9.199999809	46	70	11	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8149a	AML-SG	19	Male	AML	Favorable		0.49	1	28.2	7.400000095	30	55	56	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8150a	AML-SG	55	Male	AML	Adverse		3.86	0	60	9.5	48	85	88	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8151a	AML-SG	39	Male	AML	Favorable		2.39	0	20.3	12.80000019	37	89	86	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8152a	AML-SG	56	Male	AML	Intermediate		0.42	1	25.9	8.4	95	55	55	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8153a	AML-SG	54	Male	AML	Adverse		3.29	0						Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8154a	AML-SG	48	Male	AML	Favorable		8.51	0	5.45	6.599999905	23	85	46	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8155a	AML-SG	50	Female	AML	Intermediate		3.58	0	2.5	11	64	75	2	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8156a	AML-SG	58	Female	tAML	Adverse		0.44	1	26.3	9	19	73	54	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD8157a	AML-SG	60	Male	AML	Favorable		2.02	1	10.3	11.89999962	93	80	12	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8158a	AML-SG	56	Male	AML	Favorable		1.58	1	9.62	9.899999619	130	86	44	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8159a	AML-SG	52	Male	AML	Favorable		0.15	1	47.58	9.800000191	61	60	83	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8160a	AML-SG	47	Male	AML	Favorable		0.16	1						Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8161a	AML-SG	55	Female	AML	Intermediate		4.08	0	1.7	7.300000191	68	50	37	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8162a	AML-SG	21	Female	AML	Intermediate		7.7	0	6.9	8.5	62	92	91	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8164a	AML-SG	33	Female	AML	Intermediate		8.62	0	37.3	9.399999619	37	85	80	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD8165a	AML-SG	52	Male	AML	Favorable		0.46	1	87.4	11.80000019	74	88	79	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8166a	AML-SG	43	Male	AML	Intermediate		3.67	0	168.6	5.400000095	58	95	74	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8170a	AML-SG	40	Male	AML	Intermediate		8.38	0	2	8.5	152		2	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8171a	AML-SG	53	Female	AML	Favorable		0.66	1	5.5	7.5	38	90		Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8172a	AML-SG	55	Female	AML	Favorable		0.8	1	57.3	8.199999809	43		80	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8173a	AML-SG	57	Male	AML	Adverse		0.86	1	6.1	7.199999809	42	75	45	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8174a	AML-SG	56	Male	AML	Favorable		2.69	1	2.1	6.800000191	88	90	18	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8175a	AML-SG	38	Female	AML	Adverse		2.74	1	1.6	8.199999809	160	30	4	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD8176a	AML-SG	57	Female	AML	Favorable		1.23	1	64.8	10.2	37	90	76	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8177a	AML-SG	44	Male	oAML	Favorable		8.43	0	13.4	8.3	168	40		Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8178a	AML-SG	38	Male	AML	Favorable		7.38	0	217	8.8	63	90	100	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8179a	AML-SG	53	Male	AML	Intermediate		0.5	1	3.96	5.199999809	37	95	67	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8180a	AML-SG	44	Female	AML	Favorable		7.67	0	30.7	7.900000095	26	99	90	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8181a	AML-SG	51	Female	AML	Favorable		2.75	0	41	10.69999981	111	81	56	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8182a	AML-SG	55	Male	AML	Intermediate		0.76	1						Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8183a	AML-SG	53	Male	AML	Favorable		4.77	1	31.9	13	49	90	34	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8184a	AML-SG	31	Female	AML	Intermediate		7.62	0	24	8.2	100	50	38	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8185a	AML-SG	42	Male	AML	Adverse		1.67	1	8.4	8.6	94	70	87	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8186a	AML-SG	54	Male	oAML	Adverse		5.39	1	4.8	9.5	68	61		Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8187a	AML-SG	33	Male	AML	Favorable		2.07	1	10.4	10.3	103	30	7	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8188a	AML-SG	47	Female	AML	Adverse		0.65	1	3	8.2	140	68	56	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8189a	AML-SG	35	Female	AML	Adverse		0.57	1	6.2	11.2	41	90	10	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8190a	AML-SG	60	Female	AML	Intermediate		0.37	1	83.5	7.199999809	57	70	81	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8191a	AML-SG	53	Male	AML	Favorable		2.52	1	25.4	10.69999981	27		77	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8192a	AML-SG	38	Male	AML	Favorable		1	1	24.3	10.89999962	249	61	26	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8193a	AML-SG	31	Female	AML	Favorable		8.68	0	37	9.399999619	56		50	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8194a	AML-SG	47	Female	AML	Intermediate		0.62	1	34.9	8.5	45	95	93	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8195a	AML-SG	48	Female	AML	Favorable		8.88	0	29.1	9.5	12		62	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8196a	AML-SG	60	Female	AML	Adverse		0.04	1	7.55	7.900000095	27		65	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8197a	AML-SG	31	Female	AML	Intermediate		1.53	0	1.5	5.900000095	43	35		Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8198a	AML-SG	41	Male	AML	Adverse		0.42	1	9.4	7	64	75	88	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD8199a	AML-SG	40	Female	AML	Adverse		0.47	1	23.3	5.6	23	80	76	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD8200a	AML-SG	42	Female	AML	Favorable		1.37	1	15.7	7.6	50	95	65	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8202a	AML-SG	55	Female	sAML	Intermediate		7.6	0	67.9	7.2	142	87	90	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8203a	AML-SG	39	Male	AML	Intermediate		7.08	0	56.1	9.3	147	32	12	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8204a	AML-SG	59	Female	AML	Favorable		5.42	0	2.8	13.7	131	20	0	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8205a	AML-SG	26	Male	AML	Adverse		0.55	1	67	8.4	80	90	64	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD8206a	AML-SG	51	Female	AML	Favorable		4.02	0	66.3	9.3	43	88	9	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8208a	AML-SG	61	Female	AML	Favorable		1.2	1	153	9.9	38	90		Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8209a	AML-SG	54	Male	AML	Adverse		0.47	1	6.79	7.5	53	70	29	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8210a	AML-SG	53	Female	AML	Favorable		7.62	0	2.6	9	87	30	0	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8211a	AML-SG	42	Female	AML	Favorable		7.63	0	121.2	9.2	42	90	85	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8212a	AML-SG	40	Female	AML	Favorable		7.48	0	77.1	7.5	14	47	53	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8213a	AML-SG	48	Female	AML	Favorable		5.99	1	71.2	9.2	52	94	98	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8214a	AML-SG	56	Male	sAML	Adverse		0.36	1	7	13.3	76	90	7	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8216a	AML-SG	59	Female	AML	Intermediate		2.41	1	15.6	8.6	20	50	61	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8217a	AML-SG	30	Male	AML	Intermediate		4.55	0	1.6	10.3	33	20	0	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8218a	AML-SG	60	Male	tAML	Favorable		0.38	1	5.7	9.1	141		57	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8219a	AML-SG	49	Female	AML	Favorable		7.55	0	5.5	7.9	35	71	56	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8220a	AML-SG	59	Female	sAML	Adverse		0.07	1	61.3	11.6	321	85	70	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD8222a	AML-SG	32	Female	AML	Favorable		7.54	0	104	12	20	90	77	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8224a	AML-SG	57	Male	AML	Favorable		0.35	1	8.4	10.2	144	35	76	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8225a	AML-SG	55	Male	AML	Favorable		1.25	1	12.3	9.8	128	37	29	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8226a	AML-SG	54	Female	AML	Intermediate		0.77	1	170.4	6.6	48		71	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8227a	AML-SG	56	Female	AML	Adverse		0.46	1	7.7	10	10	81	32	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD8228a	AML-SG	51	Female	sAML	Intermediate		7.51	0	7.6	10.4	34	35	11	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8229a	AML-SG	38	Female	AML	Favorable		7.01	0	96.8	8.4	36	78	100	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8230a	AML-SG	50	Female	AML	Adverse		7.01	0	67	6.9	11	95	99	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8231a	AML-SG	44	Male	AML	Favorable		2.31	1	3.7	6	131	70	0	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8232a	AML-SG	28	Female	AML	Adverse		0.37	1	55.8	7	185	91	85	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8233a	AML-SG	53	Male	AML	Favorable		5.35	0	8.4	9.8	69	37	24	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8234a	AML-SG	49	Female	AML	Adverse		7.17	0	3.8	8.5	36	80	9	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD8235a	AML-SG	50	Male	AML	Favorable		6.84	0	21.8	6.4	141	88	44	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8236a	AML-SG	36	Female	AML	Favorable		6.28	0	38.4	10.8	90	70	27	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8237a	AML-SG	50	Female	AML	Adverse		0.37	1	4.7	7	127	36	10	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8238a	AML-SG	39	Female	AML	Favorable		7.58	0	11.3	9.4	688	44	44	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8239a	AML-SG	51	Female	AML	Adverse		0.01	1	58.2	12.8	16	80	90	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD8240a	AML-SG	48	Female	AML	Favorable		0.88	1	6.3	10.2	33	60	6	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8241a	AML-SG	41	Male	AML	Intermediate		6.66	0	1.6	10.8	168	26	0	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8242a	AML-SG	53	Female	AML	Intermediate		3.93	0	16.2	8.8	54	44	14	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8243a	AML-SG	37	Male	AML	Favorable		3.95	0	36.3	6.6	5	90	76	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8244a	AML-SG	49	Female	AML	Favorable		7.36	0	37.2	10.3	16	80	8	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8245a	AML-SG	48	Male	AML	Favorable		1.2	1	35.7	12.2	72	85	85	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8246a	AML-SG	56	Male	AML	Favorable		6.53	0	33.4	9.3	47	70	73	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8247a	AML-SG	52	Female	AML	Favorable		4.1	0	21.4	10.2	43	79	13	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8248a	AML-SG	42	Female	AML	Favorable		7.34	0	121.6	8.4	25	90	46	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8249a	AML-SG	51	Male	AML	Adverse		6.41	0	74.2	9.7	46	90	89	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8250a	AML-SG	47	Female	AML	Intermediate		1.03	1	2.2	9.3	17	50	37	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8251a	AML-SG	55	Female	AML	Favorable		3.93	1	53.9	10.1	92	95	2	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8252a	AML-SG	50	Female	AML	Intermediate		7.38	0	5.2	9.6	160	40	23	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8253a	AML-SG	30	Female	AML	Favorable		0.96	1	151.6	7.8	24	72	24	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8254a	AML-SG	52	Female	AML	Intermediate		5.27	0	73.6	9.9	29	17	31	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8255a	AML-SG	34	Female	AML	Adverse		7.36	0	9.1	11.2	46	52	45	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8256a	AML-SG	61	Male	AML	Favorable		0.97	1	9.8	11.1	135	91	37	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8257a	AML-SG	48	Female	AML	Favorable		7.24	0	4.2	5	29	50	4	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8258a	AML-SG	51	Female	sAML	Adverse		1.3	1	11	10.2	916	85	25	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8259a	AML-SG	38	Male	AML	Adverse		0	1	342	9.1	85	80	90	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8260a	AML-SG	61	Male	AML	Adverse		3.04	0	3.1	9.3	130	80	1	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD8261a	AML-SG	59	Male	AML	Intermediate		0.91	1	2.2	10.3	52	30	2	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8262a	AML-SG	55	Female	AML	Adverse		0.01	1	81.5	10.2	42	95	95	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8263a	AML-SG	58	Female	AML	Adverse		7.05	0	5	10.2	18	78		Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8264a	AML-SG	56	Male	AML	Intermediate		0.18	1	16.8	8.9	43	70	77	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8265a	AML-SG	56	Male	AML	Intermediate		2.98	0	6.2	12.7	380	80	45	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8266a	AML-SG	44	Male	AML	Adverse		0.61	1	65.4	7.5	105	86	73	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8267a	AML-SG	44	Female	AML	Favorable		8.02	0	10.7	8.7	61	52	6	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8268a	AML-SG	54	Female	AML	Favorable		6.59	0	107	9.6	155	100	90	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8269a	AML-SG	57	Male	AML	Intermediate		2.8	1	125	12.5	73	90	63	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8270a	AML-SG	40	Male	AML	Adverse		4.19	1	37.4	8.9	242	91	93	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8271a	AML-SG	46	Male	AML	Favorable		6.09	1	25.4	10.6	90	90		Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8272a	AML-SG	35	Male	AML	Intermediate		0.8	1	29.2	9.8	23	90	82	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8273a	AML-SG	58	Male	AML	Adverse		1.69	0	4.65	9.7	64	80	1	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8274a	AML-SG	49	Female	AML	Intermediate		0.75	1	41.7	8.9	67	70	46	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8275a	AML-SG	32	Male	AML	Favorable		2.35	1	92.8	8.8	83	80	90	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8276a	AML-SG	44	Male	AML	Favorable		5.25	0	14.8	7	90	80	30	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8277a	AML-SG	51	Female	AML	Favorable		2.31	1	12.5	14.7	15	75	69	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8278a	AML-SG	47	Male	AML	Intermediate		0.76	1	3	10.9	42	90	6	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8279a	AML-SG	45	Male	AML	Favorable		4.24	0	64.5	5.1	23	90	87	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8280a	AML-SG	58	Male	AML	Adverse		0.33	1	2.9	6.5	105	50	0	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD8281a	AML-SG	45	Male	AML	Adverse		2.44	1	7.8	8.9	80	35	1	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8282a	AML-SG	44	Female	tAML	Favorable		7.16	0	50.1	7.3	111	73	82	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8283a	AML-SG	61	Female	tAML	Intermediate		0.1	1	16.8	9.9	55	70	51	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8284a	AML-SG	20	Male	AML	Favorable		6.84	0	102	5.7	54	95	5	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8285a	AML-SG	52	Female	AML	Favorable		0.57	1	129.6	6.8	28	53	43	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8286a	AML-SG	36	Female	AML	Favorable		7.47	0	149.3	11.6	71	91	77	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8287a	AML-SG	59	Male	AML	Favorable		7.38	0	8.3	9.8	64	40	87	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8288a	AML-SG	43	Male	AML	Favorable		1.19	0	2.3	10.6	121	76	60	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8289a	AML-SG	44	Male	AML	Adverse		7.73	0	1.6	5.9	30	15	0	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8290a	AML-SG	52	Male	AML	Adverse		0.54	1	67.9	8	51	50	9	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8291a	AML-SG	47	Female	AML	Favorable		4.06	1	29.4	8.7	160	95	66	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8292a	AML-SG	45	Male	AML	Favorable		7.69	0	41.9	11.1	33	45	70	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8293a	AML-SG	46	Male	AML	Favorable		0.9	0	8.9	8.9	251	90	6	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8294a	AML-SG	56	Female	tAML	Favorable		1.33	1	64.2	12.1	80	80	78	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8295a	AML-SG	48	Male	AML	Intermediate		5.74	0	0.9	10.5	314	21	0	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8296a	AML-SG	25	Female	AML	Intermediate		0.96	1	1	9.1	42	29	6	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8297a	AML-SG	36	Female	AML	Favorable		7.69	0	15.9	9.4	89	70	30	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8298a	AML-SG	57	Male	AML	Intermediate		1.16	1	21.3	11	78	90	61	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8299a	AML-SG	60	Female	AML	Intermediate		2.26	1	111.3	8.3	62	90	75	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8300a	AML-SG	42	Male	AML	Intermediate		5.08	0	57.5	7.8	60	86	16	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8301a	AML-SG	60	Female	AML	Favorable		0.99	1	15.4	7.5	109	31	7	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8302a	AML-SG	42	Female	AML	Intermediate		0.69	1	23.6	11.2	23		62	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8303a	AML-SG	29	Male	AML	Favorable		0.65	1	16.5	9.9	110	75	24	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8304a	AML-SG	23	Female	AML	Favorable		7.13	0	19.8	8.7	97	25		Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8305a	AML-SG	26	Male	AML	Adverse		0.77	1	61.7	6.7	24	95	99	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8306a	AML-SG	55	Male	AML	Favorable		5.23	0	9.2	7.2	46	50	29	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8307a	AML-SG	57	Male	AML	Favorable		1.45	1	2.6	9.6	46	80	0	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8308a	AML-SG	34	Male	AML	Intermediate		5.72	0	2.1	8.8	71	20	3	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8309a	AML-SG	46	Female	AML	Favorable		7.45	0	53.6	12.4	32	100	65	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8310a	AML-SG	30	Male	AML	Adverse		6.55	0				61	36	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8312a	AML-SG	52	Female	sAML	Adverse		0.32	1	1.3	8.4	34	31	10	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD8313a	AML-SG	23	Female	AML	Favorable		6.48	0	102.1	8.3	38		6	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8314a	AML-SG	49	Male	AML	Favorable		1.83	1	33.7	7.1	123	86	87	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8315a	AML-SG	48	Female	AML	Favorable		0.28	1	2.9	10.4	111	90	29	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8316a	AML-SG	49	Male	AML	Intermediate		7.06	0	70.5	10.9	63	37	1	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8317a	AML-SG	49	Female	AML	Intermediate		1.1	1	3.2	8.2	125	74	8	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8318a	AML-SG	47	Female	AML	Favorable		6.38	0	97.7	9.4	23		30	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8319a	AML-SG	56	Female	sAML	Adverse		0.31	1	15.1	9.7	9		64	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD8320a	AML-SG	58	Male	AML	Intermediate		0.18	1	1.2	10.9	563	25	3	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8322a	AML-SG	39	Male	AML	Intermediate		6.7	0	47.3	9.3	30	67		Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8323a	AML-SG	55	Female	AML	Favorable		5.61	0	105.3	8.4	42	90	19	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8324a	AML-SG	55	Male	AML	Favorable		1.28	1	5	8.2	20	50	27	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8325a	AML-SG	57	Male	sAML	Intermediate		1.43	1	50.9	11.8	20	30	3	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8326a	AML-SG	49	Female	AML	Favorable		0.73	1	16.5	6.2	142	90	25	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8327a	AML-SG	61	Male	AML	Favorable		4.5	1	9.1	8.5	111	50	0	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8328a	AML-SG	39	Male	AML	Favorable		7.51	0	81.7	10.4	75	92	79	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8329a	AML-SG	40	Female	AML	Favorable		7.99	0	28.6	9.6	21	82	1	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8330a	AML-SG	48	Female	AML	Adverse		1.03	1	26.6	7.4	80	91	90	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8332a	AML-SG	54	Female	AML	Adverse		0.04	1	21.8	8.7	63	37	50	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8333a	AML-SG	55	Male	AML	Adverse		0.04	1	142	8	60	91	92	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD8334a	AML-SG	39	Male	AML	Favorable		5.85	0	16.1	2.7	300	45	12	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8335a	AML-SG	39	Male	AML	Favorable		6.79	0	167.5	8.1	25	99		Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8336a	AML-SG	36	Female	AML	Adverse		6.94	0	2.5	13	177	40	23	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8337a	AML-SG	55	Female	tAML	Intermediate		1.19	1	35.5	9.5	94	30	0	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8338a	AML-SG	26	Male	AML	Intermediate		0.81	1	201.5	7.5	28	90	63	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8339a	AML-SG	21	Male	AML	Adverse		5.97	0	3.1	10.8	152	83	30	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8340a	AML-SG	51	Female	AML	Favorable		6.41	0	3.2	10	207	50	14	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8342a	AML-SG	56	Female	tAML	Intermediate		1.56	1	17.2	9.1	62	30	28	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8343a	AML-SG	57	Female	AML	Intermediate		6.09	0	6	6.1	69	60	5.8	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8344a	AML-SG	28	Female	AML	Intermediate		0.86	1	44.2	7.1	21	96	30	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8345a	AML-SG	47	Male	AML	Adverse		4.85	1	0.7	6.2	94	85		Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8346a	AML-SG	52	Female	AML	Favorable		1.5	1	49.3	7.6	41	95	38	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8347a	AML-SG	41	Female	AML	Favorable		6.05	0	2.7	11.2	36	89	39	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8348a	AML-SG	60	Male	oAML	Adverse		4.82	0	2.6	7.5	435	90	36	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8349a	AML-SG	56	Male	AML	Intermediate		1.66	1	3.1	12	90	88	27	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8350a	AML-SG	42	Male	AML	Adverse		1.26	1	86	7.9	103	95	92	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8351a	AML-SG	43	Female	AML	Favorable		1.52	0	3.5	9.8	47	62	70	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8352a	AML-SG	44	Male	AML	Favorable		6.64	0	13.1	11.6	29	60	41	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8353a	AML-SG	49	Female	AML	Favorable		0.55	0	24.6	5.9	74	89.5	67	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8355a	AML-SG	30	Female	AML	Adverse		0.27	1	130.5	10.4	33	90	98	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8356a	AML-SG	60	Male	AML	Adverse		4	0	12.4	8.6	28	85		Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8358a	AML-SG	28	Female	AML	Intermediate		2.49	1	50	13.3	98	90	79	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8359a	AML-SG	31	Female	AML	Adverse		4.67	0	43.9	11.5	108	70	70	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8360a	AML-SG	37	Male	AML	Favorable		5.4	0	6.9	15.1	178	70	43	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8362a	AML-SG	61	Male	oAML	Adverse		2.64	1	117.2	7.7	71	63	22	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD8363a	AML-SG	50	Male	AML	Favorable		0.8	1	27	7.2	59	42	20	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8364a	AML-SG	55	Male	AML	Intermediate		4.82	1	5.9	7.1	208	90	80	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8365a	AML-SG	36	Male	AML	Favorable		5.46	0	14.2	11.2	91	35	18	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8367a	AML-SG	40	Female	AML	Favorable		0.75	1	6	7.8	30	84	63	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8368a	AML-SG	59	Female	AML	Favorable		5.96	0	17.1	8.8	127	20	82	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8370a	AML-SG	43	Female	AML	Adverse		0.45	1	106	8.4	19	80	72	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8371a	AML-SG	54	Male	AML	Favorable		0.06	1	7.3	6	30	90	38	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8372a	AML-SG	56	Female	AML	Favorable		7.08	0	3.5	7.3	56	20	17	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8373a	AML-SG	52	Male	AML	Favorable		1.9	1	31.3	9.5	53	65	24	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8374a	AML-SG	49	Female	AML	Intermediate		2.83	1	0.2	7.7	8	80		Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8375a	AML-SG	38	Female	AML	Intermediate		1.45	1	251.4	7	169	95	90	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8376a	AML-SG	57	Male	AML	Intermediate		1.88	1	37	7.7	29	80	20	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8377a	AML-SG	53	Male	AML	Intermediate		5.68	0	2.4	8.3	300	40	3	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8378a	AML-SG	26	Male	AML	Intermediate		6.43	0	2.1	6.8	16	7	10	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8379a	AML-SG	23	Male	AML	Favorable		6.15	0	72.5	7.8	35	80	37	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8380a	AML-SG	40	Male	AML	Intermediate		1.08	1	74.5	7.9	31	80	77	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8381a	AML-SG	45	Female	AML	Intermediate		6.68	0	3.2	8.3	86	70	5	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8382a	AML-SG	54	Male	AML	Intermediate		6.5	0	1.6	9.7	44	75	29	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8383a	AML-SG	57	Male	AML	Intermediate		0.42	1	33.3	9.3	36	41		Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8384a	AML-SG	52	Female	AML	Adverse		0.76	1	146.4	5.3	241		82	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8385a	AML-SG	41	Female	AML	Intermediate		5.21	1	22.1	6.8	15	53	66	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8386a	AML-SG	46	Female	AML	Favorable		0.06	1	4.5	8.2	39		24	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8387a	AML-SG	42	Male	sAML	Intermediate		5.57	0	14.2	8.7	25	44	26	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8388a	AML-SG	30	Female	AML	Adverse		6.61	0	22.6	10.2	239	75	0	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8389a	AML-SG	50	Male	AML	Favorable		6.34	0	21.7	10.3	16	69	98	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8390a	AML-SG	48	Female	AML	Adverse		0.97	1	1.8	9.2	70	40		Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8391a	AML-SG	60	Female	tAML	Intermediate		0.78	1	2.7	8.2	16	85	37	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8392a	AML-SG	54	Male	AML	Adverse		0.8	1	119.9	12	100	90	96	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8393a	AML-SG	34	Female	AML	Favorable		6.04	0	14.7	9.3	28	82	6	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8394a	AML-SG	49	Male	AML	Favorable		5.7	0	36.2	7.6	289	49	4	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8395a	AML-SG	60	Male	AML	Adverse		5.56	0	2	8.4	25	60	6	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8396a	AML-SG	45	Male	AML	Adverse		6.46	0	197	8.9	163	27	58	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8397a	AML-SG	61	Female	tAML	Adverse		1.25	0	53.7	9.3	90	2	90	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8398a	AML-SG	47	Female	AML	Favorable		0.84	1	53.54	12.1	63		30	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8399a	AML-SG	42	Male	AML	Favorable		1.54	1	109.5	11.2	25	80	94	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8400a	AML-SG	28	Female	AML	Intermediate		1.1	1	98.5	6.2	28	100	74	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8401a	AML-SG	53	Female	AML	Intermediate		5.57	0	1.5	9.3	395	36	2	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8402a	AML-SG	50	Male	AML	Intermediate		2.86	1	1.7	7.9	30	58	4	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8403a	AML-SG	58	Female	AML	Favorable		6.17	0	2.4	7	68	60	24	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8404a	AML-SG	58	Female	tAML	Favorable		1.46	1	6.5	8.9	14		77	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8405a	AML-SG	56	Female	AML	Favorable		1.35	0	9.3	10.4	53	78	62	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8406a	AML-SG	39	Male	AML	Favorable		1.01	1	43	12	14	78	52	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8407a	AML-SG	44	Male	AML	Favorable		0.09	1	8.9	8.7	15	90	91	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8408a	AML-SG	41	Male	AML	Intermediate		2.93	1	9.93	16.2	338	0	0	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8409a	AML-SG	35	Male	AML	Intermediate		1.06	1	184.3	8.9	51	88	40	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8410a	AML-SG	52	Male	AML	Adverse		1.24	1	235.6	13.2	70	95		Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8411a	AML-SG	56	Male	AML	Adverse		2.09	1	2.2	8.9	72	41	0	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8412a	AML-SG	51	Female	AML	Favorable		0.5	1	8.2	7.3	545	40	49	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8413a	AML-SG	57	Female	AML	Favorable		5.96	0	34.1	8.3	91	40	85	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8414a	AML-SG	24	Male	AML	Favorable		5.36	0	153	7.2	28	70	75	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8415a	AML-SG	44	Female	sAML	Intermediate		5.31	0	1.7	8.5	30	50	0	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8416a	AML-SG	61	Female	AML	Favorable		3.95	0	4.6	10.6	272	30	4	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8417a	AML-SG	50	Female	AML	Intermediate		1.78	1	37.2	7.9	32	70	58	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8418a	AML-SG	59	Male	AML	Adverse		0.46	1	7.2	9.2	15	18		Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8419a	AML-SG	44	Male	AML	Intermediate		5.42	1	42.2	10.9	77	100		Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8420a	AML-SG	56	Male	sAML	Adverse		0.83	1	34.6	8.9	87	88	95	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8421a	AML-SG	59	Female	AML	Intermediate		4.36	1	1.3	9.3	10	90	53	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8422a	AML-SG	20	Male	AML	Intermediate		5.94	0	51.6	14.6	91	80	73	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8423a	AML-SG	47	Female	oAML	Intermediate		5.99	0	106.9	10.1	36	98	88	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8424a	AML-SG	39	Female	AML	Favorable		0.99	1	16.4	5.1	128	70	66	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8425a	AML-SG	22	Male	AML	Favorable		1.47	1	27.6	9.9	86	90	15	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8426a	AML-SG	59	Male	AML	Adverse		2.08	1	4.9	10.9	304	75	35	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8427a	AML-SG	57	Female	AML	Adverse		1.28	1	22.5	6.9	71	85	67	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8428a	AML-SG	59	Male	AML	Intermediate		5.2	0	2.1	12.2	130	50	0	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8429a	AML-SG	39	Male	tAML	Adverse		5.24	0	1.8	10.5	52	62	1	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD8430a	AML-SG	61	Female	AML	Favorable		5.18	0	38.4	8.5	73	38	2	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8431a	AML-SG	48	Female	AML	Adverse		5.46	0	63	6.3	27	70	65	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD8433a	AML-SG	61	Male	AML	Intermediate		6.45	0				95		Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8434a	AML-SG	52	Male	AML	Adverse		6.17	0	2.1	7.9	72	17	4	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8435a	AML-SG	28	Male	AML	Favorable		0.96	1	23.9	10.9	47	85		Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8436a	AML-SG	42	Male	AML	Favorable		0.42	1	36.3	7.5	30	35	24	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8437a	AML-SG	59	Female	AML	Adverse		4.72	0	5.6	8.5	22	87	51	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8438a	AML-SG	35	Female	AML	Favorable		6.15	0	81.6	6.3	20	100	100	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8439a	AML-SG	50	Male	sAML	Adverse		6.05	0	6.2	9.2	85	31	21	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8440a	AML-SG	53	Male	AML	Intermediate		0.19	1	6.1	9.1	46	20	6	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8441a	AML-SG	33	Female	AML	Favorable		3.43	0	1.9	10.3	180	63	0	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8442a	AML-SG	29	Female	AML	Favorable		0.99	1	5.2	7.7	24	75	24	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8443a	AML-SG	61	Male	AML	Intermediate		1.16	1	4.5	8.6	45	31	2	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8444a	AML-SG	52	Male	AML	Favorable		4.68	0	17.6	8.3	15	85	90	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8445a	AML-SG	40	Female	AML	Favorable		5.14	0	34.79	11.7	28	90	26	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8446a	AML-SG	34	Female	AML	Favorable		6	0	5.7	8	50	52	10	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8447a	AML-SG	56	Female	AML	Adverse		1.11	1	59.7	9.9	16		9	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8448a	AML-SG	54	Male	AML	Intermediate		0.57	1	243.6	8.3	49	92	88	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8449a	AML-SG	43	Male	AML	Adverse		2.99	1	20.8	8	34	80	17	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8450a	AML-SG	51	Female	AML	Adverse		1.46	1	13.8	8.8	25	83	89	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8451a	AML-SG	58	Male	AML	Adverse		1.24	0	12.5	8.7	20	50	47	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8452a	AML-SG	55	Male	AML	Intermediate		4.25	0	63.5	10.3	17	60	0	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8453a	AML-SG	41	Male	AML	Favorable		5.28	0	47.4	10.8	56	90	83	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8454a	AML-SG	58	Male	AML	Adverse		2	1	7.2	9.4	172	75	0	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8456a	AML-SG	59	Male	AML	Favorable		1.31	1	39	9.7	31	99	48	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8457a	AML-SG	58	Male	AML	Adverse		0.42	1	74.7	8.4	38	50	5	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8458a	AML-SG	49	Male	AML	Adverse		5.79	0	5.6	8.8	5	39	2	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8460a	AML-SG	41	Male	AML	Favorable		5.79	0	5.9	7.3	58	52	58	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8463a	AML-SG	48	Male	AML	Intermediate		9.02	0	137	9.800000191	93	96	88	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8464a	AML-SG	38	Female	AML	Favorable		9.35	0	6.1	13.39999962	179	90	71	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8465a	AML-SG	58	Male	AML	Favorable		9.39	0	33.9	7	10	60	68	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8466a	AML-SG	48	Male	AML	Intermediate		11.17	0	49	10.69999981	38	93	98	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8467a	AML-SG	41	Male	AML	Favorable		7	0	24.2	12.19999981	14	73	59	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8468a	AML-SG	55	Male	AML	Favorable		7.68	0	1.5	12.60000038	8	35	35	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8469a	AML-SG	59	Female	AML	Favorable		4.07	1	41.3	8.5	155	15	0	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8470a	AML-SG	38	Female	AML	Favorable		2.14	1	8.4	7.599999905	122	80	20	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8471a	AML-SG	46	Female	AML	Favorable		14.63	0	89.5	5.199999809	44		33	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8472a	AML-SG	39	Female	AML	Favorable		13.37	0	34.2	7.199999809	11	95	89	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8473a	AML-SG	48	Male	AML	Favorable		13.58	0	94.38	9	277	90	27	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8474a	AML-SG	47	Male	AML	Intermediate		0.9	1	54.6	9.899999619	158	98	64	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8475a	AML-SG	31	Female	AML	Favorable		1.84	1	39.4	9.699999809	8	77	81	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8476a	AML-SG	61	Female	AML	Intermediate		9.77	0	88	8.600000381	378	60	83	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8477a	AML-SG	57	Male	AML	Adverse		0.16	1	10.7	7.5	50	100	88	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8478a	AML-SG	46	Female	AML	Favorable		9.44	0	2.15	5.400000095	25	100		Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8479a	AML-SG	28	Male	AML	Favorable		11.34	0	8.2	8.899999619	21	52	32	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8481a	AML-SG	57	Male	AML	Favorable		14.11	0	27.9	7.900000095	81	16	30	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8482a	AML-SG	22	Female	AML	Favorable		0.12	1	46.2	7.599999905	24	90	35	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8483a	AML-SG	39	Male	AML	Adverse		1.81	1	51.8	8.399999619	20	80	58	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8484a	AML-SG	43	Male	AML	Favorable		7.04	0	21	8.399999619	29.8	92	70	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8485a	AML-SG	39	Male	AML	Adverse		4.21	1	3.8	6	16	66	25	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD8486a	AML-SG	47	Female	AML	Intermediate		0.8	1	126.26	6.800000191	53	80	80	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8487a	AML-SG	57	Male	sAML	Adverse		0.88	1	66.4	9.600000381	105	77	88	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8488a	AML-SG	50	Male	AML	Adverse		1.15	1	34	12.5	27	30	78	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8489a	AML-SG	38	Female	AML	Intermediate		0.76	1	13.5	9.600000381	96	84	94	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8491a	AML-SG	39	Female	AML	Favorable		14.74	0	20.5	8.399999619	33	90	89	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8492a	AML-SG	37	Male	AML	Favorable		12.02	0	68	14.19999981	83	98	84	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8493a	AML-SG	39	Male	AML	Adverse		1.08	1	76.6	9.300000191	106	90	46	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8494a	AML-SG	51	Female	AML	Intermediate		0.34	1	120	8.699999809	22	95	80	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8495a	AML-SG	57	Male	AML	Favorable		8.02	0	11.5	14.60000038	746	39	14	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8496a	AML-SG	50	Male	AML	Adverse		0.76	1	2.4	7.099999905	23	26	40	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD8497a	AML-SG	37	Female	AML	Intermediate		2.76	1	101.7	10.39999962	124	56	17	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8498a	AML-SG	43	Male	AML	Favorable		0.01	1	16	13.10000038	15	90	69	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8499a	AML-SG	43	Male	AML	Intermediate		0.05	1	56.11	7.300000191	24	85	96	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8500a	AML-SG	49	Female	AML	Intermediate		11.3	0	2	10.30000019	189	90	3	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8501a	AML-SG	49	Male	AML	Favorable		14.19	0	1.4	8.600000381	29	50	30	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8502a	AML-SG	33	Male	AML	Adverse		1.38	1	2.26	8.020000458	154	32	22	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD8504a	AML-SG	45	Female	AML	Favorable		13.48	0	8.8	10.89999962	74	47	15	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8505a	AML-SG	32	Male	AML	Favorable		8.51	0	26	5.199999809	45	75	88	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8506a	AML-SG	56	Male	AML	Favorable		1.42	1	1.47	11.30000019	52	2	23	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8507a	AML-SG	61	Female	tAML	Favorable		7.69	0	0.7	8.399999619	102			Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8508a	AML-SG	59	Male	AML	Adverse		0.6	1	139.6	7.199999809	15	80	97	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8509a	AML-SG	47	Female	AML	Adverse		0.98	1	1.1	7.5	41	15	2	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD8510a	AML-SG	35	Female	AML	Adverse		0.69	1	161.5	7.900000095	79	90	92	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8511a	AML-SG	40	Female	AML	Intermediate		2.47	1	1.26	8.600000381	396	38	8	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8512a	AML-SG	28	Female	AML	Favorable		1.04	1	16.7	7.599999905	44	95	59	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8513a	AML-SG	26	Male	AML	Intermediate		4.97	0	2.4	10.60000038	110		97	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8514a	AML-SG	42	Male	AML	Intermediate		7.62	0	12.6	11.10000038	54		52	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8531a	AML-SG	42	Female	AML	Adverse		0.1	1	91.2	8	31	80	96	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD8532a	AML-SG	27	Male	AML	Adverse		2.21	1	166	8.300000191	100	8	8	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8533a	AML-SG	53	Female	AML	Intermediate		12.5	0	19.1	6.599999905	150	90	68	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8534a	AML-SG	51	Male	AML	Favorable		0.02	1	5.9	13.89999962	13	8	2	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8535a	AML-SG	45	Female	AML	Favorable		8.34	0	10.8	8.5	174	80	33	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8536a	AML-SG	53	Male	AML	Intermediate		0.29	1	132	10	94	85	80	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8537a	AML-SG	58	Male	AML	Adverse		0.78	1	31.5	8.329999924	296	69	79	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD8538a	AML-SG	53	Male	AML	Favorable		0.65	1	58.9	8.699999809	39	45	51	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8539a	AML-SG	48	Male	tAML	Favorable		0.74	1	3	5.900000095	32		50	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8540a	AML-SG	42	Female	AML	Favorable		0.54	1	172.5	11.5	92	85	76	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8541a	AML-SG	59	Male	AML	Intermediate		4.4	1	21.2	9.699999809	17	4	5	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8542a	AML-SG	20	Male	AML	Adverse		9.6	0	45.5	7.599999905	13	70	53	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8543a	AML-SG	45	Male	AML	Adverse		1.2	1	108	8.800000191	52	90	78	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8544a	AML-SG	45	Female	AML	Favorable		0.96	1	4.7	13.30000019	138	20	0	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8546a	AML-SG	59	Male	AML	Intermediate		0.07	1	13.7	9.699999809	46.4	84	81	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8547a	AML-SG	39	Female	AML	Adverse		13.32	0	9.69	6.800000191	44	80	3	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8548a	AML-SG	40	Female	AML	Favorable		8.88	0	52.3	9.399999619	47	32	32	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8549a	AML-SG	48	Female	AML	Intermediate		1.43	1	6.6	7.300000191	426	45		Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8550a	AML-SG	36	Male	AML	Adverse		0	1	427	10	89		61	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8551a	AML-SG	44	Female	AML	Favorable		0.14	1	175	6	21	100	97	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8552a	AML-SG	60	Male	AML	Adverse		0.12	1	0.5	8.100000381	24	90		Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD8553a	AML-SG	50	Female	AML	Favorable		13.9	0	4.07	6.300000191	45	70	37	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8554a	AML-SG	56	Male	AML	Intermediate		0.59	1	6.3	10.80000019	33	70	27	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8555a	AML-SG	27	Female	AML	Favorable		5.02	0	4	7.699999809	13		3	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8556a	AML-SG	40	Male	AML	Intermediate		10.62	0	10.8	8.800000191	25		8	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8557a	AML-SG	49	Male	AML	Favorable		8.5	1	52.5	11.39999962	149	31	5	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8558a	AML-SG	36	Female	AML	Favorable		1.1	1	77.8	6.090000153	99.1	90	41	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8559a	AML-SG	35	Female	AML	Intermediate		0.27	1	47.3	9.300000191	26	52	52	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8560a	AML-SG	55	Male	AML	Intermediate		0.2	1	2.3	9.699999809	41	50	0	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8562a	AML-SG	60	Female	AML	Favorable		0.74	1	172	11.19999981	65	90	90	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8567a	AML-SG	23	Male	AML	Adverse		4.18	1	10.3	9.800000191	162	90	37	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD8568a	AML-SG	48	Female	AML	Favorable		8.77	0	37.5	9	48	51	13	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8569a	AML-SG	31	Female	AML	Adverse		6.67	0	1.9	12	81	80		Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8570a	AML-SG	38	Female	AML	Favorable		7.26	0	2.9	9.199999809	38	28	17	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8572a	AML-SG	46	Male	AML	Intermediate		1.61	1	15	9.5	145	59	56	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8573a	AML-SG	48	Male	oAML	Adverse		1.39	1	69.8	8.8	207	80	79	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8574a	AML-SG	42	Female	sAML	Favorable		0.9	1	54	11.8	27	90	78	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8575a	AML-SG	53	Male	AML	Adverse		7.3	0	6.3	8.1	198	95	50	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD8576a	AML-SG	47	Female	AML	Adverse		0.01	1	76.5	6.1	23	95	90	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD8577a	AML-SG	52	Female	AML	Adverse		0.1	1	10	9.5	12	90	10	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD8578a	AML-SG	60	Male	AML	Adverse		0.57	1	2.9	7.6	57	75	47	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD8579a	AML-SG	48	Male	AML	Favorable		4.3	1	28.1	8.9	50	90	83	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8580a	AML-SG	48	Male	AML	Adverse		1.08	1	24.4	10	30	98	94	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8581a	AML-SG	54	Male	AML	Favorable		1.25	1	12.9	11.5	77	80	16	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8582a	AML-SG	35	Male	AML	Favorable		1.41	1	132.9	7.1	301	87	93	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8583a	AML-SG	46	Male	AML	Adverse		6.25	0	28.3	7.9	59	69		Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8584a	AML-SG	55	Male	AML	Adverse		7.5	0	1.9	5.6	121	79	4	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8585a	AML-SG	44	Male	AML	Favorable		0.47	1	42.5	10.6	14	80	92	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8586a	AML-SG	53	Female	AML	Intermediate		1.17	1	15.7	11.5	180	90	0	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8587a	AML-SG	47	Male	AML	Intermediate		0.01	1	74.4	12.3	21	88	79	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD8588a	AML-SG	55	Female	AML	Favorable		1.29	1	19.3	8.2	40	45	13	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD8589a	AML-SG	38	Male	AML	Favorable		7.04	0	80.9	7.1	47	95		Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD9197a	AML-SG	40	Male	AML	Favorable		7.76	0	19	8.6	46	57	9	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD9198a	AML-SG	48	Male	AML	Favorable		4.11	0	116	10.4	15	90	84	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD9199a	AML-SG	32	Male	tAML	Favorable		4.41	0	80	12.3	25		32	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD9200a	AML-SG	35	Male	AML	Adverse		1.1	1	24.8	7.5	34		97	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD9201a	AML-SG	50	Male	AML	Intermediate		4.78	0	1.1	12.9	240	80	2	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD9202a	AML-SG	49	Male	AML	Intermediate		2.73	1	2.7	10.4	196	40	28	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD9203a	AML-SG	57	Female	AML	Adverse		1.31	1	7	7.5	38	60	72	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD9204a	AML-SG	29	Male	AML	Intermediate		5.09	1	1.2	10.1	33	30		Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD9205a	AML-SG	58	Female	AML	Adverse		0.4	1	2.1	8.7	50	99	55	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD9206a	AML-SG	56	Male	AML	Adverse		4.27	0	2.4	10.1	245	30	3	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD9207a	AML-SG	28	Male	AML	Favorable		4.33	0	136.9	12.6	46	100	80	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD9208a	AML-SG	51	Male	AML	Adverse		4.15	0	4.8	9.9	261	50	17	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD9209a	AML-SG	28	Male	AML	Adverse		0.37	1	94.2	7.6	63	60	76	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD9210a	AML-SG	58	Female	AML	Adverse		0.02	1	103.5	8.6	157	74	76	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD9211a	AML-SG	37	Female	AML	Adverse		3.01	1	16	9.9	402		4	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD9212a	AML-SG	21	Male	AML	Favorable		7.29	1	138.5	9.2	112	91	95	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD9213a	AML-SG	61	Female	AML	Adverse		7.95	0	22.4	8.6	30	90	70	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD9214a	AML-SG	56	Male	AML	Favorable		7.97	0	2.2	7.7	37	85	44	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD9215a	AML-SG	40	Male	AML	Adverse		2.21	1	3.6	11.2	119	90	44	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD9216a	AML-SG	52	Female	tAML	Adverse		0.53	1	18.7	9.3	73		12	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD9217a	AML-SG	53	Female	AML	Adverse		0.39	1	2.8	10.5	89	80	47	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD9218a	AML-SG	48	Male	AML	Adverse		1.03	1	3.5	8.8	130	70	11	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD9220a	AML-SG	52	Male	AML	Intermediate		6.39	0	1.6	8	95	30	28	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD9221a	AML-SG	39	Male	AML	Adverse		0.7	1	3	11	100	22	0	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD9222a	AML-SG	41	Male	AML	Favorable		7.61	0	2.5	15.4	32	75	25	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD9223a	AML-SG	58	Female	AML	Adverse		1.92	1	151.8	6.2	20	95	67	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD9224a	AML-SG	58	Male	AML	Adverse		1.82	1	1.9	6.2	89	28	2	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD9225a	AML-SG	35	Female	AML	Intermediate		1.06	1	56.1	10	55	95	81	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD9226a	AML-SG	54	Male	AML	Favorable		0.27	1	72.9	15	100	90	82	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD9227a	AML-SG	59	Female	AML	Adverse		0.25	1	1	9.2	60	32	0	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD9228a	AML-SG	53	Male	tAML	Intermediate		1.42	1	30.6	10.1	18	65	29	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD9229a	AML-SG	25	Female	AML	Intermediate		6.37	0	3.1	9.8	64	75	20	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD9230a	AML-SG	41	Female	AML	Adverse		1.31	1	19.3	9.3	77	95	44	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD9231a	AML-SG	33	Male	AML	Intermediate		7.31	0	3	6.8	52	40		Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD9232a	AML-SG	60	Male	AML	Favorable		7.11	0	50.1	9.8	61	91	7	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD9233a	AML-SG	26	Female	AML	Favorable		1.09	0	45.6	10.2	71	95	21	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD9234a	AML-SG	60	Male	AML	Favorable		8.14	1	47.1	10.7	80	90	94	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD9235a	AML-SG	58	Male	AML	Adverse		3.72	1	7.6	7.4	12	70	55	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD9236a	AML-SG	55	Female	AML	Favorable		6.18	0	8.2	8.8	42	53	53	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD9237a	AML-SG	59	Male	AML	Adverse		2.16	1	40.6	9.7	46	70	58	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD9239a	AML-SG	46	Female	AML	Favorable		2.79	1	52	10	56	77	73	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD9240a	AML-SG	29	Female	AML	Favorable		8.28	0	143.8	9.7	61	98	31	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD9243a	AML-SG	39	Male	AML	Intermediate		1.33	1	214	7	256		82	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD9245a	AML-SG	48	Male	AML	Adverse		0.79	1	159	9.6	34		99	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD9246a	AML-SG	24	Male	AML	Adverse		6.53	0	31.2	10.3	50	30	18	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD9247a	AML-SG	29	Male	AML	Intermediate		6.54	0	4.2	9	105	28	41	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD9248a	AML-SG	47	Female	AML	Favorable		1.25	1	171.1	10	87	100	82	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD9249a	AML-SG	57	Female	tAML	Adverse		6.96	0	7.8	9.6	16	70	40	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD9250a	AML-SG	41	Male	AML	Adverse		4.93	1	5.3	8.4	26	90	2	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD9251a	AML-SG	38	Female	AML	Favorable		0.33	0	6.6	9.5	32	34	37	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD9252a	AML-SG	58	Female	AML	Favorable		7.12	0	128.9	8.1	41		21	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD9253a	AML-SG	59	Female	AML	Adverse		7	0	6.6	11.8	16	63	10	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD9254a	AML-SG	50	Male	AML	Favorable		6.91	0	1.2	12.6	177	75	0	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD9255a	AML-SG	45	Male	AML	Intermediate		6.64	0	6.1	8.7	32	80	47	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD9256a	AML-SG	44	Female	AML	Adverse		0.42	1	11.2	9.8	47	40	0	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD9258a	AML-SG	58	Female	AML	Adverse		6.64	0	2.2	7.9	31	53	9	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD9259a	AML-SG	57	Male	AML	Adverse		0.18	1	3.1	9.3	92	91	54	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD9260a	AML-SG	58	Female	tAML	Adverse		0.68	1	0.7	10	16	50	10	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD9262a	AML-SG	42	Female	AML	Intermediate		6.68	0	8.55	12.5	110	35	35	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD9265a	AML-SG	50	Male	AML	Adverse		0.21	1	18.3	7.7	16	83	80	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD9266a	AML-SG	39	Female	AML	Favorable		6.19	0	6.2	8.1	21	50	46	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD9267a	AML-SG	49	Male	sAML	Adverse		0.57	1	10.3	8.6	7	60	8	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD9268a	AML-SG	47	Female	AML	Favorable		2.22	1	79.7	11.9	74	90	6	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD9269a	AML-SG	48	Male	tAML	Adverse		1.88	1	47.5	13.5	52	95	88	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD9270a	AML-SG	54	Female	AML	Adverse		2.02	1	11.7	11.2	16	46	0	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD9271a	AML-SG	41	Female	AML	Intermediate		6.35	0	5.7	10	55	73	59	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD9272a	AML-SG	55	Male	AML	Favorable		6.52	0	18.4	7.8	19	90	10	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD9273a	AML-SG	51	Female	AML	Favorable		6.51	0	89.7	10.4	150	70	14	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD9274a	AML-SG	35	Male	AML	Favorable		6.5	0	8.2	7.6	26	70	63	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD9275a	AML-SG	23	Female	AML	Adverse		1.13	1	28.6	9.5	21	90	86	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD9276a	AML-SG	44	Male	AML	Favorable		2.9	1	4.3	8.7	23		68	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD9277a	AML-SG	33	Male	AML	Adverse		0.4	0	82.1	12.2	20	100	78	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD9278a	AML-SG	45	Male	AML	Intermediate		0.84	1	56.2	9.4	63	95	35	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD9279a	AML-SG	39	Male	AML	Favorable		6.33	0	5.3	9.3	48	43	62	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD9282a	AML-SG	61	Male	sAML	Adverse		0.27	0	11.4	7.3	21		27	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD9283a	AML-SG	40	Male	AML	Adverse		0.37	1	5.9	10.9	120	26	20	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD9284a	AML-SG	45	Female	AML	Favorable		0.69	1	45.3	12.3	122	91	32	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD9285a	AML-SG	56	Male	sAML	Adverse		2.19	1	33.6	5.8	190	81	61	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD9286a	AML-SG	26	Female	AML	Adverse		2.23	0	5.7	10.5	40	90	74	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD9287a	AML-SG	58	Female	tAML	Intermediate		4.88	0	26.1	10.9	27	85	23	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD9288a	AML-SG	55	Male	AML	Intermediate		2.74	1	1.2	10.4	84	90	26	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD9290a	AML-SG	46	Male	AML	Favorable		5.57	0	1.1	11.9	193	80	0	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD9291a	AML-SG	48	Male	AML	Adverse		2.05	1	1.6	10.9	113	45	23	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD9292a	AML-SG	38	Male	AML	Intermediate		6.19	0	36	11.1	30	100	76	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD9294a	AML-SG	22	Female	AML	Favorable		4.54	0	9.1	9.9	56	60	26	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD9295a	AML-SG	19	Male	tAML	Intermediate		3.18	1	36.6	11	45	85	1	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD9296a	AML-SG	44	Male	AML	Adverse		0.07	1	2.1	10.5	72	86	4	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD9297a	AML-SG	60	Male	AML	Intermediate		1.59	1	2.8	9.3	26	42	4	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD9298a	AML-SG	57	Female	AML	Intermediate		2.68	1	2.8	13.5	111	21	0	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD9299a	AML-SG	47	Female	AML	Intermediate		0.11	1	15.7	10.7	27		29	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD9300a	AML-SG	60	Male	AML	Intermediate		1.4	1	1	10.3	55	50	0	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD9301a	AML-SG	53	Female	AML	Intermediate		5.85	0	131	7.1	60	89	98	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD9302a	AML-SG	48	Female	AML	Favorable		5.01	0	15.2	8.6	111	33	12	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD9306a	AML-SG	44	Male	AML	Intermediate		5.83	0	4.1	10.7	197	21	2	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD9307a	AML-SG	55	Male	AML	Favorable		2.63	1	1.2	8.5	105	80	0	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD9308a	AML-SG	57	Male	AML	Adverse		1.42	1	2.1	6.6	56	90		Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD9309a	AML-SG	59	Female	AML	Adverse		0.24	1	1.2	8.3	45	20	4	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD9310a	AML-SG	56	Male	AML	Adverse		0.46	1	2.2	5.9	12	80	2	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD9311a	AML-SG	58	Male	oAML	Adverse		0.57	1	2.6	11.2	449	58	13	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD9312a	AML-SG	53	Male	tAML	Adverse		0.51	1	10.2	9.1	27	80	2	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD9313a	AML-SG	57	Male	AML	Adverse		0.79	0	80	8.8	590	35	84	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD9314a	AML-SG	49	Female	AML	Intermediate		4.04	1	4.1	8.3	60	40	37	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD9316a	AML-SG	36	Female	AML	Adverse		5.33	0	1.9	7.7	130	75	39	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD9317a	AML-SG	54	Female	AML	Adverse		8.1	0	20.6	8.3	16	90	76	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD9318a	AML-SG	56	Male	AML	Adverse		5	0	22.1	9.5	164	95	88	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD9319a	AML-SG	20	Male	tAML	Intermediate		5.49	0	32.3	13.4	25	90	2	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD9320a	AML-SG	57	Female	AML	Intermediate		1.6	1	42	10.3	88		2	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD9322a	AML-SG	27	Male	AML	Intermediate		5.31	0	121.6	10.4	71	90	90	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD9323a	AML-SG	55	Male	AML	Favorable		5.15	0	62.6	11.5	171	80	81	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD9324a	AML-SG	60	Male	AML	Adverse		0.81	1	152.3	8.9	39	57	52	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD9325a	AML-SG	54	Female	AML	Intermediate		2.43	1	22.5	8.7	53		88	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD9326a	AML-SG	39	Female	AML	Adverse		1.23	1	31.7	6.1	207	70	33	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD9327a	AML-SG	59	Male	oAML	Favorable		5.4	0	76	6.5	52	85	11	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD9328a	AML-SG	59	Male	AML	Adverse		0.37	1	121.1	10.9	19	79	96	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD9330a	AML-SG	31	Female	AML	Favorable		4.96	0	149	9.1	46	44	78	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD9331a	AML-SG	52	Male	sAML	Intermediate		5.1	0	4.5	12.4	7	40	13	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD9332a	AML-SG	60	Female	AML	Adverse		4.28	0	1.9	9.6	405	32	3	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD9333a	AML-SG	47	Male	AML	Intermediate		0.9	1	3.5	6.7	34	37	4	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD9334a	AML-SG	57	Female	AML	Favorable		4.8	1	78	9.8	23	100	38	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD9335a	AML-SG	52	Male	AML	Favorable		7.76	0	37.2	8.7	18	90	7	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD9337a	AML-SG	30	Male	AML	Adverse		2.21	1	22	10.7	82	56	28	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD9338a	AML-SG	36	Male	AML	Intermediate		4.93	0	63.1	15.2	57	90	0	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD9339a	AML-SG	61	Female	AML	Intermediate		0.01	1	296.6	7.4	41	10	99	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD9340a	AML-SG	58	Female	tAML	Favorable		2.62	1	22.89	9.6	72	60	82	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD9341a	AML-SG	56	Male	AML	Intermediate		1.97	1	20.2	10	16	40	64	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD9342a	AML-SG	25	Male	AML	Favorable		2.69	0	106.7	10.3	66	95	81	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD9343a	AML-SG	39	Male	AML	Intermediate		5.1	0	3.7	9.6	34	80	12	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD9344a	AML-SG	38	Female	AML	Adverse		5.02	0	4.5	10.2	26	90	5	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD9345a	AML-SG	49	Male	AML	Adverse		1	1	8.8	9.2	151	35	22	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD9349a	AML-SG	55	Female	AML	Adverse		1.14	0	1.3	11	161	51	2	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD9350a	AML-SG	46	Female	sAML	Favorable		4.99	0	182	9.9	251		15	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD9353a	AML-SG	42	Female	AML	Intermediate		5.31	0	0.4	7.1	151	20		Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD9354a	AML-SG	38	Female	AML	Favorable		4.63	0	6.8	8.2	42	45	70	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD9355a	AML-SG	58	Male	AML	Adverse		4.87	0	12.5	11.7	34	55	0	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD9356a	AML-SG	38	Female	AML	Adverse		4.98	0	30.3	9.7	33	57	75	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD9357a	AML-SG	59	Female	AML	Adverse		0.18	1	3.2	9.4	88		4	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD9358a	AML-SG	56	Female	AML	Favorable		2.76	0	9.4	10.5	47	38	43	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD9359a	AML-SG	61	Male	AML	Adverse		4.91	0	3.6	10.5	39	30	1	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD9361a	AML-SG	36	Female	AML	Favorable		6.85	0	9.16	7.5	54	90	32	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD9362a	AML-SG	56	Male	AML	Adverse		4.95	0	76.9	7.9	78	43	62	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD9364a	AML-SG	41	Male	tAML	Adverse		1.54	1	152.8	12.4	80	90	95	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD9365a	AML-SG	36	Female	AML	Intermediate		0.3	1	65.3	7.8	40	70	72	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD9368a	AML-SG	51	Male	AML	Adverse		0.31	1	1	8.3	176	60	0	Complex	amlsg_data/AMLSG_Clinical_Anon.RData
PD9369a	AML-SG	42	Male	AML	Adverse		0.82	1	2.5	8.6	108	28	8	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD9371a	AML-SG	31	Male	AML	Favorable		4.6	0	8.6	8.4	62	71	71	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD9372a	AML-SG	39	Female	AML	Intermediate		4.03	0	25.1	8.7	71	29	77	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD9373a	AML-SG	59	Male	AML	Intermediate		0.65	1	122.8	9.1	298	80	91	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD9374a	AML-SG	53	Female	AML	Intermediate		4.93	0	153.3	6.2	49	82	92	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD9376a	AML-SG	24	Male	AML	Adverse		3.86	0	51.5	8.8	41	50	18	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD9377a	AML-SG	54	Female	AML	Favorable		3.79	0	39	9.9	20	33	4	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD9378a	AML-SG	40	Male	AML	Adverse		0.79	1	1.1	10.7	86	47	0	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD9379a	AML-SG	54	Female	tAML	Adverse		0.39	1	43.3	7.1	12	70	48	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD9380a	AML-SG	54	Female	AML	Adverse		1.04	1	43.5	6.7	86	46	20	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD9381a	AML-SG	50	Female	AML	Adverse		4.83	0	21.3	8.3	89		12	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD9383a	AML-SG	58	Female	AML	Intermediate		0.99	1	234.8	7	105	90	80	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD9384a	AML-SG	51	Female	tAML	Adverse		4.54	0	5.4	10.6	327	50	0	Normal	amlsg_data/AMLSG_Clinical_Anon.RData
PD9385a	AML-SG	52	Male	AML	Favorable		4.1	0	27.4	8.4	98	45	21	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD9386a	AML-SG	59	Female	sAML	Intermediate		4.53	0	0.9	6.8	56	65	52	Other/Unknown	amlsg_data/AMLSG_Clinical_Anon.RData
PD14868a	UK-NCRI	79.7	Male	De novo	Favorable		0.191649555099247	1	175	9.8999939	199	89		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD14869c	UK-NCRI	65	Female	De novo	Intermediate		4.70636550308008	0	3.1	8.6999969	23	90		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD14871a	UK-NCRI	79.7	Female	De novo	Favorable		0.37782340862423	1	127	7.5999985	57	62		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD14872a	UK-NCRI	66.5	Male	De novo	Adverse		0.0492813141683778	1	8.2	7.6999969	124	40		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD14873a	UK-NCRI	71.8	Female	Secondary	Adverse		0.550308008213552	1	44.2	9.2999954	40	25		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD14874a	UK-NCRI	75	Female	De novo	Adverse		0.20807665982204	1	69	9.0999985	63	56		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD14875a	UK-NCRI	74.8	Male	De novo	Favorable		1.58795345653662	1	43.4	10.299995	64	70		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD14876c	UK-NCRI	65.7	Female	Secondary	Adverse		0.243668720054757	1	59.1	7.5999985	104	90		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD14877c	UK-NCRI	84.1	Male	De novo	Favorable		0.0657084188911704	1	144	6.2999992	47	92		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD14879a	UK-NCRI	76.5	Female	De novo	Adverse		0.112251882272416	1	4.6	10.599998	25	84		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD14880c	UK-NCRI	73.9	Female	De novo	Adverse		5.16632443531828	0	29.5	5.3999977	13	85		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD14881a	UK-NCRI	78.1	Female	De novo	Intermediate		1.13347022587269	1	14.3	11.199997	10	70		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD14882c	UK-NCRI	90.8	Female	De novo	Intermediate		0.054757015742642	1	13.1	7.5	45	90		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD14883a	UK-NCRI	77.7	Female	Secondary	Adverse		0.0219028062970568	1	52.9	9.1999969	12	87		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD14884a	UK-NCRI	78.2	Male	De novo	Intermediate		1.2539356605065	1	20.5	10.199997	29	58.7450018928678		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD14885a	UK-NCRI	74.7	Female	Secondary	Adverse		0.0301163586584531	1	81	8.1999969	105	50.599976		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD14888a	UK-NCRI	74.8	Female	Other	Adverse		0.728268309377139	1	16	9.5	402	16		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD14892c	UK-NCRI	71.2	Female	Other	Intermediate		4.20807665982204	0	1.3	10.5	104	17		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD14893c	UK-NCRI	85.5	Female	De novo	Adverse		1.19917864476386	1	1.9	8.5999985	103	85		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD14895a	UK-NCRI	71.4	Male	De novo	Adverse		0.818617385352498	1	32	10.699997	63	10		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD14898c	UK-NCRI	78.8	Female	De novo	Intermediate		0.082135523613963	1	3.5	8.6999969	182	65		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD14900a	UK-NCRI	75.6	Female	Secondary	Adverse		0.240930869267625	1	7.2	10.899994	5	40		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD14902a	UK-NCRI	79.7	Male	De novo	Favorable		0.449007529089665	1	53	11.199997	197	44.199982		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD14903a	UK-NCRI	84.3	Female	Secondary	Intermediate		0.112251882272416	1	45.7	8.8999939	30	84		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD14904c	UK-NCRI	67.4	Male	De novo	Adverse		4.76933607118412	0	27	8.1999969	74	43		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD14905a	UK-NCRI	77	Male	De novo	Intermediate		0.314852840520192	1	5.2	9.1999969	96	95		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD14908a	UK-NCRI	77.9	Female	De novo	Adverse		0.0684462696783025	1	61	9.1999969	72	58.7450018928678		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD14909c	UK-NCRI	70.7	Female	De novo	Adverse		0.262833675564682	1	58	11.599998	114	53		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD14910a	UK-NCRI	67.7	Female	De novo	Favorable		0.0191649555099247	1	75.8	11.299995	12	80		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD14911a	UK-NCRI	73.3	Male	De novo	Adverse		0.709103353867214	1	1.6	6	23	67		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD14912a	UK-NCRI	63.6	Female	Secondary	Adverse		0.295687885010267	1	130.6	8.8999939	48	10		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD14913c	UK-NCRI	74.4	Male	De novo	Adverse		0.101300479123888	1	3.4	5.7999992	58	75		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD14916c	UK-NCRI	72.5	Female	De novo	Intermediate		1.09240246406571	1	25.8	14	24	91		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD14918a	UK-NCRI	74.2	Male	De novo	Favorable		2.17385352498289	1	6.7	9.0999985	56	90		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD14919a	UK-NCRI	74.6	Female	Secondary	Adverse		1.77960301163587	1	18.6	13.299995	14	12		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD14921c	UK-NCRI	64.6	Female	De novo	Adverse		0.123203285420945	1	125	10.899994	113	58.7450018928678		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD14922a	UK-NCRI	71.5	Female	Secondary	Adverse		0.856947296372348	1	39	8.5999985	61	83.699951		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD14923a	UK-NCRI	68.4	Male	De novo	Favorable		0.0219028062970568	1	122.5	8.6999969	84	60		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD14924a	UK-NCRI	78.8	Female	Secondary	Adverse		0.42984257357974	1	6.6	7.5999985	93	26		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD14925a	UK-NCRI	72.8	Male	De novo	Adverse		0.262833675564682	1	3.7	5.0999985	25	32		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD14927a	UK-NCRI	69.6	Female	De novo	Favorable		0.26009582477755	1	45.5	8.1999969	16	75		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD14928a	UK-NCRI	76.3	Male	Secondary	Adverse		0.303901437371663	1	3.7	10.299995	83	52		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD14930a	UK-NCRI	66.9	Female	De novo	Favorable		0.054757015742642	1	84.4	10.399994	54	95		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD14931a	UK-NCRI	72	Male	De novo	Favorable		0.0657084188911704	1	22	6.6999969	60	90		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD14932a	UK-NCRI	54.5	Male	Secondary	Adverse		0.10403832991102	1	92.1	0.7999997	36	100		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD14933c	UK-NCRI	72.4	Female	Secondary	Intermediate		0.531143052703628	1	6.6	7.8999977	199	30		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD14934a	UK-NCRI	68	Female	Secondary	Adverse		0.292950034223135	1	104.7	14.799995	88	40		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD14936a	UK-NCRI	70.4	Male	De novo	Favorable		0.629705681040383	1	238.8	9.3999939	85	91		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD14937c	UK-NCRI	80.1	Female	Secondary	Adverse		0.451745379876797	1	73	1	71	30		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD14938a	UK-NCRI	65.3	Female	De novo	Favorable		0.161533196440794	1	36	8	20	96		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD14940a	UK-NCRI	71.1	Female	Secondary	Intermediate		0.243668720054757	1	107.2	9.5999985	139	33		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD14941a	UK-NCRI	78.5	Female	De novo	Intermediate		0.476386036960986	1	199	13	104	98		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD14942a	UK-NCRI	72.2	Female	Secondary	Adverse		0.366872005475702	1	9.1	9.0999985	24	40		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD14943a	UK-NCRI	77.9	Male	De novo	Favorable		0.301163586584531	1	84.6	7.8999977	47	78		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD14944a	UK-NCRI	76.5	Male	De novo	Intermediate		0.662559890485969	1	13.4	7.7999992	11	97		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD14946c	UK-NCRI	75.9	Female	Secondary	Adverse		0.744695414099932	1	13.8	15.899994	285	58.7450018928678		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD14947a	UK-NCRI	61.4	Male	De novo	Adverse		0.895277207392197	1	27.9	9.1999969	317	63		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD14948a	UK-NCRI	65.3	Female	De novo	Favorable		0.843258042436687	1	17.8	6.8999977	71	72		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD14949a	UK-NCRI	76.1	Female	De novo	Favorable		0.0492813141683778	1	6.8	11.099998	18	80		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD14951a	UK-NCRI	56.1	Female	De novo	Favorable		2.90759753593429	1	11.5	8	106	85		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD14952a	UK-NCRI	70.4	Male	De novo	Adverse		0.402464065708419	1	5	8.2999954	26	21		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD14954c	UK-NCRI	71.4	Male	De novo	Adverse		1.21286789869952	1	2	9.0999985	162	90		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD14955c	UK-NCRI	79.8	Male	De novo	Adverse		0.0164271047227926	1	14.1	11.699997	62	44		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD14956a	UK-NCRI	67.7	Male	De novo	Intermediate		1.08418891170431	1	103.5	8.0999985	96	76		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD14957a	UK-NCRI	65.2	Female	De novo	Intermediate		3.86584531143053	1	2.6	13.699997	67	23		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD14959a	UK-NCRI	68.2	Female	De novo	Adverse		0.027378507871321	1	111	10.099998	84	98		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD14960a	UK-NCRI	61.9	Male	De novo	Favorable		0.826830937713895	1	64.1	13.699997	68	58.7450018928678		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD14963a	UK-NCRI	56.8	Female	De novo	Favorable		3.60574948665298	0	74.3	10.399994	52	95		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD14964a	UK-NCRI	62.4	Female	De novo	Adverse		0.711841204654346	1	3.1	9.6999969	60	80		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD14965a	UK-NCRI	33.9	Male	De novo	Adverse		6.68583162217659	0	5.9	8.6999969	26	77		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD14966a	UK-NCRI	63.3	Female	De novo	Adverse		0.678986995208761	1	26.8	9.5	124	90		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD14968a	UK-NCRI	59.7	Female	De novo	Favorable		0.0219028062970568	1	30.4	11.699997	53	77		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD14971a	UK-NCRI	61.2	Male	De novo	Favorable		7.24161533196441	0	73.8	4.6999969	52	5		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD14972c	UK-NCRI	58.7	Male	De novo	Favorable		7.58932238193018	0	4.4	12.5	33	49		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD14973c	UK-NCRI	67.7	Male	Secondary	Adverse		0.810403832991102	1	25.9	8.6999969	21	40		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD14974c	UK-NCRI	30	Female	De novo	Intermediate		2.57905544147844	1	32	5.3999977	85	75		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD14975a	UK-NCRI	71.5	Female	De novo	Adverse		0.188911704312115	1	7.1	7.8999977	33	50		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD14976c	UK-NCRI	45.6	Male	De novo	Intermediate		5.79329226557153	0	8.3	7.5999985	66	71		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD14978a	UK-NCRI	77.8	Female	Secondary	Adverse		0.15605749486653	1	15.2	11.5	4	31		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD14988a	UK-NCRI	32.6	Female	De novo	Intermediate		6.68035592060233	0	2.4	9.5	16	45		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD14988c	UK-NCRI	33.5	Male	De novo	Adverse		0.347707049965777	1	44	9.659996	44	77		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD14990c	UK-NCRI	64.5	Male	De novo	Favorable		4.48733744010951	1	102	9.3999939	106	85		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD14993a	UK-NCRI	53.9	Female	De novo	Adverse		0.692676249144422	1	1.5	4.6999969	387	60		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD14995c	UK-NCRI	20.2	Male	De novo	Intermediate		0.681724845995893	1	111	10	86	89		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD14996a	UK-NCRI	73	Female	Secondary	Favorable		0.629705681040383	1	73	10.799995	43	92		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD14998c	UK-NCRI	25.7	Male	De novo	Adverse		7.47433264887064	0	6.8	9.8999939	113	89		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15000a	UK-NCRI	44.2	Female	De novo	Favorable		5.21013004791239	0	18.9	9.0999985	19	35		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15001a	UK-NCRI	66.2	Female	De novo	Favorable		0.851471594798084	1	1.4	5.8999977	91	25		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15003c	UK-NCRI	61.7	Female	De novo	Adverse		1.20465434633812	1	3.9	9.0999985	49	52		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15004a	UK-NCRI	53.2	Female	De novo	Favorable		1.0321697467488	1	11.3	12.399994	156	88		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15005a	UK-NCRI	83.1	Male	Secondary	Adverse		0.271047227926078	1	5.3	10.5	39	44		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15006c	UK-NCRI	65.6	Female	De novo	Adverse		0.257357973990418	1	22.3	8.3999939	43	48		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15007a	UK-NCRI	53	Male	De novo	Intermediate		1.25667351129363	1	33	9.1999969	40	90		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15008a	UK-NCRI	64	Male	De novo	Intermediate		0.0465434633812457	1	162.3	8.7999954	52	100		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15010c	UK-NCRI	83.8	Male	Secondary	Adverse		0.257357973990418	1	0.9	8.5999985	72	32.199982		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15011a	UK-NCRI	56.6	Female	De novo	Favorable		0.621492128678987	1	17.6	6.0999985	27	90		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15013a	UK-NCRI	57	Female	De novo	Favorable		0.91170431211499	1	21.1	8.5999985	47	60		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15014a	UK-NCRI	69.2	Female	De novo	Adverse		0.0739219712525667	1	35.7	8.3999939	38	90		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15017c	UK-NCRI	72	Male	De novo	Intermediate		0.339493497604381	1	1.8	8.8999939	118	58.7450018928678		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15018c	UK-NCRI	56.5	Male	De novo	Favorable		7.46611909650924	0	29.7	8.1999969	49	85		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15021c	UK-NCRI	79.9	Female	De novo	Adverse		0.180698151950719	1	4.9	5	19	19		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15022a	UK-NCRI	72.6	Male	Secondary	Intermediate		0.517453798767967	1	22.4	9.8999939	159	32		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15024c	UK-NCRI	58.4	Female	De novo	Adverse		0.407939767282683	1	3.2	9.5999985	56	19		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15026c	UK-NCRI	54.2	Female	De novo	Adverse		2.05065023956194	1	4.1	8.0999985	86	70		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15032a	UK-NCRI	66.2	Female	De novo	Favorable		0.468172484599589	1	45.6	5.8999977	214	48		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15033a	UK-NCRI	39.9	Female	De novo	Favorable		7.03080082135524	0	4.4	12.079994	56	78		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15034c	UK-NCRI	58.6	Female	De novo	Favorable		5.35797399041752	0	14.4	9.7999954	34	38		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15037a	UK-NCRI	61.8	Female	De novo	Adverse		0.298425735797399	1	3.2	8.0999985	63	28		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15037c	UK-NCRI	61.8	Female	De novo	Favorable		0.265571526351814	1	98.4	7.7999992	15	40		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15039a	UK-NCRI	55.7	Male	De novo	Intermediate		0.59958932238193	1	67.4	12.199997	105	95		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15040a	UK-NCRI	40.1	Male	De novo	Adverse		2.52977412731006	0	16.2	7.8999977	68	1.5		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15041a	UK-NCRI	38.9	Male	De novo	Adverse		6.02053388090349	0	0.7	9.3999939	168	44		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15043a	UK-NCRI	43.8	Male	De novo	Favorable		7.55920602327173	0	34.3	10.899994	114	78		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15044c	UK-NCRI	67.3	Female	De novo	Adverse		0.826830937713895	1	5.2	7.5	80.4858623868992	84		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15045c	UK-NCRI	33.8	Male	De novo	Favorable		5.26488706365503	0	89.9	8.5	90	45		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15046a	UK-NCRI	48.9	Female	Secondary	Adverse		0.659822039698836	1	67.9	11.099998	94	15		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15047a	UK-NCRI	57.2	Male	De novo	Favorable		4.94455852156057	0	1.8	8.5999985	76	67		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15053a	UK-NCRI	80.6	Female	De novo	Intermediate		0.0438056125941136	1	49.7	99	31	76		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15055a	UK-NCRI	44.8	Female	De novo	Favorable		6.11362080766598	1	31.3	9.2999954	98	15		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15056a	UK-NCRI	65.3	Female	De novo	Adverse		0.793976728268309	1	10.4	8.5999985	28	53		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15056c	UK-NCRI	66.4	Female	De novo	Adverse		0.364134154688569	1	15.5	5.6999969	29	41		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15058a	UK-NCRI	68.7	Female	Other	Adverse		0.511978097193703	1	206	7.2999992	171	33		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15059a	UK-NCRI	64.6	Male	De novo	Favorable		1.19917864476386	1	55.2	6.8999977	92	58.7450018928678		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15060a	UK-NCRI	62.6	Female	Secondary	Adverse		0.219028062970568	1	13.1	10.199997	115	52		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15062a	UK-NCRI	70	Female	De novo	Favorable		3.99452429842574	0	85.9	8.6999969	111	57		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15063a	UK-NCRI	76.4	Female	De novo	Adverse		0.53388090349076	1	1.6	7.5	13	30		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15064c	UK-NCRI	61.4	Female	De novo	Intermediate		0.42984257357974	1	20.5	8.0999985	31	95		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15067c	UK-NCRI	70.5	Male	De novo	Adverse		2.56810403832991	1	8.5	8.1999969	68	31		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15068a	UK-NCRI	66.7	Female	Secondary	Adverse		0.640657084188912	1	46.6	10.599998	25	22		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15069a	UK-NCRI	59.8	Female	De novo	Favorable		2.07802874743326	0	41.6	9	49	73		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15070a	UK-NCRI	62.9	Female	De novo	Favorable		0.210814510609172	1	4.3	7.0999985	8	74		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15071a	UK-NCRI	71.9	Female	Secondary	Adverse		0.621492128678987	1	15	9.5999985	139	20		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15073c	UK-NCRI	71.4	Male	Secondary	Adverse		0.624229979466119	1	23.2	10.699997	129	30		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15074a	UK-NCRI	77.2	Female	De novo	Adverse		0.59958932238193	1	16.3	9.8999939	84	30		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15075a	UK-NCRI	66.8	Male	De novo	Favorable		0.438056125941136	1	144.8	10.099998	71	71.5		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15077a	UK-NCRI	64.9	Male	De novo	Favorable		2.83093771389459	0	3.5	11.899994	58	74		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15078a	UK-NCRI	70.5	Male	De novo	Adverse		3.54551676933607	1	54	11.899994	202	84		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15079a	UK-NCRI	70.5	Male	Secondary	Favorable		0.528405201916496	1	40.8	6.6999969	106	16		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15081c	UK-NCRI	65.5	Female	De novo	Adverse		3.08555783709788	1	15.7	8.8999939	15	37		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15083a	UK-NCRI	70.5	Female	Secondary	Adverse		2.47775496235455	1	5.1	9.7999954	148	20		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15085a	UK-NCRI	64.2	Female	De novo	Favorable		3.63860369609856	0	14.9	8.2999954	139	50		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15086a	UK-NCRI	74.6	Male	De novo	Adverse		0.219028062970568	1	189	8.1999969	47	55		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15087a	UK-NCRI	64.5	Female	De novo	Adverse		3.56194387405886	0	9	13.099998	137	91		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15088a	UK-NCRI	66.2	Female	Secondary	Adverse		0.0985626283367557	1	96	8.6999969	48	6		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15089c	UK-NCRI	61.6	Male	De novo	Favorable		3.94798083504449	0	86.2	10.5	103	87		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15090a	UK-NCRI	61.1	Male	De novo	Favorable		3.86858316221766	0	41.4	8	95	89		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15091a	UK-NCRI	73.2	Female	De novo	Favorable		1.91649555099247	1	1	8.5	110	100		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15092c	UK-NCRI	77.9	Female	De novo	Favorable		0.243668720054757	1	28.5	7.5999985	84	94		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15094a	UK-NCRI	65.5	Female	Other	Adverse		0.328542094455852	1	36.9	9.8999939	119	10		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15095a	UK-NCRI	61.9	Male	Other	Intermediate		1.02669404517454	1	3.1	6.5	123	16		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15096a	UK-NCRI	77.3	Female	Secondary	Adverse		0.0684462696783025	1	22	8.2999954	24	90		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15098a	UK-NCRI	74.5	Male	Secondary	Intermediate		0.0848733744010951	1	11.7	9.1999969	6	70		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15100c	UK-NCRI	69.7	Male	Secondary	Adverse		0.153319644079398	1	9.6	9	117	23		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15101a	UK-NCRI	69.4	Male	De novo	Favorable		0.344969199178645	0	8.7	10.5	33	23		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15102a	UK-NCRI	74.9	Female	Secondary	Adverse		0.0520191649555099	1	14.4	6.5	28	50		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15103a	UK-NCRI	62.8	Male	De novo	Favorable		3.90965092402464	0	14.2	7.1999969	33	95		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15104a	UK-NCRI	68.4	Female	Other	Adverse		0.621492128678987	1	14	8.7999954	24	16		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15105a	UK-NCRI	74.3	Male	De novo	Favorable		0.0684462696783025	1	50	8.0999985	14	69		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15106a	UK-NCRI	62.3	Female	Secondary	Adverse		2.507871321013	1	38.9	11.199997	79	42.599976		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15107c	UK-NCRI	65.3	Male	De novo	Adverse		0.0492813141683778	1	335	9	60	69		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15109a	UK-NCRI	69.2	Female	De novo	Adverse		2.28884325804244	1	6.3	9.5999985	62	35		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15111a	UK-NCRI	83.1	Male	De novo	Intermediate		0.416153319644079	1	1.9	8.8999939	47	22		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15113a	UK-NCRI	64	Male	De novo	Favorable		3.7782340862423	0	154	10.399994	59	82		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15114a	UK-NCRI	72.2	Female	Secondary	Adverse		1.33607118412047	1	56.2	9.0999985	62	40		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15115c	UK-NCRI	72.4	Female	Secondary	Adverse		0.109514031485284	1	4.7	13.099998	14	87		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15116a	UK-NCRI	69.9	Male	De novo	Favorable		0.0438056125941136	1	16	4.5	118	85		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15117a	UK-NCRI	71.4	Male	De novo	Favorable		0.763860369609856	1	34.1	6.5	274	45		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15118a	UK-NCRI	72.2	Female	De novo	Adverse		1.27857631759069	1	13.3	9.6999969	14	24		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15119a	UK-NCRI	78.2	Male	De novo	Favorable		1.30595482546201	1	19.2	6.8999977	77	50		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15120c	UK-NCRI	68.3	Male	De novo	Adverse		2.95414099931554	0	8.9	6.7999992	145	96		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15121a	UK-NCRI	62.8	Female	De novo	Favorable		2.12731006160164	1	48	8.3999939	48	50		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15122a	UK-NCRI	64	Female	De novo	Favorable		0.878850102669405	0	44.4	7.8999977	48	68		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15123a	UK-NCRI	64.1	Male	De novo	Favorable		0.49555099247091	1	26.6	5.5999985	43	58.7450018928678		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15124a	UK-NCRI	70.3	Female	De novo	Adverse		0.605065023956194	1	5.3	11	30	58.7450018928678		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15126a	UK-NCRI	74.7	Female	De novo	Favorable		0.0328542094455852	1	169	6.8999977	37	58.7450018928678		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15127a	UK-NCRI	74.6	Female	De novo	Adverse		1.59616700889802	1	5.7	10.399994	16	60		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15128a	UK-NCRI	68	Male	De novo	Favorable		0.0684462696783025	1	15.7	8.5999985	19	90		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15129a	UK-NCRI	68.3	Female	Secondary	Favorable		2.87200547570157	0	38	9.5	38	58.7450018928678		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15130a	UK-NCRI	69.9	Female	De novo	Favorable		0.53388090349076	1	44.6	11.799995	89	89		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15132a	UK-NCRI	84.3	Female	De novo	Adverse		0.265571526351814	1	2.8	11	248	87		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15134c	UK-NCRI	61.6	Male	De novo	Favorable		0.342231348391513	1	13.5	2.5	17	80		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15135a	UK-NCRI	74.5	Female	De novo	Intermediate		0.188911704312115	1	12.2	8	72	66		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15136c	UK-NCRI	64.5	Female	De novo	Adverse		1.15811088295688	1	21.3	10.299995	15	20		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15138a	UK-NCRI	68.3	Female	Secondary	Intermediate		0.783025325119781	1	127.7	8.6999969	38	40		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15141a	UK-NCRI	74.4	Male	Secondary	Adverse		0.219028062970568	1	45.8	8.2999954	101	60		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15143a	UK-NCRI	69.3	Female	De novo	Adverse		0.835044490075291	1	2.9	8.1999969	22	25		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15148a	UK-NCRI	76.8	Female	De novo	Intermediate		0.635181382614648	1	24.8	10.399994	28	85		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15150a	UK-NCRI	64.6	Male	De novo	Favorable		0.632443531827515	1	54.6	9.3999939	37	87		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15152a	UK-NCRI	74.7	Male	De novo	Favorable		0.317590691307324	1	250.4	12.5	44	95		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15153a	UK-NCRI	79.3	Female	Other	Adverse		1.89733059548255	1	1.9	6.5999985	10	6		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15154a	UK-NCRI	73.4	Female	De novo	Favorable		0.465434633812457	1	2	6.6999969	63	75		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15155a	UK-NCRI	76.9	Female	Other	Adverse		3.22245037645448	1	12.5	10.399994	131	10		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15156a	UK-NCRI	83.2	Female	De novo	Adverse		0.65160848733744	1	4.3	9.3999939	23	95		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15157a	UK-NCRI	65.4	Female	De novo	Favorable		3.27446954140999	1	29.6	7.6999969	69	72		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15158c	UK-NCRI	66.7	Male	De novo	Intermediate		3.11841204654346	1	3.3	10.5	79	50		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15159a	UK-NCRI	77	Female	De novo	Adverse		0.314852840520192	1	70.8	9.2999954	234	21		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15160a	UK-NCRI	79.7	Female	Other	Adverse		0.0876112251882272	1	2.4	6.5999985	316	5		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15161a	UK-NCRI	62.6	Male	De novo	Intermediate		0.528405201916496	1	38.3	10.199997	96	51		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15162a	UK-NCRI	16.8	Female	De novo	Intermediate		0.432580424366872	1	12.9	5.1999969	94	46		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15163a	UK-NCRI	82.9	Male	De novo	Adverse		0.202600958247775	1	3.5	10.899994	18	30		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15164c	UK-NCRI	71.3	Male	De novo	Intermediate		0.27378507871321	1	6.9	12.699997	154	58.7450018928678		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15165a	UK-NCRI	69.9	Male	De novo	Adverse		1.68651608487337	1	100.2	11.099998	67	83		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15166a	UK-NCRI	75	Female	Secondary	Adverse		0.0766598220396988	1	60.8	7.7999992	29	90		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15169a	UK-NCRI	63.6	Male	De novo	Adverse		0.813141683778234	1	2.1	6	107	50		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15170c	UK-NCRI	66.9	Female	De novo	Adverse		0.213552361396304	1	47.3	10.199997	21	95		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15171c	UK-NCRI	83.2	Female	De novo	Adverse		0.0739219712525667	1	1.3	10	73	37		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15173a	UK-NCRI	62.1	Male	Secondary	Adverse		0.298425735797399	1	29	10.599998	26	90		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15174a	UK-NCRI	70.8	Female	Secondary	Adverse		0.240930869267625	1	4.2	9.5	13	25		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15175a	UK-NCRI	73.7	Female	Secondary	Adverse		0.11772758384668	1	1.3	8.1999969	58	62.399994		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15176a	UK-NCRI	63.4	Male	De novo	Favorable		4.97467488021903	0	106.7	3.3999996	149	90		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15177a	UK-NCRI	73.8	Female	De novo	Favorable		0.629705681040383	1	1.3	10.899994	37	64		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15179a	UK-NCRI	75.5	Female	De novo	Adverse		1.56878850102669	1	7.3	8.8999939	10	20		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15180c	UK-NCRI	78.2	Female	De novo	Adverse		1.36892539356605	1	10.7	10.799995	61	53		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15181a	UK-NCRI	76.4	Female	Other	Adverse		0.0438056125941136	1	3.6	7.2999992	60	15		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15183c	UK-NCRI	69.1	Female	Secondary	Favorable		0.134154688569473	1	58.5	9.6999969	27	95		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15184a	UK-NCRI	82.1	Male	Secondary	Adverse		0.569472963723477	1	5	9	48	32		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15185a	UK-NCRI	70.6	Female	De novo	Favorable		2.34086242299795	1	120.8	10.299995	53	97		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15186a	UK-NCRI	81.1	Female	Secondary	Adverse		0.323066392881588	1	27.3	8.5	46	90		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15187a	UK-NCRI	83	Male	De novo	Favorable		0.0602327173169062	1	52	9	26	90		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15188a	UK-NCRI	70	Female	De novo	Intermediate		0.511978097193703	1	7.2	11.599998	339	58.7450018928678		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15189a	UK-NCRI	73.4	Male	De novo	Adverse		0.306639288158795	1	27.7	5.3999977	47	71		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15190a	UK-NCRI	64.8	Male	De novo	Favorable		0.369609856262834	1	21.4	7	255	78		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15191c	UK-NCRI	72.3	Female	De novo	Favorable		2.2943189596167	1	135	8	67	73		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15192a	UK-NCRI	73.7	Male	De novo	Intermediate		3.50718685831622	1	1.5	6.5999985	30	58.7450018928678		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15193c	UK-NCRI	66.2	Female	De novo	Adverse		2.99520876112252	0	3	12.199997	74	50		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15194c	UK-NCRI	78.4	Male	De novo	Adverse		0.175222450376454	1	2.5	8.0999985	53	82		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15196a	UK-NCRI	59.3	Female	De novo	Favorable		0.662559890485969	1	117.9	5.8999977	21	92.599976		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15197a	UK-NCRI	74.5	Female	De novo	Favorable		2.05612594113621	1	9.9	9.2999954	37	80		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15198a	UK-NCRI	75.6	Female	De novo	Adverse		0.26009582477755	1	1.1	8.3999939	62	21		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15199a	UK-NCRI	68	Female	Secondary	Favorable		3.59479808350445	1	7.5	9.5	205	42		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15200c	UK-NCRI	68.5	Female	De novo	Favorable		2.31074606433949	1	15.1	9.7999954	21	16		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15201a	UK-NCRI	78.8	Female	De novo	Adverse		0.292950034223135	1	36.8	10.099998	68	85		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15202c	UK-NCRI	72.3	Female	Secondary	Adverse		1.58795345653662	1	46.5	10	25	29		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15203a	UK-NCRI	70.2	Female	Secondary	Intermediate		0.761122518822724	1	92.2	8.0999985	7	21		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15205a	UK-NCRI	72.7	Female	De novo	Adverse		0.054757015742642	1	54.5	7.5	36	90		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15206c	UK-NCRI	80.8	Female	Secondary	Favorable		0.0109514031485284	1	27	10	5	85		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15207a	UK-NCRI	76.6	Male	De novo	Adverse		0.202600958247775	1	4.9	9.3999939	55	17		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15208a	UK-NCRI	76.5	Female	De novo	Adverse		3.66324435318275	1	3.2	8.8999939	127	25		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15209a	UK-NCRI	77.4	Female	De novo	Adverse		0.0164271047227926	1	12.4	5.8999977	27	83		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15211a	UK-NCRI	77.4	Female	De novo	Adverse		0.454483230663929	1	14	8.0999985	626	20		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15213a	UK-NCRI	79.2	Male	De novo	Favorable		1.47022587268994	1	8.8	10.099998	32	20		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15215a	UK-NCRI	62.9	Female	De novo	Favorable		0.739219712525667	1	9	9.0999985	51	25		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15216a	UK-NCRI	69.4	Female	De novo	Adverse		2.79534565366188	1	7	10.699997	53	80		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15217a	UK-NCRI	76.6	Male	Secondary	Adverse		0.216290212183436	1	4.2	7.7999992	21	38		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15218a	UK-NCRI	66.9	Male	De novo	Intermediate		2.85557837097878	1	1.8	6.8999977	66	42		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15219a	UK-NCRI	76.3	Female	Secondary	Adverse		0.183436002737851	1	17.2	9	146	67		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15220a	UK-NCRI	79	Male	De novo	Favorable		1.53319644079398	1	14.4	4.3999977	15	80		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15222a	UK-NCRI	66.9	Female	Secondary	Adverse		0.553045859000684	1	1	10.899994	54	58.7450018928678		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15224a	UK-NCRI	74.3	Male	Other	Adverse		1.99863107460643	1	2.3	10.799995	148	51		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15226c	UK-NCRI	74.9	Male	De novo	Favorable		1.44284736481862	1	5	10.699997	56	81		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15227c	UK-NCRI	62	Female	De novo	Intermediate		2.39835728952772	1	2	10.099998	38	37		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15228a	UK-NCRI	66.8	Male	De novo	Favorable		0.301163586584531	1	6.6	12.5	163	36		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15229c	UK-NCRI	67.6	Female	Secondary	Adverse		0.799452429842574	1	35.9	9.5999985	15	72		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15230a	UK-NCRI	78.9	Female	De novo	Adverse		0.106776180698152	1	1	9.0999985	32	22		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15231c	UK-NCRI	73.7	Female	Secondary	Adverse		1.29500342231348	1	5.9	12.799995	31	40		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15232a	UK-NCRI	68.4	Female	Secondary	Adverse		1.77686516084873	1	50.9	11	7	50		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15233a	UK-NCRI	66.5	Female	Secondary	Favorable		1.42368240930869	1	30.8	7.7999992	23	16		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15234c	UK-NCRI	75.9	Female	De novo	Adverse		0.555783709787817	1	8.5	7.5	127	84		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15237a	UK-NCRI	75.4	Female	De novo	Adverse		0.0574948665297741	1	4.3	8.7999954	61	20		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15238c	UK-NCRI	57.6	Female	De novo	Adverse		1.39630390143737	1	0.7	6.7999992	91	76		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15239a	UK-NCRI	77.3	Female	De novo	Adverse		0.235455167693361	1	34.5	9.3999939	104	80		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15240a	UK-NCRI	68.3	Male	De novo	Favorable		0.536618754277892	1	14.6	8.6999969	350	75		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15241c	UK-NCRI	79.9	Male	Secondary	Intermediate		0.0438056125941136	1	5.2	5.8999977	25	3		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15245a	UK-NCRI	73.8	Male	Secondary	Adverse		0.68993839835729	1	21.6	10	7	60		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15246a	UK-NCRI	69	Male	De novo	Adverse		0.0301163586584531	1	2.5	8	15	61		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15247a	UK-NCRI	76.3	Male	De novo	Intermediate		1.51676933607118	1	48.6	8.2999954	334	54		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15248c	UK-NCRI	69.3	Male	De novo	Adverse		1.26488706365503	1	1.9	6.5	17	20		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15249c	UK-NCRI	73	Female	Secondary	Favorable		0.676249144421629	1	84.9	10	55	86		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15250c	UK-NCRI	57.6	Male	De novo	Favorable		0.123203285420945	1	19.3	10.599998	71	75		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15251a	UK-NCRI	70.6	Female	De novo	Adverse		2.19849418206708	1	5.4	6.2999992	159	21		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15253a	UK-NCRI	76.4	Female	De novo	Intermediate		0.706365503080082	1	4.5	7.3999977	7	21		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15254a	UK-NCRI	75.9	Male	De novo	Favorable		0.511978097193703	1	6.3	7.0999985	9	75		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15256a	UK-NCRI	72.8	Male	De novo	Favorable		0.342231348391513	1	7.9	6.5999985	38	90		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15257a	UK-NCRI	75.6	Female	De novo	Favorable		0.594113620807666	1	2.1	9.1999969	33	36		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15259a	UK-NCRI	71.2	Male	Secondary	Adverse		0.0410677618069815	1	8	7.5999985	9	20		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15260c	UK-NCRI	67	Male	De novo	Favorable		2.17659137577002	1	40.7	10.599998	169	95		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15261c	UK-NCRI	65.3	Female	De novo	Adverse		2.20123203285421	1	4.2	5.5	136	40		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15262a	UK-NCRI	81.4	Female	Other	Adverse		0.123203285420945	1	3.1	10.899994	18	16		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15263a	UK-NCRI	64.1	Female	Other	Adverse		0.232717316906229	1	7.7	10.299995	94	40		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15264c	UK-NCRI	61.4	Female	De novo	Adverse		1.10609171800137	1	215	9.5	240	58.7450018928678		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15265a	UK-NCRI	79.7	Female	Secondary	Favorable		0.150581793292266	1	45.6	7.8999977	35	37.799988		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15266a	UK-NCRI	69.8	Male	Secondary	Adverse		0.158795345653662	1	28.6	10.5	31	80		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15267a	UK-NCRI	65.4	Female	De novo	Adverse		0.799452429842574	1	37	7.8999977	74	85		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15270c	UK-NCRI	77.9	Female	De novo	Intermediate		0.0219028062970568	1	30.8	10.099998	62	80		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15271a	UK-NCRI	69.5	Female	Other	Adverse		0.249144421629021	1	18	15.006119106409	80.4858623868992	58.7450018928678		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15272c	UK-NCRI	64	Male	De novo	Adverse		1.62628336755647	1	32.6	9.1999969	133	46		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15274c	UK-NCRI	64.5	Female	Secondary	Adverse		0.922655715263518	1	17	7.2999992	55	72		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15275a	UK-NCRI	69.1	Male	Secondary	Adverse		0.725530458590007	1	13.7	10.099998	39	22		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15276a	UK-NCRI	60.3	Male	De novo	Favorable		6.00958247775496	0	4.2	6.2999992	14	73		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15279a	UK-NCRI	62.4	Female	De novo	Intermediate		1.02395619438741	1	54.8	10.899994	53	90		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15280a	UK-NCRI	72.9	Male	De novo	Favorable		0.0219028062970568	1	32.4	7.5999985	31	85		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15281a	UK-NCRI	83.5	Male	Secondary	Adverse		1.21286789869952	1	32	7.5	49	25		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15284a	UK-NCRI	67	Male	Other	Intermediate		1.42642026009582	1	1.4	8.6999969	35	4.2999992		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15286a	UK-NCRI	50.6	Male	De novo	Intermediate		5.63449691991786	0	4.7	12.099998	16	51		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15287a	UK-NCRI	63.4	Female	De novo	Intermediate		1.13894592744695	1	20	8.6999969	10	32		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15289c	UK-NCRI	80	Female	De novo	Favorable		0.0109514031485284	1	117.7	8.1999969	92	90		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15290c	UK-NCRI	72.9	Female	De novo	Adverse		0.139630390143737	1	45.6	12.799995	131	90		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15291a	UK-NCRI	68.7	Female	Secondary	Adverse		0.736481861738535	1	57.3	8.5	85	34		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15292c	UK-NCRI	83.2	Female	Secondary	Adverse		0.870636550308008	1	28	10.299995	102	20		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15294a	UK-NCRI	66	Male	Secondary	Adverse		1.63997262149213	1	15.6	9.7999954	16	58.7450018928678		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15295c	UK-NCRI	66.2	Male	De novo	Favorable		2.26146475017112	1	6.1	11.5	72	85		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15297a	UK-NCRI	76.7	Female	Other	Adverse		0.323066392881588	1	4.7	8	23	13		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15299a	UK-NCRI	64.6	Female	De novo	Intermediate		5.92197125256673	0	15	6.5999985	37	60		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15302a	UK-NCRI	73.5	Male	De novo	Intermediate		0.246406570841889	1	3	9	143	58.7450018928678		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15303a	UK-NCRI	77.1	Male	De novo	Adverse		0.0191649555099247	1	7.1	7.3999977	48	25		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15305a	UK-NCRI	71.4	Female	Secondary	Favorable		0.0711841204654346	1	33.5	8.5	117	41		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15306c	UK-NCRI	75.1	Male	De novo	Adverse		0.0465434633812457	1	14.1	6.3999977	67	81		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15307c	UK-NCRI	67.6	Female	De novo	Favorable		3.19780971937029	1	42	8.8999939	73	60		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15309c	UK-NCRI	67.3	Female	Secondary	Adverse		0.0657084188911704	1	16.2	11.399994	24	90		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15310a	UK-NCRI	69.6	Female	Secondary	Intermediate		0.438056125941136	1	41.8	8.3999939	275	58.7450018928678		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15311a	UK-NCRI	66.9	Female	De novo	Adverse		0.0027378507871321	1	336.7	10.5	224	99		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15312c	UK-NCRI	76.9	Female	De novo	Adverse		0.0574948665297741	1	34.9	4.5999985	21	67		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15313a	UK-NCRI	63.2	Male	Secondary	Adverse		0.917180013689254	1	2.7	10.899994	17	26		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15314a	UK-NCRI	65.8	Female	De novo	Favorable		0.829568788501027	1	32.5	10.199997	83	86		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15315a	UK-NCRI	65.4	Male	De novo	Adverse		1.29500342231348	1	16.4	12.699997	94	29		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15316a	UK-NCRI	76.3	Female	De novo	Adverse		0.364134154688569	1	3.7	4.5	52	57		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15318c	UK-NCRI	75.1	Male	Secondary	Adverse		1.65366187542779	1	34.7	11.299995	38	50		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15319c	UK-NCRI	72.6	Female	De novo	Adverse		0.421629021218344	1	19.3	10.099998	33	85		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15326c	UK-NCRI	60.7	Female	De novo	Adverse		1.07323750855578	1	2.4	5.1999969	47	68		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15328a	UK-NCRI	75	Female	De novo	Adverse		0.750171115674196	1	7.9	8.7999954	513	42		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15329a	UK-NCRI	82.4	Female	De novo	Adverse		0.314852840520192	1	2	13	94	35		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15331c	UK-NCRI	50.6	Female	De novo	Intermediate		6.70499657768652	0	15.7	13.199997	118	80		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15332c	UK-NCRI	77	Female	De novo	Adverse		0.114989733059548	1	2.5	7.5999985	36	48		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15333a	UK-NCRI	78	Male	De novo	Intermediate		0.136892539356605	1	1.4	9.6999969	179	58		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15334a	UK-NCRI	50.7	Female	De novo	Adverse		1.41273100616016	1	1.5	5.2999992	31	31		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15336a	UK-NCRI	72.3	Male	Secondary	Adverse		0.139630390143737	1	41.7	10.099998	135	50		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15338a	UK-NCRI	72.4	Male	De novo	Favorable		5.59616700889802	1	217	10.799995	22	90		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15339a	UK-NCRI	77.1	Female	De novo	Favorable		0.673511293634497	1	130	10.799995	82	84		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15340a	UK-NCRI	83.5	Male	De novo	Intermediate		1.00752908966461	1	8.4	7.0999985	259	84		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15341c	UK-NCRI	68.2	Female	De novo	Intermediate		0.848733744010951	1	97	9.2999954	20	21		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15342c	UK-NCRI	67.2	Female	De novo	Intermediate		0.0903490759753593	1	2.3	7.8999977	24	96		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15346a	UK-NCRI	60.3	Male	De novo	Adverse		1.06228610540726	1	45.3	9.7999954	26	58.7450018928678		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15347a	UK-NCRI	60.7	Female	De novo	Adverse		0.668035592060233	1	78.4	4.0999985	15	50		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15349a	UK-NCRI	64.7	Female	De novo	Adverse		0.0684462696783025	1	43.7	10.799995	29	60		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15351a	UK-NCRI	74.4	Male	Secondary	Intermediate		1.06502395619439	1	0	9.5	18	50		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15352a	UK-NCRI	67.4	Female	De novo	Favorable		0.0054757015742642	1	84.7	8.7999954	16	90		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15354a	UK-NCRI	72.2	Female	De novo	Adverse		1.10609171800137	1	8.1	6.2999992	16	60		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15356a	UK-NCRI	64.3	Female	De novo	Favorable		0.815879534565366	1	125.1	8.2999954	57	90		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15357c	UK-NCRI	75.4	Male	De novo	Favorable		1.40999315537303	1	3.8	9.8999939	11	80		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15359a	UK-NCRI	64.2	Male	De novo	Favorable		0.0109514031485284	1	80.6	13.399994	44	81		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15361a	UK-NCRI	65.3	Male	De novo	Favorable		2.40930869267625	1	24	15.006119106409	80.4858623868992	58.7450018928678		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15362a	UK-NCRI	69.2	Female	De novo	Adverse		2.15468856947296	1	8.8	6.6999969	51	26		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15363c	UK-NCRI	76.9	Female	De novo	Adverse		2.01779603011636	1	1.6	10.099998	76	25		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15364a2	UK-NCRI	63.2	Male	De novo	Adverse		3.35660506502396	0	6.4	10.199997	65	65		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15367a	UK-NCRI	75.4	Male	De novo	Adverse		1.71937029431896	1	10.3	8.2999954	52	58.7450018928678		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15369a	UK-NCRI	79	Female	De novo	Favorable		0.49555099247091	1	59.5	7.8999977	64	90		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15371a	UK-NCRI	73.3	Male	De novo	Adverse		0.210814510609172	1	18	9.5	27	92		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15372a	UK-NCRI	71.1	Female	De novo	Adverse		0.698151950718686	1	70.4	10	29	65		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15373a	UK-NCRI	82.2	Female	Secondary	Adverse		0.31211498973306	1	5.6	9.0999985	159	78		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15375c	UK-NCRI	73	Male	De novo	Adverse		0.774811772758385	1	48	15.006119106409	80.4858623868992	58.7450018928678		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15377a	UK-NCRI	51.4	Male	De novo	Intermediate		7.29363449691992	0	0.9	8.3799973	99	40		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15378a	UK-NCRI	70.6	Female	De novo	Favorable		0.717316906228611	1	3.8	7	83	56		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15379a	UK-NCRI	64.8	Female	De novo	Favorable		3.73990417522245	1	13	11.399994	84	40.599976		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15381a	UK-NCRI	69	Male	De novo	Favorable		3.44969199178645	0	114	11	142	88		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15382a	UK-NCRI	66.9	Male	De novo	Favorable		1.12799452429843	1	77.3	10.599998	38	80		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15383c	UK-NCRI	69.4	Female	De novo	Intermediate		0.580424366872005	1	4	10.799995	55	35		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15384a	UK-NCRI	66.5	Male	De novo	Favorable		0.186173853524983	1	239	15.006119106409	80.4858623868992	58.7450018928678		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15386a	UK-NCRI	64.2	Female	Other	Intermediate		3.33744010951403	1	1.4	8.3999939	14	18		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15387a	UK-NCRI	69.5	Female	De novo	Adverse		0.971937029431896	1	21.5	9.7999954	82	22		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15388a	UK-NCRI	66.1	Male	De novo	Favorable		0.227241615331964	1	64.8	6.7999992	75	80		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15389a	UK-NCRI	76.9	Female	De novo	Favorable		2.64476386036961	0	9.9	8.6999969	166	60		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15390c	UK-NCRI	71.8	Female	De novo	Adverse		0.054757015742642	1	15.6	6.8999977	76	92		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15392a	UK-NCRI	70.8	Female	De novo	Adverse		0.470910335386721	1	53.5	6.0999985	8	50		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15393a	UK-NCRI	74.8	Female	De novo	Adverse		0.0355920602327173	1	24.5	9.6999969	36	84		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15394a	UK-NCRI	70.3	Male	De novo	Adverse		0.164271047227926	1	213	11.899994	104	95		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15395c	UK-NCRI	88.8	Female	Secondary	Adverse		0.219028062970568	1	104.9	8.6999969	30	86		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15397a	UK-NCRI	63.1	Female	Other	Intermediate		0.898015058179329	1	27.9	8.1999969	70	23		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15398a	UK-NCRI	67.4	Male	De novo	Intermediate		3.72621492128679	0	193	10.299995	123	50		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15399a	UK-NCRI	77	Male	De novo	Adverse		1.05133470225873	1	33	9.3999939	79	74.399963		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15400a	UK-NCRI	62	Female	De novo	Intermediate		0.640657084188912	1	20.5	11.399994	74	21		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15402a	UK-NCRI	73.3	Male	De novo	Adverse		0.0711841204654346	1	48.6	8.6999969	24	50		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15403a	UK-NCRI	83.2	Female	De novo	Adverse		0.11772758384668	1	1.8	8.0999985	84	41		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15405a	UK-NCRI	66.6	Male	De novo	Favorable		1.00479123887748	1	59.2	4.1999969	77	65		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15406a	UK-NCRI	65.1	Female	Secondary	Intermediate		1.2621492128679	1	12.1	10	25	65		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15407a	UK-NCRI	78.2	Male	Other	Intermediate		1.47843942505133	1	4.1	11.099998	157	16		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15409a	UK-NCRI	78.4	Female	De novo	Adverse		0.982888432580424	1	49.8	8.5	147	30		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15411a	UK-NCRI	66.2	Female	De novo	Adverse		3.20054757015743	1	1.6	8.8999939	44	80		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15412c	UK-NCRI	68.1	Male	De novo	Adverse		1.08418891170431	1	0.9	7.5	41	71		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15414a	UK-NCRI	66	Male	De novo	Adverse		0.692676249144422	1	19.5	8.1999969	37	51		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15415c	UK-NCRI	68.7	Female	Other	Adverse		1.4072553045859	1	2	11.399994	46	15		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15417a	UK-NCRI	69	Male	Secondary	Adverse		0.0191649555099247	1	17.6	15.006119106409	80.4858623868992	58.7450018928678		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15418a	UK-NCRI	71.4	Female	De novo	Favorable		0.700889801505818	1	24.5	10.699997	72	51		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15419a	UK-NCRI	61.1	Female	De novo	Favorable		3.30458590006845	0	86.3	11.599998	30	100		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15420a2	UK-NCRI	75.1	Female	De novo	Favorable		4.09582477754962	0	32.5	6.3999977	39	69		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15421a	UK-NCRI	69.5	Female	Secondary	Adverse		0.878850102669405	1	37.6	7	148	80		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15422c	UK-NCRI	76.9	Female	De novo	Favorable		1.76043805612594	1	67.6	8.6999969	29	62		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15424a	UK-NCRI	70.7	Male	De novo	Adverse		0.213552361396304	1	45.5	10	42	58.7450018928678		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15426a	UK-NCRI	68.8	Male	De novo	Favorable		1.03490759753593	1	35.6	9.5	66	90		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15427c	UK-NCRI	63.7	Male	Secondary	Intermediate		2.51060917180014	0	1.5	11.899994	706	25		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15429c	UK-NCRI	61.7	Male	De novo	Intermediate		1.51129363449692	1	2.3	6	30	90		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15430a	UK-NCRI	64.8	Female	De novo	Adverse		0.10403832991102	1	165.8	11.5	58	58.7450018928678		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15433a	UK-NCRI	68.8	Female	Secondary	Favorable		1.08145106091718	1	8.2	8.8999939	52	48		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15434a	UK-NCRI	68.9	Female	De novo	Favorable		1.68377823408624	1	37.6	9.6999969	38	13.199997		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15435a	UK-NCRI	69.2	Male	De novo	Adverse		2.42026009582478	1	13.5	9.5	31	22		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15436a	UK-NCRI	57.5	Female	De novo	Intermediate		2.54620123203285	1	1.8	9.0999985	41	42		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15437c	UK-NCRI	27.3	Female	De novo	Adverse		1.82614647501711	1	51	11.75	143	25		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15438a	UK-NCRI	60.7	Female	De novo	Adverse		0.0657084188911704	1	3.6	7.2999992	13	50		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15440c	UK-NCRI	57.7	Female	De novo	Intermediate		7.03353867214237	0	30.4	10.699997	38	33		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15441a	UK-NCRI	33.5	Male	De novo	Favorable		1.02395619438741	1	167	4.5999985	45	70		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15442a	UK-NCRI	52.7	Female	De novo	Adverse		0.246406570841889	1	1.9	7.6999969	56	22		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15443a	UK-NCRI	83.9	Male	De novo	Intermediate		0.0465434633812457	1	25.2	10.099998	34	0		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15444c	UK-NCRI	76.4	Female	De novo	Favorable		0.0657084188911704	1	91.4	5.8999977	49	90		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15445c	UK-NCRI	75.3	Female	De novo	Favorable		0.87337440109514	1	86.1	7.0999985	15	90		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15446a	UK-NCRI	91.1	Female	Secondary	Adverse		0.369609856262834	1	8.9	7.5999985	39	71		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15447c	UK-NCRI	20.9	Male	De novo	Adverse		0.848733744010951	1	3.4	9.1999969	4	14		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15448a	UK-NCRI	72.4	Male	De novo	Favorable		0.618754277891855	1	46.4	11.699997	79	42		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15449c	UK-NCRI	55.5	Male	De novo	Favorable		4.90896646132786	1	1.8	11.599998	24	35		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15450c	UK-NCRI	50.7	Female	Other	Intermediate		7.13210130047912	0	39.2	7.5	88	25		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15451a	UK-NCRI	22.5	Female	De novo	Favorable		7.14852840520192	0	29.4	11.099998	84	55		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15453c	UK-NCRI	57.2	Female	De novo	Favorable		6.99520876112252	0	74.6	9.6999969	50	66		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15454a	UK-NCRI	77.9	Female	De novo	Adverse		0.616016427104723	1	5.4	11.699997	82	36		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15455c	UK-NCRI	76.7	Male	De novo	Favorable		0.941820670773443	1	16.1	8	78	0		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15456c	UK-NCRI	44.9	Male	De novo	Favorable		7.05817932922656	0	25.1	8.5399933	105	90		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15459c	UK-NCRI	60.8	Female	De novo	Favorable		0.865160848733744	1	389	5.2999992	19	99		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15461c	UK-NCRI	74.4	Male	Other	Adverse		1.14168377823409	1	98	9	21	15		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15462c	UK-NCRI	15.9	Male	De novo	Intermediate		3.10198494182067	0	80	11.399994	93	81		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15463c	UK-NCRI	68.8	Male	De novo	Adverse		0.199863107460643	1	58.9	11.099998	8	60		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15464c	UK-NCRI	44.7	Male	De novo	Intermediate		5.67556468172485	0	15	10.099998	71	65		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15465a	UK-NCRI	50.8	Female	De novo	Intermediate		1.83709787816564	0	1.1	5.5	128	70		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15466a	UK-NCRI	46.8	Female	De novo	Favorable		1.42915811088296	1	7.8	10.599998	24	88		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15467c	UK-NCRI	65	Female	De novo	Adverse		1.48117727583847	1	11.5	12.399994	66	40		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15468c	UK-NCRI	42.2	Male	De novo	Favorable		6.13826146475017	0	63	6.6999969	23	89		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15470a	UK-NCRI	46.4	Male	De novo	Favorable		1.59616700889802	1	12.3	8.5	59	65		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15471c	UK-NCRI	30.9	Male	De novo	Favorable		6.65571526351814	0	95	8.3699951	20	90		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15473a	UK-NCRI	67.2	Female	De novo	Adverse		0.473648186173854	1	54.2	7.6999969	42	90		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15474c	UK-NCRI	58.4	Male	De novo	Adverse		4.90349075975359	0	1.2	8.6999969	149	80		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15475c	UK-NCRI	48.9	Male	De novo	Intermediate		0.780287474332649	1	120	6.5999985	250	54		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15477c	UK-NCRI	84.1	Female	Other	Adverse		0.0465434633812457	1	9.9	8.6999969	10	10		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15480a	UK-NCRI	75.3	Female	De novo	Adverse		0.939082819986311	1	4.8	15.006119106409	128	58.7450018928678		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15482a	UK-NCRI	55.8	Male	De novo	Adverse		2.0041067761807	1	20.2	0.9799995	49	85		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15483c	UK-NCRI	53.2	Female	De novo	Intermediate		6.89390828199863	0	48.2	11.099998	39	90		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15484c	UK-NCRI	30.1	Female	De novo	Adverse		4.62422997946612	0	143.4	6.8999977	92	93		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15485c	UK-NCRI	73	Male	Secondary	Adverse		0.0985626283367557	1	12.1	10.599998	6	82		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15486c	UK-NCRI	63.1	Female	Secondary	Favorable		0.0684462696783025	1	0.9	7.8999977	28	40		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15487a	UK-NCRI	57.4	Male	De novo	Intermediate		4.45995893223819	0	2.7	9.9799957	261	56		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15490a	UK-NCRI	62.7	Female	De novo	Favorable		2.60917180013689	1	134	8.2999954	30	85		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15491c	UK-NCRI	26.7	Female	De novo	Favorable		1.22381930184805	1	98.1	10.899994	55	65		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15492a	UK-NCRI	19.9	Female	De novo	Favorable		0.334017796030116	1	7.6	7.6999969	45	92		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15494c	UK-NCRI	26.9	Male	De novo	Intermediate		9.47022587268994	0	18.2	6.2999992	26	58		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15495a	UK-NCRI	68.9	Male	De novo	Intermediate		2.95414099931554	1	41.3	15.099998	111	25		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15497a	UK-NCRI	75.3	Female	Secondary	Adverse		0.20807665982204	1	1.9	9	6	58.7450018928678		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15498c	UK-NCRI	64.6	Male	Secondary	Adverse		0.284736481861739	1	20.6	5.6999969	102	60		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15499a	UK-NCRI	61.6	Female	Secondary	Intermediate		4.44626967830253	1	4.3	7.6999969	59	85		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15503a	UK-NCRI	60.2	Female	De novo	Adverse		4.72826830937714	0	15.4	9.6999969	5	40		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15504a	UK-NCRI	60.2	Female	Secondary	Adverse		0.27378507871321	1	11.8	9.659996	101	40		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15505a	UK-NCRI	66.3	Male	Secondary	Adverse		0.364134154688569	1	0.7	7.6999969	109	20		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15506a	UK-NCRI	44	Male	De novo	Favorable		2.6009582477755	1	62.4	0.8599997	56	50		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15508c	UK-NCRI	64.8	Female	De novo	Adverse		6.81998631074606	0	159	10.629997	19	91		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15509c	UK-NCRI	62.3	Female	De novo	Favorable		7.20054757015743	0	116.2	7.5999985	21	95		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15510c	UK-NCRI	42.9	Male	De novo	Intermediate		0.626967830253251	1	137.8	3.5	50	93		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15511a	UK-NCRI	75.3	Female	De novo	Adverse		0.265571526351814	1	9.9	13.199997	169	20.299988		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15512a	UK-NCRI	40.7	Female	De novo	Intermediate		7.0362765229295	0	20	5.5	7	90		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15514a	UK-NCRI	47.9	Male	De novo	Favorable		3.19780971937029	1	6	3.7999992	85	23		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15515c	UK-NCRI	59.2	Male	De novo	Adverse		0.0657084188911704	1	3.2	11	90	79		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15516c	UK-NCRI	34.5	Male	De novo	Favorable		6.80903490759754	0	30.9	7	75	93		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15519a	UK-NCRI	59	Male	De novo	Favorable		6.88569472963724	0	32.5	6.8999977	174	97		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15520c	UK-NCRI	53.5	Male	De novo	Adverse		0.922655715263518	1	69.3	108	166	39.599976		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15522a	UK-NCRI	68.9	Male	Secondary	Intermediate		0.334017796030116	1	3.3	8.1999969	354	35		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15524a	UK-NCRI	63	Male	De novo	Intermediate		2.08898015058179	1	2.3	10.699997	91	15		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15525a	UK-NCRI	84.9	Male	De novo	Favorable		2.09719370294319	1	25.8	8.2999954	41	100		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15526a	UK-NCRI	30	Female	De novo	Favorable		6.72416153319644	0	41	10.5	104	80		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15529a	UK-NCRI	61.9	Female	De novo	Intermediate		6.74880219028063	0	1	7.3999977	242	40		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15530a	UK-NCRI	46.6	Male	De novo	Favorable		1.33333333333333	1	77.6	9.3999939	72	99		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD15531a	UK-NCRI	64.3	Female	De novo	Adverse		2.15195071868583	1	3.7	9.1999969	36	91		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19638a	UK-NCRI	87.4	Male	De novo	Adverse		0.0492813141683778	1	14.6	10.5	15	60		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19640a	UK-NCRI	65.5	Male	Other	Adverse		0.232717316906229	1	3.6	8.7999954	178	18		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19642c	UK-NCRI	75.7	Female	De novo	Adverse		0.0876112251882272	1	45.5	8.8999939	351	60		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19643c	UK-NCRI	76.4	Male	De novo	Intermediate		4.16427104722793	0	1.4	8.2999954	64	30		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19644a	UK-NCRI	74.6	Female	Other	Adverse		0.766598220396988	1	38.9	86	73	15		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19645c	UK-NCRI	72.7	Female	De novo	Intermediate		2.46680355920602	1	12.6	12.099998	22.5	18		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19646a	UK-NCRI	69.3	Female	Secondary	Adverse		0.240930869267625	1	10.7	8.3999939	13	58.7450018928678		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19647a	UK-NCRI	75	Female	Secondary	Adverse		0.109514031485284	1	2	7.5	14	25		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19648a	UK-NCRI	78.4	Male	De novo	Favorable		1.11978097193703	1	46.8	7.7999992	84	41.099976		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19650c	UK-NCRI	77.9	Male	De novo	Favorable		0.0109514031485284	1	223.2	8.2999954	45	91		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19651a	UK-NCRI	81.5	Female	Secondary	Adverse		0.626967830253251	1	51.1	13.899994	9	27		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19652c	UK-NCRI	75.3	Female	Secondary	Adverse		0.0438056125941136	1	2.5	8	15	16.5		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19654a	UK-NCRI	81.3	Male	De novo	Intermediate		1.39630390143737	1	2.7	9.7999954	144	88		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19655a	UK-NCRI	77.7	Female	De novo	Adverse		0.254620123203285	1	27.7	11.899994	69	65		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19656a	UK-NCRI	79.3	Female	Secondary	Adverse		0.657084188911704	1	4.4	9.0999985	78	60		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19657c	UK-NCRI	78.5	Female	De novo	Favorable		1.07597535934292	1	6.5	4.0999985	37	54.899994		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19658a	UK-NCRI	73.2	Male	De novo	Favorable		4.16700889801506	0	2.6	10.199997	367	7		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19659a	UK-NCRI	76.6	Female	Secondary	Adverse		2.24503764544832	1	1.6	8.0999985	330	27.5		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19660a	UK-NCRI	71.1	Female	Secondary	Adverse		0.106776180698152	1	31	9.8999939	8	60		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19661a	UK-NCRI	75.6	Female	De novo	Intermediate		4.04928131416838	1	1.4	10.099998	57	33		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19662c	UK-NCRI	73.7	Female	De novo	Favorable		1.492128678987	1	2.7	10.399994	184	50		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19663c	UK-NCRI	82.1	Male	De novo	Favorable		0.0219028062970568	1	48	9.5	43	58.7450018928678		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19664a	UK-NCRI	75.2	Female	Secondary	Favorable		0.16974674880219	1	9.7	9.3999939	12	30		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19665a	UK-NCRI	72.7	Female	De novo	Adverse		0.416153319644079	1	11.7	11	25	51		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19666a	UK-NCRI	69.2	Female	Other	Adverse		0.336755646817248	1	51	9.7999954	52	31		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19667a	UK-NCRI	75.7	Male	De novo	Adverse		0.158795345653662	1	2	8.3999939	47	28		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19668a	UK-NCRI	67.1	Female	Secondary	Intermediate		0.0958247775496235	1	1.5	10.099998	373	26.699997		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19669a	UK-NCRI	74.8	Female	De novo	Intermediate		0.082135523613963	1	60.6	8.5999985	30	26.899994		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19670a	UK-NCRI	66.7	Male	De novo	Adverse		1.2539356605065	1	1.6	8.0999985	93	40		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19671a	UK-NCRI	80.7	Female	De novo	Adverse		0.616016427104723	1	11.5	5.8999977	74	19		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19672c	UK-NCRI	66.4	Female	De novo	Adverse		0.0684462696783025	1	5.9	9.2999954	38	68		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19673a	UK-NCRI	75.6	Female	Other	Adverse		0.314852840520192	1	1.5	7.1999969	84	40		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19674c	UK-NCRI	72.6	Male	Other	Intermediate		0.881587953456537	1	0.8	7.7999992	44	16		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19675a	UK-NCRI	76.2	Male	De novo	Favorable		1.03490759753593	1	9.2	8.5999985	27	58.7450018928678		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19676a	UK-NCRI	72	Male	De novo	Adverse		0.473648186173854	1	145.1	9.3999939	50	60		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19677a	UK-NCRI	70.9	Female	De novo	Adverse		0.0985626283367557	1	27.4	8	19	58.7450018928678		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19678c	UK-NCRI	79.6	Female	Secondary	Adverse		0.0958247775496235	1	80.9	13.199997	75	84		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19679a	UK-NCRI	76.5	Female	De novo	Intermediate		2.94592744695414	1	1.5	8.8999939	33	58.7450018928678		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19680c	UK-NCRI	72.5	Female	Other	Adverse		1.40451745379877	1	1.4	9.1999969	18	10		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19681a	UK-NCRI	76.1	Male	Secondary	Intermediate		1.26762491444216	1	103.6	13.899994	101	58.7450018928678		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19694a	UK-NCRI	50.9	Male	De novo	Favorable		5.22655715263518	0	13	92	90	80		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19695c	UK-NCRI	62.5	Female	De novo	Favorable		1.80150581793292	1	113.8	7.3999977	43	90		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19696a	UK-NCRI	59.2	Male	Secondary	Adverse		1.91101984941821	1	48.5	10.199997	149	28		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19697c	UK-NCRI	54.6	Female	De novo	Intermediate		1.27583846680356	1	98.8	10.699997	99	90		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19698c	UK-NCRI	37.9	Female	De novo	Favorable		1.02943189596167	1	46.9	9.2999954	56	72		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19699c	UK-NCRI	30.9	Female	De novo	Favorable		6.43668720054757	0	35.1	8.3999939	54	30		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19700c	UK-NCRI	34.1	Male	De novo	Favorable		5.01574264202601	0	15.3	12.299995	46	50		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19701c	UK-NCRI	55.8	Female	De novo	Favorable		6.3791923340178	0	39.4	8.0999985	86	24		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19702c	UK-NCRI	43.2	Male	De novo	Favorable		6.60369609856263	0	26	10.469994	172	66		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19703c	UK-NCRI	45.4	Male	De novo	Favorable		4.49007529089665	0	61.5	10	61.5	80		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19704a	UK-NCRI	59	Female	De novo	Intermediate		0.854209445585216	1	31.4	8.5999985	19	81		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19705c	UK-NCRI	51.5	Female	Secondary	Adverse		1.28678986995209	1	10.8	7.7999992	20	10		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19706c	UK-NCRI	39.7	Female	De novo	Intermediate		6.19301848049281	0	16	9.8999939	16	80		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19707c	UK-NCRI	58.8	Female	De novo	Intermediate		0.402464065708419	1	121	12.5	34	100		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19708a	UK-NCRI	64.6	Female	De novo	Favorable		0.276522929500342	1	176.4	88	21	58.7450018928678		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19711a	UK-NCRI	65	Female	De novo	Adverse		0.555783709787817	1	3.7	13.599998	74	45		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19712c	UK-NCRI	66.5	Female	Secondary	Favorable		0.692676249144422	1	93.8	12.399994	45	67		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19713c	UK-NCRI	67	Female	De novo	Adverse		3.38672142368241	1	14.3	10.099998	28	71		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19714a	UK-NCRI	30.7	Male	De novo	Favorable		6.90212183436003	0	6.7	11.699997	194	16		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19715a	UK-NCRI	61.4	Male	De novo	Favorable		0.788501026694045	1	5.2	7.1999969	104	24		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19716a	UK-NCRI	65.4	Male	De novo	Favorable		6.46680355920602	0	46.8	9.5	39	97		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19717c	UK-NCRI	23.9	Female	De novo	Adverse		0.517453798767967	1	3.8	9.5	41	80		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19718c	UK-NCRI	58	Male	De novo	Favorable		6.55715263518138	0	4.8	10.399994	475	52		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19719c	UK-NCRI	16.1	Male	De novo	Favorable		6.49418206707734	0	6.1	6.8999977	270	38		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19720c	UK-NCRI	33.5	Male	De novo	Favorable		6.23134839151266	0	1.6	77	213	31		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19721a	UK-NCRI	63.9	Female	De novo	Intermediate		0.0848733744010951	1	6.5	109	174	58.7450018928678		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19722c	UK-NCRI	60.1	Male	Secondary	Adverse		6.27789185489391	0	67.5	8.1999969	80	80		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19723c	UK-NCRI	39.1	Female	De novo	Favorable		1.84804928131417	1	2.4	12.199997	79	80		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19725c	UK-NCRI	62.1	Female	De novo	Adverse		5.97946611909651	0	1	9.5999985	15	50		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19726c	UK-NCRI	59.9	Male	De novo	Favorable		5.13620807665982	0	147	7	35	85		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19727c	UK-NCRI	61.7	Female	De novo	Adverse		6.38193018480493	0	2.3	9.5	324	24		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19728a	UK-NCRI	46.3	Female	De novo	Favorable		1.60438056125941	1	70	88	98	38		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19729a	UK-NCRI	21.9	Female	De novo	Intermediate		3.87132101300479	0	57.4	7.5999985	52	90		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19730c	UK-NCRI	52.2	Female	De novo	Favorable		5.76043805612594	0	4.4	4.1999969	6	90		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19731c	UK-NCRI	52.8	Male	De novo	Intermediate		6.10266940451745	0	7.9	10.899994	33	66		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19732c	UK-NCRI	52.1	Female	De novo	Favorable		4.80766598220397	0	20.3	8.0599976	16	25		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19733a	UK-NCRI	62.9	Female	De novo	Favorable		6.54620123203285	0	8	10	113	40		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19734c	UK-NCRI	49.3	Female	Other	Adverse		0.616016427104723	1	4.1	8.2999954	288	11		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19735a	UK-NCRI	72.7	Male	De novo	Favorable		1.50034223134839	1	4.2	101	106	40		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19736c	UK-NCRI	61.3	Male	De novo	Favorable		3.19780971937029	1	279	8.2599945	30	95		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19737a	UK-NCRI	61.3	Female	De novo	Intermediate		4.68720054757016	1	1.8	11.299995	43	52		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19738a	UK-NCRI	45.8	Female	De novo	Intermediate		6.81998631074606	0	3.6	88	86	34		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19739a	UK-NCRI	57.5	Female	Other	Adverse		0.32580424366872	1	8	10.689995	181	16		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19740c	UK-NCRI	35.2	Female	De novo	Favorable		0.960985626283368	1	350.3	10	31	80		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19741c	UK-NCRI	49.7	Male	De novo	Favorable		6.52156057494867	0	8.7	95	182	60		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19743c	UK-NCRI	61.4	Female	Secondary	Adverse		0.503764544832307	1	33	7.8999977	34	40		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19744c	UK-NCRI	60.2	Female	Secondary	Intermediate		2.11909650924025	1	1.4	10.299995	104	50		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19745c	UK-NCRI	35.8	Male	De novo	Favorable		6.73511293634497	0	7.9	7.6999969	17	70		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19747c	UK-NCRI	41.1	Female	De novo	Intermediate		6.78713210130048	0	116.6	10	40	91		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19748c	UK-NCRI	40	Female	De novo	Favorable		6.10540725530459	0	43.3	104	24	70		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19749c	UK-NCRI	36	Female	De novo	Intermediate		0.85968514715948	1	1.2	7.6999969	30	29		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19750c	UK-NCRI	51	Male	De novo	Intermediate		3.92881587953457	0	7	10	112	95		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19751c	UK-NCRI	40.7	Male	De novo	Favorable		4.48459958932238	0	7.3	6.7999992	56	69		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19752c	UK-NCRI	53.8	Male	De novo	Favorable		6.25051334702259	0	6.6	9.5999985	45	60		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19753c	UK-NCRI	58.4	Male	De novo	Adverse		5.33333333333333	0	53.3	12.469994	36	83		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19754c	UK-NCRI	55.9	Male	De novo	Favorable		6.65023956194387	0	43.8	2.8999996	34	21		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19756a	UK-NCRI	56.3	Female	Secondary	Adverse		6.37645448323066	1	33.4	9.6999969	92	23		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19757a	UK-NCRI	65.4	Male	Secondary	Adverse		4.62970568104038	1	15	9.5999985	900	15		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19758c	UK-NCRI	24.5	Male	De novo	Adverse		1.70020533880904	1	1.6	9.6999969	29	70		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19759a	UK-NCRI	59.6	Female	De novo	Intermediate		6.53251197809719	0	11.1	11.199997	18	37		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19760a	UK-NCRI	54.5	Female	De novo	Favorable		5.4839151266256	0	27.7	8.0999985	33	20		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19761c	UK-NCRI	50	Female	De novo	Favorable		0.0520191649555099	1	2.9	7.2999992	26	75		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19762c	UK-NCRI	32.3	Female	De novo	Favorable		6.44490075290897	0	6.5	14.299995	80	75		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19763c	UK-NCRI	66	Male	De novo	Favorable		0.0629705681040383	1	60.5	7.5999985	144	18		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19764a	UK-NCRI	61.9	Male	Secondary	Favorable		1.03490759753593	1	18.9	10.899994	57	94		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19765a	UK-NCRI	52.6	Male	De novo	Intermediate		5.63449691991786	1	7.1	9.2999954	109	66		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19766c	UK-NCRI	50.8	Female	De novo	Favorable		3.52635181382615	1	58.9	11.699997	34	70		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19768a	UK-NCRI	57.3	Female	De novo	Favorable		0.684462696783025	1	109.3	52	24	70		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19769c	UK-NCRI	37.8	Female	De novo	Favorable		6.51060917180014	0	20.1	131	8	85		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19770a	UK-NCRI	59.4	Male	De novo	Adverse		2.17111567419576	1	20.8	8.5999985	13	78		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19772a	UK-NCRI	41.7	Female	De novo	Favorable		0.950034223134839	1	7.6	126	144	50		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19773c	UK-NCRI	67.8	Female	De novo	Adverse		0.194387405886379	1	2.4	10.099998	132	80		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19774a	UK-NCRI	52.2	Male	Secondary	Intermediate		2.10540725530459	1	11.7	9.8999939	24	22		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19775a	UK-NCRI	40.1	Male	De novo	Adverse		0.802190280629706	1	2.8	11.299995	190	70		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19776c	UK-NCRI	38.1	Female	De novo	Favorable		6.362765229295	0	3.7	4.6999969	9	25		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19777a	UK-NCRI	64.4	Female	De novo	Intermediate		3.93429158110883	1	1.3	11.799995	46	28		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19778c	UK-NCRI	36	Female	De novo	Intermediate		6.74058863791923	0	8.7	8.7999954	66	35		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19779a	UK-NCRI	59.4	Male	De novo	Adverse		0.27378507871321	1	20.3	4.2999992	26	90		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19780c	UK-NCRI	54.2	Male	Secondary	Adverse		0.681724845995893	1	176	8.6999969	24	35		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19781c	UK-NCRI	30.1	Male	De novo	Favorable		6.62559890485969	0	8.3	9.2999954	43	50		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19782a	UK-NCRI	44.2	Male	De novo	Intermediate		0.91170431211499	1	53.3	12.199997	154	66		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19784a	UK-NCRI	52.3	Female	De novo	Adverse		6.89390828199863	0	16.5	15.006119106409	80.4858623868992	58.7450018928678		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19785c	UK-NCRI	57.6	Female	De novo	Adverse		0.082135523613963	1	4.5	11.399994	225	95		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19786c	UK-NCRI	43	Female	De novo	Adverse		6.76249144421629	0	61	8.5	13.399994	67		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19788a	UK-NCRI	58.7	Female	Other	Intermediate		0.413415468856947	0	57.7	11.699997	65	20		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19789c	UK-NCRI	63.1	Male	Secondary	Adverse		6.91307323750856	0	1.3	8.909996	33	20		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19790a	UK-NCRI	52.9	Female	De novo	Favorable		1.27857631759069	1	17.4	8.2999954	69	86		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19791c	UK-NCRI	33.3	Female	De novo	Favorable		6.6776180698152	0	73.1	9.1999969	25	53		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19792a	UK-NCRI	60.3	Female	De novo	Adverse		6.05612594113621	0	3.1	7.3999977	34	52		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19793c	UK-NCRI	51.1	Male	Secondary	Adverse		0.375085557837098	1	48.6	12.599998	149	32		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19794c	UK-NCRI	65	Male	De novo	Intermediate		3.87132101300479	1	17.1	11.399994	390	91		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19795a	UK-NCRI	66.4	Female	De novo	Favorable		0.0985626283367557	0	5.3	11.299995	88	98		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19796c	UK-NCRI	49.8	Male	De novo	Favorable		6.79260780287474	0	29	10.789993	33	70		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19797a	UK-NCRI	43.3	Female	De novo	Intermediate		0.210814510609172	1	1.8	9.3999939	203	58.7450018928678		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19798a	UK-NCRI	59.8	Female	De novo	Favorable		5.38261464750171	1	9.8	9.2999954	29	50		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19800a	UK-NCRI	63.4	Female	Secondary	Intermediate		6.64202600958248	0	1.8	8.8999939	77	30		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19802a	UK-NCRI	59.9	Female	Secondary	Intermediate		6.42026009582478	0	3.7	8.1999969	158	80		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19803a	UK-NCRI	40.3	Male	De novo	Favorable		4.90075290896646	0	32.4	10	24	70		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19804a	UK-NCRI	50.9	Female	Other	Adverse		3.81382614647502	1	5.6	7.7999992	20	50		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19805a	UK-NCRI	72.7	Female	Secondary	Adverse		0.257357973990418	1	90.8	7	53	87		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19806c	UK-NCRI	59.5	Male	De novo	Intermediate		7.10198494182067	0	4.9	10.599998	136	40		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19808a	UK-NCRI	47.1	Male	De novo	Favorable		0.906228610540726	1	46.7	8.5999985	135	90		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19809a	UK-NCRI	56.6	Female	De novo	Favorable		7.4715947980835	0	42	8	107	54		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19812a	UK-NCRI	59.8	Male	De novo	Favorable		7.05544147843943	0	47.8	8.6999969	156	77		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19813c	UK-NCRI	53.2	Male	De novo	Favorable		6.48870636550308	0	113	14.009995	24	91		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19814a	UK-NCRI	30.2	Male	De novo	Adverse		0.731006160164271	1	29.2	5.5999985	521	0		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19815c	UK-NCRI	62.7	Female	Secondary	Adverse		0.114989733059548	1	191.6	5.7999992	22	93		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19816a	UK-NCRI	61.8	Male	De novo	Favorable		0.722792607802875	1	54.6	7.5	85	89		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19817a	UK-NCRI	20.6	Male	De novo	Favorable		1.927446954141	1	47.8	10.599998	24	63		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19818a	UK-NCRI	58.7	Male	De novo	Intermediate		1.14989733059548	1	102	6.8999977	40	85		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19819a	UK-NCRI	58.3	Male	De novo	Favorable		0.0465434633812457	1	120	7.3999977	128	90		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19820c	UK-NCRI	45.5	Female	De novo	Favorable		4.99657768651609	0	45	8.8999939	16	70		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19821a	UK-NCRI	28.7	Female	De novo	Adverse		0.736481861738535	1	41.8	9.3999939	36	60		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19822a	UK-NCRI	55.6	Male	De novo	Favorable		1.51129363449692	1	76.6	7.0999985	47	95		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19824a	UK-NCRI	40.4	Female	De novo	Favorable		7.84394250513347	0	175	10.299995	22	70		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19825a	UK-NCRI	39.3	Female	De novo	Intermediate		7.81656399726215	0	27	9	60	58.7450018928678		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19826a	UK-NCRI	36.4	Female	De novo	Favorable		7.61943874058864	0	74.4	6.5	56	17		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19827a	UK-NCRI	43.2	Male	De novo	Adverse		1.27583846680356	1	9.8	10.099998	220	55		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19830a	UK-NCRI	46	Male	De novo	Favorable		5.27310061601643	0	17.8	14	129	60		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19831a	UK-NCRI	50.5	Female	De novo	Favorable		5.14715947980835	0	27.9	10.799995	83	12		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19832c	UK-NCRI	57.8	Female	De novo	Adverse		1.64818617385353	1	8.2	9.2999954	266	65		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19833a	UK-NCRI	37.3	Female	De novo	Favorable		0.840520191649555	1	78.8	4.5999985	7	95		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19834a	UK-NCRI	58.8	Female	De novo	Intermediate		0.142368240930869	1	92.8	5.5	64	81		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19835c	UK-NCRI	54	Female	De novo	Intermediate		1.59616700889802	1	48.6	15.006119106409	80.4858623868992	58.7450018928678		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19836a	UK-NCRI	50.8	Female	De novo	Favorable		1.02669404517454	1	10.3	11.099998	87	86		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19837c	UK-NCRI	55.7	Male	De novo	Adverse		0.739219712525667	1	2.2	8.8999939	70	90		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19838a	UK-NCRI	31.7	Male	De novo	Favorable		0.0136892539356605	1	73.2	10.299995	30	94		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19839a	UK-NCRI	57.5	Male	De novo	Intermediate		1.23203285420945	1	166.2	6.2999992	75	80		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19840a	UK-NCRI	63.6	Male	De novo	Favorable		8.48186173853525	0	14.2	4.7999992	358	35		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19842c	UK-NCRI	33.9	Male	De novo	Adverse		0.670773442847365	1	54.4	4.7999992	5	95		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19843a	UK-NCRI	47.4	Male	De novo	Favorable		7.53182751540041	0	26.8	7.8999977	35	76		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19844c	UK-NCRI	31.3	Female	De novo	Favorable		5.53593429158111	0	31.1	9.0999985	110	71		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19845a	UK-NCRI	20.9	Male	De novo	Intermediate		3.74537987679671	0	33	13.849998	17.399994	80		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19846a	UK-NCRI	40.4	Female	De novo	Intermediate		8.56947296372348	0	80.1	8.3999939	39	3.75		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19847a	UK-NCRI	60.1	Male	De novo	Favorable		1.67830253251198	1	12.1	6.6999969	81	61		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19848c	UK-NCRI	46.2	Female	De novo	Favorable		4.98015058179329	0	68	8.8999939	57	88		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19849a	UK-NCRI	37.3	Female	De novo	Favorable		8.5201916495551	0	62.5	8.0999985	13	91		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19851a	UK-NCRI	54.3	Male	De novo	Favorable		8.2217659137577	0	21.7	11.399994	66	89		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19852a	UK-NCRI	21.7	Female	De novo	Favorable		8.6735112936345	0	42.1	9.6999969	42	80		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19853a	UK-NCRI	49.5	Female	De novo	Adverse		4.5968514715948	0	131.1	12.199997	69	87		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19854a	UK-NCRI	37.1	Male	De novo	Intermediate		4.57494866529774	0	69.3	8.8999939	122	50		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19855a	UK-NCRI	36.7	Female	De novo	Favorable		8.35592060232717	0	134	6.1999969	10	36		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19856a	UK-NCRI	51.5	Female	De novo	Favorable		8.75564681724846	0	256.3	7.3999977	241	92		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19857a	UK-NCRI	19.8	Female	De novo	Intermediate		0.134154688569473	1	54.4	12.299995	75	97		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19858a	UK-NCRI	50.8	Female	De novo	Adverse		0.780287474332649	1	153.2	8.5	38	90		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19859a	UK-NCRI	21.3	Male	De novo	Intermediate		0.607802874743327	1	36.4	10.299995	35	70		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19860a	UK-NCRI	23.4	Female	De novo	Favorable		6.362765229295	0	138.4	8.8999939	35	83		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19861a	UK-NCRI	29.1	Male	De novo	Favorable		7.4113620807666	0	22.7	10.5	154	60		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19862a	UK-NCRI	54.6	Male	De novo	Intermediate		2.83093771389459	1	40	7.6999969	56	15		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19863a	UK-NCRI	39.1	Male	De novo	Intermediate		0.684462696783025	1	249	7.5999985	78	88		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19864a	UK-NCRI	36.2	Male	Secondary	Adverse		1.74948665297741	1	128	79	66	21		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19867a	UK-NCRI	53.4	Male	De novo	Favorable		2.13552361396304	1	45	9	55	15		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19868a	UK-NCRI	58.3	Male	De novo	Favorable		8.69541409993155	0	192	9.2999954	49	50		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19869a	UK-NCRI	53.9	Female	De novo	Adverse		0.386036960985626	1	345	6.6999969	54	85		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19871a	UK-NCRI	58	Female	De novo	Favorable		8.74469541409993	0	12.1	5.1499977	19	30		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19873a	UK-NCRI	53.6	Male	De novo	Adverse		3.73990417522245	1	86.6	11.599998	74	92		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19874c	UK-NCRI	44.1	Female	De novo	Adverse		2.48049281314168	1	246	4.1999969	30	40		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19875a	UK-NCRI	44.1	Male	Other	Intermediate		8.63518138261465	0	9.8	11.599998	73	15		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19879a	UK-NCRI	46.8	Male	De novo	Adverse		5.91101984941821	1	25.5	11.599998	97	20		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19880a2	UK-NCRI	31.2	Male	De novo	Intermediate		1.20739219712526	1	5.8	9.7999954	75	74		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19881c	UK-NCRI	47.9	Female	De novo	Intermediate		1.02669404517454	1	75.7	9.1999969	12	90		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19882a	UK-NCRI	49.8	Male	De novo	Adverse		0.197125256673511	1	0.8	10	3	13		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19883a	UK-NCRI	42.9	Female	De novo	Favorable		8.73648186173854	0	47.9	6.6999969	64	99		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19884c	UK-NCRI	33.7	Female	De novo	Intermediate		0.862422997946612	0	1.6	9.3999939	42	62		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19885a	UK-NCRI	59.6	Female	De novo	Adverse		9.03490759753593	0	1.1	13	159	30		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19886a	UK-NCRI	48.2	Female	De novo	Adverse		1.70020533880904	1	143	9.659996	143	47		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19887a	UK-NCRI	56.1	Female	De novo	Favorable		5.63449691991786	0	28.3	12.299995	96	76		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19888a	UK-NCRI	53.9	Female	De novo	Adverse		1.03764544832307	1	23.9	9.3999939	20	56		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19889a	UK-NCRI	53.7	Female	De novo	Favorable		8.26283367556468	0	164.7	7.5	16	64		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19890a	UK-NCRI	62.3	Female	De novo	Adverse		0.465434633812457	1	63.1	10.199997	61	40		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19891a	UK-NCRI	51.9	Male	De novo	Favorable		2.73511293634497	1	196	8.6899948	23	27		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19892a	UK-NCRI	41.8	Male	De novo	Favorable		4.47638603696099	1	16.6	11.199997	58	30		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19893a	UK-NCRI	61.6	Male	De novo	Favorable		0.0684462696783025	1	21.5	11.099998	259	45		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19894a	UK-NCRI	53.8	Male	De novo	Favorable		7.32375085557837	0	76	9	14	80		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19895a	UK-NCRI	49.4	Female	De novo	Favorable		0.188911704312115	1	46	0.7199998	38	90		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19896a	UK-NCRI	27.3	Male	De novo	Favorable		7.94798083504449	0	64.6	13.599998	28	95		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19897a	UK-NCRI	44.6	Male	De novo	Favorable		8.10403832991102	0	23.9	8.5	29	65		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19901a	UK-NCRI	61.8	Female	De novo	Favorable		6.82546201232033	0	14.9	9.0999985	79	80		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19902a	UK-NCRI	52.4	Female	Other	Adverse		0.205338809034908	1	49.3	12.239998	24	20		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19903a	UK-NCRI	45.3	Female	De novo	Favorable		1.7138945927447	1	10	9.659996	82	28		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19904a	UK-NCRI	51.1	Male	De novo	Favorable		9.14989733059548	0	75.7	9.8999939	45	87		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19905a	UK-NCRI	58	Male	De novo	Favorable		0.421629021218344	1	34.8	9.1999969	173	11		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19907a	UK-NCRI	52.9	Female	De novo	Intermediate		0.462696783025325	1	92.3	9.9799957	59	50		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19909a	UK-NCRI	54.8	Male	De novo	Favorable		7.09924709103354	0	38.9	7.5999985	28	95		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19910a	UK-NCRI	19.3	Female	De novo	Intermediate		0.843258042436687	1	52.3	6.5999985	236	20		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19912a	UK-NCRI	61.6	Male	De novo	Adverse		0.769336071184121	1	94.6	8.6999969	234	61		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19913c	UK-NCRI	59.5	Male	De novo	Favorable		9.3305954825462	0	14.1	9.3999939	57	97		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19914a	UK-NCRI	59.5	Female	De novo	Favorable		7.68514715947981	0	40.5	7.3999977	37	34		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19915a	UK-NCRI	26.5	Female	De novo	Favorable		2.42026009582478	1	5.7	10.299995	110	70		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19916a	UK-NCRI	58.7	Female	De novo	Favorable		1.49760438056126	1	4.8	10.5	110	43		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19917a	UK-NCRI	39.6	Female	De novo	Favorable		2.56810403832991	1	128.1	8.7999954	130	92		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19918c	UK-NCRI	55.3	Female	Secondary	Adverse		1.86173853524983	1	8.5	10.799995	248	58.7450018928678		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19919a	UK-NCRI	47.9	Male	De novo	Intermediate		9.31964407939767	0	130.6	7.5	155	60		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19920a	UK-NCRI	46.5	Male	De novo	Favorable		9.25667351129363	0	61.6	7.8999977	46	94		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19921c	UK-NCRI	67.4	Male	Other	Intermediate		0.446269678302533	1	28	11.099998	46	80		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19922c	UK-NCRI	61	Male	De novo	Favorable		8.78576317590691	0	71	12.199997	116	89		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19923c	UK-NCRI	62.8	Female	De novo	Favorable		8.7419575633128	0	7.5	9.8999939	49	40.299988		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19924c	UK-NCRI	44.8	Female	De novo	Intermediate		5.67556468172485	1	6.9	9.7999954	43	60		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19925a	UK-NCRI	27	Male	De novo	Favorable		9.4154688569473	0	165.8	8.7999954	27	98		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19926a	UK-NCRI	35.2	Male	De novo	Favorable		6.00684462696783	0	38.5	9.3999939	29	91		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19928c	UK-NCRI	100.7	Male	De novo	Intermediate		1.37440109514031	1	169.7	10.099998	50	82		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19929a	UK-NCRI	51.1	Female	De novo	Favorable		1.76865160848734	1	80.1	5.5999985	23	94		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19932a	UK-NCRI	50.7	Male	De novo	Favorable		1.84531143052704	1	52.6	5.1999969	24	58.7450018928678		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19934c	UK-NCRI	44.8	Male	De novo	Favorable		6.85010266940452	0	134	5.6999969	24	88		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19935a	UK-NCRI	58.9	Female	De novo	Adverse		1.73579739904175	1	26.5	7.6999969	11	40		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19936a	UK-NCRI	100.2	Male	De novo	Intermediate		5.44010951403149	0	386.5	104	62	92		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19937c	UK-NCRI	44.3	Female	De novo	Intermediate		9.58521560574949	0	18.4	12.799995	14	95		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19938a	UK-NCRI	46.4	Male	De novo	Favorable		0.884325804243669	1	41.7	10.299995	47	95		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19939a	UK-NCRI	49.7	Female	De novo	Favorable		0.536618754277892	1	182	10.299995	63	54		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19940a	UK-NCRI	38.8	Male	De novo	Favorable		0.0191649555099247	1	86.9	10.599998	33	89		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19941a	UK-NCRI	60	Male	De novo	Adverse		0.276522929500342	1	266	9.659996	36	64		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19942a	UK-NCRI	47.9	Female	De novo	Favorable		9.62354551676934	0	25.3	10	80	85		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19943a	UK-NCRI	31.5	Female	De novo	Favorable		6.42026009582478	0	44	8.5	52	85		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19944a	UK-NCRI	40.7	Female	De novo	Favorable		9.07871321013005	0	37.9	11.899994	159	63		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19945c	UK-NCRI	61	Male	De novo	Favorable		5.65366187542779	1	99	9.2999954	125	47		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19946a	UK-NCRI	25.2	Female	De novo	Favorable		1.29500342231348	1	11.8	7.7999992	32	82		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19947c	UK-NCRI	59.2	Female	De novo	Intermediate		2.46406570841889	1	96.1	10.629997	63	94		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19948a	UK-NCRI	61.9	Male	De novo	Favorable		9.93018480492813	0	70.3	10.5	1523	98		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19949a	UK-NCRI	47.1	Male	De novo	Intermediate		8.32306639288159	0	84.5	8.8999939	84	96		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19950a	UK-NCRI	45.1	Male	De novo	Favorable		9.77138945927447	0	30.8	10.399994	154	50		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19951a	UK-NCRI	42	Female	De novo	Favorable		9.80971937029432	0	23.6	9.5999985	54	65		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19952a	UK-NCRI	30.4	Female	De novo	Intermediate		0.813141683778234	0	38.5	10.599998	10	81		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19953c	UK-NCRI	36.5	Female	Secondary	Adverse		1.16358658453114	0	33.7	10.599998	257	30		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19955c	UK-NCRI	48.8	Female	De novo	Favorable		8.38329911019849	1	4.3	9.8999939	22	30		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19956a	UK-NCRI	59.9	Female	De novo	Adverse		2.01232032854209	1	59.7	8.5	39	80		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19957a	UK-NCRI	46.1	Female	De novo	Favorable		9.56331279945243	0	38.9	8.5999985	31	20		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19958c	UK-NCRI	46.5	Male	De novo	Favorable		5.02943189596167	0	61.3	9.8999939	110	54		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19961d	UK-NCRI	46.2	Female	De novo	Favorable		1.87816563997262	1	12	0.8899999	57	58.7450018928678		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19962c	UK-NCRI	42.4	Male	De novo	Favorable		5.51676933607118	0	15.5	1.2999992	134	50		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19964a	UK-NCRI	45.4	Female	De novo	Favorable		9.55509924709103	0	38.2	9.8999939	17	85		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19965c	UK-NCRI	30.3	Female	De novo	Intermediate		7.82751540041068	0	55.9	8.7999954	10	94		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19966a	UK-NCRI	47	Male	De novo	Favorable		10.0780287474333	0	20.3	8.3999939	25	57		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19967a	UK-NCRI	55.1	Female	Secondary	Favorable		0.668035592060233	1	33.3	9.5	38	20		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19968a	UK-NCRI	61.9	Male	De novo	Favorable		8.93360711841205	0	49.7	7.6999969	26	11		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19969c	UK-NCRI	55.5	Female	Secondary	Intermediate		0.440793976728268	1	120	10.099998	5	40		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19970a	UK-NCRI	52.1	Male	De novo	Favorable		5.4154688569473	0	38.8	8.6999969	14	91		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19971c	UK-NCRI	59.5	Female	De novo	Favorable		6.84736481861739	0	1.3	8.6999969	85	90		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19972a	UK-NCRI	50.5	Female	De novo	Favorable		9.31964407939767	0	52.2	7.6999969	93	80		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19973c	UK-NCRI	62.5	Female	De novo	Favorable		9.02943189596167	0	285.8	9.6999969	32	79		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19974c	UK-NCRI	18	Male	De novo	Intermediate		0.722792607802875	1	285	6.7999992	32	58.7450018928678		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19975a	UK-NCRI	53.4	Male	De novo	Favorable		4.90075290896646	0	13.5	8.7999954	104	47		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19976a	UK-NCRI	56	Female	De novo	Favorable		0.32580424366872	1	190	10.399994	43	90		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19977a	UK-NCRI	63	Male	Secondary	Intermediate		1.24572210814511	1	80.5	7.2999992	17	95		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19978a	UK-NCRI	44.5	Male	De novo	Favorable		1.96851471594798	1	24.4	10.399994	89	90		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19979a	UK-NCRI	55.4	Male	De novo	Favorable		10.6776180698152	0	219	7.1999969	39	90		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19981a	UK-NCRI	59.1	Male	De novo	Adverse		3.44147843942505	1	34.4	6.2999992	52	12		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19982a	UK-NCRI	54.1	Male	De novo	Favorable		1.45106091718001	1	141.7	7.5	17	95		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19983a	UK-NCRI	19	Female	De novo	Favorable		10.299794661191	0	216.3	13	58	94		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19984a	UK-NCRI	57.3	Female	De novo	Adverse		1.86173853524983	1	70.8	9.5999985	23	99		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19985a	UK-NCRI	63.9	Male	De novo	Favorable		0.32580424366872	1	24.2	8.0999985	20	4		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19986a	UK-NCRI	82.3	Male	Secondary	Adverse		0.210814510609172	1	9.4	9.2999954	25	90		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19987a	UK-NCRI	77.8	Male	De novo	Intermediate		0.42984257357974	1	40	8.6999969	79	31		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19989a	UK-NCRI	80.2	Female	Secondary	Adverse		0.186173853524983	1	23.3	8.7999954	147	90		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19991a	UK-NCRI	85.9	Male	De novo	Favorable		4.06297056810404	0	17.5	13.399994	88	78		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19993a	UK-NCRI	70.2	Male	Secondary	Adverse		0.0246406570841889	1	100	10	22	58.7450018928678		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19994a	UK-NCRI	77	Male	De novo	Favorable		4.91991786447639	0	139.6	6.5	84	95		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19996a	UK-NCRI	77.8	Male	De novo	Favorable		0.457221081451061	1	12.9	8.7999954	67	49		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD19997a	UK-NCRI	82.1	Male	De novo	Favorable		0.517453798767967	1	44.8	7.6999969	31	69		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20000a	UK-NCRI	84.4	Male	De novo	Adverse		0.0903490759753593	1	132	9	16	58.7450018928678		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20001c	UK-NCRI	81.5	Male	De novo	Intermediate		0.082135523613963	1	3.5	9.7999954	16	80		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20002a	UK-NCRI	79.5	Female	De novo	Adverse		0.514715947980835	1	12	7.3999977	21	90		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20003a	UK-NCRI	75.3	Male	De novo	Favorable		0.188911704312115	1	12.3	6.3999977	18	37		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20004a	UK-NCRI	73.2	Male	De novo	Favorable		0.249144421629021	1	88.9	10.199997	34	81.799988		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20006a	UK-NCRI	85.9	Female	De novo	Favorable		0.153319644079398	1	19.7	9.2999954	23	80		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20007c	UK-NCRI	73.5	Female	Secondary	Adverse		0.4435318275154	1	9.8	10	54	70		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20008a	UK-NCRI	68.7	Female	Other	Adverse		0.153319644079398	1	65.1	7.8999977	20	12		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20009a	UK-NCRI	85.5	Female	De novo	Favorable		0.917180013689254	1	59.6	9.0999985	76	97		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20011c	UK-NCRI	69.6	Male	De novo	Adverse		0.153319644079398	1	75.8	9.3999939	24	30		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20012a	UK-NCRI	78.1	Male	De novo	Favorable		0.145106091718001	1	20.2	6.3999977	144	29		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20013a	UK-NCRI	76.4	Female	De novo	Favorable		0.054757015742642	1	25.5	8.7999954	19	80		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20015a	UK-NCRI	72	Male	De novo	Favorable		0.769336071184121	1	42.5	10.599998	85	91		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20016a	UK-NCRI	72.2	Male	De novo	Favorable		0.0684462696783025	1	116.8	6.7999992	33	41		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20017a	UK-NCRI	81.1	Female	De novo	Favorable		0.0520191649555099	1	50	12.899994	212	58		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20019a	UK-NCRI	70	Female	De novo	Intermediate		0.936344969199179	1	41.5	8.6999969	37	20		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20020c	UK-NCRI	68.8	Female	Secondary	Adverse		0.0383299110198494	1	40.5	6.3999977	146	70		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20022a	UK-NCRI	76.6	Female	De novo	Adverse		0.027378507871321	1	32.8	8.8999939	51	80		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20023c	UK-NCRI	80.3	Female	Secondary	Adverse		0.109514031485284	1	32	11.399994	145	32		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20026c	UK-NCRI	78.9	Male	De novo	Intermediate		1.53867214236824	1	96.9	13.099998	70	97		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20027c	UK-NCRI	71.6	Male	De novo	Favorable		0.791238877481177	1	2.6	9.8999939	123	30		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20028a	UK-NCRI	77.4	Female	De novo	Intermediate		0.120465434633812	1	13.4	8	35	58.7450018928678		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20030a	UK-NCRI	69.1	Male	Secondary	Adverse		0.0684462696783025	1	16.6	8.5	101	25		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20031a	UK-NCRI	69.4	Female	Secondary	Adverse		1.51676933607118	1	19.8	9.2999954	62	27		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20032a	UK-NCRI	67.3	Female	De novo	Favorable		1.30321697467488	1	273	6.6999969	9	99		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20033a	UK-NCRI	62.2	Female	Secondary	Adverse		0.725530458590007	1	226	5.5	49	90		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20034a	UK-NCRI	65.9	Female	De novo	Favorable		0.566735112936345	1	117	7.5999985	33	98		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20035a	UK-NCRI	64.9	Male	De novo	Favorable		0.054757015742642	1	156	9.3999939	110	80		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20036a	UK-NCRI	63.2	Male	De novo	Favorable		3.18412046543463	0	25.1	9.1999969	49	58.7450018928678		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20037a	UK-NCRI	68.4	Male	De novo	Adverse		0.0054757015742642	1	117	8.6999969	41	71		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20038a	UK-NCRI	62.7	Male	De novo	Intermediate		0.643394934976044	1	52.2	8.1999969	43	95.5		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20040a	UK-NCRI	73.5	Female	Secondary	Intermediate		0.48186173853525	0	2.2	8.5999985	12	12		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20041a	UK-NCRI	67.6	Female	De novo	Adverse		0.550308008213552	1	11.7	9.6999969	39	70		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20042a	UK-NCRI	73.7	Male	De novo	Favorable		0.0848733744010951	1	1.2	10.899994	74	82		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20043c	UK-NCRI	68	Female	De novo	Intermediate		0.0438056125941136	1	212.1	10.199997	67	90		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20047a	UK-NCRI	69.5	Female	Secondary	Adverse		0.142368240930869	1	14.2	6.7999992	50	30		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20048a	UK-NCRI	62.6	Female	Secondary	Favorable		0.788501026694045	1	31.9	7.1999969	149	39		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20049a	UK-NCRI	67.4	Male	De novo	Adverse		4.04928131416838	0	3.2	8.6999969	16	92		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20050a	UK-NCRI	71.5	Female	De novo	Intermediate		0.364134154688569	1	108	12	34	96		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20051a	UK-NCRI	67.9	Male	Other	Adverse		1.60711841204654	1	0.9	10.799995	42	40		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20054c	UK-NCRI	71.8	Female	De novo	Adverse		1.26488706365503	1	1	9	14	25		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20055a	UK-NCRI	72.7	Female	De novo	Favorable		0.580424366872005	0	43	7.6999969	49	21		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20056a	UK-NCRI	64.1	Female	Secondary	Intermediate		0.969199178644764	1	2.7	8.8999939	49	34		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20057a	UK-NCRI	67.4	Male	De novo	Adverse		1.79329226557153	1	1.4	9	111	49		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20062a	UK-NCRI	68	Male	De novo	Favorable		4.71457905544148	0	13.7	11.199997	74	30		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20063a	UK-NCRI	73.4	Female	De novo	Intermediate		0.0027378507871321	1	224.1	9.3999939	43	94		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20064a	UK-NCRI	64.5	Female	De novo	Adverse		2.49965776865161	1	71.8	5.7999992	11	80		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20065a	UK-NCRI	70.9	Female	De novo	Adverse		1.45106091718001	1	3	10	62	40		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20066a	UK-NCRI	60.6	Male	Other	Intermediate		4.56125941136208	0	2.9	7.6999969	155	10.699997		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20067a	UK-NCRI	73.1	Female	De novo	Adverse		0.0383299110198494	1	1.7	12.099998	57	85		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20068a	UK-NCRI	67.2	Male	De novo	Favorable		4.65434633812457	0	110	9.1999969	45	80		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20070a	UK-NCRI	68.4	Female	De novo	Favorable		1.26488706365503	1	12.3	10.599998	41	80		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20071a	UK-NCRI	71.4	Female	De novo	Adverse		0.339493497604381	1	6.3	9.7999954	16	54		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20072a	UK-NCRI	65.4	Male	De novo	Favorable		1.26762491444216	1	33.3	7.1999969	65	80		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20073a	UK-NCRI	68.5	Male	De novo	Favorable		1.03764544832307	1	57.7	10.199997	640	47		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20074a	UK-NCRI	70	Female	De novo	Adverse		0.9637234770705	1	7.7	10.299995	86	44		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20077a	UK-NCRI	72.7	Female	De novo	Adverse		0.16974674880219	1	3.9	11.399994	114	63		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20078a	UK-NCRI	69.6	Female	De novo	Adverse		1.01848049281314	1	62.6	7.5999985	49	80		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20079a	UK-NCRI	72.5	Female	Secondary	Adverse		0.314852840520192	1	36.7	8.3999939	53	56.5		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20080a	UK-NCRI	64	Male	De novo	Intermediate		1.83709787816564	0	1	6.8999977	99	62		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20081a	UK-NCRI	66.3	Male	De novo	Favorable		0.0136892539356605	1	31.4	7.1999969	31	77		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20082a	UK-NCRI	61.5	Male	De novo	Favorable		1.61533196440794	1	3.5	6.8999977	69	62		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20084a	UK-NCRI	65.5	Female	De novo	Favorable		0.0574948665297741	1	21.1	10.199997	22	70		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20085a	UK-NCRI	67.6	Male	Secondary	Favorable		5.03490759753593	0	86.1	9.2999954	98	89		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20087a	UK-NCRI	63.6	Female	De novo	Intermediate		5.05681040383299	0	1.5	10.399994	158	53		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20088a	UK-NCRI	65.3	Male	De novo	Favorable		4.88980150581793	0	10.5	7.7999992	49	80		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20089a	UK-NCRI	71.2	Male	De novo	Adverse		1.76865160848734	1	1.7	9.7999954	37	25		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20090a	UK-NCRI	70.4	Female	De novo	Adverse		2.63381245722108	1	2.4	9.6999969	65	40		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20093a	UK-NCRI	69.3	Male	De novo	Adverse		0.0876112251882272	1	14.8	9.0999985	225	2		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20094a	UK-NCRI	64.1	Male	De novo	Adverse		1.14442162902122	1	88	7.7999992	71	62		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20095a	UK-NCRI	66.2	Female	De novo	Favorable		1.36892539356605	1	154.5	11.199997	115	74		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20096a	UK-NCRI	72	Female	De novo	Adverse		1.5605749486653	1	16.8	11.5	13	20		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20097a	UK-NCRI	73.3	Female	De novo	Favorable		0.0684462696783025	1	182	10.099998	39	58.7450018928678		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20098a	UK-NCRI	75.4	Female	De novo	Intermediate		1.05133470225873	1	8.8	9.8999939	365	28		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20100a	UK-NCRI	64.5	Male	De novo	Favorable		5.29226557152635	0	40.9	8.5	34	35		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20101a	UK-NCRI	68.8	Female	Secondary	Adverse		0.306639288158795	1	48.2	9	28	20		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20102a	UK-NCRI	61.5	Female	De novo	Favorable		4.63791923340178	0	32.6	14.299995	56	14		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20103a	UK-NCRI	67.3	Female	De novo	Favorable		0.199863107460643	1	44	11.699997	93	58.7450018928678		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20104a	UK-NCRI	72.7	Male	De novo	Favorable		0.542094455852156	1	18.6	8	51	30		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20105a	UK-NCRI	68.1	Female	De novo	Favorable		1.87816563997262	1	2.8	6.5	26	12		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20106a	UK-NCRI	72.3	Male	De novo	Favorable		0.210814510609172	1	22.6	7.5999985	45	58.7450018928678		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20108a	UK-NCRI	74.8	Male	De novo	Adverse		0.881587953456537	1	69.2	9.2999954	11	33		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20110a	UK-NCRI	73.4	Female	Secondary	Favorable		0.580424366872005	1	10.4	9.5999985	36	17		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20111a	UK-NCRI	63	Female	De novo	Favorable		0.0082135523613963	1	293.6	9.8999939	58	58.7450018928678		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20112a	UK-NCRI	65.9	Male	De novo	Adverse		1.34428473648186	1	4.4	8	47	44		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20113a	UK-NCRI	71.8	Female	De novo	Favorable		5.42642026009583	0	398	7.6999969	24	86		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20116a	UK-NCRI	74.6	Female	Secondary	Adverse		0.183436002737851	1	12.3	10.5	47	50		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20117a	UK-NCRI	61.9	Female	De novo	Adverse		0.563997262149213	1	22.4	10.699997	19	90		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20118a	UK-NCRI	69.3	Female	De novo	Favorable		1.42368240930869	1	48.9	7.7999992	63	73		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20120a	UK-NCRI	68.9	Female	De novo	Adverse		2.16290212183436	1	99	9.5	26	35		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20121a	UK-NCRI	66.3	Female	De novo	Intermediate		0.0629705681040383	1	52.1	8.2999954	85	80		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20122a	UK-NCRI	63.8	Female	De novo	Adverse		0.698151950718686	1	13.4	5.2999992	22	43		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20123a	UK-NCRI	69.3	Female	De novo	Favorable		5.02121834360027	0	41.8	12.099998	52	93		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20125a	UK-NCRI	62.6	Female	De novo	Adverse		0.558521560574949	1	38	7	40	21		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20128a	UK-NCRI	63.3	Female	De novo	Favorable		0.517453798767967	1	38.7	6.6999969	118	30		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20129a	UK-NCRI	63.4	Male	De novo	Favorable		6.77618069815195	0	82.2	14.699997	109	88		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20130c	UK-NCRI	66.1	Female	De novo	Favorable		6.8227241615332	0	2.2	12	14	44		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20131a	UK-NCRI	64.9	Female	De novo	Favorable		6.71047227926078	0	74	9.2999954	172	58.7450018928678		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20132c	UK-NCRI	72	Female	De novo	Adverse		0.350444900752909	1	2.1	7.5	26	40		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20135c	UK-NCRI	64.6	Female	De novo	Adverse		0.511978097193703	1	1.6	9.7999954	58	60		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20136c	UK-NCRI	66.1	Female	De novo	Favorable		6.79260780287474	0	18	10	52	47		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20137c	UK-NCRI	67.4	Female	De novo	Favorable		3.84120465434634	1	4.9	10.399994	244	90		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20138a	UK-NCRI	60.3	Male	De novo	Favorable		1.91101984941821	1	43.8	8.2999954	40	51		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20139a	UK-NCRI	66	Male	De novo	Intermediate		5.40451745379877	0	18	12.599998	80	90		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20141a	UK-NCRI	67.7	Female	De novo	Adverse		0.153319644079398	1	69.8	9.5999985	55	90		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20142c	UK-NCRI	76.3	Female	De novo	Favorable		0.731006160164271	1	23	9.7999954	35	60		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20143c	UK-NCRI	78.4	Female	De novo	Favorable		7.29911019849418	0	26.4	11.299995	23	85		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20145a	UK-NCRI	75.3	Female	De novo	Adverse		0.506502395619439	1	20	10.399994	77	90		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20146a	UK-NCRI	60.7	Male	De novo	Favorable		1.44558521560575	1	46.3	11.699997	88	80		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20148c	UK-NCRI	69.5	Male	De novo	Favorable		2.29705681040383	1	21.2	10.899994	20	34		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20149c	UK-NCRI	59.9	Male	Other	Intermediate		4.36413415468857	1	43	13.299995	74	20		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20150a	UK-NCRI	68.1	Male	De novo	Favorable		4.67624914442163	1	24.2	10.599998	183	77		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20151c	UK-NCRI	39.3	Male	De novo	Favorable		7.57837097878166	0	83	8.0999985	27	95		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20152a	UK-NCRI	60.6	Male	De novo	Favorable		10.3682409308693	0	93	7.5999985	33	99		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20157a	UK-NCRI	18.5	Male	De novo	Adverse		0.503764544832307	1	10.8	6.8999977	74	61		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20158a	UK-NCRI	62.1	Male	De novo	Favorable		3.72621492128679	1	44.7	9.5999985	135	88		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20159a	UK-NCRI	22	Female	De novo	Adverse		6.72689938398357	0	2.2	15.5	173	90		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20160a	UK-NCRI	33.1	Male	De novo	Favorable		4.53661875427789	0	162	7.7999992	58	95		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20161c	UK-NCRI	42.5	Female	Secondary	Favorable		6.15195071868583	0	107.4	7.8999977	25	83		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20162a	UK-NCRI	58.7	Female	De novo	Intermediate		1.33333333333333	1	21.7	9.5	110	15		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20163a	UK-NCRI	59.9	Male	De novo	Intermediate		0.766598220396988	1	48.4	5.2999992	53	80		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20164c	UK-NCRI	54.8	Male	De novo	Intermediate		6.40657084188912	0	148.2	4.1999969	51	80		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20165a	UK-NCRI	56.8	Female	De novo	Adverse		1.32511978097194	1	45	9	96	69		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20166c	UK-NCRI	51.6	Female	De novo	Favorable		2.30800821355236	1	91.8	5.0999985	7	90		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20171a	UK-NCRI	62.8	Female	De novo	Favorable		0.0109514031485284	1	228	11.5	55	87		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20172a	UK-NCRI	55.7	Female	De novo	Favorable		0.958247775496235	1	254	9.1999969	11	95		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20173a	UK-NCRI	32.8	Male	De novo	Favorable		1.16632443531828	1	20.3	4.7999992	16	58.7450018928678		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20175a	UK-NCRI	61.7	Male	De novo	Favorable		6.48870636550308	0	22.4	8.6999969	35	70		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20176c	UK-NCRI	45.3	Female	De novo	Favorable		3.0362765229295	1	39.3	11.199997	24	80		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20177c	UK-NCRI	48.1	Male	De novo	Favorable		6.3025325119781	0	11.5	7.8999977	55	96		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20178a	UK-NCRI	61	Female	De novo	Intermediate		6.46132785763176	0	49.5	10.799995	65	86		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20179c	UK-NCRI	41.7	Male	De novo	Intermediate		2.33812457221081	1	12.3	12.299995	131	97		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20180c	UK-NCRI	39.1	Female	De novo	Adverse		0.287474332648871	1	210	5.6999969	33	58.7450018928678		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20181a	UK-NCRI	57.8	Female	De novo	Favorable		6.01779603011636	0	50.6	9	61	72		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20182a	UK-NCRI	57.1	Female	De novo	Favorable		6.34086242299795	0	281.8	11.399994	30	96		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20184c	UK-NCRI	25.7	Female	De novo	Favorable		2.67488021902806	0	68.3	10.299995	91	95		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20185c	UK-NCRI	59.5	Female	De novo	Adverse		6.23134839151266	0	21	8.8999939	143	50		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20186a	UK-NCRI	56.5	Female	De novo	Adverse		1.57700205338809	1	31.1	10	48	90		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20187a	UK-NCRI	41.7	Male	De novo	Intermediate		1.22381930184805	1	47.1	9.5999985	78	90		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20188a	UK-NCRI	52.2	Female	De novo	Favorable		5.65913757700205	0	21.5	10.599998	46	83		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20189a	UK-NCRI	37.2	Male	De novo	Intermediate		0.687200547570157	1	148.9	10.099998	50	85		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20190c	UK-NCRI	32.3	Female	De novo	Adverse		0.944558521560575	1	32.6	10.699997	14	90		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20191a	UK-NCRI	36.5	Female	Secondary	Intermediate		1.71115674195756	0	91.4	11.199997	99	90		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20192c	UK-NCRI	60.4	Female	De novo	Favorable		7.11019849418207	0	26.9	9.8999939	32	50		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20193a	UK-NCRI	59.8	Female	De novo	Adverse		0.720054757015743	1	36	8.5999985	21	80		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20194a	UK-NCRI	21.7	Male	De novo	Favorable		6.60643394934976	0	66.6	8	28	80		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20195a	UK-NCRI	46.2	Female	De novo	Intermediate		3.27994524298426	1	78.7	10.299995	61	90		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20198a	UK-NCRI	26.7	Female	De novo	Adverse		5.79603011635866	0	26.7	6.1999969	130	22		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20199a	UK-NCRI	40.2	Male	De novo	Intermediate		1.22108145106092	1	168.7	9.5	38	90		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20200a	UK-NCRI	39	Female	De novo	Favorable		2.92676249144422	1	9.8	14.099998	14	70		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20202a	UK-NCRI	47	Female	De novo	Intermediate		0.700889801505818	1	9.8	10.199997	41	90		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20203a	UK-NCRI	35.2	Female	De novo	Favorable		7.21149897330595	0	7.9	10.699997	46	90		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20204a	UK-NCRI	32.5	Female	De novo	Adverse		2.97330595482546	1	109	6.7999992	72	43		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20205c	UK-NCRI	32.2	Female	De novo	Favorable		4.06023271731691	0	27.3	14.099998	185	50		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20206a	UK-NCRI	18.3	Female	De novo	Favorable		1.637234770705	1	64.8	10.899994	46	85		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20207a	UK-NCRI	55.6	Male	De novo	Favorable		0.662559890485969	1	21.9	8.7999954	25	79		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20208a	UK-NCRI	44.3	Male	De novo	Intermediate		1.39630390143737	1	137	10.799995	45	88		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20210a	UK-NCRI	54.7	Female	De novo	Adverse		2.23682409308693	1	1.7	7.8999977	90	50		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20211a	UK-NCRI	55.7	Female	De novo	Intermediate		0.194387405886379	1	11	8.5999985	13	20		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20213a	UK-NCRI	40.8	Female	De novo	Intermediate		7.57563312799452	0	51.2	11.099998	120	44.599976		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20214a	UK-NCRI	52.4	Female	De novo	Intermediate		0.0438056125941136	1	94.4	9.7999954	270	94		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20215c	UK-NCRI	55.6	Female	De novo	Favorable		6.16837782340862	0	59.8	8.6999969	28	58.7450018928678		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20216c	UK-NCRI	64.4	Male	De novo	Favorable		0.388774811772758	1	94.6	9.7999954	18	98		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20217a	UK-NCRI	48.7	Female	De novo	Intermediate		0.991101984941821	1	70.8	11.399994	35	85		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20218c	UK-NCRI	44.7	Female	De novo	Favorable		0.219028062970568	1	20.9	11.399994	93	17		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20219c	UK-NCRI	49	Female	De novo	Favorable		6.45311430527036	0	8.3	10.399994	189	84		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20220a	UK-NCRI	46.6	Female	De novo	Favorable		7.7864476386037	0	102.5	11	31	95		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20221c	UK-NCRI	28.8	Male	De novo	Favorable		6.27789185489391	0	60	12.599998	33	75		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20222a	UK-NCRI	43.8	Male	De novo	Favorable		7.27446954140999	0	152.4	8	29	95		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20224c	UK-NCRI	39.6	Female	De novo	Favorable		7.5482546201232	0	4.2	9.0999985	15	90		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20225a	UK-NCRI	30.9	Female	De novo	Adverse		0.520191649555099	1	128	6.5999985	130	20		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20226a	UK-NCRI	36.9	Female	De novo	Intermediate		1.51129363449692	1	15.8	10.899994	31	90		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20227a	UK-NCRI	58.1	Female	De novo	Favorable		0.388774811772758	1	188.8	11.599998	53	100		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20228a	UK-NCRI	47	Female	De novo	Favorable		7.79192334017796	0	31.1	10.199997	27	58.7450018928678		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20229a	UK-NCRI	20	Female	De novo	Favorable		7.88501026694045	0	49.4	4	14	90		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20230a	UK-NCRI	59.5	Female	Secondary	Adverse		0.470910335386721	1	156.6	13.299995	23	51		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20231c	UK-NCRI	26.3	Male	De novo	Intermediate		0.48186173853525	1	107	6.7999992	88	83		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20232a	UK-NCRI	43.8	Male	Secondary	Favorable		8.02464065708419	0	79.5	6.3999977	24	82		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20233a	UK-NCRI	47.8	Male	De novo	Favorable		0.498288843258042	1	152	9	86	86		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20234a	UK-NCRI	51.6	Female	De novo	Adverse		0.405201916495551	1	277.9	9.1999969	3	86		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20235c	UK-NCRI	57.7	Female	De novo	Adverse		8.10677618069815	0	4.9	13.5	115	58.7450018928678		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20236a	UK-NCRI	52.9	Male	De novo	Favorable		0.826830937713895	1	37.8	10.399994	77	68		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20237c	UK-NCRI	40.4	Male	Secondary	Intermediate		7.76454483230664	0	4.2	10.199997	30	44		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20238c	UK-NCRI	60	Female	De novo	Favorable		8.33675564681725	0	34.8	6.1999969	38	66		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20239c	UK-NCRI	47.6	Female	De novo	Favorable		4.15879534565366	1	3.2	7.2999992	6	50		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20240c	UK-NCRI	59.8	Male	De novo	Favorable		5.90006844626968	0	2.5	10.799995	89	24		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20241c	UK-NCRI	34.2	Male	De novo	Intermediate		0.974674880219028	1	39	14.5	108	85		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20242a	UK-NCRI	42.4	Female	De novo	Favorable		6.66666666666667	0	38.4	7.6999969	17	95		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20244c	UK-NCRI	31.5	Female	De novo	Adverse		1.59890485968515	1	146	6.1999969	66	58.7450018928678		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20245a	UK-NCRI	59.3	Male	De novo	Favorable		8.61875427789185	0	4.5	9.2999954	28	58.7450018928678		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20248c	UK-NCRI	41.6	Female	De novo	Adverse		4.23271731690623	1	58.2	7.3999977	46	58.7450018928678		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20249c	UK-NCRI	61.9	Female	De novo	Favorable		1.47843942505133	1	432	4.5999985	28	91		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20250c	UK-NCRI	34.3	Male	De novo	Intermediate		1.35249828884326	1	27.9	9.5999985	37	95		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20251c	UK-NCRI	52.5	Male	De novo	Intermediate		0.676249144421629	1	45.5	10.899994	129	87		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20253a	UK-NCRI	54.5	Male	De novo	Favorable		0.610540725530459	1	46.9	5.6999969	31	45		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20254c	UK-NCRI	29.3	Female	De novo	Favorable		2.48596851471595	1	244	8.5999985	83	90		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20255a	UK-NCRI	57.9	Female	De novo	Favorable		8.69541409993155	0	58.3	9.6999969	58	90		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20256a	UK-NCRI	25	Female	De novo	Favorable		1.65092402464066	1	255.8	6.6999969	26	58.7450018928678		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20257c	UK-NCRI	70.1	Female	De novo	Favorable		1.79876796714579	1	15.1	11.199997	40	87		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20259a	UK-NCRI	39	Male	De novo	Intermediate		5.65366187542779	0	13.6	6.5999985	5	85		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20260a	UK-NCRI	44.8	Male	De novo	Favorable		5.01848049281314	0	38.8	7.3999977	62	58.7450018928678		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20261a	UK-NCRI	56.3	Female	De novo	Favorable		9.15811088295688	0	30	10.5	60	70		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20262c	UK-NCRI	42.4	Male	De novo	Favorable		2.58726899383984	1	58	8.8999939	21	58.7450018928678		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20264c	UK-NCRI	54.3	Male	De novo	Favorable		9.1854893908282	0	111.9	7.6999969	82	95		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20265c	UK-NCRI	48.4	Male	De novo	Favorable		9.27310061601643	0	50.5	9.5	52	83		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20266a	UK-NCRI	55.6	Female	De novo	Adverse		0.027378507871321	1	48.4	14.199997	77	52		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20267a	UK-NCRI	56	Female	De novo	Favorable		5.34154688569473	1	20.2	9.2999954	50	96		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20268c	UK-NCRI	51.3	Female	Secondary	Intermediate		8.98015058179329	1	7.6	5.7999992	427	30		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20270c	UK-NCRI	56.6	Female	De novo	Intermediate		1.29774127310062	1	64.1	8.3999939	224	91		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20271a	UK-NCRI	31.9	Female	De novo	Favorable		0.490075290896646	1	257	11.199997	29	98		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20272a	UK-NCRI	21.7	Female	De novo	Adverse		0.796714579055442	1	76.2	5.2999992	24	58.7450018928678		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20274a	UK-NCRI	38.1	Male	De novo	Adverse		0.427104722792608	1	18.5	9.3999939	170	86		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20278a	UK-NCRI	54.3	Female	De novo	Favorable		0.670773442847365	1	115.4	7.7999992	66	80		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20279a	UK-NCRI	52.8	Female	De novo	Favorable		0.602327173169062	1	188	10.299995	79	97		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20280c	UK-NCRI	27.9	Male	De novo	Adverse		0.958247775496235	1	0.7	7.0999985	40	58.7450018928678		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20281a	UK-NCRI	26.1	Male	De novo	Favorable		6.87200547570157	0	101.8	8.5999985	18	80		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20282a2	UK-NCRI	55.1	Male	De novo	Favorable		1.44284736481862	1	176	11.699997	21	50		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20283a	UK-NCRI	27.4	Female	De novo	Favorable		1.27310061601643	1	161.5	10.699997	78	100		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20284a	UK-NCRI	40.6	Male	De novo	Favorable		4.97741273100616	1	15.1	8.2999954	135	79		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20285c	UK-NCRI	62.6	Male	De novo	Adverse		0.550308008213552	1	103	8.8999939	106	80		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20287a	UK-NCRI	52.3	Female	De novo	Favorable		0.802190280629706	1	132	6.7999992	36	45		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20289a	UK-NCRI	20	Male	De novo	Adverse		1.05407255304586	1	60.4	11.599998	64	90		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20290a	UK-NCRI	24	Male	De novo	Intermediate		0.446269678302533	1	118.4	9.6999969	53	96		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20291a	UK-NCRI	54.7	Male	De novo	Intermediate		0.227241615331964	1	30.9	12.399994	173	58.7450018928678		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20293a	UK-NCRI	52.2	Male	De novo	Adverse		1.42642026009582	1	113.4	11.199997	62	95		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20294a	UK-NCRI	56.8	Male	De novo	Adverse		1.4154688569473	1	145.5	10.5	12	95		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20296c	UK-NCRI	48.8	Male	De novo	Adverse		10.3408624229979	0	4	10.599998	227	58.7450018928678		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20298a	UK-NCRI	55.2	Female	De novo	Intermediate		0.594113620807666	1	63.9	12.699997	49	90		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20299a	UK-NCRI	44.8	Male	De novo	Adverse		0.0492813141683778	1	190	7.1999969	19	58.7450018928678		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20300a	UK-NCRI	39.7	Male	De novo	Favorable		0.92539356605065	1	230.2	12	90	40		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20301a	UK-NCRI	42.7	Female	De novo	Favorable		4.13141683778234	1	22.5	8.5999985	84	20		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20302a	UK-NCRI	54.8	Male	De novo	Intermediate		1.78507871321013	1	27.9	10.299995	12	86		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20303a	UK-NCRI	17.7	Female	De novo	Adverse		0.941820670773443	1	75	13.599998	92	95		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20304a	UK-NCRI	52.1	Female	De novo	Favorable		11.2087611225188	0	214	8	26	58.7450018928678		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20305a	UK-NCRI	28.7	Female	De novo	Favorable		0.0082135523613963	1	185	10.199997	50	95		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20306a	UK-NCRI	67.5	Female	De novo	Intermediate		0.0492813141683778	1	15.9	8.7999954	209	97		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20307c	UK-NCRI	59.8	Male	De novo	Favorable		1.71663244353183	1	103.3	6.0999985	81	96		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20309a	UK-NCRI	66.9	Male	De novo	Favorable		0.889801505817933	1	103.8	11	59	96		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20311c	UK-NCRI	64.5	Male	De novo	Adverse		1.32785763175907	1	4.3	7.6999969	231	30		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20312a	UK-NCRI	68.1	Male	Secondary	Favorable		0.134154688569473	1	165	10.399994	53	95		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20313a	UK-NCRI	65.9	Male	De novo	Favorable		0.588637919233402	1	40	11.799995	100	58		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20314a	UK-NCRI	69	Female	De novo	Favorable		0.0027378507871321	1	197	6.0999985	22	95		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20315a	UK-NCRI	64.6	Female	De novo	Adverse		0.766598220396988	1	60	8.8999939	53	63		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20316a	UK-NCRI	67.7	Male	De novo	Favorable		0.462696783025325	1	133	9	52	98		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20317a	UK-NCRI	64.8	Female	De novo	Favorable		3.55920602327173	1	88	10.299995	43	91		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20319c	UK-NCRI	66.9	Male	De novo	Favorable		1.37440109514031	1	316	4.1999969	63	25		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20320a	UK-NCRI	74.7	Male	De novo	Favorable		0.229979466119097	1	16	9.5999985	226	95		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20321a	UK-NCRI	61.9	Female	De novo	Adverse		0.344969199178645	1	108	10.599998	41	81		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20322a	UK-NCRI	66.3	Female	Other	Adverse		1.09787816563997	1	34.6	6.8999977	54	19		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20323a	UK-NCRI	67.4	Female	De novo	Adverse		1.24572210814511	1	50	11.899994	6	68		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20324a	UK-NCRI	64	Female	Other	Intermediate		0.153319644079398	1	106.6	9	12	4		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20325a	UK-NCRI	68	Female	De novo	Adverse		1.19644079397673	1	45	11.299995	13	88		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20326a	UK-NCRI	62.5	Female	De novo	Favorable		8.70636550308008	0	82.2	7.8999977	42	80		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20327a	UK-NCRI	71.6	Female	Secondary	Adverse		0.32580424366872	1	38	11.099998	17	20		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20328a	UK-NCRI	63.5	Male	De novo	Favorable		0.884325804243669	1	85	9.0999985	156	40		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20329a	UK-NCRI	79.8	Male	De novo	Favorable		0.561259411362081	1	84.8	10	12	79		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20330a	UK-NCRI	75.7	Male	De novo	Favorable		0.763860369609856	1	92	10.699997	78	95		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20331a	UK-NCRI	41.2	Male	De novo	Favorable		0.462696783025325	1	155	5.8999977	39	86		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20332c	UK-NCRI	44.2	Female	De novo	Favorable		2.38466803559206	0	30.6	7.5	47	58.7450018928678		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20333c	UK-NCRI	51.5	Female	De novo	Favorable		1.79329226557153	1	12.9	12.299995	16	86		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20334a	UK-NCRI	62.2	Female	De novo	Adverse		0.681724845995893	1	118	6.6999969	21	58.7450018928678		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20335c	UK-NCRI	68.3	Female	De novo	Favorable		0.0520191649555099	1	32	8.6999969	55	98		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20336a	UK-NCRI	61.7	Male	De novo	Adverse		0.681724845995893	1	130	8.5	135	58.7450018928678		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20337c	UK-NCRI	72.4	Male	De novo	Intermediate		0.0930869267624914	1	1.5	13.5	75	75		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20338c	UK-NCRI	58.5	Female	De novo	Favorable		2.00684462696783	1	39	7.6999969	10	98		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20339a	UK-NCRI	60.5	Male	De novo	Favorable		10.0643394934976	0	68.5	11.699997	11	92		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD20340a	UK-NCRI	42.5	Female	De novo	Favorable		6.88569472963724	0	54	11.599998	77	36		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22516a	UK-NCRI	39.3	Female	De novo	Adverse		1.06776180698152	1	17.9	12.5	146	90		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22518c	UK-NCRI	20.3	Male	De novo	Intermediate		10.6009582477755	0	3.5	11	174	91		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22519d	UK-NCRI	64.9	Female	De novo	Adverse		0.531143052703628	1	61.4	7.8999977	9	60		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22521c	UK-NCRI	19.3	Female	De novo	Favorable		0.725530458590007	1	77.5	8.3999939	73	70		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22522a	UK-NCRI	47.4	Male	De novo	Favorable		0.80766598220397	1	93.9	6.6999969	39	58.7450018928678		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22523a	UK-NCRI	43.7	Female	De novo	Intermediate		1.03490759753593	1	20.1	16.299988	311	58.7450018928678		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22524d	UK-NCRI	67.7	Male	De novo	Intermediate		1.02943189596167	1	96.4	9.5999985	64	44		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22526a	UK-NCRI	68.3	Male	De novo	Intermediate		0.887063655030801	1	12.2	8.8999939	30	40		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22527a	UK-NCRI	57	Female	De novo	Favorable		0.783025325119781	1	70.7	6.0999985	309	100		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22528c	UK-NCRI	21	Male	De novo	Favorable		8.02737850787132	0	13.3	13.099998	128	73		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22529c	UK-NCRI	37.7	Female	De novo	Intermediate		7.3347022587269	0	2.1	9.6999969	43	88		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22530c	UK-NCRI	41.8	Female	De novo	Intermediate		2.38466803559206	1	1.9	12	89	55		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22534a	UK-NCRI	68.9	Male	De novo	Favorable		10.6666666666667	0	253.7	8.2999954	18	58.7450018928678		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22538c	UK-NCRI	47.3	Male	De novo	Favorable		10.4969199178645	0	33.7	11.599998	188	75		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22539c	UK-NCRI	39.8	Female	De novo	Adverse		5.71937029431896	1	8.9	7.5999985	198	54		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22547c	UK-NCRI	28	Female	De novo	Intermediate		10.4914442162902	0	55.5	8.5999985	75	39		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22551c	UK-NCRI	49.1	Male	De novo	Favorable		1.07049965776865	1	213	10.099998	39	94		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22552c	UK-NCRI	23.1	Male	De novo	Adverse		1.30595482546201	1	46.3	7.8999977	76	90		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22554c	UK-NCRI	43.2	Female	De novo	Favorable		10.113620807666	0	4.1	10.899994	40	60		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22556c	UK-NCRI	19.9	Male	De novo	Intermediate		2.28336755646817	1	189	5.8999977	32	5.3999977		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22558c	UK-NCRI	35.9	Male	De novo	Intermediate		1.65092402464066	1	11.3	9.5	21	76		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22560c	UK-NCRI	39.3	Female	De novo	Favorable		8.29295003422314	0	40.3	10.299995	18	51		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22561c	UK-NCRI	42.7	Female	De novo	Adverse		10.2422997946612	0	3.2	11.899994	194	27		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22562a	UK-NCRI	23.2	Male	De novo	Adverse		8.21081451060917	0	11.1	8.3999939	38	58.7450018928678		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22564a	UK-NCRI	56.8	Male	De novo	Favorable		10.0780287474333	0	2.7	5	249	33		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22565a	UK-NCRI	28.2	Male	Secondary	Intermediate		0.15605749486653	1	1.5	7.6999969	26	80		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22566a	UK-NCRI	40.4	Male	De novo	Favorable		0.758384668035592	1	174.7	10	64	100		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22567a	UK-NCRI	51.5	Male	De novo	Favorable		10.1574264202601	0	44.9	4	106	79.399963		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22569a	UK-NCRI	47.9	Female	De novo	Favorable		9.77138945927447	0	18.9	10.5	32	60		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22570a	UK-NCRI	23.8	Male	De novo	Favorable		8.27652292950034	0	8.2	6.7999992	34	80		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22576a	UK-NCRI	24.2	Male	De novo	Adverse		1.20191649555099	1	108	92	25	80.299988		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22577a	UK-NCRI	52.6	Female	De novo	Favorable		0.396988364134155	1	5	11.199997	171	90		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22580a	UK-NCRI	46.6	Female	De novo	Favorable		10.3408624229979	0	2.8	9	52	35		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22581a	UK-NCRI	57.2	Male	De novo	Adverse		0.878850102669405	1	103.2	8.7999954	37	95		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22582a	UK-NCRI	53.7	Male	De novo	Adverse		0.80766598220397	1	12.5	11.599998	727	26.599991		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22583a	UK-NCRI	57.2	Female	De novo	Adverse		1.40177960301164	1	20	8.5999985	82	48		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22585c	UK-NCRI	27.5	Female	De novo	Adverse		10.2012320328542	0	72.3	7.8999977	35	46		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22586a	UK-NCRI	22.8	Female	De novo	Intermediate		3.04722792607803	0	3.5	6.8999977	123	34		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22588c	UK-NCRI	60.6	Female	De novo	Favorable		10.1081451060917	0	17.3	111	130	4		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22591a	UK-NCRI	42.1	Female	De novo	Favorable		4.26557152635181	0	16.1	10.599998	69	52		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22592c	UK-NCRI	62.4	Female	De novo	Intermediate		5.18275154004107	1	8.9	8.1999969	101	1		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22596c	UK-NCRI	65.4	Male	De novo	Favorable		7.48528405201917	0	12	6.8999977	43	80		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22597c	UK-NCRI	75.1	Male	De novo	Favorable		0.0629705681040383	1	15.2	9.1999969	55	83		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22600a	UK-NCRI	62.4	Female	De novo	Favorable		8.67898699520876	0	3.8	4.6999969	17	52		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22601a	UK-NCRI	59.3	Male	De novo	Favorable		0.626967830253251	1	48	4.7999992	44	37.699982		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22605c	UK-NCRI	53.2	Male	Secondary	Favorable		10.0396988364134	0	2.2	6.2999992	24	49		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22608c	UK-NCRI	44.1	Male	De novo	Favorable		8.58316221765914	0	28.9	9.0999985	176	48		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22610c	UK-NCRI	54.5	Female	De novo	Adverse		3.96440793976728	1	1.4	8	110	43		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22615c	UK-NCRI	58.4	Male	De novo	Adverse		0.427104722792608	1	13.9	10.399994	99	95		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22617a	UK-NCRI	59	Female	De novo	Favorable		9.71937029431896	1	11.9	8.6999969	63	66		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22621a	UK-NCRI	61	Female	De novo	Intermediate		3.20602327173169	1	1.8	13	145	32		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22624a	UK-NCRI	37.6	Female	De novo	Favorable		7.5482546201232	0	14.5	10.099998	11	79		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22625c	UK-NCRI	59.4	Female	Other	Adverse		0.380561259411362	1	10.7	10.599998	83	18		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22626c	UK-NCRI	24.6	Male	De novo	Intermediate		8.88980150581793	0	120	9.5	37	84		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22628a	UK-NCRI	24.9	Female	De novo	Favorable		3.55099247091034	1	5.1	7.0999985	34	32		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22629c	UK-NCRI	51.1	Male	De novo	Adverse		10.0177960301164	0	1.4	12.299995	25	85		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22630a	UK-NCRI	50.3	Female	De novo	Favorable		0.766598220396988	1	70.1	8.8999939	103	40		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22632c	UK-NCRI	35.9	Male	De novo	Favorable		9.72758384668036	0	64.7	8.7999954	265	80		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22635a	UK-NCRI	54.4	Male	De novo	Adverse		0.0191649555099247	1	5.7	7.5	121	60		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22636c	UK-NCRI	57.3	Male	De novo	Intermediate		9.60164271047228	0	3.2	10.599998	150	21		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22638a	UK-NCRI	60.5	Female	De novo	Adverse		0.813141683778234	1	11.3	9.1999969	24	70.299988		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22639a	UK-NCRI	53.1	Male	Other	Adverse		3.64681724845996	1	10	9.8999939	80	15		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22640c	UK-NCRI	61.8	Female	Other	Adverse		0.0602327173169062	1	1.9	78	176	50		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22641a	UK-NCRI	49.2	Female	De novo	Adverse		1.30047912388775	1	1.4	8.6999969	106	58.7450018928678		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22642a	UK-NCRI	47.9	Male	De novo	Intermediate		8.22724161533196	0	2.9	9.6999969	123	0		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22646a	UK-NCRI	34.8	Female	De novo	Adverse		9.79876796714579	0	3.7	7.6999969	21	62		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22647a	UK-NCRI	24.2	Male	De novo	Favorable		9.75222450376454	0	7.7	3.5	40	43.399994		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22648c	UK-NCRI	47.5	Female	De novo	Favorable		9.09787816563997	0	4.3	10.699997	68	30		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22649a	UK-NCRI	57.5	Male	De novo	Favorable		0.082135523613963	1	28.8	10.399994	83	90		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22650c	UK-NCRI	47.3	Female	De novo	Favorable		2.43394934976044	1	2.4	8.5	98	24.299988		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22652a	UK-NCRI	47.5	Male	De novo	Favorable		0.16974674880219	1	275.6	7.5999985	35	94		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22653c	UK-NCRI	24	Male	De novo	Favorable		9.83983572895277	0	13.6	9.5	95	27		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22655a	UK-NCRI	45.6	Female	De novo	Favorable		9.57152635181383	0	14.6	11.699997	25	85		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22656a	UK-NCRI	60.1	Female	De novo	Intermediate		0.0574948665297741	1	2.2	81	14	10		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22657a	UK-NCRI	50.7	Male	Other	Adverse		9.51950718685832	0	2.2	8.2999954	199	7		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22660a	UK-NCRI	30.7	Female	De novo	Adverse		9.81793292265571	0	430	7.5999985	147	92		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22661a	UK-NCRI	45.8	Male	De novo	Favorable		9.35797399041752	0	29.3	8	98	82.599976		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22663c	UK-NCRI	50.5	Female	De novo	Favorable		5.20191649555099	1	8.4	82	93	30		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22666c	UK-NCRI	65	Female	De novo	Favorable		9.44558521560575	0	1.9	10.5	102	58.7450018928678		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22667c	UK-NCRI	54	Female	De novo	Adverse		1.30321697467488	1	14.4	9.3999939	57	27		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22668c	UK-NCRI	35.5	Female	Secondary	Intermediate		0.613278576317591	1	9.5	9.6999969	29	29		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22669c	UK-NCRI	41.9	Male	De novo	Favorable		3.35386721423682	0	6	85	39	14		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22670a	UK-NCRI	65.1	Male	De novo	Adverse		0.342231348391513	1	27.7	12.199997	110	25		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22671c	UK-NCRI	17.9	Male	De novo	Intermediate		8.290212183436	0	5.5	8.8999939	631	8		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22672a	UK-NCRI	62.5	Male	Secondary	Adverse		0.829568788501027	1	33.2	89	564	25		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22673c	UK-NCRI	26.9	Male	De novo	Favorable		2.67214236824093	1	41.9	7	13	94		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22674c	UK-NCRI	54.1	Female	De novo	Adverse		3.09103353867214	1	5.4	7.3999977	29	50		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22677a	UK-NCRI	59.2	Female	De novo	Favorable		0.59958932238193	1	52.9	7	179	80		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22678c	UK-NCRI	51.9	Female	De novo	Intermediate		5.43189596167009	0	5.6	6.1999969	10	88		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22679a	UK-NCRI	42.3	Male	De novo	Adverse		5.82888432580424	0	5.2	5.5999985	83	53		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22680c	UK-NCRI	52.2	Male	Other	Adverse		2.62833675564682	1	1.3	91	220	60		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22681a	UK-NCRI	53.8	Female	De novo	Favorable		0.0410677618069815	1	1.5	9.6999969	82	80		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22683c	UK-NCRI	26.9	Female	De novo	Adverse		0.835044490075291	0	39.6	5.1999969	49	90		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22684a	UK-NCRI	55.5	Female	De novo	Intermediate		4.56947296372348	1	1.8	8.8999939	74	28.299988		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22686c	UK-NCRI	21.4	Female	De novo	Intermediate		9.52498288843258	0	2	7.3999977	13	91		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22688c	UK-NCRI	67.4	Female	Other	Adverse		2.0807665982204	1	1	11.599998	56	4		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22689a	UK-NCRI	38.9	Female	De novo	Favorable		2.06707734428474	1	134	7.5	19	76.599976		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22690c	UK-NCRI	55.4	Male	De novo	Favorable		1.2703627652293	1	145	9.0999985	53	66		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22691a	UK-NCRI	59.5	Male	De novo	Favorable		6.47227926078029	0	53.1	7.6999969	97	34.5		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22692c	UK-NCRI	48	Male	De novo	Favorable		7.84394250513347	0	6	10.399994	121	54		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22693c	UK-NCRI	51.3	Male	De novo	Favorable		9.4154688569473	0	22.4	10.199997	60	90		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22694a	UK-NCRI	43.4	Male	De novo	Favorable		0.336755646817248	1	177.7	8.5999985	24	81		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22695a	UK-NCRI	26.7	Male	De novo	Intermediate		9.50308008213552	0	1.5	10.199997	50	54		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22696c	UK-NCRI	38.6	Male	De novo	Intermediate		1.63997262149213	1	8.9	10.599998	82	74		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22697c	UK-NCRI	52.4	Male	De novo	Adverse		9.1088295687885	0	2.4	10.699997	149	40		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22698a	UK-NCRI	31.3	Female	De novo	Favorable		1.50855578370979	1	30.2	8.1999969	104	47.5		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22699a	UK-NCRI	32.7	Female	De novo	Favorable		5.17180013689254	0	2.8	9.2999954	53	68		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22700c	UK-NCRI	54.1	Male	De novo	Favorable		1.43189596167009	1	22.5	9.5	54	80		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22703c	UK-NCRI	59.1	Female	De novo	Adverse		5.3223819301848	1	9.7	6.7999992	19	45		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22704a	UK-NCRI	59.4	Female	De novo	Adverse		2.57905544147844	1	1.5	9.5	20	5		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22706c	UK-NCRI	19.5	Male	De novo	Favorable		5.74674880219028	0	30.4	7.1999969	75	22.799988		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22708c	UK-NCRI	29.6	Female	De novo	Adverse		1.37987679671458	1	20.1	8	114	96		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22712c	UK-NCRI	49.1	Male	De novo	Favorable		9.32511978097194	0	19.4	10.399994	51	40		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22713a	UK-NCRI	61.6	Female	De novo	Adverse		0.0711841204654346	1	10	7.2999992	30	70		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22714a	UK-NCRI	45.2	Male	Secondary	Adverse		0.0301163586584531	1	48.1	9.2999954	19	45		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22716a	UK-NCRI	42	Male	De novo	Favorable		5.1088295687885	0	22.6	9.2999954	34	53		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22720a	UK-NCRI	51.4	Male	Secondary	Favorable		0.27378507871321	1	11.8	11.899994	64	45		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22722a	UK-NCRI	57.9	Female	Other	Favorable		8.72826830937714	0	28	6.5	14	32		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22724a	UK-NCRI	57.6	Male	De novo	Intermediate		0.889801505817933	1	137	65	114	68		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22725c	UK-NCRI	31.1	Female	De novo	Adverse		0.698151950718686	1	113.9	8.1999969	71	58.7450018928678		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22726c	UK-NCRI	22.4	Male	De novo	Favorable		8.6735112936345	1	48	7.1999969	241	65		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22727c	UK-NCRI	39.6	Female	De novo	Favorable		6.73237508555784	1	185	8.5	31	80		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22728c	UK-NCRI	51.2	Female	De novo	Intermediate		1.90828199863107	1	344.6	7.1999969	84	88		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22729c	UK-NCRI	53.1	Female	De novo	Adverse		1.45653661875428	1	9	8.6999969	91	85		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22730a	UK-NCRI	59.6	Male	De novo	Favorable		0.68993839835729	1	185	10.089996	65	95		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22731a	UK-NCRI	25	Male	De novo	Adverse		9.27857631759069	1	7.8	4.2999992	20	59		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22732c	UK-NCRI	54.8	Female	De novo	Favorable		9.31416837782341	0	28.4	6	19	67		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22733a	UK-NCRI	56	Female	De novo	Intermediate		8.33675564681725	0	9.4	9.1999969	23	80		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22734c	UK-NCRI	39.1	Male	De novo	Favorable		9.29774127310062	0	2.2	8.5	81	30		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22735c	UK-NCRI	40.9	Female	De novo	Favorable		4.9637234770705	0	7.1	10.599998	101	31.299988		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22737c	UK-NCRI	60.5	Female	De novo	Favorable		8.98562628336756	0	12.2	9	78	46		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22738c	UK-NCRI	22.2	Male	De novo	Intermediate		1.74401095140315	1	122	9.8999939	31	100		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22739c	UK-NCRI	26.3	Male	De novo	Adverse		2.04791238877481	1	0.9	10.199997	173	80		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22740c	UK-NCRI	53.4	Female	De novo	Adverse		8.78576317590691	0	5.9	10.299995	101	94		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22743c	UK-NCRI	39.7	Male	De novo	Favorable		7.22245037645448	0	23.2	9.1999969	13	11.829994		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22744c	UK-NCRI	43.1	Female	De novo	Favorable		1.39630390143737	0	17.7	7.1999969	54	25		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22745a	UK-NCRI	32.9	Female	De novo	Adverse		3.07186858316222	1	11.9	145	100	80		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22747a	UK-NCRI	48.6	Female	De novo	Adverse		0.271047227926078	1	1.7	8.7999954	90	21		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22749a	UK-NCRI	59.9	Male	De novo	Favorable		8.82135523613963	0	2.7	8.2999954	2	20		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22750c	UK-NCRI	60.6	Female	De novo	Intermediate		8.85420944558522	0	1.5	12.799995	86	38		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22751a	UK-NCRI	54	Male	De novo	Intermediate		5.40177960301164	0	6	5.6999969	8	24		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22753a	UK-NCRI	36.6	Male	De novo	Adverse		2.03148528405202	1	5.1	71	28	25		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22755a	UK-NCRI	62.8	Female	Secondary	Intermediate		4.61054072553046	0	2.8	12.599998	76	22		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22758c	UK-NCRI	56.5	Female	De novo	Adverse		2.88021902806297	1	10.7	9.6999969	61	46		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22760c	UK-NCRI	57	Female	De novo	Adverse		0.407939767282683	1	52	11.099998	160	36		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22761c	UK-NCRI	23	Male	De novo	Intermediate		1.22929500342231	1	41	10.599998	66	63.599976		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22762c	UK-NCRI	44.8	Male	Secondary	Favorable		7.35386721423682	0	16.5	6.3999977	28	80		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22763c	UK-NCRI	19.3	Female	De novo	Intermediate		1.01574264202601	1	140.1	8.2999954	47	92		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22764c	UK-NCRI	45.6	Male	De novo	Favorable		1.28678986995209	1	34.5	6.3999977	24	80		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22765c	UK-NCRI	58.9	Female	De novo	Favorable		5.52498288843258	0	5.9	8.0999985	23	67		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22768a	UK-NCRI	23.1	Male	De novo	Adverse		8.92813141683778	0	9.9	10.099998	100	80		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22769c	UK-NCRI	21	Male	Secondary	Adverse		0.960985626283368	1	6.5	79	240	0.9799995		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22771a	UK-NCRI	56.8	Female	Other	Adverse		8.8186173853525	1	3	11.399994	87	11		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22772c	UK-NCRI	60.5	Male	Secondary	Adverse		8.83504449007529	0	5.7	15.006119106409	80.4858623868992	58.7450018928678		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22773c	UK-NCRI	42.9	Male	De novo	Favorable		5.31143052703628	0	47.4	6.8999977	49	95		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22775a	UK-NCRI	52.1	Male	De novo	Adverse		1.74674880219028	1	25.8	8.5	28	90		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22776c	UK-NCRI	28.2	Male	De novo	Adverse		0.323066392881588	1	3.3	5.7999992	61	7		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22778c	UK-NCRI	54.4	Male	De novo	Adverse		1.82340862422998	1	1.3	6.8999977	109	22		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22779c	UK-NCRI	57.5	Female	Secondary	Adverse		0.487337440109514	1	11	9.0999985	128	32		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22780a	UK-NCRI	62.6	Female	De novo	Intermediate		0.372347707049966	1	2.7	9.6999969	146	23.299988		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22781a	UK-NCRI	56.4	Male	De novo	Favorable		1.57152635181383	1	30	12.5	90	64.299988		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22782a	UK-NCRI	67.9	Female	De novo	Favorable		2.362765229295	1	92.6	7	35	13		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22783a	UK-NCRI	51	Male	De novo	Adverse		0.386036960985626	1	4.2	7.2999992	29	95		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22784a	UK-NCRI	66.2	Female	De novo	Favorable		0.498288843258042	1	11.8	10.199997	187	28		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22785a	UK-NCRI	40.8	Female	De novo	Intermediate		3.1211498973306	1	6.9	7.8999977	54	49.699982		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22786a	UK-NCRI	56.7	Female	De novo	Adverse		0.900752908966461	1	25.2	8.8999939	39	19		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22788c	UK-NCRI	17.9	Female	De novo	Intermediate		8.62149212867899	0	39.9	7.1999969	37	60		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22790c	UK-NCRI	55.1	Female	Secondary	Adverse		3.11841204654346	1	2.1	9.1999969	52	14		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22792a	UK-NCRI	59	Female	Other	Intermediate		2.46132785763176	1	1.8	9.0999985	62	26.199997		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22793a	UK-NCRI	49.7	Male	De novo	Favorable		8.9719370294319	0	9.2	8.7999954	85	26		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22794c	UK-NCRI	55.7	Female	De novo	Adverse		8.80492813141684	0	3.3	11.599998	46	36		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22795a	UK-NCRI	56.6	Female	De novo	Favorable		0.0629705681040383	1	1.5	7	35	13		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22796a	UK-NCRI	62.3	Female	De novo	Intermediate		0.881587953456537	1	1.9	7.2999992	61	38		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22797a	UK-NCRI	51.5	Female	De novo	Adverse		0.366872005475702	1	1.5	8.7999954	241	87		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22798c	UK-NCRI	44.7	Male	De novo	Favorable		1.41820670773443	1	4.8	15	158	76		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22799c	UK-NCRI	59.4	Male	De novo	Adverse		0.572210814510609	1	0.9	6.7999992	84	67		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22804a	UK-NCRI	19.6	Female	De novo	Intermediate		0.960985626283368	1	268	9.1999969	85	80		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22805c	UK-NCRI	59.4	Female	Other	Adverse		0.856947296372348	1	2.8	9.7999954	25	6.5		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22806c	UK-NCRI	49.7	Female	De novo	Adverse		0.750171115674196	1	3.3	7.3999977	84	20		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22807c	UK-NCRI	50.3	Female	De novo	Adverse		0.158795345653662	1	77.3	6.2999992	4	90		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22809c	UK-NCRI	42.5	Male	De novo	Adverse		2.03969883641342	1	2.2	12	266	17		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22811a	UK-NCRI	21.6	Male	De novo	Favorable		7.97262149212868	0	3.3	9.2999954	53	64		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22812a	UK-NCRI	59.1	Male	De novo	Adverse		8.79945242984257	0	5.6	10.399994	208	45		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22814c	UK-NCRI	62	Male	Secondary	Favorable		4.83778234086242	0	15.7	15.006119106409	80.4858623868992	58.7450018928678		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22816a	UK-NCRI	51.9	Female	De novo	Adverse		0.733744010951403	1	36.5	10.399994	48	62.199982		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22817a	UK-NCRI	35.7	Male	De novo	Favorable		6.25051334702259	0	8.1	4.0999985	15	90		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22819c	UK-NCRI	41.7	Female	De novo	Favorable		3.13757700205339	1	10.4	7	91	76		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22820a	UK-NCRI	51.7	Male	De novo	Favorable		8.84052019164955	0	8.4	5.5999985	58	77		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22821c	UK-NCRI	60	Female	Other	Adverse		0.862422997946612	1	4	9.2999954	323	19		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22822a	UK-NCRI	38.7	Male	De novo	Favorable		7.09103353867214	0	6	9.5	93	56		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22823c	UK-NCRI	57.4	Male	De novo	Adverse		7.95619438740589	0	1.5	8.5	198	51		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22824c	UK-NCRI	43.7	Male	De novo	Intermediate		3.94798083504449	1	5.9	9	17	93		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22826a	UK-NCRI	39.9	Female	De novo	Intermediate		1.86995208761123	1	17.2	13.799995	155	72		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22827c	UK-NCRI	48.9	Female	De novo	Favorable		8.62149212867899	0	74.1	5.8999977	88	49		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22828c	UK-NCRI	63.2	Male	De novo	Adverse		2.32717316906229	1	2	5.5	11	39		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22829c	UK-NCRI	52.9	Female	De novo	Favorable		2.45859000684463	1	45.7	7.1999969	19	18		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22833a	UK-NCRI	53.3	Female	De novo	Intermediate		4.74469541409993	1	4.8	11.699997	18	65		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22834a	UK-NCRI	57.5	Male	De novo	Favorable		0.0410677618069815	1	52.9	10.099998	35	97		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22835a	UK-NCRI	50.1	Female	Secondary	Adverse		0.0766598220396988	1	6.3	13.5	46	24		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22836c	UK-NCRI	59.6	Male	De novo	Favorable		8.58590006844627	0	40.9	8.2999954	34	30		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22837c	UK-NCRI	56.4	Male	De novo	Adverse		8.63791923340178	0	4.2	7.2999992	58	88		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22838c	UK-NCRI	55.6	Female	De novo	Adverse		2.3709787816564	1	128	7.0999985	59	90		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22839a	UK-NCRI	65.3	Female	De novo	Intermediate		5.68651608487337	1	1.2	9	71	30		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22841a	UK-NCRI	39.3	Female	De novo	Adverse		5.04859685147159	0	4	14.299995	37	40		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22842a	UK-NCRI	62	Female	De novo	Favorable		2.78986995208761	1	72	9.8999939	18	85		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22843a	UK-NCRI	43.1	Female	De novo	Adverse		0.470910335386721	1	1.5	7.5	16	20		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22844c	UK-NCRI	17.5	Male	De novo	Favorable		8.48186173853525	0	3.1	9.5999985	162	37		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22845c	UK-NCRI	48.9	Male	De novo	Adverse		0.714579055441478	1	10.1	10.599998	10	8.8999939		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22846c	UK-NCRI	52.6	Female	De novo	Favorable		8.13689253935661	0	17.1	8.7999954	46	90		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22847c	UK-NCRI	58.6	Female	De novo	Adverse		8.17522245037645	0	10.7	5.1999969	67	36		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22849c	UK-NCRI	36.9	Female	De novo	Favorable		8.24093086926763	0	55	10.799995	94	90.5		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22850a	UK-NCRI	58.4	Female	Secondary	Adverse		0.0766598220396988	1	1.3	9.2999954	29	11		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22851a	UK-NCRI	60.5	Female	De novo	Adverse		8.39698836413415	1	3.8	9.5999985	9	74		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22852c	UK-NCRI	25.2	Male	De novo	Favorable		8.47638603696099	0	3.6	12.799995	183	85		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22853a	UK-NCRI	42.5	Female	De novo	Adverse		2.8993839835729	1	70.8	9.7999954	22	95		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22854a	UK-NCRI	53.6	Male	De novo	Intermediate		0.610540725530459	1	7.7	9	37	35		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22856a	UK-NCRI	53.1	Male	Other	Adverse		4.3668720054757	1	3.3	8.7999954	89	12		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22857c	UK-NCRI	57.1	Female	De novo	Adverse		0.249144421629021	1	4.1	11	49	96		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22858c	UK-NCRI	47.7	Female	De novo	Favorable		2.91581108829569	1	19.3	5.7999992	11	37		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22859a	UK-NCRI	64.4	Female	De novo	Intermediate		8.28473648186174	0	1.2	11.5	99	0		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22861c	UK-NCRI	19.2	Male	De novo	Adverse		7.1129363449692	0	8.2	8.1999969	30	95		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22862a	UK-NCRI	40.6	Male	De novo	Favorable		5.88364134154689	0	10.3	9.2999954	66	16		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22863c	UK-NCRI	37.3	Female	Other	Intermediate		1.82888432580424	1	1.3	9	64	34		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22866a	UK-NCRI	55.5	Male	De novo	Favorable		0.375085557837098	1	24.9	7.5999985	80	52		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22868a	UK-NCRI	56	Female	De novo	Adverse		8.25462012320328	0	3.5	10.599998	74	65		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22870a	UK-NCRI	58.3	Male	De novo	Favorable		6.56262833675565	0	1.7	8.3999939	60	30		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22872c	UK-NCRI	59.8	Male	De novo	Adverse		8.3750855578371	0	2.3	8.5999985	273	77		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22874c	UK-NCRI	41.6	Male	De novo	Favorable		3.86858316221766	0	6	5.5999985	49	100		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22875c	UK-NCRI	54.9	Male	De novo	Favorable		0.9637234770705	1	17.3	9.0999985	29	80		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22876c	UK-NCRI	25.6	Female	De novo	Intermediate		5.99315537303217	0	34.5	11.199997	18	80		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22877a	UK-NCRI	44.3	Male	De novo	Intermediate		6.98425735797399	0	43.9	8.3999939	44	58		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22878c	UK-NCRI	58.8	Female	De novo	Favorable		1.42642026009582	1	14.1	8	20	90		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22880c	UK-NCRI	57.1	Male	De novo	Intermediate		5.66735112936345	0	3.7	5.5999985	27	57		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22881a	UK-NCRI	52.8	Female	De novo	Favorable		4.11772758384668	0	31.2	70	6	90		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22882a	UK-NCRI	32.6	Female	De novo	Intermediate		2.362765229295	1	1.2	11.799995	143	43		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22884a	UK-NCRI	31.2	Male	De novo	Intermediate		2.05065023956194	1	3	9.3999939	167	20		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22885c	UK-NCRI	63.6	Female	De novo	Intermediate		6.92676249144422	0	1.1	9.3999939	21	80		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22886c	UK-NCRI	50.7	Female	De novo	Adverse		5.67008898015058	0	0.6	9.2999954	213	90		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22887c	UK-NCRI	37.2	Female	De novo	Favorable		0.974674880219028	1	20.4	7.0999985	77	96		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22889c	UK-NCRI	25.7	Male	De novo	Favorable		6.9678302532512	0	4.2	6.5999985	49	85		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22890c	UK-NCRI	44.2	Female	De novo	Adverse		0.271047227926078	1	3	5.6999969	20	58.7450018928678		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22892d	UK-NCRI	59.1	Male	De novo	Favorable		0.0219028062970568	1	3.5	10.099998	89	65		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22893c	UK-NCRI	42.6	Female	De novo	Adverse		6.10814510609172	0	5.9	8.5	103	40		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22894c	UK-NCRI	46.7	Male	De novo	Intermediate		7.34017796030116	1	5	8.6999969	78	75		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22899a	UK-NCRI	61.8	Male	De novo	Adverse		1.3990417522245	1	0.9	8.5	174	60		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22900c	UK-NCRI	45.9	Male	Secondary	Intermediate		0.870636550308008	1	9.5	9.5	20	90		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22901c	UK-NCRI	58.5	Female	De novo	Adverse		5.29226557152635	1	28.5	6.6999969	40	70		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22902a	UK-NCRI	46.9	Male	De novo	Favorable		2.16290212183436	1	40.9	7.5999985	97	90		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22903c	UK-NCRI	16.8	Male	De novo	Adverse		0.714579055441478	1	142.2	8.8999939	62	96		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22904a	UK-NCRI	59.1	Female	De novo	Adverse		4.22450376454483	1	3	7.5	65	47		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22905a	UK-NCRI	42.8	Male	De novo	Intermediate		1.29500342231348	1	136.1	12	28	90		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22906a	UK-NCRI	53.7	Female	De novo	Favorable		5.76865160848734	0	44.9	6.6999969	23	81		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22908c	UK-NCRI	26.3	Male	De novo	Intermediate		1.1854893908282	1	33.5	7.1999969	49	90		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22909c	UK-NCRI	66.2	Male	De novo	Favorable		6.89664613278576	0	12.2	9.0999985	143	80		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22910c	UK-NCRI	56.7	Male	De novo	Favorable		8.10130047912389	0	25	5.8999977	10	35		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22914c	UK-NCRI	46.1	Female	Secondary	Favorable		8.27652292950034	0	12.8	9.2999954	16	21		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22915a	UK-NCRI	31.2	Female	De novo	Intermediate		2.03422313483915	1	14.3	7.1999969	77	70		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22917c	UK-NCRI	57.2	Male	Secondary	Intermediate		8.20807665982204	0	7.6	10.299995	106	85		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22918a	UK-NCRI	55	Male	Other	Intermediate		7.74264202600958	0	2.4	12.699997	59	29		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22919c	UK-NCRI	61.6	Female	Secondary	Favorable		0.479123887748118	1	17.2	6.2999992	282	20		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22920c	UK-NCRI	55.7	Female	De novo	Adverse		0.0602327173169062	1	3.6	6.5	16	61		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22921a	UK-NCRI	48.8	Female	De novo	Favorable		4.19164955509925	1	2.5	8	177	70		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22922a	UK-NCRI	52.5	Female	De novo	Adverse		0.676249144421629	1	17.5	8.1999969	33	81		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22923a	UK-NCRI	61.7	Female	De novo	Intermediate		0.39151266255989	1	6.8	12.5	37	37		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22924c	UK-NCRI	44.9	Female	Secondary	Adverse		8.12867898699521	0	39.1	12.799995	67	17		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22926a	UK-NCRI	57.4	Male	De novo	Favorable		6.79260780287474	0	21.8	6.1999969	37	25		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22927a	UK-NCRI	61.3	Male	Secondary	Intermediate		1.00479123887748	1	37.2	8.5	97	64		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22928c	UK-NCRI	38.7	Male	De novo	Favorable		0.97741273100616	1	91.9	12.699997	34	88		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22929c	UK-NCRI	46.5	Female	De novo	Favorable		8.06023271731691	0	12.4	14.199997	119	62		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22930a	UK-NCRI	48.7	Female	De novo	Adverse		5.14989733059548	1	59.7	7.7999992	75	83		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22931c	UK-NCRI	52.8	Male	De novo	Favorable		3.15400410677618	1	28.3	9.8999939	157	86		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22934a	UK-NCRI	64	Male	De novo	Favorable		0.0438056125941136	1	100.6	97	15	58.7450018928678		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22935a	UK-NCRI	56.5	Female	De novo	Adverse		0.0848733744010951	1	4	9.3999939	21	25		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22936c	UK-NCRI	28.6	Female	De novo	Favorable		7.98083504449008	0	30.2	9.0999985	62	58.7450018928678		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22937a	UK-NCRI	31.5	Female	De novo	Adverse		7.82477754962355	0	145.8	14.099998	128	90		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22938c	UK-NCRI	39.4	Female	De novo	Adverse		0.528405201916496	1	32	5.1999969	383	91		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22939d	UK-NCRI	50.7	Male	De novo	Favorable		7.6249144421629	0	8.9	8.1999969	211	29		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22940a	UK-NCRI	21.4	Female	De novo	Favorable		7.7782340862423	0	20	9.7999954	56	45		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22942c	UK-NCRI	57	Female	Secondary	Intermediate		0.837782340862423	1	10.5	7.5	26	30		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22943a	UK-NCRI	40.1	Female	De novo	Favorable		8.04654346338125	0	36.4	9.0999985	192	43.969971		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22944a	UK-NCRI	59.2	Female	De novo	Intermediate		0.0410677618069815	1	0.6	8.6999969	171	78		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22945c	UK-NCRI	54.6	Male	De novo	Favorable		2.15468856947296	1	5.6	7	20	63.299988		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22946c	UK-NCRI	61.7	Female	De novo	Adverse		1.09240246406571	1	2	9.7999954	18	82		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22948a	UK-NCRI	28.2	Female	De novo	Adverse		1.28405201916496	1	9.9	15.099998	172	7.8999977		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22949c	UK-NCRI	65	Male	De novo	Adverse		0.479123887748118	1	15	87	19	20		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22950a	UK-NCRI	48.8	Female	Other	Favorable		4.16153319644079	0	5.3	9.8999939	121	16		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22951c	UK-NCRI	61.2	Female	De novo	Adverse		1.1006160164271	1	2.5	7.5999985	82	79		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22952c	UK-NCRI	41.6	Male	Secondary	Favorable		1.56605065023956	1	28	9.5999985	68	60		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22953c	UK-NCRI	59.7	Male	De novo	Intermediate		2.07529089664613	1	60	6.1999969	70	63		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22954a	UK-NCRI	62.2	Male	De novo	Favorable		5.33333333333333	0	23	8.0999985	69	40.699982		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22956c	UK-NCRI	58.4	Male	De novo	Favorable		0.435318275154004	1	10.1	9.2999954	15	21		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22957a	UK-NCRI	37	Male	De novo	Favorable		5.3990417522245	0	5.9	9.0999985	55	67		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22958c	UK-NCRI	47.4	Male	De novo	Adverse		7.94250513347023	0	11.8	7	74	80		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22959c	UK-NCRI	49.3	Male	De novo	Intermediate		8.08487337440109	0	1.7	7.5999985	20	58.7450018928678		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22960c	UK-NCRI	62.2	Male	De novo	Favorable		7.31553730321698	0	1.3	100	42	45		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22961a	UK-NCRI	50.3	Female	De novo	Adverse		1.1088295687885	1	154.6	10.599998	24	80		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22962a	UK-NCRI	47	Male	De novo	Favorable		0.941820670773443	1	1.6	5.3999977	30	31.399994		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22963c	UK-NCRI	43.4	Female	De novo	Favorable		7.51540041067762	0	49	73	253	75		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22964a	UK-NCRI	57.6	Male	De novo	Adverse		0.939082819986311	1	39.1	8.2999954	166	18.099991		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22965c	UK-NCRI	55.2	Male	De novo	Adverse		4.9719370294319	1	1.7	7.5	102	45		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22966c	UK-NCRI	59	Male	De novo	Adverse		0.0438056125941136	1	47.7	89	41	60		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22967c	UK-NCRI	22.5	Female	De novo	Favorable		7.97809719370294	0	9.4	9.3999939	40	84		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22968c	UK-NCRI	58.9	Male	De novo	Favorable		7.06365503080082	0	36.7	10.399994	138	93		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22969c	UK-NCRI	41.7	Male	De novo	Favorable		8.02190280629706	0	203.7	5.1999969	24	90		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22970a	UK-NCRI	47.6	Male	De novo	Adverse		6.45037645448323	0	21.2	11.699997	51	75		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22971a	UK-NCRI	38.8	Female	De novo	Intermediate		1.22655715263518	1	25.9	12.099998	61	81.699951		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22972c	UK-NCRI	50.9	Male	Other	Adverse		2.70773442847365	1	2.8	9.3999939	50	58.7450018928678		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22973a	UK-NCRI	25.8	Female	De novo	Favorable		3.34839151266256	0	19	10	10	60		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22974a	UK-NCRI	55.5	Female	De novo	Favorable		6.54346338124572	0	58.9	12.099998	216	80		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22975c	UK-NCRI	65.4	Male	De novo	Favorable		2.26146475017112	0	23.7	8.5999985	59	68		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22977a	UK-NCRI	28.4	Male	De novo	Favorable		3.07734428473648	0	38.4	14.299995	63	95		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22979c	UK-NCRI	47.4	Male	De novo	Favorable		2.93223819301848	1	1.6	7.6999969	97	40		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22980c	UK-NCRI	59.5	Female	De novo	Adverse		3.12662559890486	1	2	14.099998	153	21		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22981c	UK-NCRI	57.8	Female	De novo	Intermediate		6.5845311430527	0	16.3	13.599998	94	40		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22984c	UK-NCRI	18.7	Female	De novo	Intermediate		0.936344969199179	1	14.7	12.099998	20	73		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22985a	UK-NCRI	58.5	Male	De novo	Intermediate		1.12799452429843	1	4.5	15.006119106409	80.4858623868992	58.7450018928678		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22989a	UK-NCRI	37.1	Female	De novo	Intermediate		5.37440109514031	0	8.3	8.6999969	50	53		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22990c	UK-NCRI	53.6	Male	De novo	Favorable		7.73990417522245	0	14.4	7.1999969	129	72		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22991a	UK-NCRI	45.3	Male	Other	Favorable		0.194387405886379	1	5.1	76	12	24		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22993c	UK-NCRI	30	Male	De novo	Intermediate		0.895277207392197	1	3	11.399994	110	26.799988		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22994c	UK-NCRI	60.7	Female	De novo	Adverse		1.86173853524983	1	6.2	9.2999954	117	90		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22995c	UK-NCRI	41.7	Male	De novo	Intermediate		0.0602327173169062	1	2.9	15.006119106409	80.4858623868992	58.7450018928678		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22996a	UK-NCRI	56.4	Female	De novo	Favorable		0.418891170431211	1	91.3	13.099998	80	79		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22997a	UK-NCRI	50.7	Female	De novo	Intermediate		4.77481177275838	0	1.7	7.6999969	91	45.199982		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22998a	UK-NCRI	64	Male	Secondary	Intermediate		5.99863107460643	1	3.4	10.199997	65	65		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD22999c	UK-NCRI	61.4	Female	Secondary	Adverse		4.45995893223819	1	19.3	8.7999954	20	77		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23001c	UK-NCRI	47.8	Female	De novo	Intermediate		7.50992470910335	0	1.9	10.399994	86	85		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23003c	UK-NCRI	38.9	Male	De novo	Favorable		0.791238877481177	1	55.1	6.7999992	81	83		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23004c	UK-NCRI	48.1	Male	Secondary	Adverse		0.388774811772758	1	27.8	8.3999939	84	2.3999996		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23005a	UK-NCRI	64.4	Female	De novo	Adverse		6.99794661190965	0	6.2	8.6999969	37	62		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23007c	UK-NCRI	54.6	Male	De novo	Adverse		1.95208761122519	1	40.1	9.5	91	87		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23008c	UK-NCRI	42.1	Female	De novo	Intermediate		7.79466119096509	0	33.5	8.5999985	142	80		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23011c	UK-NCRI	46.4	Female	De novo	Adverse		5.23750855578371	1	1.5	9.1999969	75	21		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23012c	UK-NCRI	27.5	Male	De novo	Intermediate		7.709787816564	0	2.7	9.5	112	90		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23013a	UK-NCRI	57.4	Female	Secondary	Favorable		0.0492813141683778	1	43.2	8.3999939	44	13.099998		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23014a	UK-NCRI	41	Male	De novo	Favorable		7.52908966461328	0	319.6	9.1999969	33	91		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23015a	UK-NCRI	42.3	Female	Other	Adverse		0.0930869267624914	1	3.7	10.099998	57	12.699997		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23016c	UK-NCRI	26.7	Male	De novo	Favorable		7.11019849418207	0	40.5	6.0999985	37	17		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23017a	UK-NCRI	53.5	Male	De novo	Favorable		2.2861054072553	1	15.5	10.199997	14	47		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23018c	UK-NCRI	27	Female	De novo	Favorable		7.81930184804928	0	306	4.6999969	40	76.5		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23019c	UK-NCRI	39.3	Female	De novo	Intermediate		0.602327173169062	1	87.9	13.799995	36	90		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23020a	UK-NCRI	59.7	Female	Secondary	Intermediate		0.791238877481177	1	1.5	9.7999954	71	26		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23021a	UK-NCRI	29.7	Male	De novo	Favorable		4.9637234770705	0	14.1	8.2999954	9	90		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23022c	UK-NCRI	39.6	Female	De novo	Intermediate		7.60848733744011	0	2.1	8.7999954	66	21		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23026c	UK-NCRI	50.4	Male	De novo	Favorable		0.936344969199179	1	19.6	12.299995	91	30		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23027a	UK-NCRI	49.6	Male	De novo	Intermediate		1.11156741957563	1	47.2	7.7999992	127	12.299995		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23028a	UK-NCRI	58.7	Male	De novo	Intermediate		0.125941136208077	1	2	9.2999954	67	80		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23029c	UK-NCRI	36.3	Female	De novo	Intermediate		3.84941820670773	0	1.6	8.1999969	251	58.7450018928678		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23030c	UK-NCRI	55.9	Female	De novo	Intermediate		2.81177275838467	1	3	9.2999954	37	58.7450018928678		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23031a	UK-NCRI	51.1	Female	De novo	Adverse		0.97741273100616	1	56.7	5.7999992	44	68		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23032a	UK-NCRI	60.9	Female	De novo	Intermediate		3.50992470910335	1	1.2	9.5	51	75		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23033c	UK-NCRI	60.5	Male	De novo	Favorable		2.91581108829569	1	234.3	12.5	78	95		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23034c	UK-NCRI	41.2	Female	De novo	Favorable		4.96098562628337	0	18.2	6.8999977	25	90		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23035a	UK-NCRI	41.4	Female	De novo	Adverse		7.78918548939083	0	14.7	10.299995	22	70		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23036a	UK-NCRI	61.1	Male	De novo	Favorable		0.80766598220397	1	158.2	6.7999992	69	35		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23037a	UK-NCRI	57	Male	Secondary	Adverse		1.02395619438741	1	46.5	11.799995	128	80		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23038c	UK-NCRI	35.1	Female	Other	Intermediate		7.35112936344969	0	2.4	7.5999985	30	18		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23040a	UK-NCRI	62.4	Female	Other	Intermediate		5.46201232032854	0	4.5	9.2999954	20	12		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23042c	UK-NCRI	55.4	Male	De novo	Favorable		7.49075975359343	0	3.8	7.5	18	90		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23043c	UK-NCRI	53.3	Female	De novo	Intermediate		0.522929500342231	1	7.7	10.699997	52	57		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23044a	UK-NCRI	59.8	Female	De novo	Intermediate		4.05749486652977	1	2.4	10.799995	26	21		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23045a	UK-NCRI	44.9	Female	De novo	Intermediate		1.05133470225873	1	41.3	9.5999985	5	51		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23046a	UK-NCRI	56.8	Male	Other	Intermediate		7.41409993155373	0	3.7	11.199997	144	10		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23047c	UK-NCRI	40.1	Male	De novo	Favorable		5.71663244353183	0	150	8.1999969	36	35		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23048a	UK-NCRI	38.3	Male	Secondary	Favorable		0.350444900752909	1	10	4.5999985	155	53.799988		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23049c	UK-NCRI	51.4	Male	Secondary	Favorable		7.53182751540041	0	75.1	8.5	44	71		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23050c	UK-NCRI	54.7	Male	De novo	Intermediate		0.854209445585216	1	8.7	8.5	21	56		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23051a	UK-NCRI	59.7	Male	De novo	Favorable		7.40862422997947	0	35	9.3999939	94	65		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23052a	UK-NCRI	31.8	Male	De novo	Adverse		7.43600273785079	0	73.7	11.399994	24	80		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23053a	UK-NCRI	63.3	Female	De novo	Adverse		0.939082819986311	1	2.2	8.5	7	58.7450018928678		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23054c	UK-NCRI	62.1	Female	De novo	Favorable		2.51882272416153	1	88	10.599998	61	46		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23055c	UK-NCRI	46	Female	De novo	Intermediate		0.91170431211499	1	52.3	100	23	60		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23056a	UK-NCRI	57.9	Male	De novo	Favorable		7.52908966461328	0	165.3	7.6999969	58	98		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23058a	UK-NCRI	41.4	Male	Other	Adverse		7.54277891854894	0	34	9.7999954	44	72		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23062a	UK-NCRI	54.4	Female	De novo	Adverse		1.59616700889802	0	1.3	10.699997	162	22.899994		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23063a	UK-NCRI	59.3	Female	De novo	Intermediate		5.76317590691307	1	2.9	10.799995	167	0		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23065c	UK-NCRI	31.1	Male	De novo	Favorable		7.45242984257358	0	58	13.099998	54	91		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23066a	UK-NCRI	52.9	Male	De novo	Intermediate		7.67967145790554	0	7.7	10.899994	13	26		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23067c	UK-NCRI	63.5	Female	Secondary	Adverse		1.782340862423	1	107	8.6999969	16	14		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23068c	UK-NCRI	51.8	Female	Secondary	Adverse		1.73305954825462	1	2.8	8.6999969	89	12		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23071c	UK-NCRI	66.2	Male	De novo	Adverse		0.344969199178645	1	1.8	9.0999985	99	80		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23072c	UK-NCRI	61	Female	De novo	Favorable		3.64955509924709	1	73.5	89	51	76		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23073c	UK-NCRI	61.6	Female	De novo	Favorable		7.15400410677618	0	2.4	9.0999985	32	86.5		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23074c	UK-NCRI	59.6	Female	De novo	Adverse		0.10403832991102	1	1.5	8.6999969	11	65		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23075a	UK-NCRI	58	Female	De novo	Intermediate		2.32717316906229	1	1.8	8.5	25	32		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23076c	UK-NCRI	61.7	Female	De novo	Adverse		0.355920602327173	1	3.5	7.3999977	8	13		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23077c	UK-NCRI	28.8	Female	De novo	Favorable		6.72689938398357	0	19.7	10.699997	21	71		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23078c	UK-NCRI	52.3	Female	De novo	Favorable		5.13620807665982	0	21.3	11.899994	98	80		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23081a	UK-NCRI	65.2	Female	Secondary	Adverse		0.470910335386721	1	6	9	60	49		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23082a	UK-NCRI	41.9	Female	De novo	Intermediate		0.65160848733744	1	80	12.199997	34	90		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23083a	UK-NCRI	33.9	Female	De novo	Intermediate		7.56741957563313	0	24.6	10.5	121	65.799988		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23084a	UK-NCRI	42.3	Female	De novo	Intermediate		0.511978097193703	1	79.9	11.75	34	80		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23085a	UK-NCRI	49.9	Female	De novo	Favorable		1.73853524982888	1	3.8	7.8999977	46	58.7450018928678		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23086a	UK-NCRI	33.3	Female	De novo	Intermediate		0.607802874743327	1	15	11.5	307	40		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23087c	UK-NCRI	66.2	Male	Secondary	Adverse		1.74674880219028	1	0.8	7.2999992	111	67		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23088a	UK-NCRI	63.7	Male	De novo	Intermediate		4.46269678302532	0	2.9	3.8999996	59	73		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23089c	UK-NCRI	35.8	Male	De novo	Favorable		5.13620807665982	0	3.4	7.7299995	31	31		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23092a	UK-NCRI	34.8	Female	De novo	Favorable		1.53593429158111	1	95.8	8.2999954	79	53		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23093c	UK-NCRI	59.6	Male	De novo	Favorable		0.539356605065024	1	108	8.1999969	106	72		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23094a	UK-NCRI	30.1	Female	De novo	Adverse		0.657084188911704	1	99.6	9	26	90		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23095a	UK-NCRI	48.8	Female	De novo	Favorable		1.4757015742642	1	89.7	6	49	70		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23096c	UK-NCRI	67.2	Female	De novo	Intermediate		1.50034223134839	1	2.8	10.199997	193	36		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23097c	UK-NCRI	69.6	Female	De novo	Adverse		7.43874058863792	0	2.8	6.5	155	80		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23099c	UK-NCRI	41.5	Female	De novo	Favorable		7.49623545516769	0	25.2	4	13	70		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23101a	UK-NCRI	52	Male	De novo	Favorable		0.662559890485969	1	94.2	85	47	90		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23102a	UK-NCRI	47.7	Female	De novo	Favorable		7.00616016427105	0	153.3	10	36	90		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23103a	UK-NCRI	63	Male	De novo	Adverse		5.99863107460643	0	15.3	10.199997	123	86		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23105a	UK-NCRI	31.4	Female	De novo	Adverse		7.3429158110883	0	4.9	9.8999939	41	20		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23106a	UK-NCRI	62	Male	Other	Favorable		1.76043805612594	1	31.1	8.7999954	76	20		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23107c	UK-NCRI	55.2	Male	De novo	Intermediate		1.0403832991102	1	45.5	12.099998	42	90		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23108c	UK-NCRI	60.7	Female	De novo	Adverse		0.457221081451061	1	5	6.5999985	56	70		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23109a	UK-NCRI	57.2	Female	De novo	Adverse		0.271047227926078	1	25.5	8.1999969	102	75		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23110c	UK-NCRI	60.3	Female	De novo	Adverse		7.13757700205339	0	1.7	8.8999939	77	90		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23111c	UK-NCRI	48.7	Female	De novo	Intermediate		0.613278576317591	1	2.7	9.5	82	31		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23112c	UK-NCRI	46.5	Male	Other	Adverse		1.01026694045175	1	3.8	8.5999985	109	28.199997		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23113c	UK-NCRI	67.1	Female	De novo	Favorable		7.22792607802875	0	11.6	9.7999954	25	78		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23114a	UK-NCRI	60.1	Female	De novo	Adverse		0.191649555099247	1	5.8	8.2999954	39	63		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23115c	UK-NCRI	41.4	Female	De novo	Adverse		1.68651608487337	1	26.8	13.299995	96	80		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23116a	UK-NCRI	58	Female	De novo	Favorable		3.24435318275154	1	1.6	12.899994	110	32		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23117a	UK-NCRI	53.3	Female	De novo	Adverse		1.4757015742642	1	43.8	8.6999969	54	15		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23118a	UK-NCRI	47.9	Female	De novo	Favorable		0.501026694045175	1	20	5.0999985	21	62.799988		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23119c	UK-NCRI	52.4	Male	De novo	Favorable		7.41683778234086	0	22.2	9.7999954	184	73		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23121a	UK-NCRI	65.8	Female	De novo	Adverse		0.881587953456537	1	8.4	9.1999969	42	70		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23122a	UK-NCRI	62.5	Female	Other	Adverse		1.37987679671458	1	5.3	9	93	12		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23123c	UK-NCRI	51.5	Female	De novo	Favorable		6.24229979466119	0	2.8	5.8999977	36	49		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23124a	UK-NCRI	47.9	Female	De novo	Favorable		1.75496235455168	0	31.8	7.6999969	18	60		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23125c	UK-NCRI	48.2	Female	De novo	Favorable		7.42505133470226	0	7.4	4.5999985	90	36		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23126a	UK-NCRI	46.6	Male	De novo	Favorable		0.0191649555099247	1	7.1	9.8999939	444	2		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23127c	UK-NCRI	37.8	Female	De novo	Intermediate		6.90485968514716	0	86.1	8.5999985	60	79		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23129a	UK-NCRI	30.7	Female	De novo	Favorable		2.62559890485969	0	2.8	9.6999969	251	14		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23130c	UK-NCRI	55.8	Male	De novo	Adverse		0.164271047227926	1	0.9	7.0999985	13	22		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23132a	UK-NCRI	29.9	Male	De novo	Adverse		1.42094455852156	1	20.7	11.799995	95	31		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23133c	UK-NCRI	69.7	Female	De novo	Adverse		0.112251882272416	1	23.3	6.7999992	38	75		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23134a	UK-NCRI	29.8	Female	De novo	Intermediate		0.659822039698836	1	69.5	9.5999985	45	87		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23136a	UK-NCRI	60.1	Male	De novo	Favorable		4.5968514715948	0	15.6	9.5999985	166	35		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23137a	UK-NCRI	58.7	Female	De novo	Adverse		0.720054757015743	1	0.4	5.3999977	62	50		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23138a	UK-NCRI	42.5	Male	Secondary	Adverse		3.4031485284052	1	4.3	11.899994	336	20		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23139a	UK-NCRI	37.8	Female	De novo	Favorable		7.21149897330595	0	4.8	9	149	77.799988		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23140a	UK-NCRI	55.1	Male	De novo	Intermediate		7.1129363449692	0	17.5	10.399994	91	77		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23141a	UK-NCRI	47.7	Female	De novo	Favorable		7.12662559890486	0	18.6	9	130	8.8999939		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23142a	UK-NCRI	52.8	Male	Other	Favorable		1.09787816563997	1	88.5	6.5999985	139	18.199997		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23143c	UK-NCRI	41	Male	De novo	Intermediate		1.7138945927447	1	7.4	8.2999954	27	40		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23144a	UK-NCRI	47.5	Female	De novo	Adverse		0.566735112936345	1	2.2	11	51	5.5		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23145a	UK-NCRI	32.7	Female	De novo	Favorable		2.09171800136893	1	28.2	12.099998	74	80		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23146a	UK-NCRI	70.5	Female	De novo	Favorable		7.45790554414784	0	0.3	8.6999969	21	87		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23147a	UK-NCRI	68.8	Male	Secondary	Intermediate		4.38877481177276	1	1.2	8.5	54	9		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23148a	UK-NCRI	48.9	Female	De novo	Adverse		1.2703627652293	1	5	10.399994	100	69		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23149c	UK-NCRI	66.6	Female	Secondary	Adverse		0.988364134154689	1	4.4	10.099998	41	45		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23150a	UK-NCRI	58.9	Female	De novo	Adverse		1.31690622861054	1	2.7	10.099998	83	23		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23151a	UK-NCRI	67.3	Male	Secondary	Adverse		0.147843942505133	1	230	10.799995	81	90		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23153a	UK-NCRI	54.5	Female	De novo	Adverse		0.0657084188911704	1	22.3	9.2999954	22	22		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23154a	UK-NCRI	48.7	Male	De novo	Favorable		6.62833675564682	0	37.4	11	53	90		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23155a	UK-NCRI	40.7	Male	De novo	Favorable		5.82067077344285	0	3.9	7.0999985	32	25		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23156a	UK-NCRI	35.5	Male	De novo	Intermediate		1.22655715263518	1	146.2	6.7999992	47	90		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23157a	UK-NCRI	22.5	Female	De novo	Favorable		6.54893908281999	0	16.8	9.3999939	32	91		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23158a	UK-NCRI	63.1	Female	Secondary	Adverse		1.75222450376454	1	33	7.7999992	145	22		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23159c	UK-NCRI	51.8	Female	De novo	Favorable		4.83230663928816	1	3.7	9.5	52	81		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23160c	UK-NCRI	61.5	Male	De novo	Intermediate		0.728268309377139	1	35.8	10	26	89		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23161c	UK-NCRI	53.2	Female	De novo	Intermediate		1.77686516084873	1	6.1	15.006119106409	80.4858623868992	58.7450018928678		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23162a	UK-NCRI	45.5	Male	De novo	Adverse		2.60917180013689	0	4.3	9.0999985	314	53		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23163c	UK-NCRI	36.8	Female	De novo	Adverse		7.2498288843258	0	28.9	5.5	100	83		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23164a	UK-NCRI	55.4	Male	De novo	Favorable		0.492813141683778	1	33	9.3999939	179	100		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23165c	UK-NCRI	62.4	Female	De novo	Adverse		7.11019849418207	0	0.8	7.6999969	23	49		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23166a	UK-NCRI	58.5	Male	De novo	Favorable		6.9678302532512	0	27.4	8.8999939	8	76		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23168a	UK-NCRI	60.1	Male	De novo	Intermediate		6.28336755646817	1	1	6.0999985	70	87		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23169a	UK-NCRI	49.2	Male	De novo	Adverse		2.20123203285421	1	1.5	11.199997	116	66		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23170a	UK-NCRI	65.6	Female	Other	Adverse		0.257357973990418	1	1.1	10.699997	38	15		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23171c	UK-NCRI	37.1	Female	De novo	Adverse		7.13757700205339	0	6.8	7.8999977	17	97		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23172c	UK-NCRI	49.6	Female	De novo	Adverse		3.06091718001369	1	3.2	8.8999939	179	45		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23173a	UK-NCRI	46.9	Male	De novo	Adverse		0.928131416837782	1	298.6	6.2999992	117	97		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23174a	UK-NCRI	46	Female	De novo	Favorable		0.0355920602327173	1	6.5	8	42	28		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23175a	UK-NCRI	60	Male	Secondary	Adverse		0.0657084188911704	1	2.1	7.8999977	25	45		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23176c	UK-NCRI	26	Male	De novo	Favorable		4.23819301848049	1	11.4	10.399994	63	70		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23177c	UK-NCRI	53.4	Female	De novo	Adverse		0.451745379876797	1	7	9.2999954	48	22		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23178a	UK-NCRI	41.4	Male	De novo	Intermediate		4.24093086926762	1	2.3	9.5999985	77	90		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23179a	UK-NCRI	63.4	Male	Secondary	Adverse		1.85626283367556	1	4.9	10.5	37	11		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23180a	UK-NCRI	17.4	Male	De novo	Favorable		7.31279945242984	0	2.5	10.099998	75	30		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23181a	UK-NCRI	47	Male	De novo	Intermediate		7.00889801505818	0	4.7	10.299995	154	70		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23182c	UK-NCRI	63.6	Male	De novo	Adverse		6.3791923340178	0	2.1	6.2999992	396	30		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23183c	UK-NCRI	15.9	Female	De novo	Intermediate		5.17180013689254	0	1.2	11	10	77		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23184a	UK-NCRI	56.1	Male	De novo	Adverse		6.53251197809719	0	20	9.3999939	34	97		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23185a	UK-NCRI	46	Male	Other	Adverse		0.191649555099247	1	41.7	8.6999969	281	45		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23186a	UK-NCRI	58.3	Male	De novo	Adverse		0.407939767282683	1	2.7	12.299995	60	59		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23187a	UK-NCRI	20.4	Female	De novo	Favorable		6.35728952772074	0	30	8.3999939	75	33.5		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23188c	UK-NCRI	58.9	Female	Other	Intermediate		7.16495550992471	0	8.6	9.5	101	15		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23189c	UK-NCRI	48.3	Female	De novo	Favorable		7.17043121149897	0	33.6	5.4699974	14	74		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23190c	UK-NCRI	51.9	Male	De novo	Favorable		7.06365503080082	0	14.9	8.0999985	45	90		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23191a	UK-NCRI	64.2	Male	De novo	Adverse		7.05270362765229	0	2.5	3.2999992	180	78		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23192a	UK-NCRI	31.3	Male	De novo	Favorable		7.14852840520192	0	5.5	9	76	23		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23194c	UK-NCRI	65.6	Female	De novo	Adverse		0.0958247775496235	1	16	9.0999985	77	58.7450018928678		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23195a	UK-NCRI	48.5	Male	De novo	Favorable		0.509240246406571	1	42	12.099998	106	93		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23196c	UK-NCRI	41.5	Male	De novo	Adverse		0.988364134154689	1	73	5.6999969	40	98		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23199a	UK-NCRI	51.9	Female	De novo	Favorable		6.05065023956194	0	36.9	4.7999992	166	58.7450018928678		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23200c	UK-NCRI	55.4	Male	De novo	Intermediate		5.11978097193703	1	0.8	87	15	56		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23202a	UK-NCRI	39	Female	De novo	Intermediate		1.0321697467488	1	128.8	7.2999992	57	99		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23204a	UK-NCRI	56.1	Female	Secondary	Adverse		0.331279945242984	1	5.5	10.5	113	90		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23205c	UK-NCRI	56.2	Female	De novo	Favorable		6.95140314852841	0	91.1	6.6999969	46	91		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23209c	UK-NCRI	48.9	Male	De novo	Adverse		0.969199178644764	1	137.7	9.0999985	45	12.599998		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23216c	UK-NCRI	38.7	Female	De novo	Intermediate		5.21834360027379	1	1.1	96	153	45		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23217c	UK-NCRI	65.9	Female	De novo	Adverse		1.83436002737851	1	15.3	9.5	10	59.5		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23218a	UK-NCRI	54.8	Female	De novo	Favorable		1.54962354551677	1	395	4.8999977	50	95		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23219a	UK-NCRI	51.6	Female	De novo	Intermediate		6.6009582477755	0	10	13.199997	236	1		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23220c	UK-NCRI	46.8	Male	De novo	Favorable		6.99520876112252	0	48.4	11.5	79	70		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23222c	UK-NCRI	26.8	Female	De novo	Intermediate		0.161533196440794	1	3.6	6.7999992	22	58.7450018928678		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23224c	UK-NCRI	32.7	Male	De novo	Adverse		1.74948665297741	1	173.2	6.2999992	45	94		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23225a	UK-NCRI	65.9	Female	De novo	Intermediate		4.4517453798768	1	4.6	11.799995	295	29		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23226c	UK-NCRI	16.9	Female	De novo	Adverse		1.96851471594798	1	93.2	9	60	49		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23227c	UK-NCRI	42.2	Female	De novo	Intermediate		6.62559890485969	0	3.9	5.8999977	150	66		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23232c	UK-NCRI	39.7	Female	De novo	Favorable		3.87953456536619	1	9.6	12.299995	44	80		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23233a	UK-NCRI	40.2	Female	De novo	Intermediate		7.04996577686516	0	55.1	9.2999954	43	68		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23234a	UK-NCRI	66.5	Female	Secondary	Favorable		6.00136892539357	1	25	8.3999939	64	80		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23236c	UK-NCRI	60.7	Female	Secondary	Favorable		6.8993839835729	0	1.3	9.7999954	77	57		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23237a	UK-NCRI	66.4	Female	Other	Intermediate		6.52977412731006	0	1.3	10	46	11		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23238c	UK-NCRI	62.4	Female	De novo	Intermediate		3.89869952087611	0	1.5	11.399994	118	27.899994		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23240c	UK-NCRI	16.3	Male	De novo	Adverse		1.43189596167009	1	2.4	105	288	28		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23241c	UK-NCRI	61.9	Female	De novo	Favorable		0.0629705681040383	1	6.2	8.5	33	64		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23242c	UK-NCRI	63.6	Female	De novo	Adverse		6.1492128678987	0	1	9.2999954	79	51		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23245a	UK-NCRI	64.5	Female	De novo	Adverse		2.64476386036961	1	2.4	9.5999985	108	64		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23246a	UK-NCRI	59.5	Female	De novo	Favorable		1.36618754277892	1	6.1	7.6999969	56	90		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23247c	UK-NCRI	54.3	Male	De novo	Intermediate		4.32854209445585	1	105	8.2999954	47	92		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23248a	UK-NCRI	34.2	Male	De novo	Favorable		2.57905544147844	0	7.2	6.1999969	157	29		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23249c	UK-NCRI	67.7	Male	De novo	Intermediate		3.2662559890486	1	2	10	36	80		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23251a	UK-NCRI	48.4	Male	De novo	Favorable		6.40657084188912	0	10.4	11.699997	130	95		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23252a	UK-NCRI	68.7	Male	Secondary	Adverse		2.39014373716632	1	0.9	90	65	24.5		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23254a	UK-NCRI	22.9	Female	De novo	Favorable		6.11635865845311	0	48.3	12.799995	31	78		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23255c	UK-NCRI	54.5	Female	De novo	Intermediate		5.42915811088296	1	43.2	10.699997	76	52		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23256c	UK-NCRI	49.2	Female	De novo	Favorable		6.66666666666667	0	74.3	11.699997	44	68		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23258a	UK-NCRI	65.7	Male	Other	Adverse		0.191649555099247	1	42	8.5999985	62	75		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23259c	UK-NCRI	22.1	Female	De novo	Adverse		1.22655715263518	0	10.4	8.1999969	80	83		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23260c	UK-NCRI	52.1	Female	De novo	Adverse		0.407939767282683	1	5.1	9	94	88		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23261c	UK-NCRI	48.1	Male	De novo	Intermediate		1.31416837782341	1	108	9.5999985	241	90		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23265c	UK-NCRI	44.8	Female	De novo	Favorable		1.92197125256674	1	2.7	9.7999954	38	30		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23267c	UK-NCRI	52.6	Female	De novo	Favorable		4.35318275154004	0	34.8	11.399994	59	33		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23268a	UK-NCRI	29.5	Male	De novo	Intermediate		1.21286789869952	1	63.2	10.699997	36	92.199951		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23270c	UK-NCRI	65.4	Male	De novo	Intermediate		0.150581793292266	1	1.4	9	186	37.199982		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23272c	UK-NCRI	54.7	Female	De novo	Adverse		3.89048596851472	0	0.8	9	209	40		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23274c	UK-NCRI	59.5	Male	De novo	Favorable		6.50513347022587	0	33.7	8.2999954	90	80		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23276a	UK-NCRI	60	Female	Other	Adverse		1.15537303216975	1	3.4	7.6999969	46	7		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23277a	UK-NCRI	37.3	Male	De novo	Intermediate		6.49691991786448	0	2.9	7.7999992	69	32.5		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23278c	UK-NCRI	39.5	Male	De novo	Favorable		2.11909650924025	1	78.5	10	21	76		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23279a	UK-NCRI	68.2	Male	De novo	Favorable		6.48049281314168	0	4.1	9.1999969	52	50		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23280a	UK-NCRI	58.3	Female	De novo	Favorable		6.72963723477071	0	56.1	8.2999954	101	87		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23281c	UK-NCRI	40.5	Male	De novo	Adverse		4.31485284052019	1	2.1	11.5	142	42		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23282a	UK-NCRI	24.4	Male	De novo	Favorable		6.00958247775496	0	0.9	7.3999977	65	80		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23283a	UK-NCRI	43.8	Female	De novo	Intermediate		6.87748117727584	0	69	10.899994	13	75.899963		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23284c	UK-NCRI	64.3	Female	De novo	Adverse		0.120465434633812	1	98	176	33	32		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23285a	UK-NCRI	60.4	Female	De novo	Intermediate		3.79739904175222	1	2	114	76	58.7450018928678		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23286c	UK-NCRI	62.8	Female	Secondary	Adverse		0.37782340862423	1	4	8.8999939	5	32		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23287a	UK-NCRI	61	Female	De novo	Adverse		0.292950034223135	1	2.5	105	46	72		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23289a	UK-NCRI	63.5	Female	De novo	Adverse		3.04175222450376	1	2.5	10.599998	193	58.7450018928678		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23291c	UK-NCRI	65	Male	Other	Adverse		0.054757015742642	1	93.5	10.399994	36	26.899994		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23292c	UK-NCRI	59.5	Female	De novo	Intermediate		1.02669404517454	1	2.6	11.199997	74	21.699997		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23293a	UK-NCRI	62.5	Female	De novo	Adverse		1.16632443531828	1	10.7	5.6999969	40	98		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23295a	UK-NCRI	56	Female	De novo	Adverse		0.202600958247775	1	3.2	8.5	328	18.799988		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23296a	UK-NCRI	62.3	Male	De novo	Intermediate		6.8062970568104	0	6	8.2999954	11	33		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23299d	UK-NCRI	58.5	Male	De novo	Intermediate		1.4072553045859	1	1.4	115	202	46.399994		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23300c	UK-NCRI	47.4	Male	De novo	Favorable		4.78302532511978	0	23.1	6.0999985	18	46		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23301a	UK-NCRI	60.4	Male	De novo	Favorable		5.32511978097194	0	74.5	6.2999992	138	36.799988		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23303a	UK-NCRI	39	Female	Other	Adverse		6.24229979466119	0	3.7	9.8999939	79	15.5		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23305a	UK-NCRI	65.9	Female	De novo	Intermediate		1.02121834360027	1	4.3	5.5999985	13	85		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23306c	UK-NCRI	66	Male	De novo	Adverse		6.47227926078029	0	133.9	5.7999992	58	90		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23307c	UK-NCRI	51.6	Female	De novo	Adverse		0.744695414099932	1	171.3	9.3999939	128	84		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23308c	UK-NCRI	53.9	Female	De novo	Intermediate		3.83846680355921	0	10.4	11.399994	219	20		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23309a	UK-NCRI	61.5	Female	De novo	Favorable		5.82340862422998	0	46.7	8.5999985	13	80		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23310a	UK-NCRI	54	Male	Other	Favorable		6.29158110882957	0	9.6	76	176	40		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23311a	UK-NCRI	22.6	Female	De novo	Intermediate		5.84531143052704	0	5.2	9.2999954	197	70		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23312c	UK-NCRI	61.7	Female	Other	Adverse		6.63107460643395	0	12.7	11.099998	123	16		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23313c	UK-NCRI	43.5	Female	De novo	Intermediate		3.61943874058864	0	9.9	7.6999969	49	72		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23314a	UK-NCRI	55	Female	De novo	Intermediate		6.45311430527036	0	58.1	8	32	80		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23315c	UK-NCRI	63.8	Female	De novo	Favorable		2.07529089664613	1	113.8	8.3999939	71	65		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23316a	UK-NCRI	51.6	Female	De novo	Favorable		6.40109514031485	0	3.1	84	182	18		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23317c	UK-NCRI	45.1	Female	De novo	Adverse		1.18822724161533	1	2.8	9	64	90		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23320c	UK-NCRI	60.6	Female	De novo	Intermediate		6.48323066392882	0	40	7.9399986	32	50		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23321c	UK-NCRI	58.4	Male	De novo	Favorable		6.05065023956194	0	38	8.7999954	77	50		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23322c	UK-NCRI	66.6	Male	De novo	Favorable		2.09719370294319	1	125	85	218	90		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23323c	UK-NCRI	51.3	Female	De novo	Favorable		1.67830253251198	1	66.5	7.6999969	12	56		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23324a	UK-NCRI	42.6	Male	De novo	Intermediate		5.6208076659822	0	46.4	49	110	70		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23325a	UK-NCRI	59.2	Male	De novo	Favorable		4.29295003422313	0	41.1	8.2999954	129	50		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23327c	UK-NCRI	47.7	Female	De novo	Favorable		3.94798083504449	0	308.2	6	31	90		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23328c	UK-NCRI	16	Male	De novo	Favorable		6.072553045859	0	25.7	122	81	18		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23329c	UK-NCRI	48.2	Male	De novo	Favorable		0.0383299110198494	1	289.5	7.3999977	28	85		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23330c	UK-NCRI	46.3	Male	De novo	Intermediate		0.914442162902122	1	71	8.5999985	45	82		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23331a	UK-NCRI	43.8	Male	De novo	Intermediate		1.28678986995209	1	48	114	110	90		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23332c	UK-NCRI	48.9	Female	De novo	Adverse		5.1088295687885	1	22.1	7.5	100	53		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23333a	UK-NCRI	19.5	Female	De novo	Adverse		5.34976043805613	0	41	11.5	85	58.7450018928678		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23334c	UK-NCRI	79.9	Male	De novo	Intermediate		0.522929500342231	1	2.3	5.5999985	75	97		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD23335a	UK-NCRI	74.7	Male	Secondary	Favorable		1.18822724161533	1	56.5	12.299995	95	53		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25021d	UK-NCRI	61.1	Male	De novo	Favorable		3.72895277207392	0	19.2	9.3999939	81	42.199982		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25022a	UK-NCRI	69.3	Male	Other	Adverse		2.26420260095825	1	3.4	15.006119106409	80.4858623868992	58.7450018928678		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25023d	UK-NCRI	64.1	Female	De novo	Adverse		3.15947980835044	0	42.8	9.2999954	194	63		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25024d	UK-NCRI	67.6	Female	De novo	Favorable		3.06913073237509	0	11.8	7.5999985	20	58.7450018928678		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25025d	UK-NCRI	66.7	Male	De novo	Intermediate		0.607802874743327	1	6.1	9.7999954	231	52.599976		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25026a	UK-NCRI	58.2	Male	De novo	Favorable		6.04791238877481	1	7.6	11.75	332	0		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25027a	UK-NCRI	64.8	Female	Secondary	Favorable		7.00342231348391	0	12.4	9.6999969	62	15		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25028a	UK-NCRI	52.5	Male	De novo	Favorable		7.24709103353867	0	25.5	5.2999992	16	56.899994		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25029a	UK-NCRI	57.9	Male	De novo	Favorable		0.0383299110198494	1	67.1	11.429993	13	78		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25030a	UK-NCRI	63.7	Female	De novo	Adverse		0.810403832991102	1	15.5	8.8999939	27	72		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25031a	UK-NCRI	59.1	Female	Other	Adverse		1.07049965776865	1	11.4	10.799995	135	13		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25032a	UK-NCRI	48	Male	De novo	Favorable		7.20328542094456	0	4.3	10.699997	37	90		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25033a	UK-NCRI	47.8	Male	De novo	Adverse		6.53524982888433	0	6	10	88	90		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25034a	UK-NCRI	66.4	Male	De novo	Favorable		0.709103353867214	1	4.3	7.7299995	36	53		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25035a	UK-NCRI	51.3	Male	De novo	Intermediate		0.906228610540726	0	1.4	9.8999939	30	30		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25036a	UK-NCRI	38.9	Female	De novo	Favorable		2.36550308008214	0	10.5	11.899994	139	33		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25037a	UK-NCRI	51.5	Male	De novo	Intermediate		2.07529089664613	1	29	8.5	42	90		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25038a	UK-NCRI	50.1	Male	Secondary	Adverse		0.785763175906913	1	5.5	8.2999954	39	40		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25039c	UK-NCRI	24.9	Female	De novo	Adverse		1.06228610540726	1	2.2	3.5	120	40		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25040a	UK-NCRI	55.9	Female	De novo	Intermediate		6.86105407255305	0	3.1	78	27	45		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25041c	UK-NCRI	57.2	Male	De novo	Favorable		5.63449691991786	0	77.6	10.099998	16	90		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25043a	UK-NCRI	66.7	Female	De novo	Intermediate		6.75701574264203	0	2.3	11.599998	119	25		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25044a	UK-NCRI	66.7	Male	De novo	Intermediate		2.70773442847365	1	0.8	5	74	90		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25045a	UK-NCRI	64.8	Male	De novo	Adverse		5.34976043805613	0	3.1	8.5999985	134	50		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25047a	UK-NCRI	50.5	Male	De novo	Favorable		4.18069815195072	0	1.9	94	36	58.7450018928678		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25048a	UK-NCRI	62.4	Male	Secondary	Adverse		0.210814510609172	1	1.6	11.099998	63	30		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25049c	UK-NCRI	55.7	Male	De novo	Favorable		0.0602327173169062	1	1.9	8.0999985	44	65		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25050a	UK-NCRI	64.3	Male	Other	Adverse		0.210814510609172	0	87.2	8	52	20		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25051c	UK-NCRI	30.3	Male	De novo	Intermediate		6.20396988364134	0	34.5	8.0999985	28	51		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25053c	UK-NCRI	52.3	Female	De novo	Intermediate		5.08966461327858	0	177.2	11	52	98		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25054c	UK-NCRI	50.2	Female	De novo	Adverse		4.61327857631759	1	12.7	7.8999977	88	38		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25055a	UK-NCRI	63.5	Male	De novo	Intermediate		0.413415468856947	1	135	12.5	79	96		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25057a	UK-NCRI	41.6	Female	De novo	Intermediate		0.0054757015742642	1	198	66	58	58.7450018928678		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25059c	UK-NCRI	57.5	Male	De novo	Favorable		7.37029431895962	0	69.3	6	12	85		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25060a	UK-NCRI	40.2	Male	De novo	Favorable		0.240930869267625	1	8.3	9.2999954	125	31		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25061a	UK-NCRI	29.9	Female	De novo	Intermediate		0.054757015742642	1	14.2	12.5	174	81		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25062c	UK-NCRI	58.7	Female	De novo	Adverse		1.14442162902122	1	7	10.199997	37	90		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25063c	UK-NCRI	23.2	Female	De novo	Intermediate		1.58795345653662	1	18.8	110	57	94		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25064c	UK-NCRI	42.7	Female	De novo	Favorable		6.57357973990417	0	1.2	12.199997	142	90		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25065c	UK-NCRI	68.9	Female	De novo	Favorable		0.240930869267625	1	132.1	12	41	95		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25066c	UK-NCRI	48.9	Male	De novo	Favorable		4.39972621492129	0	31.1	84	60	40		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25067c	UK-NCRI	62	Male	De novo	Favorable		6.36002737850787	0	1.7	9.6999969	117	70		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25068c	UK-NCRI	53.2	Female	De novo	Adverse		6.51334702258727	0	1.6	12.639999	65	70		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25069a	UK-NCRI	56	Male	De novo	Adverse		6.16016427104723	0	55	80	170	33		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25070a	UK-NCRI	65.4	Male	De novo	Favorable		6.36002737850787	0	15.1	75	112	71		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25071a	UK-NCRI	49.7	Male	De novo	Adverse		0.0574948665297741	1	3.9	7.1999969	16	20		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25072a	UK-NCRI	53.4	Male	De novo	Adverse		2.81998631074606	1	4.7	8.6999969	134	60		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25074a	UK-NCRI	62	Male	De novo	Adverse		2.71594798083504	1	3.2	7.8999977	32	90		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25075c	UK-NCRI	49.5	Male	De novo	Adverse		0.342231348391513	1	1.4	11.399994	188	37		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25076a	UK-NCRI	67.3	Female	Secondary	Adverse		0.0711841204654346	1	47.7	10.099998	116	1		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25077a	UK-NCRI	48.1	Male	De novo	Favorable		4.80219028062971	0	2.7	10.699997	61	58.7450018928678		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25078a	UK-NCRI	62	Female	De novo	Favorable		0.574948665297741	0	9.8	87	15	50		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25079a	UK-NCRI	64.1	Male	De novo	Favorable		6.33538672142368	0	15.7	8.3999939	124	67		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25080a	UK-NCRI	57	Male	De novo	Favorable		0.687200547570157	1	8.4	9.5	105	78		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25081c	UK-NCRI	61.8	Male	De novo	Favorable		0.939082819986311	1	115	101	36	82		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25082a	UK-NCRI	72.2	Female	De novo	Intermediate		3.95619438740589	0	3.2	7.5	2	30		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25083a	UK-NCRI	53.9	Male	De novo	Intermediate		1.1772758384668	1	52.8	115	803	53		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25084a	UK-NCRI	58.7	Male	De novo	Adverse		0.147843942505133	1	34.9	8.5	86	75		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25085c	UK-NCRI	40.2	Female	De novo	Adverse		4.83230663928816	0	5.7	11.199997	43	95		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25086c	UK-NCRI	46.2	Male	De novo	Favorable		6.26694045174538	0	12.1	9.8999939	26	90		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25087c	UK-NCRI	62.4	Female	De novo	Adverse		0.16974674880219	1	1.6	8.7999954	21	12		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25088c	UK-NCRI	63.3	Female	De novo	Adverse		0.416153319644079	1	66	6.0999985	21	98		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25089c	UK-NCRI	24.9	Male	De novo	Favorable		2.87474332648871	1	3.9	96	8	73		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25090c	UK-NCRI	59.6	Female	De novo	Adverse		2.71047227926078	1	6.5	9.3999939	34	83		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25091a	UK-NCRI	24	Female	De novo	Favorable		6.16837782340862	0	14.2	11.099998	19	80		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25092c	UK-NCRI	40.1	Female	De novo	Favorable		6.27241615331964	0	7.7	13.699997	20	37		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25093c	UK-NCRI	54.8	Female	De novo	Favorable		5.1772758384668	0	2.4	98	31	90		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25095a	UK-NCRI	47.9	Female	De novo	Favorable		4.72279260780287	0	78.5	77	98	80		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25096c	UK-NCRI	66	Female	De novo	Favorable		6.33538672142368	0	45.9	10.299995	62	94		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25098c	UK-NCRI	46.3	Female	De novo	Adverse		1.65913757700205	1	1.8	9.8999939	27	31		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25100c	UK-NCRI	55.6	Male	De novo	Favorable		3.86036960985626	0	5.3	8.6999969	223	50		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25101c	UK-NCRI	62	Female	De novo	Favorable		4.33675564681725	0	52.5	9.5999985	126	70		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25102c	UK-NCRI	57.9	Male	De novo	Intermediate		6.17932922655715	0	0.8	8.3999939	61	40		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25103c	UK-NCRI	50.4	Male	De novo	Adverse		6.02327173169062	0	26.9	9.1999969	204	55		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25104a	UK-NCRI	55.8	Female	De novo	Adverse		4.33949349760438	0	4.3	9.2999954	77	80		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25105a	UK-NCRI	44.2	Female	De novo	Favorable		5.90554414784394	0	14.7	14.599998	23	50		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25106c	UK-NCRI	25.9	Male	De novo	Intermediate		3.45516769336071	1	1.3	9.2299957	157	82		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25107a	UK-NCRI	53.7	Female	De novo	Adverse		1.94934976043806	1	59	7.5	9	88		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25108c	UK-NCRI	59.6	Male	De novo	Intermediate		2.19575633127995	1	117.6	6.2999992	55	92		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25109a	UK-NCRI	25.1	Male	De novo	Intermediate		2.13278576317591	1	67.6	100	18	90		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25110c	UK-NCRI	50.8	Male	De novo	Intermediate		6.24229979466119	0	0.9	13	71	62		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25112c	UK-NCRI	19.6	Female	De novo	Favorable		1.30595482546201	1	4.2	6	146	60		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25113c	UK-NCRI	46.2	Male	De novo	Favorable		6.23956194387406	0	30.3	9.7999954	103	95		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25115c	UK-NCRI	38	Male	De novo	Favorable		0.91170431211499	1	5	8.6999969	139	65		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25116c	UK-NCRI	55.1	Female	De novo	Adverse		5.59342915811088	1	2.5	6.7999992	49	31		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25118c	UK-NCRI	59.1	Female	Secondary	Adverse		1.18001368925394	1	1.2	6.5999985	50	24		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25119c	UK-NCRI	55.8	Male	Secondary	Intermediate		1.28131416837782	1	56	9.8799973	67	90		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25120a	UK-NCRI	67.4	Male	Other	Adverse		0.720054757015743	1	205.4	12.599998	47	7.8999977		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25122c	UK-NCRI	66.2	Male	De novo	Adverse		0.279260780287474	1	40.4	8.6999969	17	74		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25125c	UK-NCRI	62.8	Female	De novo	Adverse		0.725530458590007	1	1.3	7.3999977	76	68		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25127a	UK-NCRI	31.2	Male	De novo	Adverse		2.37371663244353	0	44.6	8	139	90		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25129c	UK-NCRI	62.7	Female	De novo	Favorable		3.26078028747433	0	6.1	10.199997	209	50		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25130a	UK-NCRI	52.1	Female	De novo	Favorable		6.21218343600274	0	5.7	74	77	67		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25131c	UK-NCRI	49.3	Male	De novo	Favorable		4.26283367556468	0	3.6	4.8999977	57	50		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25132a	UK-NCRI	40.2	Female	De novo	Adverse		6.25872689938398	0	5	7.5999985	105	6		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25133c	UK-NCRI	65	Male	De novo	Intermediate		0.238193018480493	1	156	67	116	58.7450018928678		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25134c	UK-NCRI	50.6	Female	De novo	Adverse		6.16016427104723	0	2.8	114	106	90.5		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25135a	UK-NCRI	49.7	Female	De novo	Favorable		3.14579055441478	1	39.7	71	99	80		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25136c	UK-NCRI	31.6	Male	De novo	Favorable		5.95208761122519	0	11.9	11.699997	35	58		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25137c	UK-NCRI	29.8	Female	De novo	Favorable		0.39151266255989	1	21.8	11.339996	75	55		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25138c	UK-NCRI	59.9	Male	De novo	Adverse		1.87816563997262	1	2	9.5999985	148	35		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25139c	UK-NCRI	58	Female	De novo	Adverse		2.24777549623546	1	12.4	5.5	108	33		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25140c	UK-NCRI	52.7	Male	De novo	Adverse		3.57015742642026	1	5.6	8.0999985	9	12		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25141c	UK-NCRI	46.2	Male	De novo	Intermediate		2.06707734428474	1	26	9.7999954	66	80		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25142a	UK-NCRI	49.3	Male	Secondary	Favorable		5.64818617385353	0	121.3	8.0999985	50	97		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25143a	UK-NCRI	56.4	Female	Other	Adverse		0.933607118412047	1	1.6	8.8999939	49	13		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25144a	UK-NCRI	61.1	Male	De novo	Intermediate		3.66872005475702	1	1.8	111	20	27		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25145c	UK-NCRI	52.8	Female	De novo	Adverse		0.229979466119097	1	9.7	9.2299957	28	59		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25146d	UK-NCRI	54.1	Female	De novo	Favorable		6.13552361396304	0	23.3	8	22	92		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25148c	UK-NCRI	50.8	Female	De novo	Adverse		3.00068446269678	1	3.1	1.3999996	26	26		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25150a	UK-NCRI	59.3	Male	De novo	Favorable		3.88227241615332	1	4.2	9.2999954	114	40		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25151a	UK-NCRI	65.7	Female	Secondary	Adverse		0.150581793292266	1	6.8	14.199997	15	18		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25152c	UK-NCRI	46.4	Male	De novo	Intermediate		1.11978097193703	1	72.8	9.6999969	152	90		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25154c	UK-NCRI	58.5	Female	De novo	Favorable		5.71115674195756	1	15.5	9.5	39	68		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25155d	UK-NCRI	62.5	Male	De novo	Adverse		0.851471594798084	1	20	11.5	59	90		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25156c	UK-NCRI	45.5	Female	De novo	Favorable		5.28405201916496	0	4.4	15	116	50		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25157c	UK-NCRI	68.1	Male	De novo	Adverse		5.77138945927447	1	20	42	163	60		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25158c	UK-NCRI	59	Female	De novo	Intermediate		0.334017796030116	1	140.5	7.3999977	26	83		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25159c	UK-NCRI	28.3	Female	De novo	Favorable		5.88364134154689	0	4.7	7.5	40	68		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25160c	UK-NCRI	63.5	Female	De novo	Adverse		0.922655715263518	1	100.4	56	37	9		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25162c	UK-NCRI	41.6	Male	De novo	Favorable		4.38603696098563	0	0.7	7.7999992	26	62		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25163a	UK-NCRI	63.3	Female	De novo	Favorable		3.55373032169747	0	7.8	9.5999985	109	74		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25164c	UK-NCRI	69.8	Male	De novo	Intermediate		2.13278576317591	1	26.7	10.399994	93	85		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25166a	UK-NCRI	32.4	Female	De novo	Favorable		5.42094455852156	0	13.2	13.899994	4	99		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25167c	UK-NCRI	30.7	Female	De novo	Adverse		2.04243668720055	1	11.7	67	17	80		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25168a	UK-NCRI	61.5	Male	De novo	Favorable		5.89459274469541	0	32	7.2999992	44	80		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25171c	UK-NCRI	60.8	Female	De novo	Adverse		2.14647501711157	1	20.7	8.5999985	186	44		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25172c	UK-NCRI	60.2	Female	Other	Adverse		4.15879534565366	0	4.9	7.1999969	70	20		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25173c	UK-NCRI	57.9	Female	De novo	Intermediate		1.27857631759069	1	42.3	10.699997	24	90		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25174a	UK-NCRI	56.8	Female	Other	Intermediate		0.659822039698836	1	1.8	6.8999977	15	12		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25175c	UK-NCRI	29.7	Female	De novo	Favorable		2.32991101984942	0	15.4	8.3999939	19	95		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25176a	UK-NCRI	63	Male	De novo	Intermediate		0.268309377138946	1	17.3	9.3999939	170	98		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25177c	UK-NCRI	61.1	Female	De novo	Adverse		1.24572210814511	1	2	89	91	24		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25178c	UK-NCRI	60.6	Female	De novo	Favorable		5.6974674880219	0	7.8	15	296	20		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25180a	UK-NCRI	66.9	Female	Other	Intermediate		0.684462696783025	0	1.7	9.3999939	32	13		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25181a	UK-NCRI	29.6	Female	De novo	Favorable		3.35660506502396	0	42.6	129	35	8		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25182a	UK-NCRI	65.5	Female	De novo	Adverse		0.536618754277892	1	36.5	12.799995	79	90		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25183a	UK-NCRI	40.3	Female	De novo	Favorable		3.52087611225188	0	13	15.006119106409	80.4858623868992	58.7450018928678		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25184a	UK-NCRI	60.7	Male	De novo	Adverse		0.747433264887064	1	2.7	8.5999985	24	10		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25185c	UK-NCRI	67.2	Female	De novo	Adverse		1.76591375770021	1	9.6	6.6999969	87	60		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25186a	UK-NCRI	53	Male	De novo	Favorable		1.01574264202601	1	12.2	7.3999977	44	30		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25187a	UK-NCRI	66.9	Female	Secondary	Adverse		0.484599589322382	1	17.4	10	23	17		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25188c	UK-NCRI	36.9	Male	De novo	Favorable		4.54757015742642	0	3	8.2999954	149	60		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25189c	UK-NCRI	63.2	Male	De novo	Intermediate		4.18617385352498	1	7.7	9.1999969	64	82		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25191c	UK-NCRI	48.4	Female	De novo	Favorable		2.76522929500342	0	9.9	124	187	30		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25192a	UK-NCRI	40.7	Male	De novo	Intermediate		3.63586584531143	0	10	61	57	65		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25193d	UK-NCRI	43.9	Female	Secondary	Adverse		4.42162902121834	0	3.5	11.099998	106	35		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25194a	UK-NCRI	56.6	Female	De novo	Favorable		5.44284736481862	0	43.5	7.3999977	17	95		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25195c	UK-NCRI	62.5	Female	De novo	Intermediate		2.00136892539357	1	2.2	12.199997	133	32		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25196c	UK-NCRI	47.8	Male	De novo	Intermediate		2.51060917180014	1	27.4	135	156	46		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25197a	UK-NCRI	70.6	Female	De novo	Favorable		4.52566735112936	0	4.8	10.099998	41	70		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25198a	UK-NCRI	47.1	Male	De novo	Intermediate		5.4757015742642	0	3.4	6.6399994	79	84		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25199a	UK-NCRI	60.1	Female	De novo	Adverse		0.793976728268309	1	1.8	85	31	25		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25200a	UK-NCRI	70.1	Male	Other	Intermediate		1.18822724161533	1	20.3	7.2999992	22	37		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25202c	UK-NCRI	47.8	Female	De novo	Intermediate		0.0848733744010951	1	8.9	84	103	43		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25203a	UK-NCRI	60.8	Male	De novo	Intermediate		0.837782340862423	1	52.4	89	39	35		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25204a	UK-NCRI	67.5	Male	De novo	Favorable		5.83983572895277	0	35.3	9.8999939	104	86		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25205a	UK-NCRI	62.6	Female	De novo	Intermediate		0.0876112251882272	1	3.3	12.399994	54	49		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25206c	UK-NCRI	66.3	Female	De novo	Adverse		5.41273100616016	0	7.5	10.099998	105	35		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25207c	UK-NCRI	25	Female	De novo	Favorable		5.88364134154689	0	11.5	8.6999969	48	20		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25208a	UK-NCRI	56	Male	De novo	Favorable		3.28542094455852	0	30.6	6.6999969	182	79		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25209a	UK-NCRI	40.3	Male	De novo	Intermediate		0.465434633812457	1	6.5	85	99	79		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25210c	UK-NCRI	61.6	Female	Secondary	Adverse		5.9356605065024	0	1.9	81	116	58.7450018928678		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25211a	UK-NCRI	49.1	Female	De novo	Favorable		1.96577686516085	1	54.4	15.006119106409	80.4858623868992	58.7450018928678		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25213c	UK-NCRI	59.4	Female	De novo	Intermediate		0.0383299110198494	1	68.1	12.399994	197	95		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25214a	UK-NCRI	56.5	Female	De novo	Intermediate		0.342231348391513	1	36.8	9.1999969	16	90		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25215c	UK-NCRI	38.7	Male	De novo	Favorable		0.837782340862423	0	2.5	83	40	56		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25216c	UK-NCRI	40.8	Male	De novo	Intermediate		0.613278576317591	1	99.6	10.399994	73	40		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25217c	UK-NCRI	30.9	Female	De novo	Favorable		3.24709103353867	1	6.5	8.6999969	38	33		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25218c	UK-NCRI	66.8	Male	De novo	Adverse		0.837782340862423	1	10.9	7.5	32	95		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25219c	UK-NCRI	39.1	Male	De novo	Favorable		5.82067077344285	0	23.6	53	21	40		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25220a	UK-NCRI	43.6	Female	De novo	Adverse		0.298425735797399	1	13.7	8.3999939	134	55		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25221c	UK-NCRI	53.8	Male	Secondary	Favorable		3.77275838466804	1	47.6	8.7999954	108	12		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25222a	UK-NCRI	58.5	Female	De novo	Favorable		5.69199178644764	0	12	43	28	54		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25223c	UK-NCRI	48.8	Female	De novo	Favorable		2.10540725530459	1	36.4	8.3999939	36	80		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25224c	UK-NCRI	60	Male	De novo	Favorable		5.927446954141	0	73.1	97	397	68		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25225c	UK-NCRI	42.8	Male	De novo	Favorable		0.501026694045175	0	15.3	10	62	59		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25226c	UK-NCRI	56.1	Female	De novo	Favorable		5.71937029431896	0	43.3	10.799995	88	68		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25228a	UK-NCRI	53.9	Female	Secondary	Favorable		4.54483230663929	0	5.8	7.7999992	32	80		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25229a	UK-NCRI	58.9	Female	De novo	Favorable		5.75496235455168	0	32	11.5	52	58.7450018928678		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25230a	UK-NCRI	56.3	Female	De novo	Intermediate		2.97056810403833	0	1.5	10.099998	98	27		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25231a	UK-NCRI	40.1	Male	Secondary	Intermediate		1.2621492128679	1	3	10.849998	25	68		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25233a	UK-NCRI	61	Female	De novo	Adverse		3.15126625598905	1	10.3	91	50	94		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25234c	UK-NCRI	49.7	Female	De novo	Intermediate		2.32991101984942	1	8.3	9.0999985	171	14		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25235c	UK-NCRI	66.2	Female	De novo	Adverse		2.03969883641342	1	1.1	7.8999977	48	25		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25236c	UK-NCRI	24.1	Female	De novo	Adverse		1.17453798767967	1	6.3	9.0999985	285	65		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25237c	UK-NCRI	45.3	Female	De novo	Adverse		5.45379876796715	0	55.5	10	204	60		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25238c	UK-NCRI	51.1	Male	De novo	Favorable		3.36481861738535	0	116	9	27	100		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25239a	UK-NCRI	56.3	Male	De novo	Favorable		0.87337440109514	0	164.3	9.0999985	43	98		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25240c	UK-NCRI	71.7	Male	De novo	Adverse		0.725530458590007	1	39.3	61	33	90		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25241c	UK-NCRI	57.4	Male	De novo	Favorable		5.84531143052704	0	2.3	103	66	44		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25242a	UK-NCRI	55.7	Female	De novo	Adverse		1.5523613963039	1	2	10.699997	108	90		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25243c	UK-NCRI	53	Female	De novo	Adverse		0.158795345653662	1	2.2	7.5999985	18	45		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25244c	UK-NCRI	66.6	Female	De novo	Adverse		2.39835728952772	1	2.3	11	92	25		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25245c	UK-NCRI	51.5	Female	De novo	Adverse		3.34565366187543	1	2	10.699997	103	27		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25246a	UK-NCRI	60.3	Male	De novo	Intermediate		4.16153319644079	0	1.5	12.299995	168	40		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25247a	UK-NCRI	31.7	Male	De novo	Favorable		4.53388090349076	1	6	10.699997	41	40		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25248a	UK-NCRI	44.1	Female	De novo	Favorable		5.86447638603696	0	24.8	13.799995	133	90		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25249c	UK-NCRI	45	Female	De novo	Favorable		3.50718685831622	0	46.1	10.799995	53	90		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25250c	UK-NCRI	63.9	Female	De novo	Intermediate		0.665297741273101	1	4.3	94	7	46		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25252a	UK-NCRI	41.2	Male	De novo	Adverse		0.555783709787817	1	0.9	6.0999985	10	63		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25253a	UK-NCRI	64.9	Female	De novo	Intermediate		0.974674880219028	1	5.8	8.2599945	2013	21		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25254c	UK-NCRI	23.5	Female	De novo	Intermediate		1.93018480492813	1	1.8	8.8999939	152	71		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25255a	UK-NCRI	69.3	Female	De novo	Adverse		0.769336071184121	1	4	6.8999977	37	27		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25257c	UK-NCRI	24.9	Male	De novo	Favorable		5.11430527036276	0	3.3	116	106	40		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25258c	UK-NCRI	60.8	Female	Secondary	Adverse		0.183436002737851	1	1.9	126	86	52		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25259c	UK-NCRI	27.5	Female	De novo	Adverse		1.44284736481862	1	2.7	141	108	15		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25260c	UK-NCRI	59.7	Male	De novo	Intermediate		2.8911704312115	1	17.6	8.5999985	48	40		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25261a	UK-NCRI	67	Male	De novo	Favorable		5.5605749486653	0	30.8	81	70	35		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25264a	UK-NCRI	25.5	Male	De novo	Intermediate		5.41820670773443	0	4.5	7.8999977	122	86		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25265c	UK-NCRI	65.3	Male	De novo	Favorable		0.298425735797399	1	19.9	9.1999969	211	90		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25266c	UK-NCRI	62.6	Female	De novo	Adverse		5.76865160848734	0	1.4	8.3999939	40	69		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25267a	UK-NCRI	67.1	Female	Secondary	Adverse		1.99863107460643	1	102.5	9.5999985	45	19		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25268a	UK-NCRI	56.4	Male	De novo	Favorable		4.5968514715948	1	9.8	67	35	37		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25269a	UK-NCRI	47.1	Male	De novo	Favorable		0.53388090349076	1	2.4	8.3999939	13	49		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25270c	UK-NCRI	21.5	Male	De novo	Favorable		2.67488021902806	0	103	75	58	67		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25271a	UK-NCRI	69.9	Male	De novo	Adverse		0.279260780287474	1	46.6	12.799995	33	31		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25272c	UK-NCRI	60.7	Male	De novo	Favorable		5.61806981519507	0	29.6	7.6999969	52	86		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25273c	UK-NCRI	65.5	Male	De novo	Adverse		3.39493497604381	0	1.5	8.1999969	20	59		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25274c	UK-NCRI	68.4	Female	De novo	Intermediate		0.643394934976044	1	3.1	8.8999939	69	37		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25275c	UK-NCRI	45.2	Male	De novo	Intermediate		1.30869267624914	1	179.2	5.8999977	33	90		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25276a	UK-NCRI	60.2	Female	De novo	Favorable		4.30937713894593	0	15.4	9.0699997	54	32		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25277a	UK-NCRI	48.2	Female	De novo	Adverse		1.76317590691307	1	3.8	13.699997	148	75		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25278c	UK-NCRI	37.7	Female	De novo	Intermediate		2.19028062970568	1	4.5	8.3999939	29	80		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25279c	UK-NCRI	54	Female	De novo	Favorable		5.4839151266256	0	53.5	101	49	88		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25280c	UK-NCRI	61.7	Female	De novo	Adverse		3.28815879534565	0	37	89	32	97		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25281c	UK-NCRI	46.8	Female	De novo	Intermediate		5.60711841204654	0	3.1	9.8999939	163	23		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25282c	UK-NCRI	48.5	Male	Secondary	Adverse		1.05407255304586	1	1	9.8999939	251	41		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25283c	UK-NCRI	57.2	Female	De novo	Intermediate		3.67693360711841	0	1.4	11.899994	85	87		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25284a	UK-NCRI	51.7	Male	Secondary	Intermediate		1.96851471594798	1	0.7	88	613	15		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25285c	UK-NCRI	68.8	Female	Secondary	Adverse		0.854209445585216	1	22.9	11.5	47	44		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25286c	UK-NCRI	56.9	Female	De novo	Intermediate		5.75222450376454	0	107	8.6899948	62	77		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25287c	UK-NCRI	63	Female	De novo	Favorable		5.08692676249144	1	13.3	5.8999977	10	75		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25289c	UK-NCRI	40.6	Male	De novo	Favorable		4.23271731690623	0	7	139	301	42		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25290c	UK-NCRI	38.3	Male	De novo	Favorable		3.15674195756331	0	6	9.3999939	27	22		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25291c	UK-NCRI	54.4	Female	De novo	Adverse		0.731006160164271	1	63.1	11.399994	90	70		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25293c	UK-NCRI	43.4	Male	De novo	Favorable		5.55509924709103	0	166	6.5999985	5	80		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25294c	UK-NCRI	62.3	Female	De novo	Adverse		1.53867214236824	1	2.8	8.3999939	76	50		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25295c	UK-NCRI	37.9	Male	De novo	Favorable		2.75427789185489	0	2.6	7.5	31	67		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25296c	UK-NCRI	46.5	Female	De novo	Adverse		2.03969883641342	1	1.7	10.199997	76	42		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25297c	UK-NCRI	59.2	Female	De novo	Favorable		5.61806981519507	0	11.9	89	77	47		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25299a	UK-NCRI	63.8	Male	De novo	Favorable		1.94387405886379	1	23.6	10.299995	105	99		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25300c	UK-NCRI	66	Female	De novo	Adverse		3.20328542094456	0	42	9	19	75		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25301c	UK-NCRI	50	Male	De novo	Favorable		4.61054072553046	0	2.8	11.399994	115	20		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25303a	UK-NCRI	37.1	Male	De novo	Intermediate		0.876112251882272	1	10.4	10.199997	51	20		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25304a	UK-NCRI	47.5	Female	De novo	Adverse		3.32922655715264	1	2.1	78	37	20		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25305a	UK-NCRI	42.8	Female	Secondary	Intermediate		0.301163586584531	1	17.3	9.2999954	19	67		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25306a	UK-NCRI	65.3	Female	De novo	Favorable		4.19438740588638	0	2.7	8.0999985	38	35		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25307a	UK-NCRI	67	Female	De novo	Adverse		0.246406570841889	1	8.5	11.199997	129	50		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25308a	UK-NCRI	58	Female	De novo	Intermediate		3.20602327173169	0	7.2	144	261	3		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25309c	UK-NCRI	26.9	Male	De novo	Intermediate		5.69472963723477	0	3.5	83	39	32		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25310c	UK-NCRI	61.6	Male	De novo	Favorable		5.78507871321013	0	0.9	103	34	32		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25311c	UK-NCRI	51.5	Female	De novo	Intermediate		5.41820670773443	0	123.7	121	72	66		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25312a	UK-NCRI	57.7	Male	De novo	Favorable		2.61190965092402	1	11	12.199997	140	58.7450018928678		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25313a	UK-NCRI	19.4	Male	De novo	Favorable		1.09240246406571	1	72.1	88	28	95		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25315c	UK-NCRI	47.4	Male	De novo	Intermediate		5.7741273100616	0	1.1	99	158	46		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25316c	UK-NCRI	34.4	Female	De novo	Favorable		3.19507186858316	1	129.6	40	43	94		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25317a	UK-NCRI	60.4	Male	De novo	Intermediate		5.59616700889802	0	22.6	7.5999985	32	80		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25318a	UK-NCRI	47.8	Female	De novo	Adverse		4.17796030116359	0	1.6	7.3999977	67	45		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25319a	UK-NCRI	47.2	Female	De novo	Intermediate		3.16221765913758	0	6.5	125	140	54		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25321a	UK-NCRI	41.7	Female	De novo	Favorable		5.79603011635866	0	21.8	13.699997	105	90		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25322a	UK-NCRI	72.3	Female	De novo	Adverse		5.39082819986311	0	3.5	82	83	41		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25323c	UK-NCRI	22.1	Male	De novo	Favorable		3.81656399726215	0	42.4	5.1799965	5	50		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25324c	UK-NCRI	50	Male	De novo	Intermediate		5.38261464750171	0	2.8	87	33	30		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25325c	UK-NCRI	28.6	Female	De novo	Adverse		5.42094455852156	0	152	9.1999969	35	80		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25326a	UK-NCRI	46.8	Female	De novo	Intermediate		0.988364134154689	1	1.6	92	57	12		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25327c	UK-NCRI	48.4	Female	De novo	Intermediate		0.741957563312799	1	16.2	57	114	66		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25328a	UK-NCRI	69.9	Male	De novo	Adverse		0.583162217659138	1	4.4	8.5	41	58.7450018928678		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25329c	UK-NCRI	33.9	Male	De novo	Adverse		4.37782340862423	0	15	4.0299988	14	30		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25330c	UK-NCRI	58.5	Female	Other	Adverse		5.45106091718001	0	6.9	48	117	25		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25331c	UK-NCRI	62.1	Male	De novo	Favorable		5.28952772073922	0	1	6.5999985	20	5		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25332a	UK-NCRI	51.8	Male	De novo	Adverse		0.750171115674196	1	4.3	6.7999992	75	40		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25333a	UK-NCRI	60.3	Male	Secondary	Intermediate		5.4839151266256	0	1.3	9.8799973	99	25		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25334c	UK-NCRI	65.1	Male	De novo	Favorable		2.0643394934976	1	23.9	93	117	68		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25335c	UK-NCRI	60.7	Male	De novo	Intermediate		1.02669404517454	1	176.2	8.0999985	48	80		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25336c	UK-NCRI	39.8	Female	De novo	Favorable		5.13347022587269	0	10.1	12.799995	86	90		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25337a	UK-NCRI	64.2	Female	De novo	Favorable		4.82683093771389	1	22	10.599998	95	90		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25338c	UK-NCRI	59.3	Female	De novo	Intermediate		2.39288158795346	1	1.1	10.699997	45	20		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25339a	UK-NCRI	57.7	Male	De novo	Favorable		5.70841889117043	0	14	10	43	94		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25341c	UK-NCRI	22.7	Male	De novo	Adverse		5.09240246406571	0	65.6	71	141	92		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25342c	UK-NCRI	49.6	Female	De novo	Intermediate		0.344969199178645	1	49.6	115	106	57		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25343a	UK-NCRI	42.6	Female	De novo	Adverse		0.536618754277892	1	3	106	193	32		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25344c	UK-NCRI	71.4	Male	De novo	Intermediate		5.28405201916496	0	31	6.3999977	55	93		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25345c	UK-NCRI	57.4	Female	De novo	Adverse		2.92128678986995	1	11	10.699997	91	99		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25347a	UK-NCRI	63.5	Male	De novo	Intermediate		0.969199178644764	1	1.7	9.0999985	130	50		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25348c	UK-NCRI	24.7	Female	De novo	Favorable		2.05065023956194	0	4.8	13.299995	85	85		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25349a	UK-NCRI	61.6	Female	Other	Adverse		0.747433264887064	1	1.8	83	55	19		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25350a	UK-NCRI	50.6	Male	Secondary	Adverse		0.334017796030116	1	30.9	11.5	8	28		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25352c	UK-NCRI	47.3	Male	Secondary	Intermediate		0.136892539356605	1	0.9	8.7999954	124	75		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25355c	UK-NCRI	60.7	Female	De novo	Favorable		5.45379876796715	0	6.2	97	69	55		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25356a	UK-NCRI	36.6	Female	De novo	Favorable		4.07392197125257	0	70.6	4.7999992	11	85		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25357c	UK-NCRI	42.6	Male	De novo	Intermediate		0.265571526351814	1	17	9.1999969	93	75		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25358c	UK-NCRI	53.8	Male	De novo	Favorable		3.21971252566735	0	20.1	10.299995	89	70		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25359a	UK-NCRI	44.3	Female	De novo	Favorable		4.24093086926762	0	75.5	3.5	89	60		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25361c	UK-NCRI	50	Male	Secondary	Adverse		0.15605749486653	1	34.8	7	106	30		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25362a	UK-NCRI	67.1	Female	De novo	Favorable		3.99726214921287	0	9.5	10.399994	77	70		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25363a	UK-NCRI	67.4	Female	De novo	Adverse		0.139630390143737	0	2.2	6.6999969	2	20		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25364c	UK-NCRI	50	Male	De novo	Favorable		5.34702258726899	0	1	8.6999969	116	46		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25365c	UK-NCRI	41.1	Female	De novo	Adverse		0.320328542094456	1	0.8	8.0999985	137	77		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25366c	UK-NCRI	52	Female	De novo	Favorable		1.00752908966461	1	36.6	9.7999954	123	24		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25367c	UK-NCRI	23.2	Female	De novo	Favorable		2.90212183436003	0	302	7.6999969	57	80		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25369c	UK-NCRI	63.7	Female	De novo	Favorable		0.194387405886379	1	80.7	86	43	69		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25371a	UK-NCRI	56.6	Female	De novo	Intermediate		5.42368240930869	0	33.7	6	30	90		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25372a	UK-NCRI	33.2	Female	De novo	Adverse		1.6208076659822	1	209	112	78	70		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25373c	UK-NCRI	46.3	Male	De novo	Favorable		0.306639288158795	0	95.4	6.6999969	14	90		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25374a	UK-NCRI	69	Female	De novo	Favorable		1.60985626283368	1	4.9	7.6999969	216	52		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25377c	UK-NCRI	32.6	Male	De novo	Favorable		5.20191649555099	0	15.6	10.199997	76	50		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25378a	UK-NCRI	38	Female	De novo	Adverse		0.796714579055442	1	97.8	7.6999969	63	98		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25380a	UK-NCRI	54.7	Male	De novo	Adverse		1.75222450376454	0	8	8.0999985	35	89		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25381a	UK-NCRI	66.1	Male	De novo	Favorable		3.04722792607803	0	156	4.5	54	70		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25382c	UK-NCRI	42.3	Female	De novo	Favorable		5.42642026009583	0	65.1	10.399994	96	70		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25383c	UK-NCRI	64.1	Male	De novo	Favorable		5.14989733059548	0	456	3.8999996	12	58.7450018928678		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25384c	UK-NCRI	53.4	Female	De novo	Favorable		3.05817932922656	0	4.9	12.299995	194	64		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25385c	UK-NCRI	69.6	Female	De novo	Adverse		1.95208761122519	1	1.5	11.399994	104	31		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25386a	UK-NCRI	49.8	Female	De novo	Intermediate		1.95208761122519	1	1.7	92	155	21		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25387c	UK-NCRI	53.6	Female	De novo	Adverse		5.57973990417522	0	11	8.6899948	72	70		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25388a	UK-NCRI	63.9	Male	Secondary	Favorable		0.205338809034908	1	3.8	9.5	10	58.7450018928678		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25390a	UK-NCRI	33.7	Male	De novo	Favorable		4.90622861054073	0	7	10.899994	48	58.7450018928678		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25392c	UK-NCRI	49.5	Female	De novo	Favorable		4.32580424366872	0	7	4.6699982	25	82		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25393a	UK-NCRI	61.7	Male	De novo	Favorable		1.1937029431896	1	13.7	78	169	39		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25394c	UK-NCRI	57.9	Male	De novo	Intermediate		0.123203285420945	0	150	8	55	85		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25395c	UK-NCRI	24.8	Female	De novo	Adverse		0.0602327173169062	1	3.9	10.5	97	70		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25398c	UK-NCRI	57.8	Male	De novo	Favorable		5.30595482546201	0	70.6	11.339996	65	77		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25399c	UK-NCRI	40.9	Female	De novo	Adverse		2.49691991786448	1	1.6	4.1999969	42	65		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25400a	UK-NCRI	68.4	Female	De novo	Favorable		4.90622861054073	0	6.3	9.0999985	43	40		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25401c	UK-NCRI	65.7	Female	Secondary	Adverse		0.101300479123888	1	40.8	96	31	5		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25402c	UK-NCRI	45.4	Female	De novo	Adverse		1.24024640657084	1	77.3	115	53	58.7450018928678		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25404c	UK-NCRI	65.2	Female	De novo	Favorable		1.82888432580424	1	5	91	124	58.7450018928678		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25405c	UK-NCRI	48	Male	De novo	Adverse		5.34428473648186	0	10.9	7.1999969	28	95		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25406c	UK-NCRI	46.6	Male	De novo	Favorable		4.12320328542094	0	5.5	12.699997	99	73.5		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25407c	UK-NCRI	27.9	Male	Other	Adverse		4.9555099247091	0	3.8	10.699997	71	17		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25408a	UK-NCRI	61.2	Female	De novo	Intermediate		0.10403832991102	1	170.8	9.3999939	103	10		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25409c	UK-NCRI	57.6	Male	De novo	Favorable		0.82135523613963	1	0.6	10.5	91	52		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25410a	UK-NCRI	63	Male	De novo	Favorable		0.454483230663929	1	2.9	8.8999939	109	67		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25411a	UK-NCRI	55.1	Male	De novo	Intermediate		4.97741273100616	0	0.9	8.6999969	51	20		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25412c	UK-NCRI	62.9	Female	De novo	Adverse		0.161533196440794	1	1.6	7.3999977	57	22		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25413a	UK-NCRI	55.4	Male	De novo	Favorable		5.09514031485284	0	27.9	11.799995	85	87		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25414a	UK-NCRI	58	Male	De novo	Intermediate		4.03011635865845	0	4.8	6.5999985	65	58.7450018928678		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25415c	UK-NCRI	66.9	Female	De novo	Adverse		0.454483230663929	1	72	77	203	35		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25417a	UK-NCRI	62.2	Male	Other	Adverse		1.94934976043806	1	2.2	10.599998	63	18		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25418a	UK-NCRI	59.4	Female	De novo	Adverse		1.09240246406571	1	6	9	18	80		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25419c	UK-NCRI	62.9	Female	De novo	Intermediate		0.610540725530459	1	1.1	59	101	28		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25420a	UK-NCRI	60.1	Male	Secondary	Adverse		0.531143052703628	1	0.9	9.6999969	27	16		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25421c	UK-NCRI	47.4	Male	De novo	Favorable		4.99383983572895	0	40.2	102	124	20		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25422a	UK-NCRI	62.1	Female	De novo	Intermediate		1.26762491444216	1	38.2	7.0999985	100	90		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25423c	UK-NCRI	25.2	Male	De novo	Favorable		2.8911704312115	0	69	5.5	25	50		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25424a	UK-NCRI	54.5	Female	De novo	Adverse		5.15537303216975	0	106.8	11.299995	190	90		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25426a	UK-NCRI	44.2	Female	De novo	Intermediate		5.18275154004107	0	2.7	10.599998	89	24		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25427c	UK-NCRI	56.2	Male	De novo	Favorable		2.96235455167693	0	121.6	10.199997	60	86		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25428a	UK-NCRI	55.8	Female	De novo	Favorable		5.15263518138261	0	66.5	8.5999985	37	85		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25431c	UK-NCRI	68.6	Female	De novo	Favorable		5.21013004791239	0	0.7	9.2999954	60	80		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25432c	UK-NCRI	30	Female	De novo	Favorable		2.81998631074606	0	5.7	15.006119106409	80.4858623868992	58.7450018928678		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25433a	UK-NCRI	59.7	Female	De novo	Intermediate		3.81930184804928	0	1.5	9.2999954	71	34		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25434a	UK-NCRI	66.6	Female	De novo	Adverse		1.37713894592745	1	8.2	9.5999985	138	50		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25435a	UK-NCRI	46.8	Male	De novo	Intermediate		0.449007529089665	1	1.6	10.599998	20	58.7450018928678		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25436a	UK-NCRI	44.2	Female	De novo	Intermediate		5.12251882272416	0	8.7	14	75	93		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25437c	UK-NCRI	67.9	Male	De novo	Favorable		0.594113620807666	1	0.9	68	144	60		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25438a	UK-NCRI	54	Female	De novo	Favorable		2.25051334702259	0	37.8	84	24	12		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25439a	UK-NCRI	31.1	Female	De novo	Adverse		0.306639288158795	1	1.4	9.6999969	75	32		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25440c	UK-NCRI	21.7	Female	De novo	Intermediate		1.61259411362081	1	81	11.199997	35	100		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25442a	UK-NCRI	64	Male	De novo	Favorable		1.03764544832307	1	18	12.199997	42	74		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25443c	UK-NCRI	48.8	Female	De novo	Adverse		5.31964407939767	0	22.3	8.5	67	17		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25444c	UK-NCRI	69.5	Male	De novo	Adverse		0.736481861738535	1	8.3	6.8999977	20	48		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25445a	UK-NCRI	48.2	Female	De novo	Adverse		0.213552361396304	1	36.3	116	227	68		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25446c	UK-NCRI	55.5	Male	De novo	Favorable		4.59958932238193	0	10.8	9.8999939	150	80		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25447c	UK-NCRI	62.5	Male	Secondary	Favorable		3.83299110198494	0	12	8	131	24		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25448a	UK-NCRI	61.9	Female	De novo	Adverse		0.470910335386721	1	1.4	91	23	25		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25449c	UK-NCRI	54.8	Female	De novo	Favorable		1.14168377823409	1	10.1	71	50	70		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25450c	UK-NCRI	69.3	Male	De novo	Favorable		1.57152635181383	0	8.2	4	204	92		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25451c	UK-NCRI	25.7	Male	De novo	Adverse		1.74948665297741	0	4	1.1999998	15	90		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25452a	UK-NCRI	57	Female	De novo	Intermediate		1.3223819301848	0	71.6	117	24	100		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25453a	UK-NCRI	34.4	Female	De novo	Intermediate		5.35523613963039	0	1.9	116	51	96		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25454c	UK-NCRI	28.6	Male	De novo	Intermediate		1.06502395619439	1	55.1	9.1999969	72	28		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25455c	UK-NCRI	55	Male	De novo	Adverse		1.9356605065024	1	1.5	6.6999969	196	70		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25456c	UK-NCRI	72.6	Male	De novo	Intermediate		5.55783709787817	0	91.1	74	9	90		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25457a	UK-NCRI	55.2	Male	De novo	Intermediate		0.558521560574949	1	119	97	97	67		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25460a	UK-NCRI	26.3	Female	De novo	Favorable		2.68583162217659	0	105.9	13.599998	151	82		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25461c	UK-NCRI	56.1	Female	Other	Favorable		0.769336071184121	1	38.5	100	34	10		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25463a	UK-NCRI	51.3	Female	De novo	Favorable		4.98015058179329	0	2.9	9.7999954	121	36		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25464c	UK-NCRI	67.2	Female	De novo	Favorable		2.66666666666667	1	7.9	90	204	73		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25465c	UK-NCRI	63.5	Female	De novo	Intermediate		2.51060917180014	1	1.6	91	34	20		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25467a	UK-NCRI	48.7	Female	De novo	Favorable		4.92265571526352	0	83.8	76	166	20		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25473c	UK-NCRI	85.8	Female	De novo	Adverse		0.0328542094455852	1	2	10	79	55		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25475c	UK-NCRI	74.3	Female	Other	Adverse		0.706365503080082	1	13.7	8	45	11		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25477a	UK-NCRI	78	Male	De novo	Adverse		0.399726214921287	1	1.5	11.699997	83	72		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25480a	UK-NCRI	78.4	Female	De novo	Adverse		0.607802874743327	1	6.4	4.7999992	39	90		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25481c	UK-NCRI	77.7	Male	De novo	Favorable		4.17522245037645	0	4.7	10.699997	57	66		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25482c	UK-NCRI	74.8	Male	De novo	Favorable		4.13141683778234	0	16.9	7.0999985	19	74		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25484c	UK-NCRI	74.1	Male	Secondary	Adverse		0.229979466119097	1	3.7	9.6999969	21	60		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25486a	UK-NCRI	73.9	Female	Secondary	Adverse		0.054757015742642	1	4.7	9	937	56.799988		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25488c	UK-NCRI	75.4	Male	Secondary	Intermediate		1.06228610540726	1	4.5	10.299995	27	71		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25489c	UK-NCRI	75.9	Female	De novo	Adverse		1.57426420260096	1	1.4	7.5999985	105	40		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25490a	UK-NCRI	82.1	Female	De novo	Adverse		3.32101300479124	1	3	91	70	18		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25492c	UK-NCRI	76.6	Male	De novo	Adverse		0.971937029431896	1	1	5.6999969	71	25		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25493a	UK-NCRI	79.8	Female	Secondary	Adverse		1.89459274469541	1	17	9.8999939	8	20		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25494c	UK-NCRI	74.5	Female	Secondary	Intermediate		2.13552361396304	1	13.5	8.7999954	26	21		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25496a	UK-NCRI	73.2	Female	De novo	Adverse		2.09445585215606	1	2.2	9.5	75	26		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25498a	UK-NCRI	71.2	Female	Secondary	Adverse		0.454483230663929	1	1.5	9.0999985	59	20		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25499a	UK-NCRI	67.4	Male	De novo	Favorable		0.246406570841889	1	21.6	8.3999939	19.199997	20		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25501a	UK-NCRI	79.5	Female	Other	Adverse		0.383299110198494	1	2	9.1999969	10	58.7450018928678		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25502c	UK-NCRI	76.3	Male	De novo	Favorable		0.492813141683778	1	30.8	9.3999939	10	95		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25503c	UK-NCRI	81.4	Male	De novo	Intermediate		1.05681040383299	1	3.1	9.1999969	21	80		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25504c	UK-NCRI	74	Male	De novo	Adverse		0.114989733059548	1	21.5	8.1999969	31	90		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25505a	UK-NCRI	69.5	Female	Secondary	Favorable		0.109514031485284	1	21	9.1999969	123	72		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25506a	UK-NCRI	78.2	Male	De novo	Adverse		0.479123887748118	1	17.2	6.7999992	171	63		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25507a	UK-NCRI	70.8	Female	De novo	Favorable		2.97878165639973	1	5.4	8.6999969	178	20		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25509c	UK-NCRI	83.5	Male	De novo	Favorable		0.243668720054757	1	44	10.699997	96	50		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25510a	UK-NCRI	77.2	Female	Secondary	Adverse		0.188911704312115	1	47.6	12.5	113	80		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25512c	UK-NCRI	75.6	Female	De novo	Adverse		0.736481861738535	1	0.9	9.0999985	24	39		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25513a	UK-NCRI	77.2	Male	De novo	Favorable		0.0903490759753593	1	12.4	11.899994	84	90		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25515a	UK-NCRI	76.2	Female	Secondary	Adverse		3.86310746064339	1	1.5	9.5999985	34	30		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25517a	UK-NCRI	73.6	Female	Secondary	Adverse		0.91170431211499	1	4.2	10	48	57		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25519c	UK-NCRI	72.6	Male	De novo	Adverse		0.265571526351814	1	25.8	10.299995	64	35		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25520a	UK-NCRI	81	Male	De novo	Adverse		0.996577686516085	1	5.3	9.6999969	144	58.7450018928678		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25521a	UK-NCRI	72.6	Male	Secondary	Intermediate		0.314852840520192	1	4.7	7.5999985	64	66		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25524c	UK-NCRI	73.9	Male	Other	Intermediate		1.40177960301164	1	1.4	11	141	17		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25525a	UK-NCRI	75.7	Female	Secondary	Adverse		2.36002737850787	1	1	9.5999985	40	58.7450018928678		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25526a	UK-NCRI	75.7	Female	De novo	Adverse		0.197125256673511	1	14.1	8.0999985	143	10		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25528a	UK-NCRI	67	Female	De novo	Adverse		0.501026694045175	1	8.1	7.5	10	22		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25533c	UK-NCRI	85.3	Female	Secondary	Favorable		0.177960301163587	1	3.9	74	131	24		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25534c	UK-NCRI	76.7	Male	Other	Adverse		2.89664613278576	1	15.4	9.5	186	16		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25535c	UK-NCRI	68.1	Male	De novo	Adverse		0.334017796030116	1	58	6.0999985	9	95		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25536a	UK-NCRI	73.4	Female	De novo	Favorable		0.287474332648871	1	8.3	8.3999939	14	55		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25537a	UK-NCRI	78.7	Female	Other	Intermediate		0.952772073921971	1	32.1	5.7999992	96	11		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25538c	UK-NCRI	76	Female	Secondary	Intermediate		1.53867214236824	1	1.2	11.699997	60	25.099991		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25539a	UK-NCRI	78.8	Female	De novo	Favorable		2.0041067761807	1	13.4	6.5999985	30	58.7450018928678		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25540a	UK-NCRI	69.8	Female	De novo	Adverse		0.479123887748118	1	2.3	9.3999939	102	65		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25541a	UK-NCRI	72.7	Female	Other	Adverse		0.835044490075291	1	0.9	7.5	28	30		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25542a	UK-NCRI	67.9	Male	De novo	Favorable		0.388774811772758	1	10	9	59	18		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25543a	UK-NCRI	72.5	Female	Secondary	Adverse		0.191649555099247	1	37.7	9.3999939	68	57		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25544a	UK-NCRI	67.9	Female	Other	Adverse		0.583162217659138	1	140.6	8.5	84	35		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25548a	UK-NCRI	81.8	Male	De novo	Adverse		0.164271047227926	1	2.9	10.399994	113	31		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25549c	UK-NCRI	70.1	Female	Other	Adverse		2.72416153319644	1	1.8	4.0999985	32	20		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25550a	UK-NCRI	74.1	Female	De novo	Favorable		0.602327173169062	1	1.5	9.3999939	94	79.099976		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25552c	UK-NCRI	72.1	Female	De novo	Adverse		0.0930869267624914	1	19.6	9	49	80		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25553c	UK-NCRI	76.8	Female	Secondary	Adverse		0.388774811772758	1	17.3	7.8999977	5	43		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25555a	UK-NCRI	78.4	Male	De novo	Adverse		1.96303901437372	1	2.3	9.5	47	70		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25558a	UK-NCRI	80	Female	De novo	Adverse		0.0793976728268309	1	26.7	83	53	95		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25559a	UK-NCRI	78.9	Female	De novo	Favorable		0.438056125941136	1	64.3	10.599998	39	90		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25560a	UK-NCRI	72.5	Female	De novo	Adverse		3.3347022587269	0	2.5	11.199997	51	58.7450018928678		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25561a	UK-NCRI	76.8	Female	De novo	Adverse		1.73305954825462	1	35.9	10.899994	150	58.7450018928678		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25562a	UK-NCRI	79.5	Female	De novo	Favorable		0.629705681040383	1	4.3	9.5	29	90		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25563c	UK-NCRI	77.2	Male	Secondary	Intermediate		0.303901437371663	1	5.6	9.0999985	10	35		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25564c	UK-NCRI	79	Male	De novo	Adverse		0.112251882272416	1	1.3	5.0999985	28	40		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25565a	UK-NCRI	72.8	Female	De novo	Intermediate		1.25941136208077	1	1.7	11.099998	9	22		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25566a	UK-NCRI	80.9	Male	De novo	Adverse		0.054757015742642	1	29	11	66	0		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25567c	UK-NCRI	80	Female	De novo	Adverse		0.451745379876797	1	24.9	8.2999954	29	95		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25568c	UK-NCRI	69.7	Female	De novo	Adverse		0.706365503080082	1	1.6	8.2999954	31	86		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25569c	UK-NCRI	78.7	Male	De novo	Adverse		0.0574948665297741	1	3	11.5	39	60		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25570a	UK-NCRI	86.4	Female	De novo	Favorable		0.966461327857632	1	10.3	8.0999985	9	90		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25571a	UK-NCRI	74	Female	De novo	Adverse		0.147843942505133	1	3.1	10.299995	29	53		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25573a	UK-NCRI	78.9	Male	Secondary	Adverse		0.813141683778234	1	1.8	10.699997	20	40		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25574c	UK-NCRI	82.5	Male	De novo	Favorable		0.246406570841889	1	23.2	8.5	133	50		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25575c	UK-NCRI	72.4	Male	Other	Adverse		0.246406570841889	1	2.4	6.6999969	17	7		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25576c	UK-NCRI	73.2	Female	Other	Adverse		0.197125256673511	1	5.8	10	26	10.299995		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25577c	UK-NCRI	75.2	Male	De novo	Adverse		1.77138945927447	1	33.8	9.5	28	96		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25578c	UK-NCRI	79	Female	De novo	Adverse		0.328542094455852	1	0.5	6.5999985	16	48		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25579a	UK-NCRI	65.7	Female	De novo	Adverse		0.668035592060233	1	1.9	9.5999985	159	40		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25580a	UK-NCRI	69.1	Female	Secondary	Intermediate		0.331279945242984	1	3.6	10.299995	72	42		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25583a	UK-NCRI	69.8	Female	De novo	Adverse		0.741957563312799	1	3.8	15.006119106409	80.4858623868992	58.7450018928678		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25587c	UK-NCRI	72.5	Female	De novo	Favorable		3.37029431895962	0	35	7.1999969	82	58.7450018928678		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25588a	UK-NCRI	72	Female	Other	Intermediate		3.14031485284052	1	3.4	10.099998	127	58.7450018928678		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25589a	UK-NCRI	82.2	Male	De novo	Adverse		0.632443531827515	1	2.8	8	79	44		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25591a	UK-NCRI	83.8	Female	Other	Adverse		0.566735112936345	1	3.1	8.1999969	183	0		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25592c	UK-NCRI	69.3	Male	Secondary	Adverse		0.717316906228611	1	83.5	7.3999977	6	97		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25593a	UK-NCRI	63.3	Male	Secondary	Intermediate		3.2662559890486	1	2.2	10.199997	50	35		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25594a	UK-NCRI	82.1	Male	De novo	Favorable		0.0766598220396988	1	40.8	10.599998	44	90		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25595a	UK-NCRI	78.9	Female	Secondary	Favorable		0.114989733059548	1	6.4	8.2999954	85	42		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25596a	UK-NCRI	72.6	Female	De novo	Favorable		0.120465434633812	1	102.9	8.1999969	15	87.699951		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25597a	UK-NCRI	74.7	Female	Secondary	Favorable		1.73579739904175	1	5.3	6.7999992	66	61		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25598c	UK-NCRI	83.1	Female	De novo	Favorable		0.0629705681040383	1	2.5	9.1999969	57	17		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25599a	UK-NCRI	82.2	Female	De novo	Adverse		0.862422997946612	1	1.1	9.1999969	42	18.599991		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25601c	UK-NCRI	86.1	Female	De novo	Adverse		0.054757015742642	1	1.1	10.299995	399	58.7450018928678		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25602a	UK-NCRI	69.1	Female	Secondary	Adverse		0.150581793292266	1	27.6	8.8999939	33	65		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25604c	UK-NCRI	73.7	Female	De novo	Intermediate		0.0465434633812457	1	1.7	11.899994	62	1		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25606c	UK-NCRI	80.1	Male	De novo	Intermediate		0.131416837782341	1	1	7.6999969	22	70		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25607c	UK-NCRI	79.8	Female	De novo	Adverse		0.112251882272416	1	8.9	11.399994	25	44		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25608a	UK-NCRI	80.9	Male	De novo	Favorable		0.0328542094455852	1	199.6	10.299995	73	58.7450018928678		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25609c	UK-NCRI	78.5	Male	De novo	Favorable		2.35181382614648	1	13.1	11.199997	136	80		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25610c	UK-NCRI	76.6	Male	Secondary	Favorable		3.0280629705681	0	46.4	8.8999939	51	93		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25611a	UK-NCRI	85.4	Female	De novo	Adverse		0.818617385352498	1	15.6	8.1999969	198	22		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25612c	UK-NCRI	70.8	Male	Secondary	Favorable		0.26009582477755	1	21.8	7.7999992	36	90		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25613a	UK-NCRI	72.2	Male	De novo	Favorable		0.0465434633812457	1	49.6	7.7999992	35	72		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25614c	UK-NCRI	82.6	Male	De novo	Favorable		0.0410677618069815	1	59.6	9	19	91		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25615a	UK-NCRI	75.2	Female	De novo	Adverse		0.63791923340178	1	3.6	8.6999969	86	60		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25616a	UK-NCRI	72.5	Female	Secondary	Adverse		0.172484599589322	1	1.9	9.1999969	19	37.399994		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25617a	UK-NCRI	75	Female	Secondary	Adverse		0.177960301163587	1	16.9	15.299995	19	86		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25618c	UK-NCRI	84.4	Male	De novo	Favorable		0.109514031485284	1	18.1	9	32	15		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25620c	UK-NCRI	79.9	Female	De novo	Favorable		0.317590691307324	1	2.4	9.5	56	50		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25621a	UK-NCRI	74	Female	De novo	Favorable		2.62833675564682	1	29.8	10	69	80		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25622a	UK-NCRI	73.9	Male	De novo	Adverse		0.0520191649555099	1	1.6	4.5999985	28	59		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25623a	UK-NCRI	74	Female	De novo	Favorable		0.462696783025325	1	2.4	57	54	90		Other/Unknown	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25624c	UK-NCRI	76.5	Female	Secondary	Adverse		1.16632443531828	1	1.5	6.5999985	167	50		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25625a	UK-NCRI	71.3	Female	De novo	Adverse		0.320328542094456	1	3.4	10.099998	29	58.7450018928678		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25626c	UK-NCRI	80.8	Male	Other	Adverse		1.44010951403149	1	7	9.0999985	78	15		Normal	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25627a	UK-NCRI	76.9	Male	De novo	Adverse		0.0739219712525667	1	1.4	7.2999992	76	59		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
PD25629c	UK-NCRI	81.6	Male	De novo	Adverse		0.413415468856947	1	9.6	9.8999939	102	70		Complex	UK_NCRI_data/UK_NCRI_Clinical_data.csv + data/aml_prognosis_updated.tsv
